0001493152-23-009468.txt : 20230329 0001493152-23-009468.hdr.sgml : 20230329 20230329160853 ACCESSION NUMBER: 0001493152-23-009468 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 66 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230329 DATE AS OF CHANGE: 20230329 FILER: COMPANY DATA: COMPANY CONFORMED NAME: THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. CENTRAL INDEX KEY: 0001419051 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 451226465 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-54554 FILM NUMBER: 23775293 BUSINESS ADDRESS: STREET 1: 701 WILD ROSE LANE CITY: ELK CITY STATE: ID ZIP: 83525 BUSINESS PHONE: (760) 295-7208 MAIL ADDRESS: STREET 1: 701 WILD ROSE LANE CITY: ELK CITY STATE: ID ZIP: 83525 FORMER COMPANY: FORMER CONFORMED NAME: Friendly Auto Dealers, Inc. DATE OF NAME CHANGE: 20071120 10-K 1 form10-k.htm
0001419051 false FY 0001419051 2022-01-01 2022-12-31 0001419051 2022-06-30 0001419051 2023-03-29 0001419051 2022-12-31 0001419051 2021-12-31 0001419051 2021-01-01 2021-12-31 0001419051 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2020-12-31 0001419051 us-gaap:CommonStockMember 2020-12-31 0001419051 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001419051 TSOI:SharesToBeIssuedMember 2020-12-31 0001419051 TSOI:SubscriptionReceivableMember 2020-12-31 0001419051 us-gaap:RetainedEarningsMember 2020-12-31 0001419051 2020-12-31 0001419051 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-12-31 0001419051 us-gaap:CommonStockMember 2021-12-31 0001419051 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001419051 TSOI:SharesToBeIssuedMember 2021-12-31 0001419051 TSOI:SubscriptionReceivableMember 2021-12-31 0001419051 us-gaap:RetainedEarningsMember 2021-12-31 0001419051 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-12-31 0001419051 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001419051 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001419051 TSOI:SharesToBeIssuedMember 2021-01-01 2021-12-31 0001419051 TSOI:SubscriptionReceivableMember 2021-01-01 2021-12-31 0001419051 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001419051 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-12-31 0001419051 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001419051 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001419051 TSOI:SharesToBeIssuedMember 2022-01-01 2022-12-31 0001419051 TSOI:SubscriptionReceivableMember 2022-01-01 2022-12-31 0001419051 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001419051 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-12-31 0001419051 us-gaap:CommonStockMember 2022-12-31 0001419051 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001419051 TSOI:SharesToBeIssuedMember 2022-12-31 0001419051 TSOI:SubscriptionReceivableMember 2022-12-31 0001419051 us-gaap:RetainedEarningsMember 2022-12-31 0001419051 2021-08-03 2021-08-04 0001419051 srt:MaximumMember 2022-12-31 0001419051 us-gaap:LandMember 2022-12-31 0001419051 us-gaap:LandMember 2021-12-31 0001419051 us-gaap:VehiclesMember 2022-12-31 0001419051 us-gaap:VehiclesMember 2021-12-31 0001419051 us-gaap:ComputerEquipmentMember 2022-12-31 0001419051 us-gaap:ComputerEquipmentMember 2021-12-31 0001419051 TSOI:OfficeFurnitureAndEquipmentMember 2022-12-31 0001419051 TSOI:OfficeFurnitureAndEquipmentMember 2021-12-31 0001419051 TSOI:ShippingAndOtherEquipmentMember 2022-12-31 0001419051 TSOI:ShippingAndOtherEquipmentMember 2021-12-31 0001419051 TSOI:ExclusivePatentLicenseAgreementMember TSOI:ConvertiblePromissoryNoteMember 2022-02-21 2022-02-23 0001419051 TSOI:ExclusivePatentLicenseAgreementMember TSOI:ConvertiblePromissoryNoteMember 2022-02-23 0001419051 TSOI:AssetsTransferAndLicenseAgreementMember 2022-03-24 2022-03-25 0001419051 TSOI:AssetsTransferAndLicenseAgreementMember TSOI:InitialPaymentMember 2022-03-24 2022-03-25 0001419051 TSOI:AssetsTransferAndLicenseAgreementMember TSOI:SecondPaymentMember 2022-03-24 2022-03-25 0001419051 TSOI:ConvertiblePromissoryNoteMember 2022-12-31 0001419051 TSOI:ConvertiblePromissoryNoteMember 2022-01-01 2022-12-31 0001419051 TSOI:ConvertiblePromissoryNoteMember 2021-12-31 0001419051 TSOI:ConvertiblePromissoryNoteMember 2021-01-01 2021-12-31 0001419051 TSOI:ConvertiblePromissoryNoteMember srt:MinimumMember 2021-12-31 0001419051 TSOI:ConvertiblePromissoryNoteMember srt:MaximumMember 2021-12-31 0001419051 us-gaap:DerivativeMember 2022-01-01 2022-12-31 0001419051 us-gaap:DerivativeMember us-gaap:MeasurementInputConversionPriceMember srt:MinimumMember 2022-12-31 0001419051 us-gaap:DerivativeMember us-gaap:MeasurementInputConversionPriceMember srt:MaximumMember 2022-12-31 0001419051 us-gaap:DerivativeMember us-gaap:MeasurementInputSharePriceMember srt:MinimumMember 2022-12-31 0001419051 us-gaap:DerivativeMember us-gaap:MeasurementInputSharePriceMember srt:MaximumMember 2022-12-31 0001419051 us-gaap:DerivativeMember us-gaap:MeasurementInputExpectedDividendRateMember 2022-12-31 0001419051 us-gaap:DerivativeMember us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2022-12-31 0001419051 us-gaap:DerivativeMember us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2022-12-31 0001419051 us-gaap:DerivativeMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2022-12-31 0001419051 us-gaap:DerivativeMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2022-12-31 0001419051 us-gaap:DerivativeMember us-gaap:MeasurementInputExpectedTermMember 2022-01-01 2022-12-31 0001419051 TSOI:ConvertibleNotesMember 2022-01-01 2022-12-31 0001419051 TSOI:ConvertibleNotesMember 2022-12-31 0001419051 TSOI:ConvertibleNotesMember us-gaap:MeasurementInputConversionPriceMember srt:MinimumMember 2022-12-31 0001419051 TSOI:ConvertibleNotesMember us-gaap:MeasurementInputConversionPriceMember srt:MaximumMember 2022-12-31 0001419051 TSOI:ConvertibleNotesMember us-gaap:MeasurementInputSharePriceMember srt:MinimumMember 2022-12-31 0001419051 TSOI:ConvertibleNotesMember us-gaap:MeasurementInputSharePriceMember srt:MaximumMember 2022-12-31 0001419051 us-gaap:DerivativeMember us-gaap:ConvertibleNotesPayableMember us-gaap:MeasurementInputExpectedDividendRateMember 2022-12-31 0001419051 TSOI:ConvertibleNotesMember us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2022-12-31 0001419051 TSOI:ConvertibleNotesMember us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2022-12-31 0001419051 TSOI:ConvertibleNotesMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2022-12-31 0001419051 TSOI:ConvertibleNotesMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2022-12-31 0001419051 TSOI:ConvertibleNotesMember us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2022-01-01 2022-12-31 0001419051 TSOI:ConvertibleNotesMember us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2022-01-01 2022-12-31 0001419051 TSOI:RemainingConvertibleNotesMember 2022-12-31 0001419051 TSOI:RemainingConvertibleNotesMember 2022-01-01 2022-12-31 0001419051 TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputExercisePriceMember 2022-12-31 0001419051 TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputSharePriceMember 2022-12-31 0001419051 TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputExpectedDividendRateMember 2022-12-31 0001419051 TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2022-12-31 0001419051 TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2022-12-31 0001419051 TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001419051 TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2022-01-01 2022-12-31 0001419051 TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2022-01-01 2022-12-31 0001419051 us-gaap:DerivativeMember 2021-01-01 2021-12-31 0001419051 us-gaap:DerivativeMember us-gaap:MeasurementInputConversionPriceMember srt:MinimumMember 2021-12-31 0001419051 us-gaap:DerivativeMember us-gaap:MeasurementInputConversionPriceMember srt:MaximumMember 2021-12-31 0001419051 us-gaap:DerivativeMember us-gaap:MeasurementInputSharePriceMember srt:MinimumMember 2021-12-31 0001419051 us-gaap:DerivativeMember us-gaap:MeasurementInputSharePriceMember srt:MaximumMember 2021-12-31 0001419051 us-gaap:DerivativeMember us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0001419051 us-gaap:DerivativeMember us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2021-12-31 0001419051 us-gaap:DerivativeMember us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2021-12-31 0001419051 us-gaap:DerivativeMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2021-12-31 0001419051 us-gaap:DerivativeMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2021-12-31 0001419051 us-gaap:DerivativeMember us-gaap:MeasurementInputExpectedTermMember 2021-01-01 2021-12-31 0001419051 TSOI:ConvertibleNotesMember 2021-01-01 2021-12-31 0001419051 TSOI:ConvertibleNotesMember us-gaap:MeasurementInputConversionPriceMember srt:MinimumMember 2021-12-31 0001419051 TSOI:ConvertibleNotesMember us-gaap:MeasurementInputConversionPriceMember srt:MaximumMember 2021-12-31 0001419051 TSOI:ConvertibleNotesMember us-gaap:MeasurementInputSharePriceMember srt:MinimumMember 2021-12-31 0001419051 TSOI:ConvertibleNotesMember us-gaap:MeasurementInputSharePriceMember srt:MaximumMember 2021-12-31 0001419051 TSOI:ConvertibleNotesMember us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0001419051 TSOI:ConvertibleNotesMember us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2021-12-31 0001419051 TSOI:ConvertibleNotesMember us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2021-12-31 0001419051 TSOI:ConvertibleNotesMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2021-12-31 0001419051 TSOI:ConvertibleNotesMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2021-12-31 0001419051 TSOI:ConvertibleNotesMember us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2021-01-01 2021-12-31 0001419051 TSOI:ConvertibleNotesMember us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2021-01-01 2021-12-31 0001419051 TSOI:RemainingConvertibleNotesMember 2021-12-31 0001419051 TSOI:RemainingConvertibleNotesMember 2021-01-01 2021-12-31 0001419051 TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputConversionPriceMember srt:MinimumMember 2021-12-31 0001419051 TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputConversionPriceMember srt:MaximumMember 2021-12-31 0001419051 TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputSharePriceMember 2021-12-31 0001419051 TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0001419051 TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2021-12-31 0001419051 TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2021-12-31 0001419051 TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001419051 TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2021-01-01 2021-12-31 0001419051 TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2021-01-01 2021-12-31 0001419051 us-gaap:ConvertibleNotesPayableMember 2022-01-01 2022-12-31 0001419051 us-gaap:ConvertibleNotesPayableMember 2021-01-01 2021-12-31 0001419051 us-gaap:ConvertibleNotesPayableMember 2022-12-31 0001419051 TSOI:NotesPayableOneMember 2022-12-31 0001419051 TSOI:NotesPayableOneMember 2021-12-31 0001419051 TSOI:NotesPayableTwoMember 2022-12-31 0001419051 TSOI:NotesPayableTwoMember 2021-12-31 0001419051 TSOI:NotesPayableThreeMember 2022-12-31 0001419051 TSOI:NotesPayableThreeMember 2021-12-31 0001419051 TSOI:NotesPayableFourMember 2022-12-31 0001419051 TSOI:NotesPayableFourMember 2021-12-31 0001419051 TSOI:NotesPayableFiveMember 2022-12-31 0001419051 TSOI:NotesPayableFiveMember 2021-12-31 0001419051 TSOI:ScientificAdvisoryBoardMember TSOI:NotesPayableOneMember 2022-12-31 0001419051 TSOI:ScientificAdvisoryBoardMember TSOI:NotesPayableOneMember 2021-12-31 0001419051 TSOI:ScientificAdvisoryBoardMember TSOI:NotesPayableOneMember 2022-01-01 2022-12-31 0001419051 TSOI:ScientificAdvisoryBoardMember TSOI:NotesPayableOneMember 2021-01-01 2021-12-31 0001419051 srt:ChiefExecutiveOfficerMember TSOI:NotesPayableTwoMember srt:MinimumMember 2022-12-31 0001419051 srt:ChiefExecutiveOfficerMember TSOI:NotesPayableTwoMember srt:MinimumMember 2021-12-31 0001419051 srt:ChiefExecutiveOfficerMember TSOI:NotesPayableTwoMember srt:MaximumMember 2022-12-31 0001419051 srt:ChiefExecutiveOfficerMember TSOI:NotesPayableTwoMember srt:MaximumMember 2021-12-31 0001419051 srt:ChiefExecutiveOfficerMember TSOI:NotesPayableTwoMember 2022-01-01 2022-12-31 0001419051 srt:ChiefExecutiveOfficerMember TSOI:NotesPayableTwoMember 2021-01-01 2021-12-31 0001419051 srt:ChiefFinancialOfficerMember TSOI:NotesPayableFourMember 2022-12-31 0001419051 srt:ChiefFinancialOfficerMember TSOI:NotesPayableFourMember 2021-12-31 0001419051 srt:ChiefFinancialOfficerMember TSOI:NotesPayableFourMember 2022-01-01 2022-12-31 0001419051 srt:ChiefFinancialOfficerMember TSOI:NotesPayableFourMember 2021-01-01 2021-12-31 0001419051 TSOI:BusinessAdvisoryBoardMember TSOI:NotesPayableFiveMember srt:MinimumMember 2022-12-31 0001419051 TSOI:BusinessAdvisoryBoardMember TSOI:NotesPayableFiveMember srt:MinimumMember 2021-12-31 0001419051 TSOI:BusinessAdvisoryBoardMember TSOI:NotesPayableFiveMember srt:MaximumMember 2022-12-31 0001419051 TSOI:BusinessAdvisoryBoardMember TSOI:NotesPayableFiveMember srt:MaximumMember 2021-12-31 0001419051 TSOI:BusinessAdvisoryBoardMember TSOI:NotesPayableFiveMember 2022-01-01 2022-12-31 0001419051 TSOI:BusinessAdvisoryBoardMember TSOI:NotesPayableFiveMember 2021-01-01 2021-12-31 0001419051 srt:OfficerMember 2019-12-31 0001419051 srt:OfficerMember 2018-12-31 0001419051 TSOI:OneOfficersMember us-gaap:RestrictedStockMember TSOI:AccruedSalariesMember 2021-01-01 2021-12-31 0001419051 TSOI:OneOfficerAndOneDirectorMember us-gaap:RestrictedStockMember 2021-06-17 2021-06-18 0001419051 TSOI:FourOfficerAndOneDirectorMember us-gaap:RestrictedStockMember 2021-11-30 2021-11-30 0001419051 TSOI:OneOfficersMember us-gaap:RestrictedStockMember TSOI:AccruedSalariesMember 2022-01-01 2022-12-31 0001419051 TSOI:FourOfficerAndOneDirectorMember us-gaap:RestrictedStockMember 2022-04-05 2022-04-05 0001419051 TSOI:OneOfficerAndOneDirectorMember us-gaap:RestrictedStockMember 2022-09-08 2022-09-08 0001419051 TSOI:FourOfficerOneDirectorMember us-gaap:RestrictedStockMember 2022-11-02 2022-11-02 0001419051 TSOI:FourOfficerAndOneDirectorMember us-gaap:RestrictedStockMember 2022-12-30 2022-12-30 0001419051 us-gaap:PrivatePlacementMember 2021-01-01 2021-12-31 0001419051 TSOI:ConsultingServicesMember 2021-01-01 2021-12-31 0001419051 TSOI:SalariesMember 2021-01-01 2021-12-31 0001419051 TSOI:LandDevelopmentMember 2021-01-01 2021-12-31 0001419051 us-gaap:PrivatePlacementMember 2022-01-01 2022-12-31 0001419051 TSOI:ConsultingServicesMember 2022-01-01 2022-12-31 0001419051 TSOI:ConsultingServicesMember us-gaap:SubsequentEventMember 2023-01-03 2023-01-03 0001419051 TSOI:SalariesMember 2022-01-01 2022-12-31 0001419051 us-gaap:LicenseMember 2022-01-01 2022-12-31 0001419051 TSOI:PrepaidFeesMember 2022-01-01 2022-12-31 0001419051 us-gaap:ConvertibleNotesPayableMember us-gaap:SubsequentEventMember 2023-01-03 2023-01-03 0001419051 us-gaap:SubsequentEventMember 2023-01-03 2023-01-03 0001419051 us-gaap:SubsequentEventMember 2023-01-03 0001419051 us-gaap:ConvertibleNotesPayableMember us-gaap:SubsequentEventMember 2023-01-04 2023-01-04 0001419051 us-gaap:SubsequentEventMember TSOI:AccruedSalariesMember 2023-01-09 2023-01-09 0001419051 us-gaap:SubsequentEventMember 2023-01-09 2023-01-09 0001419051 us-gaap:SubsequentEventMember 2023-01-09 0001419051 us-gaap:SubsequentEventMember us-gaap:ConvertibleNotesPayableMember 2023-02-06 2023-02-06 0001419051 us-gaap:SubsequentEventMember us-gaap:ConvertibleNotesPayableMember 2023-02-07 2023-02-07 0001419051 us-gaap:PrivatePlacementMember us-gaap:SubsequentEventMember 2023-02-21 2023-02-21 0001419051 us-gaap:PrivatePlacementMember us-gaap:SubsequentEventMember 2023-02-21 0001419051 us-gaap:SubsequentEventMember us-gaap:PreferredClassAMember srt:DirectorMember 2023-03-21 2023-03-21 0001419051 us-gaap:SubsequentEventMember TSOI:CampbellNeurosciencesIncMember 2023-03-21 2023-03-21 0001419051 us-gaap:SubsequentEventMember 2023-03-21 2023-03-21 0001419051 us-gaap:SubsequentEventMember TSOI:CampbellNeurosciencesIncMember 2023-03-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares utr:sqft xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-K

 

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2022

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____to_____

 

Commission File Number: 000-54554

 

Therapeutic Solutions International, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada   45-1226465

(State or other jurisdiction of

incorporation or organization)

  

(I.R.S. Employer

Identification No.)

 

701 Wild Rose Lane
Elk City, Idaho 83525
(Address of principal executive offices, including zip code)
 
(760) 295-7208
(Registrant’s telephone number, including area code)
 
Securities registered pursuant to Section 12(b) of the Act:
 None
 
Securities registered pursuant to Section 12(g) of the Act:
 
Title of class
Common Stock, $0.001 par value per share

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

 

Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

 

Yes ☐ No ☒

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☐ No ☒

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☒

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

☐ Large accelerated filer ☐ Accelerated filer
☒ Non-accelerated filer ☒ Smaller reporting company
☐ Emerging growth company    

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

 

The aggregate market value of the voting and non-voting common equity held by non-affiliates was $1,296,570,604 based on a closing price of $0.0415 as of June 30, 2022.

 

As of March 29, 2023, 2,734,250,749 shares of the registrartant’s common stock, par value of $0.001 per shares, were outstanding.

 

 

 

 
 

 

INDEX

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

 

    PAGE NO
PART I    
     
ITEM 1 BUSINESS 4
ITEM 1A RISK FACTORS 19
ITEM 1B UNRESOLVED STAFF COMMENTS 23
ITEM 2 PROPERTIES 23
ITEM 3 LEGAL PROCEEDINGS 23
ITEM 4 MINE SAFETY DISCLOSURES 23
     
PART II    
     
ITEM 5 MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES 23
ITEM 6 SELECTED FINANCIAL DATA 24
ITEM 7 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 24
ITEM 7A QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 26
ITEM 8 FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 26
ITEM 9 CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 27
ITEM 9A CONTROLS AND PROCEDURES 27
ITEM 9B OTHER INFORMATION 28
     
PART III    
     
ITEM 10 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 28
ITEM 11 EXECUTIVE COMPENSATION 34
ITEM 12 SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 34
ITEM 13 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 35
ITEM 14 PRINCIPAL ACCOUNTANT FEES AND SERVICES 35
     
PART IV    
     
ITEM 15 EXHIBITS AND FINANCIAL STATEMENT SCHEDULES 35
     
SIGNATURES 36

 

2
 

 

PART I.

 

FORWARD-LOOKING STATEMENTS

 

This Annual Report on Form 10-K contains forward-looking statements within the meaning of federal securities laws, which are subject to a number of risks and uncertainties. All statements that are not historical facts are forward-looking statements, including statements about our business strategy, uncertainty regarding our future operating results and our profitability, anticipated sources of funds and all plans, objectives, expectations and intentions and any statements regarding future potential revenue, gross margins and our prospects for 2022 and thereafter. These statements may appear in a number of places and can be identified by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “future,” “intend,” or “certain” or the negative of these terms or other variations or comparable terminology, or by discussions of strategy.

 

The following factors are among those that may cause actual results to differ materially from our forward-looking statements:

 

●Need for additional capital;
●Limited operating history in our new business model;
●Limited experience introducing new products;
●Our ability to successfully expand our operations and manage our future growth;
●Difficulty in managing our growth and expansion;
●Dilutive effects of any raising of additional capital;
●The deterioration of global economic conditions and the decline of consumer confidence and spending;
●Material weaknesses reported in our internal control over financial reporting;
●Our ability to protect intellectual property rights and the value of our products;
●The potential for product liability claims against us;
●Our dependence on third party manufacturers to manufacture our products;
●Our common stock is currently classified as a penny stock;
●Our stock price may experience future volatility;
●The illiquidity of our common stock; and
●Substantial sales of shares of our common stock.

 

Actual results may vary materially from those in such forward-looking statements as a result of various factors, including those identified in “Item 1A. Risk Factors” and elsewhere in this document. No assurance can be given that the risk factors described in this Annual Report on Form 10-K are all of the factors that could cause actual results to vary materially from the forward-looking statements. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties, and assumptions. The Company’s future results and shareholder values may differ materially from those expressed in these forward-looking statements. Readers are cautioned not to put undue reliance on any forward-looking statements. Forward-looking statements also include statements in which words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “consider,” or similar expressions are used. References in this Annual Report on Form 10-K to the “Company,” “TSOI,” “we,” “our,” and “us” refer to Therapeutic Solutions International, Inc.

 

3
 

 

ITEM 1BUSINESS.

 

Corporate History

 

Therapeutic Solutions International, Inc. (“TSOI” or the “Company”) was organized August 6, 2007 under the name Friendly Auto Dealers, Inc., under the laws of the State of Nevada. In the first quarter of 2011 the Company changed its name from Friendly Auto Dealers, Inc. to Therapeutic Solutions International, Inc., and acquired Splint Decisions, Inc., a California corporation.

 

On December 17, 2020, Therapeutic Solutions International, Inc. Board of Directors made a decision to move our corporate headquarters to Elk City, Idaho 83525 and has purchased real property at 701 Wild Rose Lane and 50 Bullock Lane, Elk City Idaho 83525. The Company continues to maintain a satellite office at the current address of 4093 Oceanside Blvd., Suite B, Oceanside CA, 92056.

 

Business Description

 

Currently the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system.

 

Activating one’s immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions.

 

TSOI is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, traumatic brain injury, and for daily health.

 

Nutraceutical Division – TSOI has been producing high quality nutraceuticals. Its current flagship product, QuadraMune®, is a multi-patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquinone. QuadraMune has been shown to increase Natural Killer Cell activity and healthy Cytokine production. Our synergistic blend of ingredients helps the immune system fight off common and complex ailments and promote healthy T Cell activity. Recently the Company was approved to sell certain nutraceuticals on the Amazon Platform.

 

Cellular Division – TSOI obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and Lung Pathology (LP).

 

The stem cell licensed, termed “JadiCell” is unique in that it possesses features of mesenchymal stem cells, however, outperforms these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and neurogenic ability.

 

Chronic Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe. TSOI has previously filed several patents in the area of CTE based on modulating the brain microenvironment to enhance receptivity of regenerative cells such as stem cells. On March 4, 2021, the Company received an IND Serial # 27377 for a clinical trial of 10 patients with CTE.

 

On August 4th, 2021, the Company announced clearance from the Food and Drug Administration (FDA) to initiate a Phase III pivotal trial for registration of the Company’s JadiCell™ universal donor stem cell as a treatment for COVID-19 associated lung failure under IND # 19757. In previous studies the Company has demonstrated the superior activity of JadiCell to other types of stem cells including bone marrow, adipose, cord blood, and placenta. Furthermore, the JadiCell was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91%. The Company also recently announced the launching of Phase III for IND # 19757 with Biorasi LLC, a global, full-service CRO, who will run the clinical trial.

 

In addition, the Company has filed data with the FDA, as part of IND #17448, which demonstrated that treatment of cancer patients with StemVacs™ resulted in enhanced activity of a type of immunological cell called “natural killer” cells, otherwise known as “NK cells.”

 

The Company has also developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body’s NK cells.

 

Most recently the Company announced filing of a patent application covering the use of JadiCells™ for treatment of epilepsy and associated conditions.

 

4
 

 

Investigational Drug Applications:

 

Treatment of Metastatic Breast Cancer by StemVacs-V Cancer Immunotherapeutic IND transferred to Res Nova Bio,Inc.

 

The Primary Objective is safety and feasibility of StemVacs-V administration at 12 months as assessed by lack of adverse medical events. The Secondary Objective is efficacy as judged by tumor response, time to progression, and immunological monitoring.

 

Safety, Feasibility, and Immunomodulatory Activities of StemVacs in Patients with Advanced Solid Tumors IND # 17448

 

The Primary Objective is safety and feasibility of StemVacs administration at 12 months as assessed by lack of adverse medical events. The Secondary Objective is efficacy as judged by tumor response, time to progression, and immunological monitoring.

 

Umbilical Cord-derived Mesenchymal Stem Cells for Patients with COVID-19 (“UC-MSC for COVID-19”) IND # 19757

 

The primary objective will be to assess effectiveness of UC-MSC treatment on proportion of patients alive and free of respiratory failure at Day 60 after randomization. The secondary objectives will be to assess all-cause mortality at Day 60, survival at day 31, number of subjects experiencing serious adverse events (SAEs) by day 31, SAE-free survival, time to recovery (evaluated until day 60), and time to oxygen requirement equal or below 40% oxygen.

 

Investigation of Umbilical Cord-derived Mesenchymal Stem Cells for the Treatment of Chronic Traumatic Encephalopathy Patients IND # 27377

 

To determine safety and efficacy of 100 million intravenously administered JadiCell™ allogeneic umbilical cord mesenchymal stem cells. Efficacy will be determined by behavioral scores, brain imaging, and reduction in inflammatory markers. Toxicity of treatment was evaluated for the duration of the study and will be graded according to the criteria of the World Health Organization.

 

JadiCell Therapy for COPD IND transferred to Breathe Biologics, Inc.

 

To determine safety and efficacy of intravenously administered allogeneic JadiCell umbilical cord blood mesenchymal stem cells in patients with moderate-to-severe COPD. The Primary Endpoint, which is toxicity, will be assessed by number of adverse events (AEs). The Secondary Endpoint, which is efficacy will be evaluated at baseline and days 30, 60, and 90.

 

Nutraceutical Division (TSOI)

 

  ● ProJuvenol® is a patented, (US No.: 9,682,047) and powerful synergistic blend of complex anti-aging ingredients in capsules.
     
  ● NanoStilbene® is an easily absorbed nanoemulsion of nanoparticle pterostilbene derived from the ‘047 patent.
     
  ● DermalStilbene is a topical form of pterostilbene delivered via spray application onto skin, derived from the ‘047 patent.
     
  ● IsoStilbene an injectable formulation of pterostilbene is available by prescription only, derived from the ‘047 patent.
     
  ● NeuroStilbene is an intranasal form of pterostilbene delivered via spray application inside the nostril, derived from the ‘047 patent.
     
  ● NanoPSA is a blend of NanoStilbene® and Broccoli Sprout Extract (BSE) providing 74mg of BSE and 125mg of our patented NanoStilbene, a proprietary formulation of nanoparticle pterostilbene.
     
  ● NLRP3 Trifecta is a two-product combo and consists of one bottle of NanoPSA and one bottle of GTE-50 green tea extract.
     
  ● QuadraMune® is a multi-patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquinone.

 

5
 

 

Patents:

 

On February 14, 2023, the Company filed a patent application titled “Enhancement of Anti-Angiogenic Cancer Immunotherapy by Abortogenic Agents” which discloses the parallels between pregnancy and cancer that have been historically made, however, the ability to leverage abortogenic immunity against neoplasia has not been widely examined. The current invention provides means of suppressing tumor associated immune inhibition through administration of progesterone and/or glucocorticoid receptor antagonists such as RU-486. In one embodiment the invention provides the concurrent utilization RI-486 and anti-angiogenic immunotherapy. In another embodiment, abortogenic inhibitors of immunity such as indolamine 2,3 dioxygenase are administered together with RU-486 and/or anti-angiogenic immunotherapy. Various antiangiogenic agents can be utilized in the practice of the invention including the ValloVax immunotherapy and/or the StemVacs-V therapy.

 

On January 09, 2023, the Company filed a patent application titled “Prediction of Stem Cell Therapy Responsiveness by Quantification of Pre-Existing B Regulatory Cells” which disclosed novel means of stratifying patients into potential of positive response to mesenchymal stem cell therapy based on quantification of pretreatment levels of B regulatory cells. In one embodiment quantification of cells concurrently expressing CD5 and CD19. In another embodiment B regulatory cells are CD19+CD39–IL10+. In one embodiment the selection of B regulatory cells is quantified by flow cytometric means and patients possessing more than 7 % IL-10 secreting CD19 cells are chosen for stem cell therapy. In some embodiments numbers of B regulatory cells are increased prior to treatment by administration of various interventions including providing GM-CSF, microbiome alteration or manipulation of oxidative stress.

 

On January 04, 2023, the Company filed a patent application titled “Enhanced Efficacy of Tolerogenic Vaccination” which disclosed means, methods, and compositions of matter useful for induction of antigen specific suppression of immunity and/or tolerogenesis through administration of tolerogenic agents together with antigens and/or modified antigens delivered via multiple intradermal injections. In one embodiment the invention teaches the use of a tattoo gun or a similar device to administer over an extended area of skin a compound which induces a tolerogenic microenvironment and subsequently administration of said antigen in the artificially created microenvironment. The essence of the disclosed invention is the superior tolerogenic effects observed when tolerogenic stimuli and antigen are administered over an extended area of skin through the use of a tattoo gun or similar device.

 

On November 14, 2022, the Company filed a patent titled “Treatment of Chronic Obstructive Pulmonary Disease with Myeloid Derived Suppressor Cells” which discloses compositions of matter, protocols, and treatment means for prevention and/or reversing Chronic Obstructive Pulmonary Disease (COPD) using myeloid derived suppressor cells as a monotherapy or adjuvant therapy. In one embodiment umbilical cord low density myeloid cells are expanded using interleukin-3 and GM-CSF and administered in an allogeneic manner to a mammal suffering from COPD. In some embodiments combinations of myeloid derived suppressor cells and mesenchymal stem cells are disclosed.

 

On October 24, 2022, the Company filed a patent application titled “Mesenchymal Stem Cell Therapy of Epilepsy and Seizure Disorders” which discloses novel compositions of matter and treatment methods for reducing and/or reversing epilepsy through administration of mesenchymal stem cells in order to induce immune modulation and/or regenerative processes. In one embodiment umbilical cord mesenchymal stem cells are administered to a patient suffering from epilepsy at a concentration and frequency sufficient to inhibit neuronal hyperactivation and/or reduce neuroinflammatory status of the patient.

 

On October 03, 2022, the Company filed a patent application titled “Stimulation of Pulmonary Regenerative Exosomes by Mesenchymal Stem Cells and Derivatives Thereof” which discloses therapeutic means for pulmonary degenerative conditions through the administration of mesenchymal stem cells in order to induce regenerative exosomes from dendritic cells expressing CD103. In one embodiment cultures of mesenchymal stem cells with dendritic cell progenitors are disclosed wherein said mesenchymal stem cells induce a modulation of STAT3 signaling in said dendritic cell endowing a regenerative property to said dendritic cells and exosomes derived from said cells.

 

On September 19, 2022, the Company filed a patent application titled “Treatment of Bipolar Disorder Using Mesenchymal Stem Cells and Modification of Mesenchymal Stem Cells” that discloses the utilization of mesenchymal stem cells, exosomes from mesenchymal stem cells, conditioned media from mesenchymal stem cells, apoptotic bodies from mesenchymal stem cells, and modified mesenchymal stem cells for treatment of bipolar disorder. In one embodiment mesenchymal stem cells isolated from umbilical cord tissue are treated with carbon monoxide at a concentration sufficient to induce activation of heme-oxygenase I and infused into a patient at risk or suffering from bipolar disorder.

 

On September 12, 2022, the Company filed a patent application titled “Treatment of COPD by Stimulation of Stem Cell Mobilization” which discloses means of inducing pulmonary regeneration and/or protection from oxidative stress by stimulation of endogenous stem cell mobilization together with one or more inhibitors of NF-kappa B and/or one or more inhibitors of oxidative stress. The invention discloses the unexpected finding that G-CSF administration enhances oxidative stress and pulmonary damage, however, coadministration with pterostilbene, results in synergistic suppression of COPD pathology.

 

On August 29, 2022, the Company filed a patent application titled “Gene Silencing Therapy of Acute Respiratory Disorder” that teaches treatment means, compositions of matter and protocols useful for suppression of acute respiratory disorder (ARDS) through induction of RNA interference in the pulmonary microenvironment alone and/or in conjunction with mucolytic and/or DNA disrupting agents. In one embodiment short interfering RNA (siRNA) is prepared which targets complement receptors C3R and/or C5R together with TNF-receptor, IL-6 receptor and/or TLR4 and TLR9. In some embodiments NanoStilbene is utilized as a delivery vehicle for siRNA delivery.

 

6
 

 

On August 12, 2022, the Company filed a patent application titled “Treatment of Chronic Obstructive Pulmonary Disease by Mesenchymal Stem Cell Apoptotic Bodies and Compositions Thereof” that discloses means, treatments and compositions of matter useful for treatment of chronic obstructive pulmonary disease (COPD). In one embodiment the invention provides the administration of mesenchymal stem cell apoptotic bodies alone or in combination with “regenerative adjuvants” to prevent and/or reverse reduction in lung function associated with COPD. In other embodiments the invention teaches the utilization of stem cell apoptotic bodies for induction of pulmonary regeneration directly or indirectly.

 

On July 29, 2022, the Company filed a patent application titled “Gene Modified iPSC Derived Cellular Compositions for Regeneration and Immune Modulation” that disclosed cells and cellular compositions useful for treatment of degenerative and/or autoimmune diseases derived from gene edited/gene modified pluripotent stem cells. In one embodiment pluripotent stem cell such as inducible pluripotent stem cells are gene modified to express tissue associated transcription factors such as pdx-1 if endodermal tissue is desired and cells are differentiated into regenerative-type cells such as along the mesenchymal lineage. In one embodiment the invention teaches transfection with IL-27 to induce expression of coinhibitory molecules for suppression of autoimmunity. In some embodiments the invention provides generation of iPSC derived MSC which cannot stimulate inflammation due to gene-editing based removal of inflammatory associated transcription factors.

 

On May 12, 2022, the Company filed a patent application titled “Inhibition and Reversion of Chronic Obstructive Pulmonary Disease (COPD) by Endothelial Cell Regeneration” that teaches means, treatment methods, and compositions of matter useful for prevention and/or reversion of chronic obstructive pulmonary disease (COPD). In one embodiment the invention provides the administration of mesenchymal stem cells and exosome thereof as a means of augmenting endogenous endothelial regeneration and/or endothelial regeneration stimulated by exogenous means. In some embodiments the invention provides administration of allogeneic mesenchymal stem cells together with autologous endothelial progenitor cells and/or mobilization of said autologous endothelial progenitor cells.

 

On March 7, 2022, the Company filed a patent application titled “Treatment of Trauma Associated Cognitive Dysfunction Using Mesenchymal Stem Cell Apoptotic Bodies and Compositions Thereof” which teaches means, treatments and compositions of matter useful for treatment of chemotherapy/radiotherapy associated cognitive dysfunction. In one embodiment the invention provides the administration of mesenchymal stem cell apoptotic bodies alone or in combination with “regenerative adjuvants” to prevent and/or reverse cognitive dysfunction associated with chemotherapy and/or radiation therapy. In other embodiments the invention teaches the utilization of stem cell apoptotic bodies for induction of neuroregeneration directly or indirectly.

 

On February 7, 2022, the Company filed a patent application titled “Treatment of COVID-19 Associated Cognitive Dysfunction by Nutraceutical Preparations” that teaches means and methods of treating cognitive dysfunction associated with COVID-19 and/or other associated with inflammatory conditions. In one embodiment treatment of COVID-19 cognitive dysfunction performed by administration of nutraceutical means, wherein said nutraceuticals are administered at a frequency and/or concentration sufficient to induce proliferation of endogenous neural progenitor cells and/or protect cells from inflammatory damage. In one embodiment said nutraceuticals are comprised of green tea extract, and/or nigella sativa, and/or pterostilbene, and/or sulforaphane. In some embodiments nutraceutical compositions are utilized to overcome treatment resistant of currently used antidepressants.

 

On November 1, 2021, the Company filed a patent application titled “Induction of Concurrent Pulmonary Immune Modulation and Regeneration by Protein Mediated Conjugation of Immune Regulatory Cells with Endogenous Progenitor Cells” that discloses means, methods and compositions of matter useful for treatment of inflammatory pulmonary diseases such as COVID-19 through administration of agents that facilitate interaction between immune modulatory cells and endogenous pulmonary progenitor cells. In one embodiment a bispecific antibody capable of facilitating the interaction between CD25 on T regulatory cells and CD47 on pulmonary epithelial stem cells is described.

 

On October 11, 2021, the Company filed a patent application titled “Umbilical Cord Derived Regenerative and Immune Modulatory Stem Cell Populations” which provides universal donor cellular populations derived from umbilical cords possessing ability to elicit immune modulation and evoke regeneration when administered into a mammalian host. Generation of cellular products for clinical use are provided including methodologies of expansion, characterization, and means of therapeutic implementation.

 

On October 4, 2021, the Company filed a patent application titled “Reduction of Neutrophil Extracellular Trap formation by Mesenchymal Stem Cells and their Exosomes” that disclosed methods of reducing lung inflammation in acute respiratory distress syndrome elicited by various factors such as COVID-19 infection by reduction of neutrophil extracellular trap formation through administration of mesenchymal stem cells and/or exosomes thereof. The invention provides means of inhibiting neutrophil release of extracellular traps by mesenchymal stem cells and/or exosomes derived from said mesenchymal stem cells. Additionally, synergies are provided between mesenchymal stem cells and/or exosomes derived from mesenchymal stem cells and agents approaches which reduce neutrophil extracellular trap formation.

 

7
 

 

On September 22, 2021, the Company filed a patent application titled “Stimulation of Mesenchymal Stem Cell Therapeutic Activities by T Regulatory Cells” teaches novel means of enhancing mesenchymal stem cell regenerative activities including, intra alia, production from pulmonary leakage and suppression of scar tissue formation by co-administration with T regulatory cells. In some embodiments the invention provides an interaction between T regulatory cells and mesenchymal stem cells in which T regulatory cells stimulate upregulation of mesenchymal stem cell activity in a GITR dependent manner.

 

On September 16, 2021, the Company filed a patent application titled “Ivermectin Compositions for Treatment of COVID-19” that discloses novel mechanisms of action of ivermectin therapy as related to treatment of COVID-19 and means of augmenting therapeutic activities by co-administration with one or more of the following: pterostilbene, thymoquinone, epigallocatechin-3-gallate, and sulforaphane. In one embodiment the invention provides enhanced reduction of inflammation induced pulmonary leakage without augmenting immune suppressive mechanisms.

 

On August 23, 2021, the Company filed a patent application titled “Umbilical Cord Mesenchymal Stem Cells for Treatment of Chronic Obstructive Pulmonary Disease and Lung Degeneration” that discloses means of treating lung degenerative diseases including chronic obstructive pulmonary disease (CODP) using umbilical cord mesenchymal stem cells such as JadiCells alone, and/or using said cells under conditions that are activated in order to endow enhanced regenerative activity. In one embodiment said activation of said mesenchymal stem cells is performed through stimulation with a toll like receptor agonist at a concentration and duration sufficient to induce a >50% increase in keratinocyte growth factor expression from said stem cells. In another embodiment the invention provides the use of JadiCells as a means of producing exosomes, wherein said exosomes possess therapeutic properties capable of reducing inflammation, fibrosis and degeneration associated with COPD, as well as stimulation of regenerative activity. In some JadiCells are activated by a treatment with Activated Protein C.

 

On August 18, 2021, the Company filed a patent application titled “Enhancement of Umbilical Cord Mesenchymal Stem Cell Therapeutic Activity by Stimulators of T Regulatory Cells and/or Cells Expressing CD73” that teaches compositions of matter and protocols useful for treatment of COVID-19 and/or other inflammatory pathologies through stimulation of T regulatory cells and/or T cells expressing CD73 using administration of umbilical cord derived mesenchymal stem cells such as JadiCells. In one embodiment dosage of JadiCells needed to treat a patient is determined by the increase of T regulatory cells and/or CD73 expressing cells that are increased in number and/or activity subsequent to a test dose of JadiCells. In another embodiment stimulators of T regulatory cells and/or CD73 expressing T cells are utilized together with JadiCells in order to augment therapeutic activity. In some embodiments administration of JadiCell is performed with low dose interleukin-2 as a treatment for COVID-19 or other inflammatory related pathologies.

 

On August 11, 2021, the Company filed a patent application titled “Induction of Neurogenesis using Umbilical Cord Derived Mesenchymal Stem Cells and Derivatives Thereof” that disclosed compositions of matter and protocols useful for treatment of neurological dysfunctions through stimulation of adult neurogenesis using administration of umbilical cord derived mesenchymal stem cells such as JadiCells. In one embodiment viral induced neuropathy is reduced by administration of JadiCells to stimulate neurogenesis. In another embodiment the neurogenic activity of selective serotonin reuptake inhibitors is enhanced by administration of JadiCells. In some embodiments administration of JadiCell exosomes, conditioned media, microvesicles and/or apoptotic bodies is utilized to stimulate neurogenesis.

 

On July 28, 2021, the Company filed a patent application titled “Neuroprotection and Neuroregeneration by Pterostilbene and Compositions Thereof” with new data demonstrating that the blueberry derived compound pterostilbene possesses numerous brain protective and potentially brain regenerative activities. The data disclosed by the Company indicates: a) pterostilbene suppresses inflammatory cytokines TNF-alpha, IL-1 beta and IL-6; b) pterostilbene inhibits death of neurons caused by inflammatory mediators; c) pterostilbene stimulates production of regenerative factors from cells in the brain such as BDNF, NGF, FGF-1, and FGF-2; and d) pterostilbene allows/enhances proliferation of endogenous brain stem cells.

Granted on November 23, 2022.

 

On July 6, 2021, the Company filed a patent application titled “Treatment of Parkinson’s Disease by Immune Modulation and Regenerative Means” in which we describe and disclose means, methods and compositions of matter for treatment Parkinson’s Disease through concurrent immune modulation and regenerative means. In one embodiment Parkinson’s Disease is treated by augmentation of T regulatory cell numbers and/or activity while concurrently providing regenerative cells such as mesenchymal stem cells, and/or dopamine secreting cells. In one embodiment administration of immunoglobulins such as IVIG together with low dose interleukin-2 and/or low dose naltrexone is disclosed as a preparatory means prior to administration of therapeutic cells such as stem cells. Other therapeutic means utilized in an adjuvant manner are also provided for hormonal rebalancing, transcranial magnetic stimulation, and deep brain stimulation.

 

8
 

 

On May 24, 2021, the Company filed a patent application titled “Immunotherapies for Targeting of Tumor Vasculature” that disclosed novel means, protocols, and compositions of matter for creating targeted immune responses and/or induction of immunological memory towards the tumor vasculature. In one embodiment pluripotent stem cells are transfected with one or more genes capable of eliciting immunity, induced to differentiate into endothelial-like cells which resemble the tumor endothelial cells, and utilized as a vaccine. In some embodiment’s genes are engineered under control of specific promoters to allow for various specificities of activity. In one specific embodiment pluripotent stem cells engineered to endow properties capable of inducing expression of the α- Gal epitope (Galα1,3Galα1,4GlcNAc-R). Addition of adjuvants to enhance antigen presentation of the vaccine composition, as well as means of stimulating systemic enhancement of circulating endothelial specific T cells are also disclosed.

Published on November 24, 2022.

 

On May 21, 2021, the Company filed a patent application titled “Lithium as a Monotherapy and/or Stem Cell Adjuvant Therapy for Pulmonary Fibrosis” that disclosed compositions of matter, therapeutics, and protocols useful for reduction and/or reversion of pulmonary fibrosis. In one specific embodiment lithium chloride is administered together with a regenerative cell in a patient suffering from, or at risk of pulmonary fibrosis. In one embodiment said lithium chloride is administered as an adjuvant to a regenerative therapy, wherein said regenerative therapy is a gene therapy, a protein therapy, a cell therapy, or a tissue transplant. In one embodiment lithium chloride, or a salt thereof is utilized alone, or with a regenerative means, to evoke preservation and/or elongation of telomere length in pulmonary tissue. In one embodiment the invention teaches administration of umbilical cord mesenchymal stem cells (MSC) and/or products derived from said cells in order to induce an inhibition of natural or pathological reduction of telomere length, to preserve telomere length or to enhance telomere length. In one embodiment the MSC described in the invention as useful are umbilical cord derived MSC. Published on November 24, 2022.

 

On May 17, 2021, the Company filed a patent application titled “Treatment of Major Depressive Disorder by Low Dose Interleukin-2” which teaches methods, compositions of matter, and protocols useful for treatment of major depressive disorder through administration of low dose interleukin- 2 at a concentration and/or frequency sufficient to increase expansion of T regulatory cell numbers and/or enhancement of T regulatory cell activity. In some embodiments administration of interleukin-2 is provided as means of enhancing efficacy of standard antidepressant therapies. Furthermore, administration of interleukin-2 receptor agonists is also described in the current invention as a treatment of major depressive disorder.

 

On April 13, 2021, the Company filed a patent application titled “Amelioration and Treatment of Opioid Addiction” that discloses compositions of matter, protocols and treatment means for reducing and/or preventing opioid addiction. In one embodiment the invention teaches intranasal administration of umbilical cord blood plasma, or extracts thereof, together with pterostilbene or pterostilbene containing nanoparticles, and/or oxytocin, and/or human chorionic gonadotropin.

 

On March 29, 2021, the Company filed a patent application titled “Compositions Capable of Stimulating Immunity Towards Tumor Blood Vessels” which discloses novel means, protocols, and compositions of matter for eliciting an immune response against blood vessels supplying neoplastic tissue. In one embodiment pluripotent stem cells are transfected with one or more genes capable of eliciting immunity. In some embodiments such genes are engineered under control of specific promoters to allow for various specificities of activity. In one specific embodiment pluripotent stem cells engineered to endow properties capable of inducing expression of the α-Gal epitope (Galα1,3Galα1,4GlcNAc-R).

 

On March 23, 2021, the Company filed a patent application titled “Chimeric Cells Comprising Dendritic Cells and Endothelial Cells Resembling Tumor Endothelium” which disclosed are means, methods and compositions of matter useful for induction of immunological responses towards tumor endothelial cells. In one embodiment the invention teaches fusion of dendritic cells and cells resembling tumor endothelial cells and administration of such chimeric cells as an immunotherapy for stimulation of tumor endothelial cell destruction. In other embodiments pluripotent stem cells are utilized to generate dendritic cells, wherein said dendritic cells are fused with pluripotent stem cell derived endothelial cells created in a manner to resemble tumor endothelial cells.

 

On March 16, 2021, the Company filed a patent application titled “Pluripotent Stem Cell Derived Dendritic Cells and Engineered Dendritic Cells for Cancer Immunotherapy” which disclosed are populations of dendritic cells generated from stem cells capable of inducing immunity towards cancer. In one embodiment said dendritic cells are generated from allogeneic inducible pluripotent stem cells, for some uses, said pluripotent stem cells are genetically engineered/edited to induce cancer specific immunity and/or resist immunosuppressive effect of tumor derived microenvironment. In one embodiment pluripotent stem cells are transfected with cancer stem cell antigens such as BORIS and/or NR2F6.

 

On March 4, 2021, the Company filed a patent application titled “Therapeutic Monocytes for Prevention of Suicidal Ideation” that discloses compositions of matter, protocols, and therapeutic means for treatment of suicidal ideations and/or suppression of suicidal attempts. In one embodiment the invention provides the use of umbilical cord derived monocytes as a means of treatment. In another embodiment, monocytes are de-differentiated from adult monocytes using reprogramming means to create monocyte capable of producing anti-inflammatory as well as regenerative properties useful in reducing suicidal ideations and/or attempts. Published on September 8, 2022.

 

On February 2, 2021, the Company filed a patent application titled “Ex Vivo Generation of Immunocytes Recognizing Brother Of The Regulator of Imprinted Sites (BORIS) Expressing Cancer Stem Cells” that discusses means, methods and compositions of matter useful for induction of immunity towards cancer stem cells by providing a dendritic cell, wherein said dendritic cells express BORIS and/or peptides derived from BORIS, wherein said dendritic cell is cultured in the presence of one or more immunocytes. In one embodiment said dendritic cells are derived from umbilical cord blood sources and allogeneic to T cells, which are expanded ex vivo and used for the purposes of immunotherapy. Published on August 25, 2022.

 

9
 

 

On February 8, 2021, the Company filed a patent application titled “Stimulation of Natural Kill Cell Memory by Administration of Dendritic Cells” which disclosed means, methods and compositions of matter useful for induction of natural killer cell memory by administration of dendritic cells and/or exosomes thereof. In one embodiment a mammal suffering from cancer is administered allogeneic cord blood derived dendritic cells that are not pulsed exogenously. In one embodiment the dendritic cells are stimulated to possess chemotactic activity towards the tumor by culture of dendritic cell progenitors in hypoxia. Natural killer cell memory is induced, in part, by triggering of upregulation of cytokines associated with homeostatic expansion such as interleukin 7 and interleukin 15.

 

On January 26, 2021, the Company filed a patent application titled “Stimulation of Dendritic Cell Activity by Homotaurine and Analogues Thereof” which discloses means, methods, and compositions of matter useful for enhancement of dendritic cell activity. In one embodiment the invention provides the use of GABA agonists such as homotaurine for stimulation of dendritic cell activity. In one embodiment said dendritic cell activity is enhancement of natural killer cell activity and/or of T cell activity. In one embodiment NK cell activity is ability to induce cytotoxicity in neoplastically transformed cells, whereas T cell activity is either cytokine production for CD4 cells or cytotoxicity for CD8 cells.

 

On December 21, 2020, the Company filed a patent application titled “Immunotherapy for Opioid Addiction” which teaches means, methods and compositions of matter useful for reduction of brain inflammation and prevention of opioid addiction and/or tolerance. In one embodiment the invention provides utilization of platelet rich plasma (PRP), alone, or admixed with regenerative/anti-inflammatory adjuvants, for reduction of neural inflammation. In one embodiments PRP is admixed with oxytocin and administered intranasally in a patient at risk of opioid addiction. In another embodiment, PRP is admixed with fortified and non-fortified nigella sativa oil, and/or pterostilbene and administered intranasally. Other embodiments include utilization of autologous stromal vascular fraction cells alone and/or admixed with regenerative/anti-inflammatory adjuvants.

 

On December 8, 2020, the Company filed a patent application titled “Treatment of Major Depressive Disorder and Suicidal Ideations Through Stimulation of Hippocampal Neurogenesis Utilizing Plant-Based Approaches” that teaches means and methods of treating major depressive disorder and/or other disorders that predispose to suicide by administration of nutraceutical means, wherein said nutraceuticals are administered at a frequency and/or concentration sufficient to induce proliferation of endogenous neural progenitor cells. In one embodiment said nutraceuticals are comprised of green tea extract, and/or nigella sativa, and/or pterostilbene, and/or sulforaphane. In some embodiment’s nutraceutical compositions are utilized to overcome treatment resistant of currently used antidepressants.

 

On November 24, 2020, the Company filed a patent application titled “Stimulation of NK Cell Activity by QuadraMune Alone and together with Metformin” that disclosed means, compounds, and compositions of matter useful for stimulation of natural killer cell activity. In some embodiments the invention teaches the administration of a therapeutic combination of ingredients comprising of metformin, pterostilbene, nigella sativa, sulforaphane, and epigallocatechin-3-gallate (EGCG) to a mammal in need of natural killer cell immune modulation. In another embodiment, the invention teaches administration of said therapeutic combination to a mammal infected with said SARS-CoV-2. In some embodiments dosage of said therapeutic combination is based on inflammatory and/or immunological parameters observed in patients with COVID-19.

 

On October 27, 2020, the Company filed a patent application titled “Protection/Regeneration of Neurological Function by Endothelial Protection/Rejuvenation” using Stem Cells for Treatment of Conditions such as Chronic Traumatic Encephalopathy and Schizophrenia” which therapeutic compounds, protocols, and compositions of matter useful for treatment of neurological conditions. In one embodiment the invention teaches the treatment of chronic traumatic encephalopathy (CTE) through protecting/regenerating the endothelial by administration of cells such as stem cells. In one embodiment stem cells are administered in order to protect the endothelium from apoptosis and to preserve the blood brain barrier. In another embodiment stem cells are administered together with endothelial progenitor cells in order to regenerate neural endothelium. In other embodiments preservation of brain integrity in conditions of degeneration is accomplished by administration of stem cells and/or endothelial cells.

 

On October 18, 2020, the Company filed a patent application titled “Nutraceutical Reduction Prevention and/or Reversion of Multiple Sclerosis” that discloses compositions of matter, protocols, and treatment means for preventing and/or reversing multiple sclerosis in a mammal. In one embodiment administration of compositions containing pterostilbene, and/or nigella sativa, and/or sulforaphane, and/or epigallocatechin-3-gallate (EGCG) are provided.

 

On September 24, 2020, the Company filed a patent application titled “Personalized Immunotherapies for Reduction of Brain Inflammation and Suicide Prevention” that discloses means, methods and compositions of matter useful for reduction of brain inflammation and prevention of suicidal ideations and suicidal attempts. In one embodiment the invention provides utilization of autologous platelet rich plasma, alone, or admixed with regenerative/anti-inflammatory adjuvants, for reduction of neural inflammation. In one embodiment autologous PRP is admixed with oxytocin and administered intranasally in a patient at risk of suicidal ideation. In another embodiment, PRP is admixed with fortified and non-fortified nigella sativa oil and administered intranasally. Other embodiments include utilization of autologous stromal vascular fraction cells alone and/or admixed with regenerative/anti-inflammatory adjuvants.

 

10
 

 

On September 14, 2020, the Company filed a patent application titled “Immunotherapy of Schizophrenia and Schizophrenia Associated Suicidal Ideation/Suicide” Disclosed are methods, means, and protocols of modifying the immune system so as to induce an immunologically tolerant state insofar as T regulatory cell number and/or activity is augmented in a patient suffering from schizophrenia. In one embodiment T regulatory cells are administered to the patient from exogenous sources, be they allogeneic or autologous. In other embodiments, T regulatory cells are generated endogenously through administration of immature dendritic cells, mesenchymal stem cells, and/or pharmaceutical means.

 

On August 28, 2020, the Company filed a patent application titled “Upregulation of Therapeutic T Regulatory Cells and Suppression of Suicidal Ideations in Response to Inflammation by Administration of Nutraceutical Compositions Alone or Combined with Minocycline” which discloses compositions of matter, treatments and protocols useful for induction of T regulatory cells in response to inflammation, as well as inhibition of suicidal ideations and/or neuroinflammation. In some embodiments the invention teaches the administration of a therapeutic combination of ingredients comprising of minocycline, pterostilbene, nigella sativa, sulforaphane, and epigallocatechin-3-gallate (EGCG) to a mammal undergoing upregulation of inflammatory mediators.

 

On August 21, 2020, the Company filed a patent application titled “Methods of Determining Risk of Suicide and/or Suicidal Ideation by Immunological Assessment” which discloses means and methods of identifying risk of suicide and/or suicidal ideation by assessment of immunologically related cytokines and cells. In one embodiment, a score, termed the “Campbell Score” is devised based on assessment of serum cytokines, ability of immune cells to make cytokines when stimulated ex vivo, and ability of immune cells to produce neurotransmitters when stimulated ex-vivo. In one embodiment the concentration of interleukin-6 is utilized as a means of assessing suicidal propensity along, and/or in combination with metabolites of the enzyme indolamine 2,3 deoxygenase.

 

On August 05, 2020, the Company filed a patent application titled “Prevention of Neuroinflammation associated Memory Loss Using Nutraceutical Compositions” which discloses means, methods, and therapeutic compositions for prevention of memory loss during situations of neuroinflammation. In one embodiment the invention teaches administration of the therapeutic combination of ingredients comprising of pterostilbene, Nigella sativa, sulforaphane, and epigallocatechin-3-gallate (EGCG) to a mammal suffering from inflammation in order to preserver memory function.

 

On July 22, 2020, the Company filed a patent application titled “Additive and/or Synergistic Combinations of Metformin with Nutraceuticals for the Prevention, Inhibition and Treatment of SARS-Cov-2 and Associated COVID-19” showing potent synergy between QuadraMune™ and the antidiabetic drug metformin in treating COVID-19 associated lung damage models. It was discovered that the ability of QuadraMune™ to protect the lungs from inflammation that resembles coronavirus-induced pathology is markedly amplified by concurrent administration of metformin. At a mechanistic level, it was shown that metformin increased the ability of QuadraMune™ to a) increase the number of “healing macrophages” (“M2” macrophages); b) augment production of anti-inflammatory and regenerative proteins; and c) suppress production of pathological inflammatory proteins.

 

On July 13, 2020, the Company filed a patent application titled “Prevention of Pathological Coagulation in COVID-19 and other Inflammatory Conditions” s directed to the utilization of pterostilbene, and/or nigella sativa extract, and/or sulforaphane, and/or Epigallocatechin gallate (EGCG) alone or in combination, for the prevention of pathological coagulation. In on embodiment a composition containing all four ingredients is administered to a patient at risk of hypercoagulation in order to prevent aberrant expression of pro-coagulation molecules and/or induce expression of molecules known to suppress coagulation. In one embodiment the invention teaches administration of pterostilbene, thymoquinone, sulforaphane, and EGCG as a means of decreasing expression of tissue factor.

 

On June 30, 2020, the Company filed a patent application titled “Augmentation of Natural Killer Cell Activity and Induction of Cytotoxic Immunity Using Leukocyte Lysate Activated Allogeneic Dendritic Cells: StemVacs™” which describes the process of preparing allogeneic dendritic cells utilizing a leukocyte lysate based approach. These data support development of StemVacs for conditions that would benefit from NK activation such as cancer and COVID-19.

 

On June 22, 2020, the Company filed a patent application titled “Treatment of SARS-CoV-2 with Dendritic Cells for Innate and/or Adaptive Immunity” that disclosed means, methods, and compositions of matter for prophylaxis and/or treatment of SARS-CoV-2 by administration of dendritic cells in a manner and frequency sufficient to induce activation of innate and/or adaptive immune responses. In one embodiment the invention teaches administration of dendritic cells pulsed with one or more innate immune stimulants in a manner endowing said dendritic cell with ability to induce augmentation of natural killer (NK) cell number and/or activity. In another embodiment the invention teaches the use of dendritic cells stimulated with innate immune activators in a manner to allow for uptake of viral particles and presentation of viral epitopes to T cells in order to stimulate immunological activation and/or memory responses.

 

On June 15, 2020, the Company filed a patent application titled “Nutraceuticals for Suppressing Indolamine 2,3 Deoxygenase” from new data showing QuadraMune™ significantly inhibited inflammation associated with memory impairment, as well as reduced levels of kynurenine. Elevation of kynurenine is associated with activation of indolamine 2,3 deoxygenase, an enzyme associated with inflammation and depression.

 

11
 

 

On June 11, 2020, the Company filed a patent application titled “Nutraceuticals for Reducing Myeloid Suppressor Cells” which disclosed compositions of matter, treatments and protocols useful for reduction of number and/or activity of myeloid suppressor cells (MSC). In some embodiments the invention teaches the administration of a therapeutic combination of ingredients comprising of pterostilbene, Nigella sativa, sulforaphane, and epigallocatechin-3-gallate (EGCG) to a mammal at possessing an increased number and/or activity of said MSC in which reduction of number and/or activity is desired. In another embodiment, the invention teaches administration of said therapeutic combination to a mammal infected with viral and/or bacterial infections and/or neoplasia. In some embodiments dosage of said therapeutic combination is based on inflammatory and/or immunological parameters observed in patients.

 

On May 11, 2020, the Company filed a patent application titled “Treatment of COVID-19 Lung Injury Using Umbilical Cord Plasma Based Compositions” which disclosed means, methods, and compositions of matter useful for the treatment of lung inflammation associated with viral and bacterial infections, as well as with systemic inflammation, through the administration of umbilical cord blood derived plasma-based compositions. In one embodiment the invention teaches administration of umbilical cord blood plasma together with pterostilbene, and/or sulforaphane, and/or thymoquinone, and/or Epigallocatechin gallate (EGCG) and/or n-acetylcysteine in an aerosolized manner to patients suffering from COVID-19 associated pulmonary deficiencies. In another embodiment, umbilical cord blood plasma is administered with immune-stimulatory agents in order to concurrently inhibit propagation of viral load in the lung while suppressing pulmonary deficiencies.

 

On May 4, 2020, the Company filed a patent application titled “Nutraceuticals for the Prevention, Inhibition and Treatment of SARS-Cov-2 and Associated COVID-19” which teaches compositions of matter, treatments and protocols useful for prevention of SARS-CoV-2 infection, as well as inhibition of viral propagation and acceleration of viral cure. In some embodiments the invention teaches the administration of a therapeutic combination of ingredients comprising of pterostilbene, nigella sativa, sulforaphane, and epigallocatechin-3-gallate (EGCG) to a mammal at risk of infection with SARS-CoV-2. In another embodiment, the invention teaches administration of said therapeutic combination to a mammal infected with said SARS-CoV-2. In some embodiments dosage of said therapeutic combination is based on inflammatory and/or immunological parameters observed in patients with COVID-19.

 

On November 4, 2019, the Company filed a patent application titled “Cellular, Organ, and Whole-Body Rejuvenation Utilizing Cord Blood Plasma and Pterostilbene” that disclosed methods, means, and protocols for stimulation of rejuvenation in single cells, organs, and organisms by administration of cord blood derived plasma, cord blood plasma concentrates, and cord blood derived exosomes together with pterostilbene. The invention describes the previously unexpected finding that addition of pterostilbene to cord blood enhances the rejuvenation properties of cord blood. Said rejuvenation properties include telomere preservation, reduction in beta galactosidase, and retention of cellular activities.

 

On September 9, 2019, the Company filed a patent application titled “Pterostilbene and Formulations Thereof for Protection of Hematopoiesis from Chemotherapy and Radiation” which disclosed compositions of matter useful for treatment and/or prevention of hematopoietic injury using pterostilbene and formulations thereof. In one embodiment nanoparticle delivered pterostilbene is administered subsequent to chemotherapy induced neutropenia in order to accelerate recovery of the hematopoietic compartment. In another embodiment, pterostilbene is provided concurrently with chemotherapy in order to concurrently assist the neoplasia killing action of the chemotherapy while protecting the bone marrow from suppression. In contrast to conventionally used agents that protect from neutropenia such as G-CSF and GM-CSF, the products disclosed can be chronically administered, thus allowing for concurrent use with chemotherapeutic or radiotherapeutic agents.

 

On January 21, 2019, the Company filed a patent application titled “Prevention and Reversion of Chronic Traumatic Encephalopathy through Administration of “Educated” Monocytes and Progenitors Thereof” that provides means of preventing and/or reversing chronic traumatic encephalopathy in a patient through the modulation of monocytes as well as monocytic progenitors. In one embodiment the invention teaches administration of monocytes that have been previously “educated” by exposure to mesenchymal stem cells in order to endow onto said monocytes properties associated with stimulation of neuroregenerative properties. In some embodiments monocytes are educated by treatment of monocytic progenitors with conditions capable of endowing anti-inflammatory and regenerative conditions, said conditions include culture with epigenetic modifying agents. In other embodiments, the invention teaches the manipulation of cord blood derived monocytes as a starting population of cells for education by culture with mesenchymal stem cells.

 

On January 21, 2019, the Company filed a patent application titled “Autologous Neurogenic Cells and Uses Thereof for Professional Athletes at Risk of Chronic Traumatic Encephalopathy” which disclosed are means, compositions of matter and methods of business for treating Chronic Traumatic Encephalopathy (CTE) using autologous primary cells and modified cells of autologous origin which have been banked. In one embodiment of the invention autologous dedifferentiation cells are generated and stored for future administration in patients which have suffered CTE. In other embodiments, dedifferentiated cells are differentiated into neurons or neuronal progenitor cells and subsequently administered locally or systemically or in a combination. In other embodiments autologous cells are maintained in an undifferentiated manner and/or neurologically differentiated state and utilized as a conditioning source in an extracorporeal circulatory system replicating clinical stage extracorporeal liver perfusion (ECLP) with substitution of autologous dedifferentiated, neurologically differentiated or a combination of said cells instead of hepatic cells.

 

12
 

 

On December 18, 2018, the Company filed a patent application titled “Treatment of Chronic Traumatic Encephalopathy via RNA Administration” which disclosed are protocols, treatment means, and compositions of matter useful for treatment of Chronic Traumatic Encephalopathy through administration of RNA or modified RNA molecules. In one embodiment said RNA is generated to activate various toll like receptors (TLR), of which said activation leads to production of cytokines which paradoxically lead to protection from Chronic Traumatic Encephalopathy, wherein said protection constitutes a) reduction in glial cell activation, b) neuronal apoptosis due to excitotoxicity; and c) stimulation of endogenous regenerative processes including endothelial progenitor cell mobilization, proliferation of neuronal progenitor cells in the dentate gyrus and subventricular zones. In one particular embodiment targeting of RNA molecules is performed to specific brain cells including pyramidal neurons through the use of liposomes, exosomes, apoptotic bodies, nanoparticles and shark or cameloid antibodies is disclosed.

 

On September 25, 2018, the Company filed a patent application titled “Pterostilbene and Formulations Thereof for Treatment of Pathological Immune Activation” that teaches treatments, protocols, and compositions of matter are described for reduction of pathological immune system activation. In one embodiment, pterostilbene and/or formulations thereof are administered in a patient suffering from cytokine release syndrome at a concentration and frequency sufficient to reduce abnormal cytokine production and thus treat the cause of said cytokine release syndrome. Formulations of pterostilbene are disclosed for rapid release, enhanced biodistribution, and targeting to cytokine releasing effectors are disclosed for use in the practice of the invention.

 

On September 17, 2018, the Company filed a patent application titled “Pterostilbene and Compositions Thereof for Prevention and Treatment of Chronic Traumatic Encephalopathy” that teaches means, methods, and compositions of matter useful for prevention of chronic traumatic encephalopathy. In one embodiment of the invention, disclosed is utilization of pterostilbene and/or pterostilbene based compounds for prevention and/or treatment of chronic traumatic encephalopathy. In one embodiment, the invention teaches administration of pterostilbene and/or pterostilbene based compounds for reduction of taupathy associated with chronic traumatic encephalopathy.

 

On August 13, 2018, the Company filed a patent application titled “Enhancement of Ozone Therapy using Pterostilbene” that disclosed methods, means and compositions of matter using pterostilbene for enhancing therapeutic efficacy of ozone therapy in the field of oncology. The invention provides previously unknown synergies between ozone administration together with pterostilbene at inducing direct and indirect cytotoxicity to cancer cells. The invention provides means of delivery, administration, and therapeutic protocols for treatment of cancer patients. In one embodiment combination of ozone therapy together with pterostilbene is utilized to overcome drug resistance.

 

On October 08, 2017, the Company filed a patent application titled “Synergistic Inhibition of Glioma Using Pterostilbene and Analogues Thereof” that teaches methods, means and compositions of matter for utilizing pterostilbene and analogues thereof for suppression of viability, metastasis and proliferation of glioma cells alone, or together with immunotherapy, chemotherapy, or radiotherapy means. In one embodiment said pterostilbene augments immunogenicity of glioblastoma cells so as to enhance killing by immune cells or complement subsequent to damage of said glioblastoma cells by chemotherapy, radiotherapy, or immunotherapy.

 

On April 26, 2017, the Company filed a patent application titled “Augmentation of Stem Cell Activity using Pterostilbene and Compositions Containing Pterostilbene” that disclosed means of augmenting circulating endogenous stem cells through administration of an effective amount of pterostilbene or derivatives thereof. In one embodiment a patient with reduced levels of circulating endothelial progenitor cells is treated with pterostilbene at a concentration and frequency sufficient to restore, and/or enhance levels of circulating endothelial progenitor cells (EPC). In another embodiment endogenous levels of stem cells are restored or enhanced by administration of pterostilbene, said endogenous stem cells comprising cells of the dentate gyrus, subventricular zone, hepatic stem cells, cardiac stem cells, and hematopoietic stem cells.

 

On March 29, 2017, the Company filed a patent application titled “Stimulation of Immunity to Tumor Stem Cell Specific Proteins by Peptide Immunization” that discloses treatment of cancer is disclosed through administration of proteins or specific peptides found on tumor stem cells in vivo, in a matter eliciting monocyte or dendritic cell migration in order to allow uptake of said administrated proteins or peptides, followed by administration of a maturation signal in vivo. The invention provides for treatment of cancer through induction of anticancer immunity and/or immunity towards tumor initiating stem cells.

 

On March 29, 2017, the Company filed a patent application titled “Targeting the Tumor Microenvironment through Nutraceutical Based Immunoadjuvants” that disclosed compositions useful for the treatment of cancer which modulate tumor associated immunosuppression, thus acting as immunoadjuvants. In one embodiment a composition containing apigenin, is provided, said composition useful for inhibition of tumor associated immune suppression mediated through the molecule indolamine 2,3 deoxygenase (IDO). In another embodiment, liposomal apigenin is administered as a means of decreasing IDO expression.

 

13
 

 

On March 29, 2017, the Company filed a patent application titled “Activated Leukocyte Extract for Repair of Innate Immunity in Cancer Patients” that disclosed are compositions, methods of use, and pharmaceutical preparations useful for modulation of immune responses. In one embodiment a composition is extracted polyvalently activated peripheral blood mononuclear cells through dialysis. Said immune modulator is useful for treatment of cancer and alleviation of cancer associated immune depression. In one embodiment, said immunomodulator acts as a costimulatory of T cell activation by modulation of cytokine production. In one embodiment said immune modulator is concentrated for miRNA species capable of activating innate immune cells.

 

On March 29, 2017, the Company filed a patent application titled “Augmentation of Anti-Tumor Immunity by Mifepristone and Analogues Thereof” which relates to compositions of matter and methods useful for improving a treatment outcome and/or an alteration of immunity in a condition that benefits from immune stimulation. In particular, one embodiment of the invention teaches administration of sufficient doses of mifepristone or a derivative, alone, or in combination with an immunotherapeutic such as, but not limited to, an antibody, a vaccine, a cytokine, or a medicament whose therapeutic activity is associated with immune modulation.

 

On March 29, 2017, the Company filed a patent application titled “Methods of Re-Activating Dormant Memory Cells with Anticancer Activity” that disclosed methods, protocols, and compositions of matter useful for stimulation of anticancer immune responses. In one embodiment of the invention culture of buffy coat cells is performed in an environment resembling non-physiological conditions. Buffy coat derived products are subsequently harvested, concentrated, and added to a culture of monocytes and lymphocytes. Conditioned media from said second culture is subsequently utilized as an injectable solution for stimulation of anticancer immunity.

 

On March 29, 2017, the Company filed a patent application titled “Modulation of Oral Microbiome for Treatment of Periodontitis” that disclosed methods, means, and compositions of matter useful for inhibition of, reduction in progression and reversion of periodontitis. In one embodiment the invention provides prebiotic and/or probiotic compositions which modulation the oral microbiome in order to ameliorate, prevent or reverse periodontitis. In one embodiment a composition is administered into the oral cavity containing Actinomyces naeslundii, Actinomyces odontolyticus, Streptococcus thermophilius, Lactobaccilus brevis and Lactobacilius plantarum. Administration may be performed using various means including a mouthwash, a patch, a toothpaste, or in a preferred embodiment said prebiotic and/or probiotic compositions are delivered via a mouth tray.

 

On July 20, 2016, the Company filed a patent application titled “Prevention of Pregnancy Complications by Probiotic Administration” which disclosed methods, protocols and compositions of matter for the treatment of pregnancy complications through immune modulation of a mammal in need. In one embodiment the invention provides probiotic compositions for immune modulation to decrease risk of pregnancy complications. Pregnancy complications include recurrent spontaneous abortions (RSA), preterm birth, pre-eclampsia including hemolysis elevated liver enzymes low platelets (HELP), premature rupture of the membrane, Antepartum hemorrhage including placental abruption, chorioamnionitis, Intrauterine growth restriction, placenta pravaevia, sequalae of intraamniotic infection. Published on January 26, 2017.

 

On July 20, 2016, the Company filed a patent application titled “Exosome Mediated Innate and Adaptive Immune Stimulation for Treatment of Cancer” that teaches means of stimulating innate and/or adaptive immunity to cancer by administration of exosomes. Stimulation of innate immunity involves modifying exosomes by chemical addition of innate immune stimulators, whereas stimulation of adaptive immunity involves pulsing dendritic cells generating exosomes with antigens, in some cases, pulsing with Brother of the Regulator of Imprinted Sites (BORIS) proteins, peptides, or altered peptide ligands thereof.

 

On July 8, 2015, the Company filed a patent application titled “Augmentation of Oncology Immunotherapies by Pterostilbene Containing Compositions” that disclosed compositions of matter and methods useful to augmentation of immune responses to tumors. In one embodiment, a pterostilbene containing composition is administered to a cancer patient at a sufficient concentration and frequency to induce de-repression of tumor targeting immune responses. In one specific embodiment of the present invention, pterostilbene enhances antibody dependent cellular toxicity (ADCC) and in turn augments efficacy of FDA approved antigen specific immunotherapeutics such as trastuzumab (Herceptin) and other monoclonal antibody therapies used for treating cancer.

 

Issued and Granted Patents:

 

On June 20, 2017, the US Patent and Trademark Office issued and granted U.S. Patent No.: 9,682,047 titled “Augmentation of oncology immunotherapies by pterostilbene containing compositions” that discloses compositions and methods useful to enhancing, improving, or eliciting anti-tumor immune responses are disclosed. A pterostilbene containing composition is administered to a cancer patient at a sufficient concentration and frequency to induce de-repression of tumor targeting immune responses. The composition enhances antibody dependent cellular toxicity (ADCC) and augments efficacy of antigen specific immunotherapeutics such as trastuzumab and other monoclonal antibody therapies useful for treating cancer.

See: https://patents.justia.com/patent/9682047.

 

14
 

 

On January 25, 2022, the US Patent and Trademark Office issued and granted U.S. Patent No.: 11,229,674 titled “Nutraceuticals for suppressing indolamine 2,3 deoxygenase” which disclosed are compositions of matter, treatments and protocols useful for reduction of expression and/or activity of indolamine 2,3 deoxygenase (IDO). In some embodiments the invention teaches the administration of a therapeutic combination of ingredients comprising of pterostilbene, Nigella sativa, sulforaphane, and epigallocatechin-3-gallate (EGCG) to a mammal at possessing an increased expression and/or activity of said IDO in which reduction of number and/or activity is desired. In another embodiment, the invention teaches administration of said therapeutic combination to a mammal infected with viral and/or bacterial infections and/or neoplasia. In some embodiments dosage of said therapeutic combination is based on inflammatory and/or immunological parameters observed in patients.

 

On March 08, 2022, the US Patent and Trademark Office issued and granted U.S. Patent No.: 11,266,707 titled “Nutraceuticals for the prevention, inhibition, and treatment of SARS-CoV-2 and associated COVID-19” that disclosed methods of treating or preventing complications associated with a SARS-CoV-2 infection, comprising: administration of a combination comprising: a) Green Tea and/or extract thereof; b) Blueberry and/or extract thereof; c) Nigella sativa and/or extract thereof; and d) broccoli and/or extract thereof in an amount and frequency sufficient to treat or prevent complications associated with said SARS-CoV-2 infection.

 

On November 23, 2022, the US Patent and Trademark Office issued and granted U.S. Patent No.: 11,504,410 titled “Neuroprotection and Neuroregeneration by Pterostilbene and Compositions Thereof” with new data demonstrating that the blueberry derived compound pterostilbene possesses numerous brain protective and potentially brain regenerative activities. The data disclosed by the Company indicates: a) pterostilbene suppresses inflammatory cytokines TNF-alpha, IL-1 beta and IL-6; b) pterostilbene inhibits death of neurons caused by inflammatory mediators; c) pterostilbene stimulates production of regenerative factors from cells in the brain such as BDNF, NGF, FGF-1, and FGF-2; and d) pterostilbene allows/enhances proliferation of endogenous brain stem cells.

 

*The data provided here is partial and does not contain all materials submitted for publication and is preliminary until peer review is complete. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

 

Chronic Traumatic Encephalopathy (CTE), and Traumatic Brain Injury (TBI) – Right To Try

 

On December 10, 2018, Therapeutic Solutions International, Inc., announced the signing of an agreement between TSOI and Jadi Cell LLC for licensing of the Jadi Cell universal donor adult stem cell, as covered in US Patent No.: 9,803,176 B2 for use in Chronic Traumatic Encephalopathy (CTE), and Traumatic Brain Injury (TBI).

 

In addition, on February 9, 2021, we obtained exclusive rights under the same for use of US Patent No.: 9,803,176 B2 in the treatment of acute respiratory distress syndrome (ARDS) and other lung pathologies. The JadiCell was reported in a publication from the University of Miami following a Phase 1/2 clinical trial, demonstrating intravenous administration of JadiCells, resulted in a significant survival improvement in COVID-19 patients. The Phase 1/2 double blind, placebo-controlled trial treated 12 advanced COVID-19 patients with 100 million JadiCells™ intravenously at days 0 and 3, and 12 patients received placebo control. At 28 days 91% of JadiCell treated patients survived whereas only 42% of patients in the placebo group survived. There were no adverse effects associated with JadiCell administration. For those treated with the JadiCell under the age of 85 the survival rate was 100% and in those over 85 the survival rate was 91% making the JadiCell the most effective therapy to date in the entire world to treat ARDS.

 

The JadiCell product, which belongs to the mesenchymal stem cell (MSC) family of cells, is a unique adult stem cell, which produces higher levels of therapeutic factors compared to other stem cells. The cells have demonstrated safety in animal models and pilot human trials. The Jadi Cell product is generated from umbilical cords, which are a source of medical waste and available in large quantities at inexpensive prices.

 

Chronic Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe.

 

Traumatic brain injury (TBI) is an insult to the brain, not of a degenerative or congenital nature, but caused by external physical force that may produce a diminished or altered state of consciousness, which results in an impairment of cognitive abilities or physical functioning.

 

CTE represents a significant unmet medical need which we believe is amenable to stem cell intervention. We are eager to accelerate treatments and potential cures for debilitating conditions such as CTE and traumatic brain injury and plan to leverage New regulatory pathways such as the recently approved “Right to Try” Law to deliver these medicines as soon as possible to patients which currently have no other options.

 

The JadiCell product because of its advanced stage of development in contrast to other stem cell types, which require years, if not decades of development before entry into American patients, will allow us we believe to be treating patients within 12 months. Currently means of isolating, producing, scaling up, and delivery of the cells has all been worked out by Jadi Cell and Collaborators.

 

15
 

 

On December 17, 2020, the Company filed an Investigational New Drug (IND) application seeking permission from the Food and Drug Administration (FDA) to initiate a Phase I/II clinical trial assessing safety and signals of efficacy for treatment of Chronic Traumatic Encephalopathy (CTE) patients with JadiCells™.

 

On August 4th, 2021, the Company announced clearance from the Food and Drug Administration (FDA) to initiate a Phase III pivotal trial for registration of the Company’s JadiCell universal donor stem cell as a treatment for COVID-19 associated lung failure under IND # 19757. In previous studies the Company has demonstrated the superior activity of JadiCell to other types of stem cells including bone marrow, adipose, cord blood, and placenta. Furthermore, the JadiCell was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91%. The Company also recently announced the launching of Phase III for IND # 19757 with Biorasi LLC, a global, full-service CRO, who will run the clinical trial.

 

Schizophrenia/Suicide Clinical Programs

 

On October 29, 2020, the Company announced publication on the NIH clinical trials website of its newly initiated trial aiming to validate a blood-based diagnostic for predicting suicide risk and is listed as NCT04606875.

 

The Campbell Score™, which is a patent-pending method of quantifying inflammatory-associated biological markers, has previously been shown in pilot investigator-initiated studies to correlate with propensity for suicide. Based on positive feedback from collaborators, the Company decided to initiate a formal clinical trial to validate correlations between the Campbell Score™ and established psychiatric assessment tools of suicidal propensity. Currently the only means of quantifying predisposition to suicide is based on psychological, question-based techniques.

 

On December 31, 2020, the Company signed license agreements with Campbell Neurosciences Inc., a partially owned company, for access to the 11 patents filed related to the previous Campbell Neurosciences Division. The patents are:

 

● Application No.: 63/128759 Immunotherapy for Opioid Addiction

● Application No.: 63/122862 Treatment of Major Depressive Disorder and Suicidal Ideations Through Stimulation of Hippocampal Neurogenesis Utilizing Plant-Based Approaches

● Application No.: 63/105964 Protection/Regeneration of Neurological Function by Endothelial Protection/Rejuvenation using Stem Cells for Treatment of Conditions such as Chronic Traumatic Encephalopathy and Schizophrenia

● Application No.: 17/030416 Personalized Immunotherapies for Reduction of Brain Inflammation and Suicide Prevention

● Application No.: 63/077723 Immunotherapy of Schizophrenia and Schizophrenia Associated Suicidal Ideation/Suicide

● Application No.: 63/071381 Upregulation of Therapeutic T Regulatory Cells and Suppression of Suicidal Ideations in Response to Inflammation by Administration of Nutraceutical Compositions Alone or Combined with Minocycline

● Application No.: 63/068388 Methods of Determining Risk of Suicide and/or Suicidal Ideation by Immunological Assessment

● Application No.: 63/061202 Prevention of Neuroinflammation associated Memory Loss Using Nutraceutical Compositions

● Application No.: 63/057315 Neuroprotection and Neuroregeneration by Pterostilbene and Compositions Thereof

● Application Serial No. 63/174291 filed by Licensor and titled as: Amelioration and Treatment of Opioid Addiction.

● Patent Application Serial No. 63/189630 filed by Licensor and titled as: Treatment of Major Depressive Disorder by Low Dose Interleukin-2.

 

Additionally, Campbell Neurosciences Inc. has entered into purchase agreements with Therapeutic Solutions International ensuring a continued supply, at a discounted rate, of nutraceuticals which are being explored for antiinflammation/suicide prevention activity.

 

Treatment of Chronic Obstructive Pulmonary Disease (COPD) Using JadiCell™ Universal Donor Adult Stem Cells

 

On October 7, 2022, the Company formed Breathe Biologics, Inc. and licensed to them a patent application titled “Umbilical Cord Mesenchymal Stem Cells for Treatment of Chronic Obstructive Pulmonary Disease and Lung Degeneration” that discloses means of treating lung degenerative diseases including chronic obstructive pulmonary disease (CODP) using umbilical cord mesenchymal stem cells such as JadiCells.

 

In addition, the Company has transferred ownership of the filed investigational drug application titled “JadiCell Therapy for COPD” to determine safety and efficacy of intravenously administered allogeneic JadiCell umbilical cord blood mesenchymal stem cells in patients with moderate-to-severe COPD. The Primary Endpoint, which is toxicity, will be assessed by number of adverse events (AEs). The Secondary Endpoint, which is efficacy will be evaluated at baseline and days 30, 60, and 90.

 

COPD is a consistently progressive, ultimately fatal disease for which no treatment exists capable of either reversing or even interrupting its course. It afflicts more than 5% of the population in many countries, and it accordingly represents the third most frequent cause of death in the U.S., where it accounts for more than 600 billion in health care costs, morbidity, and mortality.

 

16
 

 

COPD possesses several features making it ideal for stem cell-based interventions: a) the quality of life and lack of progress demands the ethical exploration of novel approaches. For example, bone marrow stem cells have been used in over a thousand cardiac patients with some indication of efficacy. Adipose-based stem cell therapies have been successfully used in thousands of race-horses and companion animals without adverse effects, as well as numerous clinical trials are ongoing and published human data reports no adverse effects.

 

Mesenchymal Stem Cells (MSCs) are potent immunomodulatory cells that recognize sites of injury, limit effector T cell reactions, and stimulate regulatory cell populations (i.e., T-regs) via growth factors, cytokines, and other mediators. Simultaneously, MSCs also stimulate local tissue regeneration via paracrine effects inducing angiogenic, anti-fibrotic and remodeling responses. Consequently, MSCs-based therapy represents a viable treatment option for autoimmune conditions and other inflammatory disorders, yielding beneficial effects in models of autoimmune Type 1 Diabetes, Systemic Lupus Erythematosus, Autoimmune Encephalomyelitis, Multiple Sclerosis, cardiac insufficiency, and organ transplantation. MSCs have been reported to inhibit inflammation and fibrosis in the lungs, have shown safety in clinical trials for ARDS, and have been recently suggested as useful to treat patients with severe COVID-19 based on their effects preventing or attenuating the immunopathogenic cytokine storm.

 

Unfortunately, evaluation of stem cell therapy in COPD has lagged behind other areas of regenerative investigation; b) the underlying cause of COPD appears to be inflammatory and/or immunologically mediated. The destruction of alveolar tissue is associated with T cell reactivity, pathological pulmonary macrophage activation, and auto-antibody production. Mesenchymal stem cells have been demonstrated to potently suppress autoreactive T cells, inhibit macrophage activation, and autoantibody responses. Additionally, mesenchymal stem cells can be purified in high concentrations from adipose stromal vascular tissue together with high concentrations of T regulatory cells, which in animal models are approximately 100 times more potent than peripheral T cells at secreting cytokines therapeutic for COPD such as IL-10. Additionally, use of adipose derived cells has yielded promising clinical results in autoimmune conditions such as multiple sclerosis; and c) Pulmonary stem cells capable of regenerating damaged parenchymal tissue have been reported. Administration of mesenchymal stem cells into neonatal oxygen-damaged lungs, which results in COPD-like alveoli dysplasia, has been demonstrated to yield improvements in two recent publications.

 

Based on the above rationale for stem cell-based COPD treatments, we are proposing a 10 patient Phase I safety trial to assess ability of JadiCell, a type of umbilical cord derived stem cells to improve objective and quality of life parameters in patients with moderate to severe COPD.

 

MSCs can be derived in large number from the Umbilical Cord (UC). JadiCells are a type of UC-MSCs, which can be utilized in the allogeneic setting and have demonstrated safety and efficacy in clinical trials for a number of disease conditions including inflammatory and immune-based diseases. UC-MSCs have been shown to inhibit inflammation and fibrosis in the lungs.

 

JadiCell UC-MSCs have been utilized to treat patients with severe COVID-19 and have yielded promising results, preventing, or attenuating the cytokine storm. JadiCells have been recently introduced intravenously in patients with a neurodegenerative disorder and have been approved for testing in patients with Type 1 Diabetes (T1D). We hypothesize that JadiCells will exert beneficial therapeutic effects in COPD.

 

Breast Cancer Immunotherapy

 

Recently the Company announced the formation of a Spin-Off Company, Res Nova Bio, Inc., dedicated to the development of cancer inhibiting anti-angiogenesis immunotherapies. Res Nova Bio has licensed from Therapeutic Solutions International intellectual property covering StemVacs-V which is our iPSC derived platform technology announced in May of 2021. The technology utilizes pluripotent stem cells called iPSCs in order to generate new cells which resemble tumor blood vessels that are made to act as a “therapeutic vaccine”. Specifically, the administration of StemVacs-V stimulates the immune system to selectively kill blood vessels that feed the tumor but not healthy blood vessels. It is believed that for every 1 tumor blood vessel cell that is killed, 200-300 tumor cells are also killed as a result.

 

In addition to the license, the Company has transferred ownership of the IND titled “Treatment of Metastatic Breast Cancer by StemVacs-V Cancer Immunotherapeutic” to Res Nova Bio with the primary objective being safety and feasibility of StemVacs-V administration at 12 months as assessed by lack of adverse medical events. The secondary objective is efficacy as judged by tumor response, time to progression, and immunological monitoring.

 

Cellular Manufacturing and Cell Banking

 

On October 18, 2021, the Company announced the formation of Allogen Biologics Inc, a wholly owned subsidiary of TSOI. Allogen Biologics will house intellectual property and Standard Operating Procedures related to generation of the Company’s existing and anticipated cellular therapeutics. In addition, Allogen will house and maintain all relevant cell banks.

 

On May 10, 2022, Allogen Biologic, Inc, and Therapeutic Solutions International Inc, entered into an Exclusive Patent License Agreement (EPLA) for Patent Application Serial No. 63/254,469, filed by Licensor and titled as: Umbilical Cord Derived Regenerative and Immune Modulatory Stem Cell Populations.

 

17
 

 

GOVERNMENT REGULATION

 

The Company’s business is subject to varying degrees of regulation by a number of government authorities in the United States, including the United States Food and Drug Administration (FDA), the Federal Trade Commission (FTC), and the Consumer Product Safety Commission. The Company will be subject to additional agencies and regulations if it enters the manufacturing business. Various agencies of the state and localities in which we operate and in which our products are sold also regulate our business, such as the California Department of Health Services, Food and Drug Branch. The areas of our business that these and other authorities regulate include, among others:

 

●product claims and advertising;
●product labels;
●product ingredients; and
●how we package, distribute, import, export, sell and store our products.

 

The FDA, in particular, regulates the formulation, manufacturing, packaging, storage, labeling, promotion, distribution and sale of vitamins and other nutritional supplements in the United States, while the FTC regulates marketing and advertising claims. The FDA issued a final rule called “Statements Made for Dietary Supplements Concerning the Effect of the Product on the Structure or Function of the Body,” which includes regulations requiring companies, their suppliers and manufacturers to meet Good Manufacturing Practices in the preparation, packaging, storage and shipment of their products. Management is committed to meeting or exceeding the standards set by the FDA.

 

The FDA has also issued regulations governing the labeling and marketing of dietary and nutritional supplement products. They include:

 

●the identification of dietary or nutritional supplements and their nutrition and ingredient labeling;
●requirements related to the wording used for claims about nutrients, health claims, and statements of nutritional support;
●labeling requirements for dietary or nutritional supplements for which “high potency” and “antioxidant” claims are made;
●notification procedures for statements on dietary and nutritional supplements; and
●pre-market notification procedures for new dietary ingredients in nutritional supplements.

 

The Dietary Supplement Health and Education Act of 1994 (DSHEA) revised the existing provisions of the Federal Food, Drug and Cosmetic Act concerning the composition and labeling of dietary supplements and defined dietary supplements to include vitamins, minerals, herbs, amino acids and other dietary substances used to supplement diets. DSHEA generally provides a regulatory framework to help ensure safe, quality dietary supplements and the dissemination of accurate information about such products. The FDA is generally prohibited from regulating active ingredients in dietary supplements as drugs unless product claims, such as claims that a product may heal, mitigate, cure or prevent an illness, disease or malady, trigger drug status.

 

The Company is also subject to a variety of other regulations in the United States, including those relating to taxes, labor and employment, import and export, and intellectual property.

 

EMPLOYEES

 

As of December 31, 2022, we had three full-time employees, all non-union. We believe that our relations with our employees are good.

 

COMPETITION

 

The bio-technology, bio-pharma, and nutraceutical industries are subject to rapid technological change. Competition from domestic and foreign companies, large pharmaceutical companies and other interested businesses is intense and expected to increase. A number of companies with significantly greater resources are pursuing the development of pharmaceuticals, biologics, and nutraceuticals in our targeted areas.

 

18
 

 

ITEM 1ARISK FACTORS

 

As a smaller reporting company we are not required to provide a statement of risk factors. However, we believe this information may be valuable to our shareholders for this filing. We reserve the right to not provide risk factors in our future filings. Our primary risk factors and other considerations include:

 

This Annual Report on Form 10-K contains forward-looking statements concerning our future programs, expenses, revenue, liquidity and cash needs as well as our plans and strategies. These forward-looking statements are based on current expectations and we assume no obligation to update this information, except as required by applicable laws and regulations. Numerous factors could cause actual results to differ significantly from the results described in these forward-looking statements, including the following risk factors.

 

Internal Control

 

Our management has concluded that our internal control over financial reporting is not effective. Material weaknesses in our internal control over financial reporting could cause our financial reporting to be unreliable and could lead to misinformation being disseminated to the public.

 

Our management concluded that as of December 31, 2022, our internal control over financial reporting was not effective, and that material weaknesses existed in the following areas as of December 31, 2022:

 

(1)we do not employ full time in-house personnel with the technical knowledge to identify and address some of the reporting issues surrounding certain complex or non-routine transactions. With respect to material, complex and non-routine transactions, management has and will continue to seek guidance from third-party experts and/or consultants to gain a thorough understanding of these transactions;

 

(2)we have inadequate segregation of duties consistent with the control objectives including but not limited to the disbursement process, transaction or account changes, and the performance of account reconciliations and approval; and

 

(3)we have ineffective controls over the period end financial disclosure and reporting process caused by reliance on third-party experts and/or consultants and insufficient accounting staff.

 

Based on our current plan, we believe we will need additional capital to support our operations.

 

Based on our current business plan, we believe that our cash and cash equivalents at December 31, 2022 will not be sufficient to meet our anticipated cash requirements during the twelve-month period subsequent to the issuance of the financial statements included in this Annual Report on Form 10-K. Our current commercialization of products and clinical trial strategy will undergo continual prioritization and in the future we may adjust our commercialization efforts to preserve our existing cash. We need to raise additional capital to fund our operations. We may raise additional capital through equity offerings, debt financings, collaborations and/or licensing arrangements. Additional funds may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available, we may be required to delay, reduce the scope of, or curtail, our operations. To the extent that we raise additional funds by issuing equity securities, our shareholders will experience dilution, and debt financing or other preferred equity instruments, if available, may involve restrictive covenants.

 

There is substantial doubt about our ability to continue as a going concern.

 

Our recurring losses from operations raise substantial doubt about our ability to continue as a going concern, and as a result, our independent registered public accounting firm included an explanatory paragraph in its report on our financial statements as of and for the year ended December 31, 2022 with respect to this uncertainty. This going concern uncertainty, and any future going concern uncertainty, could materially limit our ability to raise additional capital. We have incurred significant losses since our inception, and it is possible we will never achieve future profitability. As a result, we continue to incur significant general and administrative expenses related to our operations. As a result, we have incurred substantial net losses to date. Our net losses for the years ended December 31, 2022 and 2021 were $3.3 million and $3 million, respectively. As of December 31, 2022, we had an accumulated deficit of $17.2 million. The perception that we may not be able to continue as a going concern may cause potential partners or investors to choose not to deal with us due to concerns about our ability to meet our contractual and financial obligations.

 

We may not be able to effectively manage our potential growth and the execution of our business plan.

 

Our potential growth and the execution of our business plan together are likely to place significant strain on our managerial, operational and financial resources. To effectively manage our potential growth and execute our business plan, we will need to, among other things:

 

There can be no assurance that we will be able to accomplish any or all of the above goals. If we prove unable to effectively execute our business plan or manage our growth, it is likely to have a material adverse effect on our business, financial condition, including liquidity and profitability, and our results of operations.

 

19
 

 

If our proposed product sales model does not successfully operate at a profit our growth strategy may be impeded.

 

To effectively expand and meet our growth objectives our products sales model must be executed upon in a profitable manner. Profitability is dependent upon a variety of factors, some beyond our control, including, but not limited to the amount of traffic we can consistently attract to our brand, to retail sales in “brick and mortar” retailers, to our website, and our ability to stock or otherwise make available products that our customers purchase, our ability to stock or otherwise make available the best new products as they enter the market, our ability to provide consistent and superior customer service, the general economic conditions, particularly in the U.S., that could impact the amount of money customers spend collectively on the products we sell, and/or that could reduce the amount of money our average customer spends, and/or could reduce the number or frequency of repeat orders for products, and/or could result in customers finding products in other venues if they can find those products for a lower price. Other factors that could impact our ability to execute on our business model in a profitable manner include, but are not limited to, competition in our markets, recruiting, training and retaining qualified personnel and management, maintenance of required local, state and federal governmental approvals and permits, costs associated with principal component products and supplies, delivery shortages or interruptions, consumer trends, our ability to finance operations externally, changes in supply or prices of the products we sell and disruptions or business failures among our product suppliers, distributors, warehouses or shippers. Any failure to operate in a profitable manner could hurt our ability to meet our growth objectives by attracting licensees, and our business, financial condition, including liquidity and profitability, and our results of operations would be negatively affected.

 

We face significant competition for our products.

 

The markets in which we operate are intensely competitive, continually evolving and, in some cases, subject to rapid change. Our competitors include:

 

●traditional and well established companies with recognized and well patronized brands in the nutritional supplements and health products industry segment;
●entrenched nutritional supplements and health products companies with well known customer on-line services and portals and other high-traffic web sites that provide sales access to healthcare and nutritional supplements and related products; and
●companies that focus on providing on-line and/or off-line healthcare related content, including some that promote competitor brands.
●retain additional personnel across several departments in the Company;
●develop strong customer loyalty for new products in a crowded competitive marketplace;
●continue to establish and continue to increase awareness of our brands;
●price our products and services at points which will allow us to maximize sales while at the same time maximizing gross profit margins;
●establish, maintain, expand and manage multiple relationships with various vendors, strategic partners, licensees and other third parties, including suppliers of the products we sell on our website and elsewhere, warehousing distributors, shipping companies and others;
●rapidly respond to competitive developments, particularly when new high-demand products become available;
●build an operations structure to support our business and provide efficient and effective customer service and support;
●expand our IT infrastructure to respond to increasing customer traffic to our website, demand for content from site users and to manage growing e-commerce transactions;
●establish and maintain effective financial and management controls, reporting systems and procedures;
●control our expenses;
●provide competitive employee salaries and benefit packages; and,
●avoid lawsuits and other adverse claims.

 


Many of our competitors have greater financial, technical, product development, marketing and other resources than we do. These companies may be better known than we are and have more customers than we do. We cannot provide assurance that we will be able to compete successfully against these companies or any alliances they have formed or may form. If we are unable to compete with one or more of our competitors, our growth strategy may be impeded, which could negatively affect our business, financial condition, including liquidity and profitability, and our results of operations.

 

Government regulation could adversely affect our business.

 

Our products and their associated component ingredients are subject to existing and potential government regulation. Our failure, or the failure of our business partners or third party providers, to accurately anticipate the application of laws and regulations affecting our products and the manner in which we deliver them, or any failure to comply, could create liability for us, result in adverse publicity, or negatively affect our business. In addition, new laws and regulations, or new interpretations of existing laws and regulations, may be adopted with respect to consumer protection and other issues, including pricing, products liability, copyrights and patents, distribution and characteristics and quality of products and services. We cannot predict whether these laws or regulations will change or how such changes will affect our business. Any of this government regulation could impact our growth strategy, which could negatively affect our business, financial condition, including liquidity and profitability, and our results of operations.

 

20
 

 

Third parties may claim that we are infringing their intellectual property, and we could suffer significant litigation or licensing expense or be prevented from providing certain services, and which may otherwise harm our business.

 

We could be subject to claims that we are misappropriating or infringing intellectual property, trade secrets or other proprietary rights of others. These claims, even if not meritorious, could be expensive to defend and divert management’s attention from our operations. If we become liable to third parties for infringing these rights, we could be required to pay substantial damage awards and to develop non-infringing products, obtain a license or cease selling the products that use or contain the infringing intellectual property. We may be unable to develop non-infringing products or obtain a license on commercially reasonable terms, or at all. Any claims against our company for infringement could impede our growth strategy, which could negatively affect our business, financial condition, including liquidity and profitability, and our results of operations.

 

We may be subject to claims brought against us as a result of product associated content we provide.

 

Consumers are reasonably expected to access health-related information regarding our products through our on-line web site. If our content, or content we obtain from third parties, contains inaccuracies, it is possible that consumers or others may sue us for various causes of action. Although our planned web site contains terms and conditions, including disclaimers of liability, that are intended to reduce or eliminate our liability, the law governing the validity and enforceability of on-line agreements with consumers that provide the terms and conditions for use of our public or private portals are unenforceable. A finding by a court that these agreements are invalid and that we are subject to liability could harm our business and require costly changes to our business. We have planned editorial procedures in place to provide quality control of the information that we publish or provide. However, we cannot assure you that our editorial and other quality control procedures will be sufficient to ensure that there are no errors or omissions in particular content. Even if potential claims do not result in liability to us, the fact that we would need to investigate and defend against these claims could be expensive and time consuming and could divert management’s attention away from our operations. In addition, our business is in part based on establishing a reputation amongst consumers that our portals as trustworthy and dependable sources of healthcare information. Allegations of impropriety or inaccuracy, even if unfounded, could therefore harm our reputation and business, which could negatively affect our business, financial condition, including liquidity and profitability, and our results of operations.

 

Changes in commodity and other operating costs or supply chain and business disruptions could adversely affect our results of operations.

 

Changes in product costs are a part of our business; any increase in the prices that suppliers charge for their products could adversely affect our operating results. We remain susceptible to increases in prices as a result of factors beyond our control, such as general economic conditions, seasonal fluctuations, weather conditions, demand, safety concerns, product recalls, labor disputes and government regulations. We rely on third-party distribution companies to deliver ingredients to our manufacturers and ultimately our products to customers. Interruption of distribution services due to financial distress or other issues could adversely affect our operations.

 

We face substantial competition in attracting and retaining qualified senior management and key personnel and may be unable to develop and grow our business if we cannot attract and retain such senior management and key personnel.

 

As an early stage company, our ability to develop and grow our business, to a large extent, depends upon our ability to attract, hire and retain highly qualified and knowledgeable senior management and key personnel who possess the skills and experience necessary to satisfy our business needs. Our ability to attract and retain such senior management and key personnel will depend on numerous factors, including our ability to offer salaries, benefits and professional growth opportunities that are comparable with and competitive to those offered by more established companies operating in our marketplace. We may be required to invest significant time and resources in attracting and retaining additional senior management and key personnel as needed. Moreover, many of the companies with which we will compete for any such individuals have greater financial and other resources, affording them the ability to undertake more extensive and aggressive hiring campaigns, than we can. The normal running of our operations may be interrupted, and our financial condition and results of operations negatively affected, as a result of any inability on our part to attract or retain the services of qualified and experienced senior management and key personnel, or should our prospective key personnel refuse to serve, or, once appointed, leave prior to a suitable replacement being found.

 

COVID-19

 

On January 30, 2020, the World Health Organization declared the COVID-19 outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the COVID-19 include restrictions on travel, quarantines in certain areas, and forced closures for certain types of public places and businesses. COVID-19, and actions taken to mitigate it, have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company operates. While it is unknown how long these conditions will last and what the complete financial effect will be to the Company, COVID-19 has had an adverse effect on our business, including our supply chains and distribution systems. While we are taking diligent steps to mitigate disruptions to our supply chain, we are unable to predict the extent or nature of these impacts, at this time, to our future financial condition and results of operations.

 

21
 

 

Risks Associated With Our Restricted Securities

 

Because there is currently a limited public trading market for our common stock, investor may not be able to resell stock.

 

Our stock is now traded in OTC Markets under the stock symbol TSOI, which results in a very illiquid and limited market for our common stock.

 

There is currently no liquid trading market for our common stock and we cannot ensure that one will ever develop or be sustained.

 

The trading market for our common stock is currently not liquid. We cannot predict how liquid the market for our common stock might become. Our common stock is quoted in OTC Markets under the symbol TSOI.

 

Our common stock may be deemed a “penny stock”, which would make it more difficult for investors to sell their shares.

 

Our common stock is subject to the “penny stock” rules adopted under the Exchange Act. The penny stock rules apply to companies whose common stock is not listed on the NASDAQ Stock Market or other national securities exchange and trades at less than $4.00 per share, other than companies that have had average revenue of at least $6,000,000 for the last three years or that have tangible net worth of at least $5,000,000 ($2,000,000 if the company has been operating for three or more years). These rules require, among other things, that brokers who trade penny stock to persons other than “established customers” complete certain documentation, make suitability inquiries of investors and provide investors with certain information concerning trading in the security, including a risk disclosure document and quote information under certain circumstances. Many brokers have decided not to trade penny stocks because of the requirements of the penny stock rules and, as a result, the number of broker-dealers willing to act as market makers in such securities is limited. If we remain subject to the penny stock rules for any significant period, it could have an adverse effect on the market, if any, for our securities and investors may find it more difficult to dispose of our securities.

 

Offers or availability for sale of a substantial number of shares of our common stock may cause the price of our common stock to decline.

 

If our stockholders have the right to sell substantial amounts of common stock in the public market, e.g. upon the expiration of any statutory holding period under Rule 144, it could create a circumstance commonly referred to as an “overhang” and in anticipation of which the market price of our common stock could fall. The existence of an overhang, whether or not sales have occurred or are occurring, also could make our ability to raise additional financing through the sale of equity or equity-related securities in the future, at a time and price that we deem reasonable or appropriate, more difficult.

 

The elimination of monetary liability against our directors and officers under the Company’s Articles of Incorporation and Nevada law, and the existence of indemnification rights to our directors, officers and employees, may result in substantial expenditures by the Company.

 

Article 6 of our Articles of Incorporation exculpates our directors and officers from certain monetary liabilities. Article 7 of our Articles of Incorporation provides that we shall indemnify all directors (and all persons serving at our request as a director or officer of another corporation) to the fullest extent permitted by Nevada law.

 

Further pursuant to Article 7, the expenses of the indemnified person incurred in defending a civil suit or proceeding must be paid by us as incurred and in advance of the final disposition of the action, suit, or proceeding under receipt of an undertaking by or on behalf of the indemnified person to repay the amount if it is ultimately determined by a court of competent jurisdiction that he or she is not entitled to be indemnified by us.

 

The foregoing indemnification obligations could result in us incurring substantial expenditures, which we may be unable to recoup. These provisions and resultant costs may also discourage us from bringing a lawsuit against directors and officers for breaches of their fiduciary duties even though such actions, if successful, might otherwise benefit us and our stockholders.

 

Public company compliance may make it more difficult to attract and retain officers and directors.

 

The Sarbanes-Oxley Act and related rules implemented by the SEC have required changes in corporate governance practices of public companies. As a public entity, these rules and regulations increase compliance costs and make certain activities more time consuming and costly. As a public entity, these rules and regulations also make it more difficult and expensive for us to obtain director and officer liability insurance and we may be required to accept reduced policy limits and coverage. As a result, it may be more difficult for us to attract and retain qualified persons to serve as directors or as executive officers.

 

22
 

 

We do not plan to pay any cash or stock dividends in the foreseeable future.

 

The payment of dividends upon our capital stock is solely within the discretion of our future board of directors and is dependent upon our financial condition, results of operations, capital requirements, restrictions contained in our future financing instruments and any other factors our board of directors may deem relevant. We have never declared or paid any cash or stock dividends on our capital stock and we currently anticipate that we will retain earnings, if any, to finance the development and expansion of our business and, as such, do not intend on paying any cash or stock dividends in the foreseeable future.

 

ITEM 1BUNRESOLVED STAFF COMMENTS

 

As a Smaller Reporting Company, we are not required to furnish information under this Item 1B.

 

ITEM 2PROPERTIES.

 

On December 17, 2020, Therapeutic Solutions International, Inc. Board of Directors made a decision to move our corporate headquarters to Elk City, Idaho 83525 and has purchased real property at 701 Wild Rose Lane and 50 Bullock Lane, Elk City Idaho 83525. The Company continues to maintain a satellite office at the current address of 4093 Oceanside Blvd., Suite B, Oceanside CA, 92056.

 

ITEM 3LEGAL PROCEEDINGS.

 

From time to time, claims are made against us in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from selling one or more products or engaging in other activities. The occurrence of an unfavorable outcome in any specific period could have a material adverse effect on our results of operations for that period or future periods.

 

However, as of the date of this report, management believes the outcome of currently identified potential claims and lawsuits will not have a material adverse effect on our financial condition or results of operations.

 

ITEM 4MINE SAFETY DISCLOSURES.

 

No disclosure required.

 

PART II

 

ITEM 5MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.

 

Our stock is now traded in OTC Markets under the stock symbol TSOI, which results in a very illiquid and limited market for our common stock. As of the date of Annual Report on Form 10-K there are approximately 208 stockholders of record of our common stock.

 

The following table sets forth the quarterly high and low closing sales prices for our common stock from January 1, 2021 through December 31, 2022.

 

Quarter Ended  High   Low 
December 31, 2022  $0.0063   $0.0055 
September 30, 2022  $0.014   $0.0121 
June 30, 2022  $0.022   $0.0199 
March 31, 2022  $0.0257   $0.0241 
December 31, 2021  $0.0319   $0.0273 
September 30, 2021  $0.052   $0.05 
June 30, 2021  $0.044   $0.04 
March 31, 2021  $0.0015   $0.0013 

 

Dividends

 

We did not declare or pay dividends during 2021 to 2022.

 

23
 

 

Issuances of Unregistered Securities

 

In 2021, we issued 4,850,075 shares of common stock for an investment in the Company’s Private Placement of $285,500.

 

In 2021, we issued 21,000,000 shares of common stock, valued at $858,900 for consulting services.

 

In 2021, we issued 8,341,723 shares of common stock, valued at $239,799 for salaries.

 

In 2021, we issued 1,500,000 shares of common stock, valued at $58,900 for land development.

 

In 2021, we issued 21,690,671 shares of common stock for the conversion of convertible notes of $1,019,014.

 

In 2022, we issued 44,500,000 shares of common stock for an investment in the Company’s Private Placement of $445,000.

 

In 2022, we issued 28,302,577 shares of common stock, valued at $537,778 for consulting services.

 

In 2022, we issued 4,812,259 shares of common stock, valued at $67,399 for salaries.

 

In 2022, we issued 4,110,000 shares of common stock, valued at $51,742 for land development.

 

In 2022, we issued 149,402,390 shares of common stock, valued at $3,107,570 for an license.

 

In 2022, we issued 64,139,744 shares of common stock for the conversion of convertible notes of $1,313,772.

 

ITEM 6SELECTED FINANCIAL DATA.

 

Not required for a “smaller reporting company”.

 

ITEM 7MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

The following discussion and analysis should be read in conjunction with the consolidated Financial Statements and Notes thereto appearing elsewhere in this Annual Report.

 

Overview

 

Currently the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system.

 

Activating one’s immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions.

 

TSOI is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, traumatic brain injury, and for daily health.

 

Nutraceutical Division. TSOI has been producing high quality nutraceuticals. Its current flagship product, QuadraMune®, is a multi-patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquinone. QuadraMune has been shown to increase Natural Killer Cell activity and healthy Cytokine production. Our synergistic blend of ingredients helps the immune system fight off common and complex ailments and promote healthy T Cell activity. Recently the Company was approved to sell certain nutraceuticals on the Amazon Platform.

 

Cellular Division. SOI recently obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic traumatic encephalopathy (CTE), traumatic brain injury (TBI), and lung pathology.

 

The stem cell licensed, termed “JadiCell” is unique in that it possesses features of mesenchymal stem cells, however, outperforms these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and neurogenic ability.

 

24
 

 

Chronic Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe. TSOI has previously filed several patents in the area of CTE based on modulating the brain microenvironment to enhance receptivity of regenerative cells such as stem cells. On March 4, 2021, the Company received an IND Serial # 27377 for a clinical trial of 10 patients with CTE.

 

On August 4th, 2021, the Company announced clearance from the Food and Drug Administration (FDA) to initiate a Phase III pivotal trial for registration of the Company’s JadiCell™ universal donor stem cell as a treatment for COVID-19 associated lung failure under IND # 19757. In previous studies the Company has demonstrated the superior activity of JadiCell™ to other types of stem cells including bone marrow, adipose, cord blood, and placenta. Furthermore, the JadiCell™ was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91%.

 

In addition, the Company has filed data with the FDA, as part of IND #17448, which demonstrated that treatment of cancer patients with StemVacs™ resulted in enhanced activity of a type of immunological cell called “natural killer” cells, otherwise known as “NK cells.”

 

The Company has also developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body’s NK cells.

 

Most recently the Company announced filing of a patent for a new hybrid cell created by the Company capable of training the immune system to kill blood vessels feeding cancer but sparing healthy blood vessels. These discoveries are an extension of previous findings from the Company showing that StemVacs is capable of suppressing new blood vessel production.

 

On May 9, 2022, the Company filed an Investigational New Drug Application for Treatment of Chronic Obstructive Pulmonary Disease (COPD) Using JadiCell™ Universal Donor Adult Stem Cells under IND Serial # 28508.

 

Results of Operations

 

We had a net loss of approximately $3.2 million in 2022 compared to a net loss of approximately $3 million in 2021.

 

Net sales increased $60,811 from $145,956 to $206,767, for the years ended December 31, 2021 and 2022, respectively. This increase was mainly due to an increase in sales of the Company’s nutraceutical line of products.

 

Cost of goods sold increased $36,896, from $42,544 to $79,440, for the years ended December 31, 2021 and 2022, respectively. This increase was mainly due to higher net sales of the Company’s new nutraceutical line of products in 2022 vs 2021.

 

Operating expenses for the years ended December 31, 2022 and 2021 were approximately $3.2million and $2.5 million, respectively, an increase of $700,000. This increase was mainly due a combination of increased general and administrative expenses, an increase in consulting fees, an increase in legal and accounting fees, and an increase in research and development.

 

General and administrative expenses increased approximately $355,000, from $139,000 to $494,000, for the years ended December 31, 2021 and 2022, respectively. This increase was mainly due to an icrease in amortization, marketing and travel during the year.

 

Salaries, wages and related expenses increased approximately $8,000, from $437,000 to $445,000, for the years ended December 31, 2021 and 2022, respectively. This increase was mainly due to an increase in salaries.

 

Consulting fees increased approximately $150,000 from $265,000 to $414,000 for the years ended December 31, 2021 and 2022, respectively, due to an increase in overall consulting services during 2022.

 

Legal and professional fees decreased approximately $388,000, from $773,000 to $385,000 for the years ended December 31, 2021 and 2022, respectively, due to a decrease in overall patent and general counsel services.

 

Research and development costs increased approximately $696,000 from $795,000 to $1,441,000, for the years ended December 31, 2021 and 2022, respectively. This increase was mainly due to research and development expenses related to the Company’s nutraceutical line of products.

 

Total loss from derivatives liabilities decreased approximately $405,000 from $539,000 to $134,000 for the years ended December 31, 2021 and 2022, respectively. This decrease was due to a derivative liability expense from certain convertible notes in 2022 compared to 2021.

 

Net interest expense increased approximately $34,000 from $612,000 to $646,000 for the years ended December 31, 2021 and 2022, respectively. This increase was mainly due to increased debt balances.

 

25
 

 

Liquidity and Capital Resources

 

We have experienced recurring losses over the past years which have resulted in accumulated deficits of approximately $17.3 million and a working capital deficit of approximately $1.9 million at December 31, 2022. These conditions raise significant doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is contingent upon its ability to secure additional financing, increase sales of its products and attain profitable operations. It is the intent of management to continue to raise additional capital. However, there can be no assurance that the Company will be able to secure such additional funds or obtain such on terms satisfactory to the Company, if at all.

 

There is no guarantee we will receive the required financing to complete our business strategies, and it is uncertain whether future financing will be available to us on acceptable terms. If financing is not available on satisfactory terms, we may be unable to continue, develop or expand our operations.

 

As of December 31, 2022 we had approximately $28,000 in cash and cash equivalents, representing a decrease in cash and cash equivalents of approximately $66,000 from December 31, 2021. Sources of cash were predominantly from the sale of equity and debt. We anticipate that our current sources of liquidity, including cash and cash equivalents, together with our current projections of cash flow from operating activities, will provide us with liquidity into the end of 2023.

 

Cash Flows from Operating Activities

 

Our cash flows from operating activities are significantly affected by our cash outflows to support the growth of our business in areas such as R&D and G&A expenses. Our operating cash flows are also affected by our working capital needs to support personnel related expenditures, accounts payable and other current assets and liabilities.

 

During the year ended December 31, 2022, cash used in operating activities was $1,018,304, which was primarily the result of our net loss incurred of $3,677,812, partially offset by increases in the various accounts payable and accrued liability accounts totaling $174,826 and non-cash expenses including stock-based compensation of $537,778, change in value on derivative liabilities of $291,123, amortization of debt discount of $593,463 and amortization and depreciation of $244,631.

 

During the year ended December 31, 2021, cash used in operating activities was $718,922, which was primarily the result of our net loss incurred of $2,961,445, partially offset by increases in the various accounts payable and accrued liability accounts totaling $283,117 and non-cash expenses including stock-based compensation of $858,900, change in fair value of derivative liabilities of a gain of $44,505, and amortization of debt discount of $541,612.

 

Cash Flows from Investing Activities

 

During the year ended December 31, 2022, net cash used by investing activities was $0, compared to $256,550 during the year ended December 31, 2021. The decrease of approximately $257,000 in net cash used by investing activities is mainly attributable to an decrease of $257,000 in investment in land and equipment.

 

Cash Flows from Financing Activities

 

During the year ended December 31, 2022, net cash provided by financing activities was $943,088, compared to $817,382 during the year ended December 31, 2021. The increase of approximately $126,000 in net cash provided by financing activities is mainly attributable to an increase of $160,000 in cash received from the sale of common stock. Other cash flows provided by financing activities during the year ended December 31, 2022 included proceeds from convertible notes payable to related and third parties totaling $505,000 offset by payments on notes payable to related parties and third parties of $6,900.

 

Off-Balance Sheet Arrangements.

 

We currently do not have any off-balance sheet arrangements.

 

ITEM 7AQUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

Not required for a “smaller reporting company”.

 

ITEM 8FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

 

Our financial statements and the accompanying notes that are filed as part of this Annual Report on Form 10-K are listed and set forth beginning on page F-1 immediately following the signature page of this Form 10-K.

 

26
 

 

ITEM 9CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

 

None.

 

ITEM 9ACONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act is recorded, processed , summarized and reported , within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

 

At the end of the period covered by this Annual Report on Form 10-K for the fiscal year ended December 31, 2022, an evaluation was carried out under the supervision of and with the participation of our management, including the Chief Executive Officer (“CEO”), of the effectiveness of the design and operations of our disclosure controls and procedures (as defined in Rule 13a-15I and Rule 15d-15(e) under the Exchange Act). Based on that evaluation the CEO has concluded that as of the end of the period covered by this Annual Report, our disclosure controls and procedures were not effective.

 

Internal Control Over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a- 15(f) promulgated under the Securities Exchange Act of 1934 as a process designed by, or under the supervision of, a company’s principal executive and principal financial officers and effected by a company’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:

 

Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company;

 

Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and

 

Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company’s assets that could have a material effect on the financial statements.

 

All internal control systems, no matter how well designed, have inherent limitations and can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.

 

Our management, including the Chief Executive Officer, assessed the effectiveness of our internal control over financial reporting as of December 31, 2022. In making our assessment, we used the framework and criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission(“COSO”) (2013) in Internal Control-Integrated Framework. Based on that assessment, our management has identified certain material weaknesses in our internal control over financial reporting.

 

(1)Our management concluded that as of December 31, 2022 our internal control over financial reporting was not effective, and that material weaknesses existed in the following areas as of December 31, 2022) we do not employ full time in-house personnel with the technical knowledge to identify and address some of the reporting issues surrounding certain complex or non-routine transactions. With respect to material, complex and non-routine transactions, management has and will continue to seek guidance from third-party experts and/or consultants to gain a thorough understanding of these transactions;

 

27
 

 

(2)we have inadequate segregation of duties consistent with the control objectives including but not limited to the disbursement process, transaction or account changes, and the performance of account reconciliations and approval ;

 

(3)we have ineffective controls over the period end financial disclosure and reporting process caused by reliance on third-party experts and/or consultants and insufficient accounting staff.

 

Changes in Internal Control Over Financial Reporting

 

No substantial changes in our internal control over financial reporting occurred during 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting, except that we have increased our use of external accounting services, adopted policies to improve timely reviews by management and coordination with accounting consultants, and engaged corporate and securities legal counsel with better capabilities than our previous provi’er’s.

 

ITEM 9BOTHER INFORMATION.

 

None

PART III

 

ITEM 10DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.

 

The Company’s executive officers and directors and their respective ages as of December 31, 2022 are as follows:

 

Directors:

 

Name of Director   Age
Timothy G. Dixon   64
Dr. Thomas E. Ichim   47

 

Executive Officers:

 

Name   Position   Age
Executive Officers:        
Timothy G. Dixon   President and Chief Executive Officer   64
Famela Ramos   Vice President   46
James Veltmeyer, MD   Chief Medical Officer   57
Feng Lin, MD, PhD   Chief Scientific Officer   52

 

The term of office for each director is one year, or until the next annual meeting of the stockholders.

 

Biographical Information

 

Timothy G. Dixon

 

Mr. Dixon currently serves as Chief Executive Officer, President, and Chairman of Therapeutic Solutions International, Inc. Mr. Dixon previously served as the President of TMD Courses, Inc. from 2006 to 2012 and; as the President of Splint Decisions Inc. from 2010 to 2011. Mr. Dixon has attended hundreds of hours of continuing medical/dental education throughout the years and has produced many educational DVD’s used by dental professionals worldwide on the subject of parafunctional control, migraine prevention, therapeutic Botox injections, migraine pathophysiology, dental sleep medicine, and other therapeutic protocols. Mr. Dixon also has extensive experience in dealing with corporate compliance matters with the U.S. Food and Drug Administration, (FDA) as well as many international regulatory bodies. Mr. Dixon is inventor or co-inventor on 72 Patents and Patent Applications.

 

Thomas E. Ichim, Ph.D.

 

Dr. Ichim was appointed to the Board of Directors on January 22, 2016. Dr. Ichim also serves as Chief Executive Officer of Emvolio, Inc. Dr. Ichim is a seasoned biotechnology entrepreneur with a track record of scientific excellence. He has founded/co-founded several companies including Batu Biologics, Inc., Medvax Pharma Corp, ToleroTech, Inc, bioRASI, and OncoMune LLC. To date he has published 125 peer-reviewed articles and is co-editor of the textbooks “RNA Interference: From Bench to Clinical Translation” and “Immuno-Oncology Text Book.”

 

28
 

 

Dr. Ichim is an ad-hoc editor and sits on several editorial boards. Dr. Ichim is inventor on over 150 patents and patent applications. Dr. Ichim has extensive experience with stem cell therapy and cellular product development through FDA regulatory pathways. Dr. Ichim spent over 7 years as the President and Chief Scientific Officer of Medistem, developing and commercializing a novel stem cell, the Endometrial Regenerative Cell, through drug discovery, optimization, preclinical testing, IND filing, and up through Phase II clinical trials with the FDA. Dr. Ichim has extensive experience in product development, regulatory filings, and business development.

 

Dr. Ichim has a BSc in Biology from the University of Waterloo, Waterloo, Ontario, Canada, a MSc in Microbiology and Immunology a University of Western Ontario, London, Ontario, Canada and a Ph.D. in Immunology from the University of Sciences Arts and Technology, Olveston Monserrat.

 

James Veltmeyer, M.D., – Chief Medical Officer

 

Dr. Veltmeyer is a board-certified family physician in La Mesa, California. A graduate of UC San Diego and the Ross University School of Medicine, he completed his residency through the UC San Francisco system where he became Chief of Family Medicine Residency, overseeing 36 doctors.

 

Dr. Veltmeyer, a member of the San Diego Critical Care Medical Group, has been elected for four years (2012, 2014, 2016, and 2017) by his colleagues in the San Diego County Medical Society as a “Physician of Exceptional Excellence,” the most prestigious honor awarded to a “Top Doctor” in San Diego County. He is among a select group of San Diego physicians who was chosen four of the last fifteen years and he consistently ranks in the top 1% to 2% for patient satisfaction. He is currently the Chief of the Department of Family Medicine at Sharp Grossmont Hospital where he provides senior leadership to over 200 doctors.

 

Feng Lin, MD, Ph.D., – Chief Scientific Officer

 

Dr. Lin has a stellar track record of drug development in the area of immunology innumo-oncology having worked with the public company Inovio Pharmaceuticals, where he developed technologies for gene delivery and therapeutic DNA vaccines against cancer and infectious diseases in both R&D and clinical settings. Subsequently, Dr. Lin served as Director of Chinese Operations for MediStem Inc, which was acquired by Intrexon in May 2014. It was the rapid clinical translation model developed by Dr. Lin at MediStem that resulted in the company’s accelerated FDA clearance to begin clinical trials, which resulted in the sale of the company.

 

Dr. Lin received his postdoctoral training at the Sanford-Burnham Medical Research Institute and his MD and Ph.D. at the Xiangya Medical School of Central South University, China. He has authored over 20 peer-reviewed scientific publications, including several in top journals such as Science, Cell, and Cancer Cell. He holds several patents.

 

Famela Ramos – Vice President Business Development

 

Famela Ramos is a Nurse, a Researcher, and a Politician. Famela was running for Congress in the 53nd Congressional District. Ms. Ramos came to the United States from the Philippines at the age of two, when her father joined the United States Navy. Her parents worked tirelessly to support the family of 5 children, all of which became successful entrepreneurs and Government Employees. As a nurse, Famela has experience from the beginning of life, having practiced in pediatric nursing, to the end of life, having worked as a hospice nurse. Her excellence in nursing and research is attested by 7 peer reviewed publications that she collaborated with Academy and Industry in advancing cutting edge research in immunology and regenerative medicine.

 

The first paper, was a collaboration with the Moores Cancer Center and several biotechnology companies, describing the state of the art in cancer immunotherapy, and proposing future directions. The second paper discussed the possibility of stimulating regeneration of injured lung stem cells using specific types of laser and light based interventions, this was a collaboration between the University of Utah and the University of California, San Diego. The third paper, a collaboration between a nutraceutical company and Indiana University, demonstrated the beneficial effects of a nutritional supplement on circulating stem cells in healthy volunteers. The fourth publication was the first successful use of two different types of stem cells in a patient with heart failure, which resulted in a profound improvement. The fifth publication is a report of 114 patients that were treated with umbilical cord blood stem cells and demonstrated safety and signals of efficacy in collaboration with a Chinese Biotech company. The sixth publication was successful treatment of a spinal cord injury patient with stem cells. The seventh publication was the basis for an investigational new drug (IND) application to the FDA, describing use of fat stem cells to treat aplastic anemia.

 

Ms. Ramos has established the Right to Try Foundation, which assists companies in utilizing this new law that allows for accelerated patient access to experimental medication. Through this Foundation Ms Ramos facilitated the first utilization of a cancer vaccine in the United States, and has been assisting both public and private companies. Most recently the Foundation has collaborated on filing new patents for means of implementing the Right to Try Law. Ms. Ramos is a board member of Silent Voices, a Pregnancy Resource Center that provides counselling to woman in emergency pregnancies, alternatives to abortion, and for woman that do choose abortion, post abortion support. Ms. Ramos has been endorsed by business and community leaders as well as nationally known athletes including Dr. Peter Farrell, founder of Resmed, a $18 billion company, and Wes Chandler, an NFL Hall of Fame San Diego Charger.

 

29
 

 

Information with Respect to Our Board of Directors

 

The following is a brief description of the structure and certain functions of our Board of Directors. Each of the current directors is serving until his respective successor is duly elected, subject to earlier resignation. We do not have standing audit, compensation or nominating committees of our Board of Directors. However, the full Board of Directors performs all of the functions of a standing audit committee, compensation committee and nominating committee.

 

Audit Committee Related Function

 

We do not have a separately designated standing audit committee in place. Our full Board of Directors currently serves in that capacity. This is due to the small number of members of our Board of Directors, the small number of executive officers involved with our company, and the fact that we operate with few employees. Our Board of Directors will continue to evaluate, from time to time, whether a separately designated standing audit committee should be put in place. We do not have an audit committee charter.

 

The Board of Directors reviews with management and the Company’s independent public accountants the Company’s financial statements, the accounting principles applied in their preparation, the scope of the audit, any comments made by the independent accountants upon the financial condition of the Company and its accounting controls and procedures and such other matters as the Board of Directors deems appropriate. Because our common stock is traded on the OTC Markets Pink Sheet, we are not subject to the listing requirements of any securities exchange regarding audit committee related matters.

 

The Board of Directors consisted of two directors: Mr. Dixon and Dr. Ichim. Because we do not have an audit committee at all, we disclose that we do not have any “audit committee financial expert” serving on an audit committee.

 

Compensation Committee Related Function

 

We do not currently have a standing compensation committee, and do not have a compensation committee charter. The full Board of Directors currently has the responsibility of reviewing and establishing compensation for executive officers and making policy decisions concerning salaries and incentive compensation for executive officers of the Company.

 

The Company’s executive compensation program is administered by the Board of Directors, which determines the compensation of the Chief/Executive Officer/President and the Chief Financial Officer of the Company. In reviewing the compensation of the individual executive officers, the Board of Directors considers the recommendations of the Chief Executive Officer, other market information and current market conditions, as well as any existing employment agreements with them.

 

Nominating Committee Related Function

 

We do not currently have a standing nominating committee. We have not adopted procedures by which security holders may recommend nominees to serve on our board of directors.

 

SCIENTIFIC ADVISORY BOARD

 

The following are members of the Company’s Scientific Advisory Board as of December 31, 2022:

 

Dr. Santosh Kesari is a board-certified neurologist and neuro-oncologist and is currently Chair, Department of Translational Neuro-Oncology and Neurotherapeutics, John Wayne Cancer Institute.

 

He is also Director of Neuro-Oncology, Providence Saint John’s Health Center and Member, Los Angeles Biomedical Research Institute. Dr. Kesari is ranked among the top 1% of neuro-oncologists and neurologists in the nation, according to Castle Connolly Medical Ltd and an internationally recognized scientist and clinician. He is a winner of an Innovation Award by the San Diego Business Journal. He is on the advisory board of American Brain Tumor Association, San Diego Brain Tumor Foundation, Chris Elliott Fund, Nicolas Conor Institute, Voices Against Brain Cancer, and Philippine Brain Tumor Alliance. He has been the author of over 250 scientific publications, reviews, or books. He is the inventor on several patents and patent applications, and founder and advisor to many cancer and neurosciences biotech startups.

 

Dr. Kesari has had a long-standing interest in cancer stem cells and studies their role in the formation of brain tumors and resistance to treatment. He believes that in order to cure patients with brain tumors we first need to gain a better molecular and biological understanding of the disease. A physician/scientist, Kesari harnesses his experience in surgery, chemotherapy, immunotherapy, radiation therapy and novel devices to help develop Precision Therapeutic Strategies that will advance medicine to a new stage in the battle against brain tumors and eradicate the disease.

 

30
 

 

Dr. Francesco Marincola joined Kite in 2021 as Global Head of Cell Therapy Research. Before joining Kite, Francesco was President and Chief Scientific Officer at Refuge Biotechnologies where responsible for the development and implementation of research and clinical development strategies for adoptive cell therapy products and lead therapeutic programs based on nuclease deactivated CRISPR circuits. He is also a National Institutes of Health (NIH) tenured senior investigator in cancer immunotherapy and biomarker research, and spent 23 years at the NIH, including 15 years as the Chief of the Infectious Disease and Immunogenetics Section at the NIH Clinical Center. Previously, he also served as a distinguished research fellow in immune oncology discovery at AbbVie and as Chief Research Officer at Sidra Research in Doha, Qatar.

 

The former President of the Society for Immunotherapy of Cancer (SITC; 2013-2014), Francesco currently serves as Editor-in-Chief for several prominent peer-reviewed publications, including Journal of Translational Medicine, Translational Medicine Communications and Immunotherapy, and is the author of more than 600 peer-reviewed publications. He has edited several books including the SITC-affiliated Cancer Immunotherapy Principles and Practice Textbook.

 

Dr. Donald Banerji is a Clinical development professional with 33 years of global clinical research and development experience (Phase I-IV) in the pharmaceutical industry. Recently retired from Novartis as Global Clinical Development Head of Respiratory and Allergy Medicine. Recognized by peers and external scientific community as an expert in pulmonary and allergy drug development bringing several iconic brands to market with millions of patients benefitting from treatment through improving care and outcomes for patients with respiratory diseases. Managed multidisciplinary teams in the filing of several new drug applications. Responsibilities included strategic and tactical planning, regulatory interactions with global health authorities, appropriate resource and budgetary management and timely execution, approval of high-quality large drug development programs and delivery of groundbreaking data. These global programs over a span of 3 decades resulted in the approval and competitive labeling of 14 innovative medicines, including 3 inhaled steroids for asthma, a triple combination of 2 bronchodilator and an inhaled steroid for asthma, 3 non-steroidal inhaled controller drugs for asthma, 3 intranasal steroids for allergic rhinitis and 4 bronchodilator drugs for COPD. Signature achievements at Novartis included first to market with the development and approval of the first to market inhaled dual combination medicine in COPD (Ultibro) and the first to market triple combination medicine in asthma (Enerzair). With reimagining medicine as a core driver, these treatments changed the practice of medicine and were incorporated in global treatment guidelines for COPD and asthma. Recipient of numerous corporate awards including the highest scientific award of Distinguished Scientist 2016 for pioneering work in COPD. Published over 400 primary manuscripts and abstracts, including the landmark study FLAME in NEJM.

 

Francisco Silva joined BRT (BioRestorative Therapies, Inc.) in April 2011 and is Vice President of Research and Development. Mr. Silva is responsible for all laboratory operations and is involved in the development and growth of our stem cell programs. Mr. Silva previously served as Chief Executive Officer of two companies engaged in the commercialization of human-based biologics for both research and therapeutic applications.

 

From 2003 to 2007, Mr. Silva was Vice President of Research and Development for PrimeGen Biotech LLC, a company engaged in the development of cell-based platforms. He was responsible for the development of experimental designs that focused on germ line reprogramming stem cell platforms. Mr. Silva has taught courses in biology, anatomy and advanced tissue culture at California State Polytechnic University. He has obtained a number of patents relating to stem cells and has had numerous articles published with regard to stem cell research.

 

Mr. Silva graduated from California State Polytechnic University with a degree in Biology. He also obtained a Graduate Presidential Fellowship and MBRS Fellowship from California State Polytechnic University.

 

Dr. Boris Reznik is the Chairman of Venvalo Group, a venture value optimization firm. During his career, Dr. Reznik founded and built technology companies into market leaders and successfully dealt with both Fortune 500 and emerging companies as clients and partners. He has been a lead or co-investor in startups and mid-market firms and has participated in M&A transactions ranging from Millions to Billions. Dr. Reznik has a depth of experience in processes and systems and a unique perspective in the drug and device development world. As the Chairman of BioRASI, a global CRO, he led development of novel therapeutics, from filing INDs to getting approved NDAs, for companies ranging from startups to Big Pharma.

 

Dr. Boris Minev is a highly accomplished physician-scientist with extensive industrial and academic experience in Immuno-Oncology, oncolytic viruses and stem cell biology and applications. He has a significant track record in tumor immunology and cancer vaccine development, having worked closely on the development of the first cancer vaccine to be approved by a regulatory body (Melacine). Dr. Minev has also extensive expertise in immunotherapy clinical trial designs, logistics, and regulatory issues. He has a considerable supervision & management experience in industrial and academic settings and has excellent skills in biotech business development, communication, and collaboration. Previously he held a position as the Director of Immunotherapy and Translational Oncology at Genelux Corporation, where he was directing several preclinical and translational projects on oncolytic virotherapy, immunotherapy, and nanotechnology.

 

31
 

 

Dr. Minev is also an adjunct professor at the Moores UCSD Cancer Center. There, he served previously as Principal Investigator and Director, Laboratory of Tumor Immunology and Immunotherapy where, for more than 15 years, his research has been focused on the discovery of new target antigens for immunotherapy of cancer and the development of optimized cancer vaccines. Prior to that, Dr. Minev worked in Dr. Steven Rosenberg’s Tumor Immunology Section at the Surgery Branch of the National Cancer Institute.

 

Dr. Minev is an Advisory Board Member of the European Society for Translational Medicine (EUSTM). He is a member of the Scientific and Clinical Advisory Boards of several biotechnology companies and has been an advisor for Amgen, Johnson & Johnson, Geron Corporation, McKinsey Consulting and Thomson Current Drugs, among others. He is the recipient of the European Association of Cancer Research Fellowship and the Fogarty International Fellowship.

 

Dr. Pablo Guzman is a cardiologist in Fort Lauderdale, Florida where he is on staff at Holy Cross Hospital. He received his medical degree from University of Puerto Rico School of Medicine and his Cardiology Fellowship at The Johns Hopkins Hospital where he then spent the first part of his career continuing his basic science and clinical research along with his clinical duties. His CV includes over 25 papers published in peer-reviewed journals and more than 15 abstracts.

 

He is a Fellow of the American College of Cardiology and practiced for more than 30 years. Dr. Guzman is well experienced in basic and clinical research, having participated in many clinical trials. He is also the acting Chief Medical Officer of Variant Pharmaceuticals, a Specialty Pharma company developing treatments for kidney diseases.

 

Dr. Juergen Winkler is presently practicing at Quantum Functional Medicine in Carlsbad, CA, which he founded in July of 2012. In 2005 he was the co-founder of Genesis Health Systems (Integrative Cancer and Medical Treatment Center) located in Oceanside, CA. He has been a featured speaker for: the NSCC Women’s Health Seminar, Annual IPT/IPTLD Integrative Cancer Care Conference (Multiple years), Health Freedom Expo 2011 & 2012, the Japanese Society of Oxidative Medicine in Osaka Japan, ACOSPM 2010 & 2011 conferences, NSCC Health and Wellness Series 2013, and various other events. He is the physician author of Chapter 5 in the Defeat Cancer book and has been a featured physician in the Townsend Letter.

 

Dr. Nassir Azimi is a cardiologist in La Mesa, California and attended Dartmouth Medical School and completed his residency at the University of Colorado. He finished his four year fellowship in Cardiovascular and Peripheral Interventions at Yale University in New Haven. Dr. Azimi has been in private practice for over 13 years establishing a thriving clinical practice for cardiac patients as well as treating patients for peripheral vascular disease. He is active in Interventional Cardiology and Peripheral Interventions. Dr. Azimi is the director of La Mesa Cardiac Center’s Nuclear Cardiology Laboratory. He is also an investigator in multiple clinical research studies for various cardiac and peripheral diseases. He has been recognized as San Diego’s Top Interventional Cardiologists by San Diego Magazine 2013,2014,2016, 2017 and also by Castle Connoly for 2013, 2014, 2015,2016, 2017, and 2018. He is a former chief of biomedical ethics (6 years), former chief of Medicine and former chief of Endovascular Medicine as well as Vice Chief of Cardiology at SGH. He is on the board of directors of the California ACC where he serves as chair of the public relations committee. He is on Editorial Review Board for multiple medical journals. He is a national speaker on various topics in cardiology and internal medicine.

 

Dr. James Veltmeyer is a board-certified family physician in La Mesa, California. A graduate of UC San Diego and the Ross University School of Medicine, he completed his residency through the UC San Francisco system where he became Chief of Family Medicine Residency, overseeing 36 doctors. Dr. Veltmeyer, a member of the San Diego Critical Care Medical Group, has been elected for four years (2012, 2014, 2016, and 2017) by his colleagues in the San Diego County Medical Society as a “Physician of Exceptional Excellence,” the most prestigious honor awarded to a “Top Doctor” in San Diego County. He is among a select group of San Diego physicians who was chosen four of the last fifteen years and he consistently ranks in the top 1% to 2% for patient satisfaction. He is currently the Chief of the Department of Family Medicine at Sharp Grossmont Hospital where he provides senior leadership to over 200 doctors.

 

Dr. Barry Glassman, DMD, DAAPM, DAACP, FICCMO, Diplomate ABDSM, FADI, is a Diplomate of the American Academy of Craniofacial Pain and the American Academy of Pain Management, as well as a Fellow of the International College of Craniomandibular Orthopedics and the Academy of Dentistry International, he is also on staff at the Lehigh Valley Hospital where he serves as a resident instructor of Craniofacial Pain and Dysfunction and Dental Sleep Medicine.

 

Dr. Glassman is a Diplomate of the Academy of Dental Sleep Medicine. He is on the staff at the Sacred Heart Hospital Sleep Disorder Center, as well as serving as the Chief Dental Consultant to three other sleep centers in the Lehigh Valley. A popular and dynamic speaker, Dr. Glassman lectures internationally, as well as throughout the United States. In addition to his extensive schedule which includes guest lecture appearances and in-depth courses on joint dysfunction, chronic pain, headache, sleep disorders, and migraine headache, Dr. Glassman is a frequent speaker at major chronic pain and joint dysfunction professional conferences. A graduate of the University of Pittsburgh: Bachelor of Science 1969, Pittsburgh, Pennsylvania University of Pittsburgh School of Dental Medicine; D.M.D. 1973, Pittsburgh Pennsylvania Post Graduate Hours in Craniomandibular Dysfunction and Sleep Disorders: Over 2500

 

32
 

 

J. Christopher Mizer founded Vivaris in June of 1998. Vivaris (formerly Lake Erie Capital) invests in and acquires middle-market businesses in a broad range of industries that are leaders in their market niches. Mr. Mizer serves as the chairman of each of the portfolio companies and guides key strategic decisions and their execution. He also serves as the operating president on an interim basis when companies are going through periods of ownership succession and new management team members are being assembled.

 

Mr. Mizer is a former Vice President and Officer of the investment banking division of Key Capital Markets, where he focused on merger, acquisition, and financing projects for Fortune 500 clients, private companies, and successful entrepreneurs. Prior to joining Key Corp., he was Consultant in the Capital Markets practice with Ernst & Young. He began his career as a Research Assistant with The Center for Economic Issues, a think-tank focused on economic development. He earned the B.S. (biology, applied math), B.A. (economics), M.S. degrees (biology – neurogenetics), and MBA (finance, accounting) degrees from Case Western Reserve University. Mr. Mizer has taught business strategy, finance and entrepreneurship at the graduate level at Case Western Reserve University, John Carroll University, and the University of California, San Diego and at the undergraduate at San Diego State University.

 

Howard Leonhardt is an inventor and serial entrepreneur. He has 21 U.S. patents with over 100 patent claims for products for treating cardiovascular disease and has over 40 new patent claims pending. His TALENT (Taheri-Leonhardt) stent graft developed in the early 1990′s holds a leading world market share for repairing aortic aneurysms without surgery.

 

His inventions have treated over 500,000 patients in 60 countries. In early 1999 Leonhardt founded Bioheart, Inc. www.bioheartinc.com a leader in applying adult muscle stem cells to treat heart failure.. Leonhardt holds a Diploma in International Trade from Anoka Technical College. He attended the University of Minnesota,Anoka Ramsey College and UCLA Extension. He holds an honorary Doctorate in Biomedical Engineering from the University of Northern California and is an honorary alumnus of the University of Florida and Florida International University. He is co-leader of Startup California and Founder and Chairman of The California Stock Exchange TM (Cal-X) preparing to be the first social good impact stock exchange currently operating the Cal-X 30 Social Good Impact fund powered by Motif Investing- www.calstockexchange.com – He founded Cal-X Crowdfund Connect www.calxcrowdfund.com a crowdfunding campaign management co. and Cal-X Stars Business Accelerator, Inc.www.calxstars.com a business incubator and accelerator focused on cardiovascular life sciences and social good impact innovations.

 

There are 30 regenerative medtech and regenerative economy startups in the current portfolio class. His Leonhardt Ventures angels network has raised and put to work over $145 million in 32 companies to date, most of them founded by Leonhardt. BioLeonhardt www.bioleonhardt.com is developing the first implantable programmable and re-fillable stem cell pump. He leads CerebraCell for brain regeneration. EyeCell for eye regeneration and AortaCell for aorta regeneration and number of other organ regeneration spin offs from his patented core technologies. Leonhardt serves as state spokesperson in California for the JOBS ACT and Crowdfunding for Startup California and has given over 40 speeches on the subject. He has operated Leonhardt’s Launchpads NorCal at the University of Northern California Science & Technology Innovation Center in Rohnert Park, CA since 2008 and recently opened Leonhardt’s Launchpads Utah in Salt Lake City just off the campus of the University of Utah. He has served on the Board of Directors of the University of Northern California, a private biomedical engineering school, since 1999.

 

Section 16(a) Beneficial Ownership Reporting Compliance

 

Section 16(a) of the Exchange Act requires our directors and executive officers, and persons who own more than 10% of a registered class of our equity securities, to file with the SEC initial reports of ownership and reports of changes in ownership of common stock and other of our equity securities. Officers, directors and greater than 10% stockholders are required by SEC regulation to furnish us with copies of all Section 16(a) forms they file.

 

To our knowledge, based solely on a review of the copies of such reports furnished to us during the fiscal year ended December 31, 2021, all Section 16(a) filing requirements applicable to our officers, directors and greater than 10% beneficial owners were complied with.

 

Code of Ethics

 

We have adopted a Code of Ethics for our principal executive and financial officers. Our Code of Ethics was filed as an Exhibit to our Annual Report on Form 10-K for fiscal year 2010. We hereby undertake to provide a copy of this Code of Ethics to any person, without charge, upon request. Requests for a copy of this Code of Ethics may be made in writing addressed to: Therapeutic Solutions International, Inc., 4093 Oceanside Blvd, Suite B, Oceanside, California 92056, Attn: Corporate Secretary.

 

33
 

 

ITEM 11EXECUTIVE COMPENSATION.

 

Summary Compensation Table

 

The following table summarizes the compensation paid, with respect to years ended December 31, 2022 and 2021 for services rendered to us in all capacities, to each person who served as an executive officer of the Company.

 

Name and Principal     Salary   Bonus   Stock Awards   Option Awards   Nonequity Incentive Plan Compensation   All Other Compensation   Total 
Position  Year  ($)   ($)   ($)   ($)   ($)   ($)   ($) 
Timothy G. Dixon  2022   240,000        -    140,800            -               -                -    380,800 
President, CEO and CFO  2021   227,000    -    367,600    -    -    -    594,600 
                                       
Dr. James Veltmeyer  2022   -    -    25,100    -    -    -    25,100 
Chief Medical Officer  2021   -    -    32,000    -    -    -    32,000 
                                       
Feng Lin  2022   -    -    25,100    -    -    -    25,100 
Chief Scientific Officer  2021   -    -    32,000    -    -    -    32,000 
                                       
Famela Ramos  2022   -    -    25,100    -    -    -    25,100 
Vice President  2021   -    -    79,300    -    -    -    79,300 

 

  (1) $120,000 was accrued and $67,400 paid with stock as of December 31, 2022
     
  (2) $120,000 was accrued and paid with stock as of December 31, 2021

 

Outstanding Equity Awards

 

None

 

Employment Agreements

 

We do not have any employment agreements as of December 31, 2022.

 

Director Compensation

 

When our employees serve on our Board of Directors, we do not give them any additional compensation in respect of such Board service. Directors currently serve without compensation.

 

ITEM 12SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

 

The following table sets forth, as of December 31, 2022, information regarding the ownership of the Company’s outstanding shares of common stock by (i) each person known to management to own, beneficially or of record, more than 5% of the outstanding shares of our common stock, (ii) each director of the Company, (iii) each executive officer of the Company, and (iv) all directors and executive officers as a group. As of December 31, 2022, a total of 2,617,390,830 shares of our common stock were outstanding.

 

Name of Beneficial Owners  Amount and Nature of Beneficial Ownership   Percent of Shares Outstanding 
Timothy G. Dixon (1)   280,811,471    10.73%
Thomas E. Ichim (2)   114,000,000    4.35%
Feng Lin   50,000,000    1.91%
Famela Ramos   4,000,000    0.15%
All directors and executive officers as a group (2 persons) (1)(2)   448,811,471    17.15%

 

1) Under SEC rules (i) a person is deemed to be the beneficial owner of shares if that person has, either alone or with others, the power to vote or dispose of those shares. The persons named in the table have sole voting and dispositive power with respect to all shares shown as beneficially owned by them, subject to community property laws where applicable.

 

34
 

 

ITEM 13CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

 

Our Board of Directors currently consists of two directors, one of whom is an officer of the Company. As of December 31, 2022 we disclose that we had no independent directors.

 

In general, it is our policy to submit all proposed related party transactions (those of the kind and size that may require disclosure under Regulation S-K, Item 404) to the Board of Directors for approval. The Board of Directors only approves those transactions that are on terms comparable to, or more beneficial to us than, those that could be obtained in arm’s length dealings with an unrelated third party. Examples of related party transactions covered by our policy are transactions in which any of the following individuals has or will have a direct or indirect material interest: any of our directors or executive officers, any person who is known to us to be the beneficial owner of more than 5% of our common stock, and any immediate family member of one of our directors or executive officers or person known to us to be the beneficial owner of more than 5% of our common stock.

 

ITEM 14PRINCIPAL ACCOUNTANT FEES AND SERVICES.

 

Representatives of our principal accountants, Fruci & Assoicates II, PLLC, will be available for the current year and for the most recently completed fiscal year at the stockholder’s meeting to provide the financial statements and be available for questions. At this time, we are not planning to have a stockholder’s meeting.

 

Audit Fees

 

The aggregate fees billed to us by our principal accountants, Fruci & Associates II, PLLC for auditing and accounting services for fiscal year 2022 was $66,100 (inclusive of the review of the quarterly reports on Form 10-Q) and for year 2021 was $61,600.

 

Audit-Related Fees, Tax Fees and All Other Fees

 

There were no fees billed to us by our principal accountant for fiscal year 2022 and 2021 for assurance and related services (audit-related fees), tax services or other products and services.

 

Audit Committee Matters

 

We do not have an audit committee. The executive officers and BOD perform the role of the audit committee. The executive officers and BOD review and approve the audit. The audit fees were 100% and the audit related fees were 0% of the total fees and were approved by the executive officers and BOD.

 

PART IV

 

ITEM 15 EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 

a) The following documents have been filed as a part of this Annual Report on Form 10-K

 

  1. Financial Statements

 

  Page
Report of Independent Registered Public Accounting Firm (PCAOB ID #5525) F-1
Consolidated Balance Sheets F-2
Consolidated Statements of Operations F-3
Consolidated Statements of Changes in Stockholders’ Deficit F-4
Consolidated Statements of Cash Flows F-5
Consolidated Notes to Financial Statements F-6

 

2.Financial Statement Schedules.

 

All schedules are omitted because they are not applicable or not required or because the required information is included in the Financial Statements or the Notes thereto.

 

3.Exhibits.

 

The following exhibits are filed as part of, or incorporated by reference into, this Annual Report on Form 10-K:

 

EXHIBIT

NUMBER

   DESCRIPTION
3.1   Articles of Incorporation
3.1.1   Certificate of Merger, filed February 22, 2011
3.1.2   Certificate of Amendment to Articles of Incorporation filed October 15, 2012 (incorporated herein by reference to Form 8-K, filed on October 17, 2012)
3.2   Bylaws (incorporated herein by reference to Form SB-2, filed on November 21, 2007)
3.2.1   Bylaws amendments adopted August 22, 2012, August 24, 2012 and September 26, 2012
31.1   Rule 13a-14(a)/Section 302 Certification of Principal Executive Officer
31.2   Rule 13a-14(a)/Section 302 Certification of Principal Financial Officer
32.1   Certification pursuant to 18 U.S.C. Section 1350/Rule 13a-14(b)

 

35
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.
     
  By: /s/ Timothy G. Dixon
    Timothy G. Dixon
    Chief Executive Officer and President
     
  Date: March 29, 2023
     
  By: /s/ Thomas E. Ichim
    Thomas E. Ichim
    Director
     
  Date: March 29. 2023

 

36
 

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and Shareholders of Therapeutic Solutions International, Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of Therapeutic Solutions International, Inc. (“the Company”) as of December 31, 2022 and 2021, and the related consolidated statements of operations, changes in shareholders’ deficit, and cash flows for each of the years in the two-year period ended December 31, 2022, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021 and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.

 

Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has an accumulated deficit, net losses, and negative cash flows from operations. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there were no critical audit matters.

 

/s/ Fruci & Associates II, PLLC  
We have served as the Company’s auditor since 2019.  
   
Spokane, Washington  
March 29, 2023  

 

F-1
 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Balance Sheets

 

  

December 31,

 2022

  

December 31,

 2021

 
         
ASSETS          
Current assets:          
Cash and cash equivalents  $18,040   $94,036 
Restricted cash   11,003    10,223 
Accounts receivable   25,398    16,613 
Inventory   42,428    39,817 
Prepaid expenses and other current assets   212,352    959,307 
Total current assets   309,221    1,119,996 
           
Property and equipment, net   273,078    284,024 
Right-of-use asset   8,612    34,184 
Other assets   3,014,620    277,571 
           
Total assets  $3,605,531   $1,715,775 
           
LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)          
           
Current liabilities:          
Accounts payable  $401,992   $394,035 
Accounts payable-related parties   7209    9,791 
Accrued expenses and other current liabilities   531,783    487,208 
Lease liability   8,612    25,374 
Notes payable, current portion   4,638    4,071 
Convertible notes payable, net of discount of $175,063 and $225,800, at December 31, 2022 and 2021, respectively   65,187    79,200 
Notes payable-related parties, net   988,672    965,211 
Derivative liabilities   202,144    531,525 
Total current liabilities   2,210,237    2,496,415 
           
LONG TERM LIABILITIES          
Notes payable, net of current portion   10,507    15,532 
Lease liability, net of current portion   -    8,810 
TOTAL LIABILITIES   2,220,744    2,520,757 
           
Commitments and contingencies   -    - 
           
Shareholders’ Equity (Deficit):          
Preferred stock, $0.001 par value; 5,000,000 shares authorized, 2 shares and 0 shares issued and outstanding at December 31, 2022 and 2021, respectively   -    - 
Common stock, $0.001 par value; 3,500,000,000 shares authorized; 2,617,390,830 and 2,311,123,860 shares issued and outstanding at December 31, 2022 and 2021, respectively.   2,617,392    2,311,125 
Additional paid-in capital   16,334,129    10,899,139 
Shares to be issued   126,324    - 
Subscription receivable   (21,000)   (21,000)
Accumulated deficit   (17,672,058)   (13,994,246)
Total shareholders’ equity (deficit)   1,384,787    (804,982)
           
Total liabilities and shareholders’ equity (deficit)  $3,605,531   $1,715,775 

 

See accompanying notes to consolidated financial statements.

 

F-2
 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Statements of Operations

 

   For the Year Ended December 31, 2022   For the Year Ended December 31, 2021 
         
Net sales  $206,767   $145,956 
Cost of goods sold   79,440    42,544 
           
Gross profit   127,327    103,412 
           
Operating expenses:          
General and administrative   491,928    138,710 
Salaries, wages, and related costs   444,865    436,555 
Consulting fees   432,033    264,540 
Legal and professional fees   397,302    773,203 
Research and development   1,441,128    794,750 
Total operating expenses   3,207,256    2,407,758 
           
Loss from operations   (3,079,929)   (2,304,346)
           
Other income (expense):          
Loss on derivative liabilities   (131,475)   (539,006)
Change in fair value of derivative liabilities   291,123    494,501 
Interest expense   (646,089)   (611,794)
Other expense   (110,642)   - 
Total other income (expense)   (597,083)   (656,299)
           
LOSS BEFORE PROVISION FOR INCOME TAXES   (3,677,012)   (2,960,645)
           
Provision for income taxes   800    800 
           
Net loss  $(3,677,812)  $(2,961,445)
           
Net loss per share - basic and diluted  $(0.00)  $(0.00)
           
Weighted average shares outstanding - basic and diluted   2,528,062,958    2,263,126,970 

 

See accompanying notes to consolidated financial statements.

 

F-3
 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Statement of Changes in Sharehold’rs’ Deficit

For the Years Ended December 31, 2022 and 2021

 

   Shares   Amount   Shares   Amount   Capital   Issued   Receivable   Deficit   Deficit 
   Series A Preferred Stock   Common Stock   Additional Paid-in   Shares to be   Subscription   Accumulated   Total Shareholders’ 
   Shares   Amount   Shares   Amount   Capital   Issued   Receivable   Deficit   Deficit 
December 31, 2020   -   $-    2,233,741,391   $2,233,742   $7,041,960   $-   $(21,000)  $(11,032,801)  $(1,778,099)
                                              
Common stock issued for services   -    -    21,000,000    21,000    837,900    -    -    -    858,900 
Common stock issued for prepaid fees   -    -    20,000,000    20,000    1,452,450    -    -    -    1,472,450 
Common stock issued for salaries   -    -    8,341,723    8,342    231,457    -    -    -    239,799 
Common stock issued for cash   -    -    4,850,075    4,850    280,649    -    -    -    285,499 
Common stock issued for land development   -    -    1,500,000    1,500    57,400    -    -    -    58,900 
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities   -    -    21,690,671    21,691    508,044    -    -    -    529,735 
Relief of derivative liabilities   -    -    -    -    489,279    -    -    -    489,279 
Net loss   -    -    -    -    -    -    -    (2,961,445)   (2,961,445)
December 31, 2021   -   $-    2,311,123,860   $2,311,125   $10,899,139   $-   $(21,000)  $(13,994,246)  $(804,982)
                                              
Common stock issued for services   -    -    32,412,577    32,413    557,107    102,000    -    -    691,520 
Common stock issued for prepaid fees   -    -    11,000,000    11,000    231,320    -    -    -    242,320 
Common stock issued for salaries   -    -    4,812,259    4,812    62,587    -    -    -    67,399 
Common stock issued for cash   -    -    44,500,000    44,500    400,500    -    -    -    445,000 
Common stock issued for license   -    -    149,402,390    149,402    2,958,168    -    -    -    3,107,570 
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities   -    -    64,139,744    64,140    1,225,308    24,324    -    -    1,313,772 
Issuance of preferred stock   2    -    -    -    -    -    -    -    - 
Net loss   -    -    -    -    -    -    -    (3,677,812)   (3,677,812)
December 31, 2022   2   $-    2,617,390,830   $2,617,392   $16,334,129   $126,324   $(21,000)  $(17,672,058)  $1,384,787 

 

See accompanying notes to consolidated financial statements.

 

F-4
 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Statements of Cash Flows

 

   For the Year Ended December 31, 2022   For the Year Ended December 31, 2021 
         
Cash flows from operating activities          
Net loss  $(3,677,812)  $(2,961,445)
Adjustments to reconcile net loss to net cash used in operating activities:          
Stock-based compensation to consultants   380,820    397,750 
Stock-based compensation to related parties   310,700    461,150 
Loss on derivative liabilities   131,475    539,006 
Change in fair value of derivative liabilities   (291,123)   (494,501)
Amortization of prepaid stock-based compensation   951,748    480,135 
Amortization of debt discount   593,463    541,612 
Patent amortization   233,685    11,295 
Depreciation   10,946    6,772 
Changes in operating assets and liabilities:          
Accounts receivable   (8,785)   (14,172)
Inventory   (2,611)   (34,418)
Prepaid expenses and other current assets   174,364    64,777 
Right-of-use asset   25,572    24,792 
Accounts payable   15,166    91,557 
Accounts payable - related parties   (9,791)   2,581 
Accrued expenses and other current liabilities   169,451    188,979 
Lease liability   (25,572)   (24,792)
Net cash used in operating activities   (1,018,304)   (718,922)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchases of property and equipment   -    (260,565)
Deposits   -    4,015 
Net cash used in investing activities   -    (256,550)
           
Cash flows from financing activities          
Payments on notes payable to related party   (2,453)   (4,799)
Proceeds from convertible notes payable   505,000    538,750 
Payments on notes payable   (4,459)   (2,068)
Proceeds from sale of common stock   445,000    285,499 
Net cash provided by financing activities   943,088    817,382 
           
Net increase (decrease) in cash, cash equivalents and restricted cash   (75,216)   (158,090)
Cash, cash equivalents and restricted cash at beginning of period   104,259    262,349 
Cash, cash equivalents and restricted cash at end of period  $29,043   $104,259 
           
Supplemental cash flow information:          
Cash paid for interest  $3,173   $3,312 
Cash paid for income taxes  $800   $800 
           
Non-cash investing and financing transactions:          
Original issuance discount on convertible notes payable  $39,000   $33,500 
Debt discount recorded in connection with derivative liability  $503,726   $538,750 
Common stock issued in conversion of convertible notes payable and interest  $1,313,772   $1,019,014 
Property and equipment purchased with note payable  $-   $21,671 
Common stock issued for prepaid fees  $242,320   $1,472,450 
Common stock issued for accrued salaries  $67,399   $239,799 
Accrued interest added to principal  $25,914   $25,912 
Common stock issued for license  $3,107,570   $- 
Common stock issued for land development  $-   $58,900 
           
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:          
Cash and cash equivalents  $18,040   $94,036 
Restricted cash   11,003    10,223 
Total cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows:  $29,043   $104,259 

 

See accompanying notes to consolidated financial statements.

 

F-5
 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Notes to Financial Statements

December 31, 2022

 

Note 1 – Organization and Business Description

 

Therapeutic Solutions International, Inc. (“TSI” or the “Company”) was organized August 6, 2007 under the name Friendly Auto Dealers, Inc., under the laws of the State of Nevada. In the first quarter of 2011 the Company changed its name from Friendly Auto Dealers, Inc. to Therapeutic Solutions International, Inc., and acquired Splint Decisions, Inc., a California corporation.

 

Business Description

 

Currently, the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system.

 

Activating one’s immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions.

 

TSOI is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, traumatic brain injury, lung pathologies, and for daily health.

 

Cellular Division – TSOI obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and Lung Pathology (LP).

 

The stem cell licensed, termed “JadiCell” is unique in that it possesses features of mesenchymal stem cells, however, outperforms these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and neurogenic ability.

 

Chronic Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe. TSOI has previously filed several patents in the area of CTE based on modulating the brain microenvironment to enhance receptivity of regenerative cells such as stem cells. On March 4, 2021 the Company received an IND Serial # 27377 for a clinical trial of 10 patients with CTE.

 

On August 4th, 2021, the Company announced clearance from the Food and Drug Administration (FDA) to initiate a Phase III pivotal trial for registration of the Company’s JadiCell™ universal donor stem cell as a treatment for COVID-19 associated lung failure under IND # 19757. In previous studies the Company has demonstrated the superior activity of JadiCell™ to other types of stem cells including bone marrow, adipose, cord blood, and placenta. Furthermore, the JadiCell™ was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91%.

 

In addition, the Company has filed data with the FDA, as part of IND #17448, which demonstrated that treatment of cancer patients with StemVacs™ resulted in enhanced activity of a type of immunological cell called “natural killer” cells, otherwise known as “NK cells.”

 

The Company has also developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body’s NK cells.

 

Most recently the Company announced filing of a patent for a new hybrid cell created by the Company capable of training the immune system to kill blood vessels feeding cancer, but sparing healthy blood vessels. These discoveries are an extension of previous findings from the Company showing that StemVacs is capable of suppressing new blood vessel production.

 

On May 9, 2022, the Company filed an Investigational New Drug Application for Treatment of Chronic Obstructive Pulmonary Disease (COPD) Using JadiCell™ Universal Donor Adult Stem Cells under IND Serial # 28508.

 

F-6
 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Notes to Financial Statements

December 31, 2022

 

Management does not expect existing cash as of December 31, 2022 or as of March 31, 2023 to be sufficient to fund the Company’s operations for at least twelve months from the issuance date of these financial statements. These financial statements have been prepared on a going concern basis which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of December 31, 2022, the Company has incurred losses totaling $17.3 million since inception, has not yet generated material revenue from operations, and will require additional funds to maintain its operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern within one year after the consolidated financial statements are issued. The Company’s ability to continue as a going concern is dependent upon its ability to generate future profitable operations and obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. The Company intends to finance operating costs over the next twelve months through its existing financial resources and we may also raise additional capital through equity offerings, debt financings, collaborations and/or licensing arrangements. If adequate funds are not available on acceptable terms, we may be required to delay, reduce the scope of, or curtail, our operations. The accompanying consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Note 2 – Basis of presentation and significant accounting policies

 

Basis of Presentation

 

The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented.

 

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. No material activity in any subsidiaries.

 

Accounts Receivable

 

Accounts receivable are stated at amounts due from customers, net of an allowance for doubtful accounts, and the Company generally does not require collateral. As a general policy, the Company determines an allowance for doubtful accounts by considering a number of factors, including the length of time trade accounts receivable are past due, the Company’s previous loss history, the customer’s current ability to pay its obligation to the Company, and the condition of the general economy and industry as a whole. The Company writes off accounts receivable when they become uncollectible, and payments subsequently received on such receivables are credited to the allowance for doubtful accounts.

 

The Company recorded an allowance for doubtful accounts of $6,807 as of both December 31, 2022 and 2021, respectively.

 

Revenue Recognition

 

The Company recognizes revenue in accordance with ASC 606,”Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the Company applies the following methodology to recognize revenue:

 

1)Identify the contract with a customer.
2)Identify the performance obligations in the contract.
3)Determine the transaction price.
4)Allocate the transaction price to the performance obligations in the contract.
5)Recognize revenue when (or as) the entity satisfies a performance obligation.

 

ASC 606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which the customer obtains control of the product or service.

 

Returns. We will gladly accept the return of products that are defective due to defects in manufacturing and/or workmanship.

 

Wholesale policies:

 

Delivery. The Goods shall be deemed delivered when Buyer has accepted delivery at the above-referenced location. The shipping method shall be determined by Seller, but Buyer will not be responsible for shipping costs.

 

F-7
 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Notes to Financial Statements

December 31, 2022

 

Note 2 – Basis of presentation and significant accounting policies (Continued)

 

Purchase Price & Payments. Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail.

 

Inspection of Goods & Rejection. Buyer is entitled to inspect the Goods upon delivery. If the Goods are unacceptable for any reason, Buyer must reject them at the time of delivery up to five (5) business days from the date of delivery. If Buyer has not rejected the Goods within five (5) business days from the date of delivery, Buyer shall have waived any right to reject that specific delivery of Goods. In the event Buyer rejects the Goods, Buyer shall allow Seller a reasonable time to cure the deficiency. A reasonable time period shall be determined by industry standards for the particular Goods, as well as the Seller and Buyer.

 

Risk of Loss. Risk of loss will be on the Seller until the time when the Buyer accepts delivery. Seller shall maintain any and all necessary insurance in order to insure the Goods against loss at Seller’s own expense

 

Retail policies of e-commerce:

 

Returns. We will gladly accept the return of products that are defective due to defects in manufacturing and/or workmanship. Fulfillment mistakes that may be made which result in the shipment of incorrect products to you will also be accepted for return.

 

Shipping. Shipping Time –Most orders will ship the next business day, provided the product ordered is in stock. Orders are not processed or shipped on Saturday or Sunday, except by prior arrangement. We cannot guarantee when an order will arrive. Consider any shipping or transit time offered to you by this site or other parties only as an estimate. We encourage you to order in a timely fashion to avoid delays caused by shipping or product availability. Shipping for Amazon and Walmart are shipped to the fullfillment centers based on inventory amounts. Orders are shipped to customers by the companies as ordered on their websites.

 

Out of Stock. We will ship your product as it becomes available. Usually, products ship by the next business day. However, there may be times when the product you have ordered is out-of-stock, which will delay fulfilling your order. We will keep you informed of any products that you have ordered that are out-of-stock and unavailable for immediate shipment. You may cancel your order at any time prior to shipping.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.

Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At December 31, 2022 and 2021, the Company had $0 in excess of the FDIC insured limit.

 

Inventories

 

Inventories are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials and assembly items.

 

Derivative Liabilities

 

A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities.

 

F-8
 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Notes to Financial Statements

December 31, 2022

 

Note 2 – Basis of presentation and significant accounting policies (Continued)

 

As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2022 and 2021, as disclosed in Note 5, containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis.

 

The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified.

 

Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $202,144 and $531,525 at December 31, 2022 and 2021, respectively.

 

Fair Value of Financial Instruments

 

The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items.

 

Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy:

 

Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.

 

Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.

 

Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.

 

When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of December 31, 2021 and 2020, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations:

 

The following is the change in derivative liability for the years ended December 31, 2022 and 2021:

 

Balance, December 31, 2020  $437,549 
      
Issuance of new derivative liabilities   1,077,756 
Conversions   (489,279)
Change in fair market value of derivative liabilities   (494,501)
      
Balance, December 31, 2021   531,525 
      
Issuance of new derivative liabilities   674,971 
Conversions   (713,229)
Change in fair market value of derivative liabilities   (291,123)
Balance, December 31, 2022  $202,144 

 

F-9
 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Notes to Financial Statements

December 31, 2022

 

Use of Estimates

 

Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates.

 

Comprehensive Loss

 

Comprehensive loss for the periods reported was comprised solely of the Company’s net loss.

 

Net Loss Per Share

 

Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive.

 

As of December 31, 2022 and 2021, a total of 267,136,056 and 95,273,690, respectively, potential common shares, consisting of shares underlying outstanding convertible notes payable were excluded as their inclusion would be antidilutive.

 

Depreciation and Amortization

 

Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. Depreciation expense for the years ended December 31, 2022 and 2021 was $10,946 and $6,772, respectively.

 

Intangible Assets

 

Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Amortization expense for the years ended December 31, 2022 and 2021 was $233,685 and $11,295, respectively.

 

Long-lived Assets

 

In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value.

 

Shipping and Handling

 

The Company recognizes shipping and handling billed to customers as a component of net revenues, and the cost of shipping and handling within general administrative expenses.

 

Advertising

 

Advertising costs are expensed as incurred. Advertising expense for the years ended December 31, 2022 and 2021 were $4,132 and $0, respectively.

 

Research and Development

 

Research and Development costs are expensed as incurred. Research and Development expenses were $1,441,128 and $794,750 for the years ended December 31, 2022 and 2021, respectively.

 

Income Taxes

 

The Company accounts for income taxes under ASC 7”0 “Income Tax”s,” which codified SFAS 10”, “Accounting for Income Ta”es” and FIN 48 “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.

 

F-10
 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Notes to Financial Statements

December 31, 2022

 

Note 2 – Basis of presentation and significant accounting policies (Continued)

 

Stock-Based Compensation

 

Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted and nonrefundable shares.

 

Leases

 

On February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company recorded a Right-of-use asset and a Lease Liability of $8,612 as of December 31, 2022.

 

Note 3 – Restricted cash

 

Included in current assets is a $10,000 certificate of deposit with an annual interest rate of 0.6%. This certificate matures on June 17, 2023, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011.

 

Note 4 – Prepaid expense and other current assets

 

Prepaid expenses and other current assets consist of the following:

 

   December 31, 2022   December 31, 2021 
         
Prepaid consulting  $148,550   $930,893 
Insurance   1,141    987 
Prepaid costs   62,661    27,427 
Total  $212,352   $959,307 

 

Note 5 – Fixed assets

 

Fixed assets consist of the following:

 

   December 31, 2022   December 31, 2021 
         
Land  $235,223   $235,223 
Vehicles   50,514    50,514 
Computer hardware   6,135    5,935 
Office furniture and equipment   7,912    7,912 
Shipping and other equipment   1,575    1,575 
Total   301,359    301,159 
Accumulated depreciation   (28,281)   (17,135)
Property and equipment, net  $273,078   $284,024 

 

Depreciation expense was $10,946 and $6,772 for the years ended December 31, 2022 and 2021, respectively.

 

Note 6 – Other assets

 

Other assets consist of the following:

 

   December 31, 2022   December 31, 2021 
         
Prepaid consulting  $7,537   $108,673 
Deposit   4,123    39,823 
Licenses, net   3,002,960    129,075 
Total  $3,014,620   $277,571 

 

F-11
 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Notes to Financial Statements

December 31, 2022

 

Prepaid consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above consists of the following:

 

   December 31, 2022   December 31, 2021 
         
Licenses  $3,261,122   $153,552 
Accumulated amortization   (258,162)   (24,477)
Licenses, net  $3,002,960   $129,075 

 

Amortization expense for the years ended December 31, 2022 and 2021 was $233,685 and $24,477, respectively.

 

As of June 1, 2019, we entered into a license agreement, which will be amortized over the life of the Patent. The Patent expires December 31, 2032. The Exclusive Patent License to the Jadi Cell is for use under the designated areas of CTE (Chronic Traumatic Encephalopathy), and TBI (Traumatic Brain Injury). The Jadi Cell is an cGMP grade and Research grade manufactured allogenic mesenchymal stem cells derived from US Patent No.: 9,803,176 B2. Forward looking the Company intends to file an Investigational New Drug Application (IND) for brain injured patients who have been intensively cared for and mechanically ventilated due to covid-19 illness and a second IND for CTE/TBI as well in keeping with the spirit of the licensing agreement to advance the Jadi Cell through to FDA Approval for CTE/TBI.

 

On February 9, 2021, the Company issued a Convertible Promissory Note (CPN) to JadiCell LLC that was never fully executed while the parties worked to finalize the agreement that resulted in an Exclusive Patent License Agreement (EPLA) being executed on September 15, 2021. Finally, a Settlement Agreement was entered into on February 23, 2022. On February 23, 2022, we issued 149,402,390 shares of common stock, valued at $0.0208 per share, for the EPLA, with a final value of the license being recorded at $3,107,570. The Patent expires December 31, 2032. The Exclusive Patent License to the Jadi Cell is for use under the designated areas of all applicable Lung Pathology. The Jadi Cell is an cGMP grade and Research grade manufactured allogenic mesenchymal stem cells derived from US Patent No.: 9,803,176 B2 and will be amortized over the 10 year life of the Patent. As of March 25, 2022, we entered into a asset transfer and license agreement, which will be amortized over the life of the agreement. The agreement is until March 24, 2027. The Company has made an initial payment of $200,000. Within six months, the Company will make a second payment of $1.8 million. The agreement is in default and the initial paymentof $200,000 was expensed to research & development.

 

Note 7 – Convertible notes payable

 

At various times during the year ended December 31, 2022, the Company entered into convertible promissory notes with principal amounts totaling $544,000 with third parties for which the proceeds were used for operations. The Company received net proceeds of $505,000, and a $39,000 original issuance discount was recorded. The convertible promissory notes incur interest at a rate of 10% per annum and mature on dates ranging from January 1, 2023 to December 5, 2023. The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to a percentage of 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable con’ersion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%. The Company was required to reserve at December 31, 2022 a total of 267,136,056 common shares in connection with these promissory notes.

 

F-12
 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Notes to Financial Statements

December 31, 2022

 

Note 7 – Convertible notes payable (continued)

 

At various times during the year ended December 31, 2021, the Company entered into convertible promissory notes with principal amounts totaling $572,250 with third parties for which the proceeds were used for operations. The Company received net proceeds of $538,750, and a $33,500 original issuance discount was recorded. The convertible promissory notes incur interest at rates ranging from 10% to 12% per annum and mature on dates ranging from January 25, 2022 to December 15, 2022. The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to apercentage ranging from 61% to 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%. The Company was required to reserve at December 31, 2021 total of 95,273,690 common shares in connection with these promissory notes.

 

Derivative liabilities

 

These convertible promissory notes are convertible into a variable number of shares of common stock for which there is not a floor to the number of common stock we might be required to issue. Based on the requirements of ASC 815 Derivatives and Hedging, the conversion feature represented an embedded derivative that is required to be bifurcated and accounted for as a separate derivative liability. The derivative liability is originally recorded at its estimated fair value and is required to be revalued at each conversion event and reporting period. Changes in the derivative liability fair value are reported in operating results each reporting period.

 

For the notes issued during the year ended December 31, 2022, the Company valued the conversion features on the date of issuance resulting in initial liabilities totaling $674,971. Since the fair value of the derivative was in excess of the proceeds received, a full discount to convertible notes payable and a day one loss on derivative liabilities of $171,245 was recorded during the year ended December 31, 2022. The Company valued the conversion feature using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $0.0058 to $0.0143, the closing stock price of the Company’s common stock on the dates of valuation ranging from $0.008 to $0.0272, an expected dividend yield of 0%, expected volatilities ranging from 148%-216%, risk-free interest rate ranging from 0.48% to 4.77%, and an expected term of one year.

 

During the year ended December 31, 2022, convertible notes principal plus their accrued interest totaling $774,176 were converted into 68,193,798 shares of common stock, of which 4,054,054 are yet to be issued as of December 31, 2022. At each conversion date, the Company recalculated the value of the derivative liability associated with the convertible note recording a gain (loss) in connection with the change in fair market value. In addition, the fair value of the shares of common stock issued in excess or deficit of the pro-rata portion of the derivative liability as compared to the portio of the convertible note converted was recorded as a loss or gain on derivative liabilities. During the year ended December 31, 2022, the Company recorded $39,770 to gain on derivative liabilities. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $0.0038 to $0.016, the closing stock price of the Company’s common stock on the dates of valuation ranging from $0.006 to $0.026, an expected dividend yield of 0%, expected volatility ranging from 63% to 191%, risk-free interest rates ranging from 0.51% to 4.74%, and expected terms ranging from 0.44 to 0.50 years.

 

On December 31, 2022, the derivative liabilities on the remaining convertible notes were revalued at $202,144 resulting in a gain of $291,123 for the year ended December 31, 2022 related to the change in fair value of the derivative liabilities. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following assumptions: exercise price of $0.0038, the closing stock price of the Company’s common stock on the date of valuation of $0.006, an expected dividend yield of 0%, expected volatility ranging from 96% to 120%, risk-free interest rate of 4.71%, and an expected term ranging from 0.49 to 0.93 years.

 

For the notes issued during the year ended December 31, 2021, the Company valued the conversion features on the date of issuance resulting in initial liabilities totaling $1,077,756. Since the fair value of the derivative was in excess of the proceeds received, a full discount to convertible notes payable and a day one loss on derivative liabilities of $539,006 was recorded during the year ended December 31, 2021. The Company valued the conversion feature using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $0.0039 to $0.0351, the closing stock price of the Company’s common stock on the dates of valuation ranging from $0.0217 to $0.0540, an expected dividend yield of 0%, expected volatilities ranging from 197%-264%, risk-free interest rate ranging from 0.05% to 0.29%, and an expected term of one year.

 

F-13
 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Notes to Financial Statements

December 31, 2022

 

Note 7 – Convertible notes payable (Continued)

 

During the year ended December 31, 2021, convertible notes principal plus their accrued interest totaling $529,735 were converted into 21,690,671 shares of common stock. At each conversion date, the Company recalculated the value of the derivative liability associated with the convertible note recording a gain (loss) in connection with the change in fair market value. In addition, the pro-rata portion of the derivative liability as compared to the portion of the convertible note converted was reclassed to additional paid-in capital. During the year ended December 31, 2021, the Company recorded $489,279 to additional paid-in capital. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $0.0136 to $0.035, the closing stock price of the Company’s common stock on the dates of valuation ranging from $0.022 to $0.057, an expected dividend yield of 0%, expected volatility ranging from 125% to 251%, risk-free interest rates ranging from 0.06% to 0.29%, and expected terms ranging from 0.48 to 0.50 years.

 

On December 31, 2021, the derivative liabilities on the remaining five convertible notes were revalued at $531,525 resulting in a gain of $494,501 for the year ended December 31, 2021 related to the change in fair value of the derivative liabilities. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $0.0123 to $0.0127, the closing stock price of the Company’s common stock on the date of valuation of $0.029, an expected dividend yield of 0%, expected volatility ranging from 165% to 218%, risk-free interest rate of 0.39%, and an expected term ranging from 0.53 to 0.96 years.

 

The Company amortizes the discounts over the term of the convertible promissory notes using the straight line method which is similar to the effective interest method. During the years ended December 31, 2022 and 2021, the Company amortized $593,463 and $541,612 to interest expense, respectively. As of December 31, 2022, discounts of $175,063 remained for which will be amortized through December 2023.

 

Note 8 – Notes payable-related parties

 

Notes payable-related parties consist of:

 

  

December 31,

2022

  

December 31,

2021

 
         
  $-   $2,356 
Note payable – Scientific Advisory Board Member, unsecured, including interest at 10% per annum, with a maturity date of December 31, 2019  $-   $2,356 
           
One notes payable – Chief Executive Officer, unsecured, including interest at 8% and 10% per annum, respectively, with maturity date of December 31, 2019   29,090    27,577 
           
One note payable – Chief Executive Officer, unsecured, no interest, paid from a % of revenues   534,448    534,544 
           
Note payable – Chief Financial Officer, unsecured, including interest at 8% per annum, with a maturity date of December 31, 2019   124,800    118,400 
           
Three notes payable – Business Advisory Board Member, unsecured, including interest at 8% and 10% per annum, convertible into common stock at $0.005 and $0.004, respectively, with maturity date of April 20, 2019   30,334    282,334 
    988,672    965,211 
           
   $988,672   $965,211 

 

F-14
 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Notes to Financial Statements

December 31, 2022

 

Note 9 – Related party transactions

 

As of December 31, 2019 and 2018, the Company had accrued officers’ salary of $439,534 and $663,100, respectively. One of the officers settled with the company for a note payable that is unsecured on November 8, 2019 and doesn’t accrue interest and will be paid as 0.5% of revenues. This decreased accrued officers’ salary. The note is still outstanding as of December 31, 2022 and 2021. Payments for the years ended December 31, 2022 and 2021 was $97 and $101, respectively.

 

In 2021, we issued 7,544,848 shares of common stock for $239,800 of accrued salaries to one officer of the Company under a Restricted Stock Award.

 

On June 18, 2021, we issued 2,000,000 shares of common stock, to one officer and one director of the Company under a Restricted Stock Award for $94,600.

 

On November 30, 2021, we issued 7,000,000 shares of common stock to four officers and one director under a Restricted Stock Award for $224,000.

 

In 2022, we issued 4,812,259 shares of common stock for $67,399 of accrued salaries to one officer of the Company under a Restricted Stock Award.

 

On April 5, 2022, we issued 7,000,000 shares of common stock, to four officers and one director of the Company under a Restricted Stock Award for $175,700.

 

On September 8, 2022, we issued 4,000,000 shares of common stock to one officer and one director under a Restricted Stock Award for $46,400.

 

On November 2, 2022, we issued 3,000,000 shares of common stock to one director under a Restricted Stock Award for $29,700.

 

On December 30, 2022, we committed to issue 14,000,000 shares of common stock, to four officers and one director of the Company under a Restricted Stock Award for $84,000, which were subsequently issued on January 3, 2023.

 

F-15
 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Notes to Financial Statements

December 31, 2022

 

Note 10 – Income taxes

 

The Company is subject to United States federal and state income taxes at an approximate rate of 30%. The reconciliation of the provision for income taxes at the United States federal statutory rate compared to the Company’s income tax expense as reported is as follows:

 

   December 31, 2022   December 31, 2021 
         
Expected income tax at statutory rate  $(709,666)  $(621,735)
State tax   (101,347)   168 
Permanent differences   405,376    404,872 
Other   -    (71,992)
Change in valuation allowance   406,437    289,487 
Provision for income taxes  $800   $800 

 

The significant components of deferred income tax assets and liabilities at December 31, 2022 and 2021 are as follows:

 

   December 31, 2022   December 31, 2021 
         
Net operating loss carry-forward  $2,364,249   $1,957,812 
Valuation allowance   (2,364,249)   (1,957,812)
Net deferred tax asset  $-   $- 

 

The Company has Federal net operating loss carryforwards of approximately $9.4 million and $7.5 million as of December 31, 2022 and 2021, respectively. The Company has state net operating loss carryforwards of approximately $7.4 million and $5.5 million as of December 31, 2022 and 2021, respectively. The net operating loss carryforwards are available to offset taxable income in future years, of which approximately $5 million expires beginning in fiscal 2032. Net operating loss carrforwards incurred after 2018 are carried on indefinitely.

 

As of and for the years ended December 31, 2022 and 2021, management does not believe the Company has any uncertain tax positions. Accordingly, there are no recognized tax benefits at December 31, 2022 and 2021.

 

The Company is subject to tax in the United States and files tax returns in the U.S. Federal jurisdiction and California state jurisdiction. The Company is subject to U.S. Federal, state and local income tax examinations by tax authorities starting in 2019. The Company currently is not under examination by any tax authority.

 

Note 11 – Equity

 

Our authorized capital stock consists of an aggregate of 3,505,000,000 shares, comprised of 3,500,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, which may be issued in various series from time to time and the rights, preferences, privileges and restrictions of which shall be established by our board of directors. As of December 31, 2022, we have 2,617,390,830 shares of common stock and 2 preferred shares issued and outstanding.

 

In 2021, we issued 4,850,075 shares of common stock for an investment in the Company’s Private Placement of $285,500.

 

In 2021, we issued 21,000,000 shares of common stock, valued at $858,900 for consulting services.

 

In 2021, we issued 8,341,723 shares of common stock, valued at $239,799 for salaries.

 

In 2021, we issued 1,500,000 shares of common stock, valued at $58,900 for land development.

 

In 2021, we issued 21,690,671 shares of common stock for the conversion of convertible notes of $1,019,014.

 

F-16
 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Notes to Financial Statements

December 31, 2022

 

Note 11 – Equity (continued)

 

In 2022, we issued 44,500,000 shares of common stock for an investment in the Company’s Private Placement of $445,000.

 

In 2022, we issued 32,412,577 shares of common stock, valued at $691,520 for consulting services.

 

In 2022, we committed to issue 3,000,000 shares of common stock, valued at $18,000 for consulting services, which were issued on January 3, 2023.

 

In 2022, we issued 4,812,259 shares of common stock, valued at $67,399 for salaries.

 

In 2022, we issued 149,402,390 shares of common stock, valued at $3,107,570 for a license.

 

In 2022, we issued 11,000,000 shares of common stock, valued at $242,320 for prepaid fees.

 

In 2022, we issued 64,139,744 shares of common stock for the conversion of convertible notes of $1,313,772.

 

In 2022, we committed to issue 4,054,054 shares of common stock for the conversion of convertible notes of $15,000, which were issued on January 3, 2023.

 

Note 12 – Legal proceedings

 

From time to time, claims are made against us in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from selling one or more products or engaging in other activities. The occurrence of an unfavorable outcome in any specific period could have a material adverse effect on our results of operations for that period or future periods.

 

However, as of the date of this report, management believes the outcome of currently identified potential claims and lawsuits will not have a material adverse effect on our financial condition or results of operations.

 

Note 13 – Commitments and Contingencies

 

Effective March 1, 2020, the Company entered into a fifth amendment to a Lease Agreement for property located in Oceanside, CA. The lease consists of approximately 1,700 square feet and the amendment is for a term of 36 months and expires on April 30, 2023.

 

During the year ended December 31, 2022 and 2021, the Company incurred rent expense of $25,044 and $22,768.

 

The lease will expire in 2023. The weighted average discount rate used for this lease is 5% (average borrowing rate of the Company). Maturities of Leases were:

 

Future minimum lease payments as of December 31, 2022 are as follows:

 

For the year ending December 31,    
      
2023  $8,612 

 

Effective November 8, 2019, the Company entered into a royalty agreement with one of the officers, refer to Note 9.

 

Note 14 – Subsequent events

 

On January 3, 2023, we issued 4,054,054 shares of common stock for the partial conversion of $15,000 for convertible note dated June 27, 2022.

 

On January 3, 2023, we issued 17,000,000 shares of common stock, valued at $0.006 per share, for consulting services.

 

On January 4, 2023, we issued 10,052,083 shares of common stock for the complete conversion of $36,188 for convertible note dated June 27, 2022.

 

On January 9, 2023, we issued 4,081,632 shares of common stock for $20,000 of accrued salaries.

 

F-17
 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Notes to Financial Statements

December 31, 2022

 

Note 14 – Subsequent events (continued)

 

On January 9, 2023, we issued 4,000,000 shares of common stock, valued at $0.049 per share, for consulting services.

 

On February 6, 2023, we issued 6,060,606 shares of common stock for the partial conversion of $20,000 for convertible note dated August 2, 2022.

 

On February 7, 2023, we issued 11,386,719 shares of common stock for the complete conversion of $36,438 for convertible note dated August 2, 2022.

 

On February 21, 2023, we issued 60,224,825 shares of common stock, valued at $0.00216 per share, for an investment in the Company’s Private Placement.

 

On or about March 21, 2023, the Board of Directors of Therapeutic Solutions International, Inc. (“TSOI”), by unanimous approval, and with the unanimous approval of the Preferred A Stock holders representing at least 51% of all shareholders with the right to vote, pursuant to Nevada Revised Statutes Section NRS 78.215, has approved a one-time dividend, to be awarded to stockholders of TSOI in subsidiary Campbell Neurosciences, Inc., a Delaware corporation (“CNSI”). To receive the dividend by future election you must hold TSOI common at the market close of April 7, 2023. The dividend rate of conversion shall be for every share of TSOI common you will receive 0.0034 shares of CNSI.

 

TSOI, which owns 15,660,000 (31%) of the shares of CNSI common stock, would like to issue a dividend consisting of 10,000,000 shares of its holdings in CNSI to TSOI shareholders at a ratio of 0.00365 shares of CNSI stock for each one (1) share owned in TSOI stock as of April 7, 2023 (“Dividend Offer”) on April 8, 2023 (“Dividend Offer Date”). The Dividend Offer will remain open for Ninety (90) days from the Dividend Offer Date.

 

A letter will be mailed to every shareholder of record details of how to accept the Dividend Offer and a fully pre-paid return acceptance letter containing the necessary information for issuance. In addition, a Shareholder’s Rights Agreement will be enclosed, an executed copy to be returned with acceptance.

 

Required forms and documents shall be filed with FINRA describing the identity of the parties and the Dividend Offer timely.

 

In accordance with ASC 855, the Company has analyzed its operations subsequent to December 31, 2022 through the date these financial statements were issued, and has determined that it does not have any other material subsequent events to disclose in these financial statements.

 

F-18

 

 

 

 EX-31.1 2 ex31-1.htm

 

Exhibit 31.1

 

Section 302 Certification of Principal Executive Officer

 

I, Timothy G. Dixon, certify that:

 

1. I have reviewed this annual report on Form 10-K of Therapeutic Solutions International, Inc.

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15€ and 15d–15€) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: March 29, 2023

 

/s/ Timothy G. Dixon  
Timothy G. Dixon  
President and Chief Executive Officer  
(Principal Executive Officer)  

 

 

 

 EX-31.2 3 ex31-2.htm

 

Exhibit 31.2

 

Section 302 Certification of Principal Executive Officer

 

I, Timothy G. Dixon, certify that:

 

1. I have reviewed this annual report on Form 10-K of Therapeutic Solutions International, Inc.

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15€ and 15d–15€) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: March 29, 2023

 

/s/ Timothy G. Dixon  
Timothy G. Dixon  
Chief Financial Officer  
(Principal Financial Officer  

 

 

 

 

 EX-32.1 4 ex32-1.htm

 

Exhibit 32.1

 

SARBANES-OXLEY SECTION 906 CERTIFICATION

 

In connection with the Annual Report on Form 10-K of Therapeutic Solutions International, Inc. (the “Company”) for the year ending December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Timothy G. Dixon, Chief Executive Officer, President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: March 29, 2023

 

By: /s/ Timothy G. Dixon  
  Timothy G. Dixon  
  Chief Executive Officer and President  
  (Principal Executive Officer)  
  Chief Financial Officer  
  (Principal Financial Officer)  

 

 

 

 

 GRAPHIC 5 form10-k_004.jpg begin 644 form10-k_004.jpg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tsoi-20221231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Changes in Shareholders' Deficit link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Organization and Business Description link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Basis of presentation and significant accounting policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Restricted cash link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Prepaid expense and other current assets link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Fixed assets link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Other assets link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Convertible notes payable link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Notes payable-related parties link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Related party transactions link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Legal proceedings link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Subsequent events link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Basis of presentation and significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Basis of presentation and significant accounting policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Prepaid expense and other current assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Fixed assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Other assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Notes payable-related parties (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Income taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Organization and Business Description (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Schedule of Change in Derivative Liability (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Basis of presentation and significant accounting policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Restricted cash (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Schedule of Fixed Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Fixed assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Schedule of Other Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Schedule of Net Licenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Other assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Convertible notes payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Schedule of Notes Payable Related Parties (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Schedule of Notes Payable Related Parties (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Related party transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Schedule of Income tax Expense (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Income taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Schedule of Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Subsequent events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 tsoi-20221231_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 tsoi-20221231_def.xml XBRL DEFINITION FILE EX-101.LAB 9 tsoi-20221231_lab.xml XBRL LABEL FILE Equity Components [Axis] Preferred Stock [Member] Class of Stock [Axis] Series A Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Shares To Be Issued [Member] Subscription Receivable [Member] Retained Earnings [Member] Statistical Measurement [Axis] Maximum [Member] Long-Lived Tangible Asset [Axis] Land [Member] Vehicles [Member] Computer Equipment [Member] Office Furniture and Equipment [Member] Shipping and Other Equipment [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Exclusive patent license agreement [Member] Short-Term Debt, Type [Axis] Convertible Promissory Note [Member] Assets Transfer and License Agreement [Member] Scenario [Axis] Initial Payment [Member] Second Payment [Member] Long-Term Debt, Type [Axis] Minimum [Member] Financial Instrument [Axis] Derivative [Member] Measurement Input Type [Axis] Measurement Input, Conversion Price [Member] Measurement Input, Share Price [Member] Measurement Input, Expected Dividend Rate [Member] Measurement Input, Price Volatility [Member] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Expected Term [Member] Convertible Notes [Member] Convertible Notes Payable [Member] Remaining Convertible Notes [Member] Measurement Input, Exercise Price [Member] Debt Instrument [Axis] Notes Payable One [Member] Notes Payable Two [Member] Notes Payable Three [Member] Notes Payable Four [Member] Notes Payable Five [Membe] Title of Individual [Axis] Scientific Advisory Board [Member] Chief Executive Officer [Member] Chief Financial Officer [Member] Business Advisory Board [Member] Officer [Member] One Officers [Member] Award Type [Axis] Restricted Stock [Member] Income Statement Location [Axis] Accrued Salaries [Member] One Officer and One Director [Member] Four Officer and One Director [Member] Four Officer One Director [Member] Sale of Stock [Axis] Private Placement [Member] Product and Service [Axis] Consulting Services [Member] Salaries [Member] Land Development [Member] Subsequent Event Type [Axis] Subsequent Event [Member] License [Member] Balance Sheet Location [Axis] Prepaid Fees [Member] Preferred Class A [Member] Director [Member] Investment, Name [Axis] Campbell Neurosciences Inc [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Auditor Firm ID Auditor Name Auditor Location Statement of Financial Position [Abstract] ASSETS Current assets: Cash and cash equivalents Restricted cash Accounts receivable Inventory Prepaid expenses and other current assets Total current assets Property and equipment, net Right-of-use asset Other assets Total assets LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT) Current liabilities: Accounts payable Accounts payable-related parties Accrued expenses and other current liabilities Lease liability Notes payable, current portion Convertible notes payable, net of discount of $175,063 and $225,800, at December 31, 2022 and 2021, respectively Notes payable-related parties, net Derivative liabilities Total current liabilities LONG TERM LIABILITIES Notes payable, net of current portion Lease liability, net of current portion TOTAL LIABILITIES Commitments and contingencies Shareholders’ Equity (Deficit): Preferred stock, $0.001 par value; 5,000,000 shares authorized, 2 shares and 0 shares issued and outstanding at December 31, 2022 and 2021, respectively Common stock, $0.001 par value; 3,500,000,000 shares authorized; 2,617,390,830 and 2,311,123,860 shares issued and outstanding at December 31, 2022 and 2021, respectively. Additional paid-in capital Shares to be issued Subscription receivable Accumulated deficit Total shareholders’ equity (deficit) Total liabilities and shareholders’ equity (deficit) Debt instrument, unamortized discount, current Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares, issued Common stock, shares, outstanding Income Statement [Abstract] Net sales Cost of goods sold Gross profit Operating expenses: General and administrative Salaries, wages, and related costs Consulting fees Legal and professional fees Research and development Total operating expenses Loss from operations Other income (expense): Loss on derivative liabilities Change in fair value of derivative liabilities Interest expense Other expense Total other income (expense) LOSS BEFORE PROVISION FOR INCOME TAXES Provision for income taxes Net loss Net loss per share - basic and diluted Weighted average shares outstanding - basic and diluted Statement [Table] Statement [Line Items] Balance Balance, shares Common stock issued for services Common stock issued for services, shares Common stock issued for prepaid fees Common stock issued for prepaid fees, shares Common stock issued for salaries Common stock issued for salaries, shares Common stock issued for cash Common stock issued for cash, shares Common stock issued for land development Common stock issued for land development, shares Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares Relief of derivative liabilities Net loss Common stock issued for license Common stock issued for license, shares Issuance of preferred stock Issuance of preferred stock, shares Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation to consultants Stock-based compensation to related parties Loss on derivative liabilities Change in fair value of derivative liabilities Amortization of prepaid stock-based compensation Amortization of debt discount Patent amortization Depreciation Changes in operating assets and liabilities: Accounts receivable Inventory Prepaid expenses and other current assets Right-of-use asset Accounts payable Accounts payable - related parties Accrued expenses and other current liabilities Lease liability Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchases of property and equipment Deposits Net cash used in investing activities Cash flows from financing activities Payments on notes payable to related party Proceeds from convertible notes payable Payments on notes payable Proceeds from sale of common stock Net cash provided by financing activities Net increase (decrease) in cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Supplemental cash flow information: Cash paid for interest Cash paid for income taxes Non-cash investing and financing transactions: Original issuance discount on convertible notes payable Debt discount recorded in connection with derivative liability Common stock issued in conversion of convertible notes payable and interest Property and equipment purchased with note payable Common stock issued for prepaid fees Common stock issued for accrued salaries Accrued interest added to principal Common stock issued for license Common stock issued for land development Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets: Cash and cash equivalents Restricted cash Total cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows: Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Business Description Accounting Policies [Abstract] Basis of presentation and significant accounting policies Cash and Cash Equivalents [Abstract] Restricted cash Prepaid Expense And Other Current Assets Prepaid expense and other current assets Property, Plant and Equipment [Abstract] Fixed assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Other assets Convertible Notes Payable Convertible notes payable Debt Disclosure [Abstract] Notes payable-related parties Related Party Transactions [Abstract] Related party transactions Income Tax Disclosure [Abstract] Income taxes Equity [Abstract] Equity Commitments and Contingencies Disclosure [Abstract] Legal proceedings Commitments and Contingencies Subsequent Events [Abstract] Subsequent events Basis of Presentation Principles of Consolidation Accounts Receivable Revenue Recognition Cash and Cash Equivalents Inventories Derivative Liabilities Fair Value of Financial Instruments Use of Estimates Comprehensive Loss Net Loss Per Share Depreciation and Amortization Intangible Assets Long-lived Assets Shipping and Handling Advertising Research and Development Income Taxes Stock-Based Compensation Leases Schedule of Change in Derivative Liability Schedule of Prepaid Expenses and Other Current Assets Schedule of Fixed Assets Schedule of Other Assets Schedule of Net Licenses Schedule of Notes Payable Related Parties Schedule of Income tax Expense Schedule of Deferred Tax Assets and Liabilities Schedule of Future Minimum Lease Payments Entity incorporation date Unusual or infrequent item, description Net loss Beginning Balance Issuance of new derivative liabilities Conversions Change in fair market value of derivative liabilities Ending Balance Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Allowance for doubtful accounts Payments description Cash, FDIC insured amount Antidilutive securities excluded from computation of earnings per share Depreciation expense Amortization expense Advertising expense Research and development expense Lease liability Restricted cash and non-cash equivalents Annual interest rate Restricted cash description Schedule Of Prepaid Expenses And Other Current Assets Prepaid consulting Insurance Prepaid costs Total Total Accumulated depreciation Property and equipment, net Prepaid consulting Deposit Licenses, net Total Licenses Accumulated amortization Licenses, net Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Amortization expenses Stock Issued During Period, Shares, New Issues Share Price Stock Issued During Period, Value, New Issues [custom:PatentExpiresAgreementDate] Finite-Lived Intangible Assets, Remaining Amortization Period Amortized life of agreement Payments to Acquire Intangible Assets Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Line Items] Debt principal amount Debt original issuance discount Debt discount Interest rate percentage Debt maturity date description Debt conversion description Common shares reserve Derivative issuance liability Loss on derivative liability Derivative liability, measurement input Derivative liability, measurement input term Debt conversion of convertible shares, value Debt conversion of convertible shares Common stock, subscribed and issued Gain loss on derivative liabilities Additional paid in capital on convertible debt features Interest expenses Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Notes payable related party, current Notes payable related party, non-current Debt interest percentage Debt maturity date Share price Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Accrued Salaries, Current Related Party Transaction, Rate Payments Number of common stock issued Number of common stock issued, value Expected income tax at statutory rate State tax Permanent differences Other Change in valuation allowance Provision for income taxes Net operating loss carry-forward Valuation allowance Net deferred tax asset Federal and state income taxes rate Federal net operating loss carryfowards State net operating loss carryfowards Net operating loss carryforwards are available to offset taxable income Net operating loss carryforwards, expiration, description Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary, Sale of Stock [Line Items] Aggregate authorized capital Preferred Stock, Shares Authorized Common stock, shares outstanding Conversion of convertible notes Common stock issued for cash, shares Common stock issued for cash, shares 2023 Area of land Lease contract term Lease expiration date Payment for rent Operating lease discount rate Subsequent Event [Table] Subsequent Event [Line Items] Conversion of common stock, shares Conversion of common stock Shares issued for consulting services Shares issued price per share Right of voting Dividend conversion rate Common stock shares percentage Common stock divident Dividend, description Dividend offer date Prepaid consulting current. Prepaid consulting, noncurrent. Licenses noncurrent. Shares To Be Issued [Member] Subscription Receivable [Member] Exclusive patent license agreement [Member] Convertible Promissory Note [Member] Patent expires agreement date. Common stock issued for prepaid fees. Common stock issued for prepaid fees, shares. Amortized life of agreement. Assets Transfer and License Agreement [Member] Initial Payment [Member] Second Payment [Member] Relief of derivative liabilities. Stock issued during period value for license. Stock issued during period shares for license. Stock issued during period value new issues preferred stock. Share based compensation to related parties. Amortization of prepaid stock based compensation. Increase decrease in right of use asset. Common stock issued for prepaid fees value. Common stock issued for accrued salaries value. Accrued interest added to principal. Common stock issued for license value. Wholesale Purchase Price And Payments Description. Derivative liability, measurement input term. Remaining Convertible Notes [Member] Deferred Costs Capitalized Prepaid And Other Assets [Text Block] Shares to be issued. Schedule Of Net Licenses [Table Text Block] Stock issued during period values for salaries. Stock issued during period shares for salaries. Stock issued during period shares new issues preferred stock. Annual interest rate. Notes Payable Related Parties [Table Text Block] Scientific Advisory Board [Member] Notes Payable One [Member] Business Advisory Board [Member] Notes Payable Two [Member] Notes Payable Three [Member] Notes Payable Four [Member] Notes Payable Five [Membe] One Officers [Member] Four Officer One Director [Member] Effective Income tax rate reconciliation at federal statutory income tax and state and local iincome taxes rate. Net operating loss carryforwards are available to offset taxable income. Net operating loss carryforwards, expiration, description. Consulting Services [Member] Salaries [Member] Land Development [Member] Prepaid Fees [Member] Convertible Notes [Member] One Officer and One Director [Member] Four Officer and One Director [Member] Office Furniture and Equipment [Member] Shipping and Other Equipment [Member] Shipping and Handling Cost [Policy Text Block] Dividend conversion rate. Campbell Neurosciences Inc [Member] Accrued Salaries [Member] Increase decrease in Accounts payable - related parties. Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Note, Subscriptions Receivable Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) Interest Expense Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Shares, Outstanding Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense and Other Assets IncreaseDecreaseInRightOfUseAsset Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Increase (Decrease) in Operating Lease Liability Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Repayments of Related Party Debt Repayments of Notes Payable Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations CommonStockIssuedForPrepaidFeesValue CommonStockIssuedForLicenseValue Stock Issued Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash and Cash Equivalents Disclosure [Text Block] Other Assets Disclosure [Text Block] Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs Operating Lease, Liability Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Prepaid consulting, noncurrent Finite-Lived Intangible Assets, Accumulated Amortization Finite-Lived Intangible Assets, Net Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance EX-101.PRE 10 tsoi-20221231_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2022
Mar. 29, 2023
Jun. 30, 2022
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2022    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2022    
Current Fiscal Year End Date --12-31    
Entity File Number 000-54554    
Entity Registrant Name Therapeutic Solutions International, Inc.    
Entity Central Index Key 0001419051    
Entity Tax Identification Number 45-1226465    
Entity Incorporation, State or Country Code NV    
Entity Address, Address Line One 701 Wild Rose Lane    
Entity Address, City or Town Elk City    
Entity Address, State or Province ID    
Entity Address, Postal Zip Code 83525    
City Area Code 760    
Local Phone Number 295-7208    
Title of 12(g) Security Common Stock, $0.001 par value per share    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current No    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 1,296,570,604
Entity Common Stock, Shares Outstanding   2,734,250,749  
Auditor Firm ID 5525    
Auditor Name Fruci & Associates II, PLLC    
Auditor Location Spokane, Washington    
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 18,040 $ 94,036
Restricted cash 11,003 10,223
Accounts receivable 25,398 16,613
Inventory 42,428 39,817
Prepaid expenses and other current assets 212,352 959,307
Total current assets 309,221 1,119,996
Property and equipment, net 273,078 284,024
Right-of-use asset 8,612 34,184
Other assets 3,014,620 277,571
Total assets 3,605,531 1,715,775
Current liabilities:    
Accounts payable 401,992 394,035
Accounts payable-related parties 7,209 9,791
Accrued expenses and other current liabilities 531,783 487,208
Lease liability 8,612 25,374
Notes payable, current portion 4,638 4,071
Convertible notes payable, net of discount of $175,063 and $225,800, at December 31, 2022 and 2021, respectively 65,187 79,200
Notes payable-related parties, net 988,672 965,211
Derivative liabilities 202,144 531,525
Total current liabilities 2,210,237 2,496,415
LONG TERM LIABILITIES    
Notes payable, net of current portion 10,507 15,532
Lease liability, net of current portion 8,810
TOTAL LIABILITIES 2,220,744 2,520,757
Commitments and contingencies
Shareholders’ Equity (Deficit):    
Preferred stock, $0.001 par value; 5,000,000 shares authorized, 2 shares and 0 shares issued and outstanding at December 31, 2022 and 2021, respectively
Common stock, $0.001 par value; 3,500,000,000 shares authorized; 2,617,390,830 and 2,311,123,860 shares issued and outstanding at December 31, 2022 and 2021, respectively. 2,617,392 2,311,125
Additional paid-in capital 16,334,129 10,899,139
Shares to be issued 126,324
Subscription receivable (21,000) (21,000)
Accumulated deficit (17,672,058) (13,994,246)
Total shareholders’ equity (deficit) 1,384,787 (804,982)
Total liabilities and shareholders’ equity (deficit) $ 3,605,531 $ 1,715,775
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Debt instrument, unamortized discount, current $ 175,063 $ 225,800
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 2 0
Preferred stock, shares outstanding 2 0
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 3,500,000,000 3,500,000,000
Common stock, shares, issued 2,617,390,830 2,311,123,860
Common stock, shares, outstanding 2,617,390,830 2,311,123,860
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]    
Net sales $ 206,767 $ 145,956
Cost of goods sold 79,440 42,544
Gross profit 127,327 103,412
Operating expenses:    
General and administrative 491,928 138,710
Salaries, wages, and related costs 444,865 436,555
Consulting fees 432,033 264,540
Legal and professional fees 397,302 773,203
Research and development 1,441,128 794,750
Total operating expenses 3,207,256 2,407,758
Loss from operations (3,079,929) (2,304,346)
Other income (expense):    
Loss on derivative liabilities (131,475) (539,006)
Change in fair value of derivative liabilities 291,123 494,501
Interest expense (646,089) (611,794)
Other expense (110,642)
Total other income (expense) (597,083) (656,299)
LOSS BEFORE PROVISION FOR INCOME TAXES (3,677,012) (2,960,645)
Provision for income taxes 800 800
Net loss $ (3,677,812) $ (2,961,445)
Net loss per share - basic and diluted $ (0.00) $ (0.00)
Weighted average shares outstanding - basic and diluted 2,528,062,958 2,263,126,970
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Changes in Shareholders' Deficit - USD ($)
Preferred Stock [Member]
Series A Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Shares To Be Issued [Member]
Subscription Receivable [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2020 $ 2,233,742 $ 7,041,960 $ (21,000) $ (11,032,801) $ (1,778,099)
Balance, shares at Dec. 31, 2020 2,233,741,391          
Common stock issued for services $ 21,000 837,900 858,900
Common stock issued for services, shares 21,000,000          
Common stock issued for prepaid fees $ 20,000 1,452,450 1,472,450
Common stock issued for prepaid fees, shares 20,000,000          
Common stock issued for salaries $ 8,342 231,457 239,799
Common stock issued for salaries, shares 8,341,723          
Common stock issued for cash $ 4,850 280,649 285,499
Common stock issued for cash, shares 4,850,075          
Common stock issued for land development $ 1,500 57,400 58,900
Common stock issued for land development, shares 1,500,000          
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities $ 21,691 508,044 529,735
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares 21,690,671          
Relief of derivative liabilities 489,279 489,279
Net loss (2,961,445) (2,961,445)
Balance at Dec. 31, 2021 $ 2,311,125 10,899,139 (21,000) (13,994,246) (804,982)
Balance, shares at Dec. 31, 2021 2,311,123,860          
Common stock issued for services $ 32,413 557,107 102,000 691,520
Common stock issued for services, shares 32,412,577          
Common stock issued for prepaid fees $ 11,000 231,320 242,320
Common stock issued for prepaid fees, shares 11,000,000          
Common stock issued for salaries $ 4,812 62,587 67,399
Common stock issued for salaries, shares 4,812,259          
Common stock issued for cash $ 44,500 400,500 445,000
Common stock issued for cash, shares 44,500,000          
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities $ 64,140 1,225,308 24,324 1,313,772
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares 64,139,744          
Net loss (3,677,812) (3,677,812)
Common stock issued for license $ 149,402 2,958,168 3,107,570
Common stock issued for license, shares 149,402,390          
Issuance of preferred stock
Issuance of preferred stock, shares 2          
Balance at Dec. 31, 2022 $ 2,617,392 $ 16,334,129 $ 126,324 $ (21,000) $ (17,672,058) $ 1,384,787
Balance, shares at Dec. 31, 2022 2 2,617,390,830          
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities    
Net loss $ (3,677,812) $ (2,961,445)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation to consultants 380,820 397,750
Stock-based compensation to related parties 310,700 461,150
Loss on derivative liabilities 131,475 539,006
Change in fair value of derivative liabilities (291,123) (494,501)
Amortization of prepaid stock-based compensation 951,748 480,135
Amortization of debt discount 593,463 541,612
Patent amortization 233,685 11,295
Depreciation 10,946 6,772
Changes in operating assets and liabilities:    
Accounts receivable (8,785) (14,172)
Inventory (2,611) (34,418)
Prepaid expenses and other current assets 174,364 64,777
Right-of-use asset 25,572 24,792
Accounts payable 15,166 91,557
Accounts payable - related parties (9,791) 2,581
Accrued expenses and other current liabilities 169,451 188,979
Lease liability (25,572) (24,792)
Net cash used in operating activities (1,018,304) (718,922)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of property and equipment (260,565)
Deposits 4,015
Net cash used in investing activities (256,550)
Cash flows from financing activities    
Payments on notes payable to related party (2,453) (4,799)
Proceeds from convertible notes payable 505,000 538,750
Payments on notes payable (4,459) (2,068)
Proceeds from sale of common stock 445,000 285,499
Net cash provided by financing activities 943,088 817,382
Net increase (decrease) in cash, cash equivalents and restricted cash (75,216) (158,090)
Cash, cash equivalents and restricted cash at beginning of period 104,259 262,349
Cash, cash equivalents and restricted cash at end of period 29,043 104,259
Supplemental cash flow information:    
Cash paid for interest 3,173 3,312
Cash paid for income taxes 800 800
Non-cash investing and financing transactions:    
Original issuance discount on convertible notes payable 39,000 33,500
Debt discount recorded in connection with derivative liability 503,726 538,750
Common stock issued in conversion of convertible notes payable and interest 1,313,772 1,019,014
Property and equipment purchased with note payable 21,671
Common stock issued for prepaid fees 242,320 1,472,450
Common stock issued for accrued salaries 67,399 239,799
Accrued interest added to principal 25,914 25,912
Common stock issued for license 3,107,570
Common stock issued for land development 58,900
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:    
Cash and cash equivalents 18,040 94,036
Restricted cash 11,003 10,223
Total cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows: $ 29,043 $ 104,259
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Organization and Business Description
 12 Months Ended
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Business Description

Note 1 – Organization and Business Description

 

Therapeutic Solutions International, Inc. (“TSI” or the “Company”) was organized August 6, 2007 under the name Friendly Auto Dealers, Inc., under the laws of the State of Nevada. In the first quarter of 2011 the Company changed its name from Friendly Auto Dealers, Inc. to Therapeutic Solutions International, Inc., and acquired Splint Decisions, Inc., a California corporation.

 

Business Description

 

Currently, the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system.

 

Activating one’s immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions.

 

TSOI is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, traumatic brain injury, lung pathologies, and for daily health.

 

Cellular Division – TSOI obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and Lung Pathology (LP).

 

The stem cell licensed, termed “JadiCell” is unique in that it possesses features of mesenchymal stem cells, however, outperforms these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and neurogenic ability.

 

Chronic Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe. TSOI has previously filed several patents in the area of CTE based on modulating the brain microenvironment to enhance receptivity of regenerative cells such as stem cells. On March 4, 2021 the Company received an IND Serial # 27377 for a clinical trial of 10 patients with CTE.

 

On August 4th, 2021, the Company announced clearance from the Food and Drug Administration (FDA) to initiate a Phase III pivotal trial for registration of the Company’s JadiCell™ universal donor stem cell as a treatment for COVID-19 associated lung failure under IND # 19757. In previous studies the Company has demonstrated the superior activity of JadiCell™ to other types of stem cells including bone marrow, adipose, cord blood, and placenta. Furthermore, the JadiCell™ was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91%.

 

In addition, the Company has filed data with the FDA, as part of IND #17448, which demonstrated that treatment of cancer patients with StemVacs™ resulted in enhanced activity of a type of immunological cell called “natural killer” cells, otherwise known as “NK cells.”

 

The Company has also developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body’s NK cells.

 

Most recently the Company announced filing of a patent for a new hybrid cell created by the Company capable of training the immune system to kill blood vessels feeding cancer, but sparing healthy blood vessels. These discoveries are an extension of previous findings from the Company showing that StemVacs is capable of suppressing new blood vessel production.

 

On May 9, 2022, the Company filed an Investigational New Drug Application for Treatment of Chronic Obstructive Pulmonary Disease (COPD) Using JadiCell™ Universal Donor Adult Stem Cells under IND Serial # 28508.

 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Notes to Financial Statements

December 31, 2022

 

Management does not expect existing cash as of December 31, 2022 or as of March 31, 2023 to be sufficient to fund the Company’s operations for at least twelve months from the issuance date of these financial statements. These financial statements have been prepared on a going concern basis which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of December 31, 2022, the Company has incurred losses totaling $17.3 million since inception, has not yet generated material revenue from operations, and will require additional funds to maintain its operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern within one year after the consolidated financial statements are issued. The Company’s ability to continue as a going concern is dependent upon its ability to generate future profitable operations and obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. The Company intends to finance operating costs over the next twelve months through its existing financial resources and we may also raise additional capital through equity offerings, debt financings, collaborations and/or licensing arrangements. If adequate funds are not available on acceptable terms, we may be required to delay, reduce the scope of, or curtail, our operations. The accompanying consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Basis of presentation and significant accounting policies
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Basis of presentation and significant accounting policies

Note 2 – Basis of presentation and significant accounting policies

 

Basis of Presentation

 

The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented.

 

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. No material activity in any subsidiaries.

 

Accounts Receivable

 

Accounts receivable are stated at amounts due from customers, net of an allowance for doubtful accounts, and the Company generally does not require collateral. As a general policy, the Company determines an allowance for doubtful accounts by considering a number of factors, including the length of time trade accounts receivable are past due, the Company’s previous loss history, the customer’s current ability to pay its obligation to the Company, and the condition of the general economy and industry as a whole. The Company writes off accounts receivable when they become uncollectible, and payments subsequently received on such receivables are credited to the allowance for doubtful accounts.

 

The Company recorded an allowance for doubtful accounts of $6,807 as of both December 31, 2022 and 2021, respectively.

 

Revenue Recognition

 

The Company recognizes revenue in accordance with ASC 606,”Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the Company applies the following methodology to recognize revenue:

 

1)Identify the contract with a customer.
2)Identify the performance obligations in the contract.
3)Determine the transaction price.
4)Allocate the transaction price to the performance obligations in the contract.
5)Recognize revenue when (or as) the entity satisfies a performance obligation.

 

ASC 606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which the customer obtains control of the product or service.

 

Returns. We will gladly accept the return of products that are defective due to defects in manufacturing and/or workmanship.

 

Wholesale policies:

 

Delivery. The Goods shall be deemed delivered when Buyer has accepted delivery at the above-referenced location. The shipping method shall be determined by Seller, but Buyer will not be responsible for shipping costs.

 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Notes to Financial Statements

December 31, 2022

 

Note 2 – Basis of presentation and significant accounting policies (Continued)

 

Purchase Price & Payments. Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail.

 

Inspection of Goods & Rejection. Buyer is entitled to inspect the Goods upon delivery. If the Goods are unacceptable for any reason, Buyer must reject them at the time of delivery up to five (5) business days from the date of delivery. If Buyer has not rejected the Goods within five (5) business days from the date of delivery, Buyer shall have waived any right to reject that specific delivery of Goods. In the event Buyer rejects the Goods, Buyer shall allow Seller a reasonable time to cure the deficiency. A reasonable time period shall be determined by industry standards for the particular Goods, as well as the Seller and Buyer.

 

Risk of Loss. Risk of loss will be on the Seller until the time when the Buyer accepts delivery. Seller shall maintain any and all necessary insurance in order to insure the Goods against loss at Seller’s own expense

 

Retail policies of e-commerce:

 

Returns. We will gladly accept the return of products that are defective due to defects in manufacturing and/or workmanship. Fulfillment mistakes that may be made which result in the shipment of incorrect products to you will also be accepted for return.

 

Shipping. Shipping Time –Most orders will ship the next business day, provided the product ordered is in stock. Orders are not processed or shipped on Saturday or Sunday, except by prior arrangement. We cannot guarantee when an order will arrive. Consider any shipping or transit time offered to you by this site or other parties only as an estimate. We encourage you to order in a timely fashion to avoid delays caused by shipping or product availability. Shipping for Amazon and Walmart are shipped to the fullfillment centers based on inventory amounts. Orders are shipped to customers by the companies as ordered on their websites.

 

Out of Stock. We will ship your product as it becomes available. Usually, products ship by the next business day. However, there may be times when the product you have ordered is out-of-stock, which will delay fulfilling your order. We will keep you informed of any products that you have ordered that are out-of-stock and unavailable for immediate shipment. You may cancel your order at any time prior to shipping.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.

Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At December 31, 2022 and 2021, the Company had $0 in excess of the FDIC insured limit.

 

Inventories

 

Inventories are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials and assembly items.

 

Derivative Liabilities

 

A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities.

 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Notes to Financial Statements

December 31, 2022

 

Note 2 – Basis of presentation and significant accounting policies (Continued)

 

As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2022 and 2021, as disclosed in Note 5, containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis.

 

The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified.

 

Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $202,144 and $531,525 at December 31, 2022 and 2021, respectively.

 

Fair Value of Financial Instruments

 

The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items.

 

Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy:

 

Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.

 

Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.

 

Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.

 

When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of December 31, 2021 and 2020, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations:

 

The following is the change in derivative liability for the years ended December 31, 2022 and 2021:

 

Balance, December 31, 2020  $437,549 
      
Issuance of new derivative liabilities   1,077,756 
Conversions   (489,279)
Change in fair market value of derivative liabilities   (494,501)
      
Balance, December 31, 2021   531,525 
      
Issuance of new derivative liabilities   674,971 
Conversions   (713,229)
Change in fair market value of derivative liabilities   (291,123)
Balance, December 31, 2022  $202,144 

 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Notes to Financial Statements

December 31, 2022

 

Use of Estimates

 

Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates.

 

Comprehensive Loss

 

Comprehensive loss for the periods reported was comprised solely of the Company’s net loss.

 

Net Loss Per Share

 

Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive.

 

As of December 31, 2022 and 2021, a total of 267,136,056 and 95,273,690, respectively, potential common shares, consisting of shares underlying outstanding convertible notes payable were excluded as their inclusion would be antidilutive.

 

Depreciation and Amortization

 

Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. Depreciation expense for the years ended December 31, 2022 and 2021 was $10,946 and $6,772, respectively.

 

Intangible Assets

 

Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Amortization expense for the years ended December 31, 2022 and 2021 was $233,685 and $11,295, respectively.

 

Long-lived Assets

 

In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value.

 

Shipping and Handling

 

The Company recognizes shipping and handling billed to customers as a component of net revenues, and the cost of shipping and handling within general administrative expenses.

 

Advertising

 

Advertising costs are expensed as incurred. Advertising expense for the years ended December 31, 2022 and 2021 were $4,132 and $0, respectively.

 

Research and Development

 

Research and Development costs are expensed as incurred. Research and Development expenses were $1,441,128 and $794,750 for the years ended December 31, 2022 and 2021, respectively.

 

Income Taxes

 

The Company accounts for income taxes under ASC 7”0 “Income Tax”s,” which codified SFAS 10”, “Accounting for Income Ta”es” and FIN 48 “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.

 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Notes to Financial Statements

December 31, 2022

 

Note 2 – Basis of presentation and significant accounting policies (Continued)

 

Stock-Based Compensation

 

Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted and nonrefundable shares.

 

Leases

 

On February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company recorded a Right-of-use asset and a Lease Liability of $8,612 as of December 31, 2022.

 
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Restricted cash
 12 Months Ended
Dec. 31, 2022
Cash and Cash Equivalents [Abstract]  
Restricted cash

Note 3 – Restricted cash

 

Included in current assets is a $10,000 certificate of deposit with an annual interest rate of 0.6%. This certificate matures on June 17, 2023, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011.

 
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Prepaid expense and other current assets
 12 Months Ended
Dec. 31, 2022
Prepaid Expense And Other Current Assets  
Prepaid expense and other current assets

Note 4 – Prepaid expense and other current assets

 

Prepaid expenses and other current assets consist of the following:

 

   December 31, 2022   December 31, 2021 
         
Prepaid consulting  $148,550   $930,893 
Insurance   1,141    987 
Prepaid costs   62,661    27,427 
Total  $212,352   $959,307 

 
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Fixed assets
 12 Months Ended
Dec. 31, 2022
Property, Plant and Equipment [Abstract]  
Fixed assets

Note 5 – Fixed assets

 

Fixed assets consist of the following:

 

   December 31, 2022   December 31, 2021 
         
Land  $235,223   $235,223 
Vehicles   50,514    50,514 
Computer hardware   6,135    5,935 
Office furniture and equipment   7,912    7,912 
Shipping and other equipment   1,575    1,575 
Total   301,359    301,159 
Accumulated depreciation   (28,281)   (17,135)
Property and equipment, net  $273,078   $284,024 

 

Depreciation expense was $10,946 and $6,772 for the years ended December 31, 2022 and 2021, respectively.

 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Other assets
 12 Months Ended
Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Other assets

Note 6 – Other assets

 

Other assets consist of the following:

 

   December 31, 2022   December 31, 2021 
         
Prepaid consulting  $7,537   $108,673 
Deposit   4,123    39,823 
Licenses, net   3,002,960    129,075 
Total  $3,014,620   $277,571 

 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Notes to Financial Statements

December 31, 2022

 

Prepaid consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above consists of the following:

 

   December 31, 2022   December 31, 2021 
         
Licenses  $3,261,122   $153,552 
Accumulated amortization   (258,162)   (24,477)
Licenses, net  $3,002,960   $129,075 

 

Amortization expense for the years ended December 31, 2022 and 2021 was $233,685 and $24,477, respectively.

 

As of June 1, 2019, we entered into a license agreement, which will be amortized over the life of the Patent. The Patent expires December 31, 2032. The Exclusive Patent License to the Jadi Cell is for use under the designated areas of CTE (Chronic Traumatic Encephalopathy), and TBI (Traumatic Brain Injury). The Jadi Cell is an cGMP grade and Research grade manufactured allogenic mesenchymal stem cells derived from US Patent No.: 9,803,176 B2. Forward looking the Company intends to file an Investigational New Drug Application (IND) for brain injured patients who have been intensively cared for and mechanically ventilated due to covid-19 illness and a second IND for CTE/TBI as well in keeping with the spirit of the licensing agreement to advance the Jadi Cell through to FDA Approval for CTE/TBI.

 

On February 9, 2021, the Company issued a Convertible Promissory Note (CPN) to JadiCell LLC that was never fully executed while the parties worked to finalize the agreement that resulted in an Exclusive Patent License Agreement (EPLA) being executed on September 15, 2021. Finally, a Settlement Agreement was entered into on February 23, 2022. On February 23, 2022, we issued 149,402,390 shares of common stock, valued at $0.0208 per share, for the EPLA, with a final value of the license being recorded at $3,107,570. The Patent expires December 31, 2032. The Exclusive Patent License to the Jadi Cell is for use under the designated areas of all applicable Lung Pathology. The Jadi Cell is an cGMP grade and Research grade manufactured allogenic mesenchymal stem cells derived from US Patent No.: 9,803,176 B2 and will be amortized over the 10 year life of the Patent. As of March 25, 2022, we entered into a asset transfer and license agreement, which will be amortized over the life of the agreement. The agreement is until March 24, 2027. The Company has made an initial payment of $200,000. Within six months, the Company will make a second payment of $1.8 million. The agreement is in default and the initial paymentof $200,000 was expensed to research & development.

 
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Convertible notes payable
 12 Months Ended
Dec. 31, 2022
Convertible Notes Payable  
Convertible notes payable

Note 7 – Convertible notes payable

 

At various times during the year ended December 31, 2022, the Company entered into convertible promissory notes with principal amounts totaling $544,000 with third parties for which the proceeds were used for operations. The Company received net proceeds of $505,000, and a $39,000 original issuance discount was recorded. The convertible promissory notes incur interest at a rate of 10% per annum and mature on dates ranging from January 1, 2023 to December 5, 2023. The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to a percentage of 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable con’ersion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%. The Company was required to reserve at December 31, 2022 a total of 267,136,056 common shares in connection with these promissory notes.

 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Notes to Financial Statements

December 31, 2022

 

Note 7 – Convertible notes payable (continued)

 

At various times during the year ended December 31, 2021, the Company entered into convertible promissory notes with principal amounts totaling $572,250 with third parties for which the proceeds were used for operations. The Company received net proceeds of $538,750, and a $33,500 original issuance discount was recorded. The convertible promissory notes incur interest at rates ranging from 10% to 12% per annum and mature on dates ranging from January 25, 2022 to December 15, 2022. The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to apercentage ranging from 61% to 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%. The Company was required to reserve at December 31, 2021 total of 95,273,690 common shares in connection with these promissory notes.

 

Derivative liabilities

 

These convertible promissory notes are convertible into a variable number of shares of common stock for which there is not a floor to the number of common stock we might be required to issue. Based on the requirements of ASC 815 Derivatives and Hedging, the conversion feature represented an embedded derivative that is required to be bifurcated and accounted for as a separate derivative liability. The derivative liability is originally recorded at its estimated fair value and is required to be revalued at each conversion event and reporting period. Changes in the derivative liability fair value are reported in operating results each reporting period.

 

For the notes issued during the year ended December 31, 2022, the Company valued the conversion features on the date of issuance resulting in initial liabilities totaling $674,971. Since the fair value of the derivative was in excess of the proceeds received, a full discount to convertible notes payable and a day one loss on derivative liabilities of $171,245 was recorded during the year ended December 31, 2022. The Company valued the conversion feature using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $0.0058 to $0.0143, the closing stock price of the Company’s common stock on the dates of valuation ranging from $0.008 to $0.0272, an expected dividend yield of 0%, expected volatilities ranging from 148%-216%, risk-free interest rate ranging from 0.48% to 4.77%, and an expected term of one year.

 

During the year ended December 31, 2022, convertible notes principal plus their accrued interest totaling $774,176 were converted into 68,193,798 shares of common stock, of which 4,054,054 are yet to be issued as of December 31, 2022. At each conversion date, the Company recalculated the value of the derivative liability associated with the convertible note recording a gain (loss) in connection with the change in fair market value. In addition, the fair value of the shares of common stock issued in excess or deficit of the pro-rata portion of the derivative liability as compared to the portio of the convertible note converted was recorded as a loss or gain on derivative liabilities. During the year ended December 31, 2022, the Company recorded $39,770 to gain on derivative liabilities. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $0.0038 to $0.016, the closing stock price of the Company’s common stock on the dates of valuation ranging from $0.006 to $0.026, an expected dividend yield of 0%, expected volatility ranging from 63% to 191%, risk-free interest rates ranging from 0.51% to 4.74%, and expected terms ranging from 0.44 to 0.50 years.

 

On December 31, 2022, the derivative liabilities on the remaining convertible notes were revalued at $202,144 resulting in a gain of $291,123 for the year ended December 31, 2022 related to the change in fair value of the derivative liabilities. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following assumptions: exercise price of $0.0038, the closing stock price of the Company’s common stock on the date of valuation of $0.006, an expected dividend yield of 0%, expected volatility ranging from 96% to 120%, risk-free interest rate of 4.71%, and an expected term ranging from 0.49 to 0.93 years.

 

For the notes issued during the year ended December 31, 2021, the Company valued the conversion features on the date of issuance resulting in initial liabilities totaling $1,077,756. Since the fair value of the derivative was in excess of the proceeds received, a full discount to convertible notes payable and a day one loss on derivative liabilities of $539,006 was recorded during the year ended December 31, 2021. The Company valued the conversion feature using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $0.0039 to $0.0351, the closing stock price of the Company’s common stock on the dates of valuation ranging from $0.0217 to $0.0540, an expected dividend yield of 0%, expected volatilities ranging from 197%-264%, risk-free interest rate ranging from 0.05% to 0.29%, and an expected term of one year.

 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Notes to Financial Statements

December 31, 2022

 

Note 7 – Convertible notes payable (Continued)

 

During the year ended December 31, 2021, convertible notes principal plus their accrued interest totaling $529,735 were converted into 21,690,671 shares of common stock. At each conversion date, the Company recalculated the value of the derivative liability associated with the convertible note recording a gain (loss) in connection with the change in fair market value. In addition, the pro-rata portion of the derivative liability as compared to the portion of the convertible note converted was reclassed to additional paid-in capital. During the year ended December 31, 2021, the Company recorded $489,279 to additional paid-in capital. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $0.0136 to $0.035, the closing stock price of the Company’s common stock on the dates of valuation ranging from $0.022 to $0.057, an expected dividend yield of 0%, expected volatility ranging from 125% to 251%, risk-free interest rates ranging from 0.06% to 0.29%, and expected terms ranging from 0.48 to 0.50 years.

 

On December 31, 2021, the derivative liabilities on the remaining five convertible notes were revalued at $531,525 resulting in a gain of $494,501 for the year ended December 31, 2021 related to the change in fair value of the derivative liabilities. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $0.0123 to $0.0127, the closing stock price of the Company’s common stock on the date of valuation of $0.029, an expected dividend yield of 0%, expected volatility ranging from 165% to 218%, risk-free interest rate of 0.39%, and an expected term ranging from 0.53 to 0.96 years.

 

The Company amortizes the discounts over the term of the convertible promissory notes using the straight line method which is similar to the effective interest method. During the years ended December 31, 2022 and 2021, the Company amortized $593,463 and $541,612 to interest expense, respectively. As of December 31, 2022, discounts of $175,063 remained for which will be amortized through December 2023.

 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Notes payable-related parties
 12 Months Ended
Dec. 31, 2022
Debt Disclosure [Abstract]  
Notes payable-related parties

Note 8 – Notes payable-related parties

 

Notes payable-related parties consist of:

 

  

December 31,

2022

  

December 31,

2021

 
         
  $-   $2,356 
Note payable – Scientific Advisory Board Member, unsecured, including interest at 10% per annum, with a maturity date of December 31, 2019  $-   $2,356 
           
One notes payable – Chief Executive Officer, unsecured, including interest at 8% and 10% per annum, respectively, with maturity date of December 31, 2019   29,090    27,577 
           
One note payable – Chief Executive Officer, unsecured, no interest, paid from a % of revenues   534,448    534,544 
           
Note payable – Chief Financial Officer, unsecured, including interest at 8% per annum, with a maturity date of December 31, 2019   124,800    118,400 
           
Three notes payable – Business Advisory Board Member, unsecured, including interest at 8% and 10% per annum, convertible into common stock at $0.005 and $0.004, respectively, with maturity date of April 20, 2019   30,334    282,334 
    988,672    965,211 
           
   $988,672   $965,211 

 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Notes to Financial Statements

December 31, 2022

 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Related party transactions
 12 Months Ended
Dec. 31, 2022
Related Party Transactions [Abstract]  
Related party transactions

Note 9 – Related party transactions

 

As of December 31, 2019 and 2018, the Company had accrued officers’ salary of $439,534 and $663,100, respectively. One of the officers settled with the company for a note payable that is unsecured on November 8, 2019 and doesn’t accrue interest and will be paid as 0.5% of revenues. This decreased accrued officers’ salary. The note is still outstanding as of December 31, 2022 and 2021. Payments for the years ended December 31, 2022 and 2021 was $97 and $101, respectively.

 

In 2021, we issued 7,544,848 shares of common stock for $239,800 of accrued salaries to one officer of the Company under a Restricted Stock Award.

 

On June 18, 2021, we issued 2,000,000 shares of common stock, to one officer and one director of the Company under a Restricted Stock Award for $94,600.

 

On November 30, 2021, we issued 7,000,000 shares of common stock to four officers and one director under a Restricted Stock Award for $224,000.

 

In 2022, we issued 4,812,259 shares of common stock for $67,399 of accrued salaries to one officer of the Company under a Restricted Stock Award.

 

On April 5, 2022, we issued 7,000,000 shares of common stock, to four officers and one director of the Company under a Restricted Stock Award for $175,700.

 

On September 8, 2022, we issued 4,000,000 shares of common stock to one officer and one director under a Restricted Stock Award for $46,400.

 

On November 2, 2022, we issued 3,000,000 shares of common stock to one director under a Restricted Stock Award for $29,700.

 

On December 30, 2022, we committed to issue 14,000,000 shares of common stock, to four officers and one director of the Company under a Restricted Stock Award for $84,000, which were subsequently issued on January 3, 2023.

 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Notes to Financial Statements

December 31, 2022

 
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Income taxes
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Income taxes

Note 10 – Income taxes

 

The Company is subject to United States federal and state income taxes at an approximate rate of 30%. The reconciliation of the provision for income taxes at the United States federal statutory rate compared to the Company’s income tax expense as reported is as follows:

 

   December 31, 2022   December 31, 2021 
         
Expected income tax at statutory rate  $(709,666)  $(621,735)
State tax   (101,347)   168 
Permanent differences   405,376    404,872 
Other   -    (71,992)
Change in valuation allowance   406,437    289,487 
Provision for income taxes  $800   $800 

 

The significant components of deferred income tax assets and liabilities at December 31, 2022 and 2021 are as follows:

 

   December 31, 2022   December 31, 2021 
         
Net operating loss carry-forward  $2,364,249   $1,957,812 
Valuation allowance   (2,364,249)   (1,957,812)
Net deferred tax asset  $-   $- 

 

The Company has Federal net operating loss carryforwards of approximately $9.4 million and $7.5 million as of December 31, 2022 and 2021, respectively. The Company has state net operating loss carryforwards of approximately $7.4 million and $5.5 million as of December 31, 2022 and 2021, respectively. The net operating loss carryforwards are available to offset taxable income in future years, of which approximately $5 million expires beginning in fiscal 2032. Net operating loss carrforwards incurred after 2018 are carried on indefinitely.

 

As of and for the years ended December 31, 2022 and 2021, management does not believe the Company has any uncertain tax positions. Accordingly, there are no recognized tax benefits at December 31, 2022 and 2021.

 

The Company is subject to tax in the United States and files tax returns in the U.S. Federal jurisdiction and California state jurisdiction. The Company is subject to U.S. Federal, state and local income tax examinations by tax authorities starting in 2019. The Company currently is not under examination by any tax authority.

 
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Equity
 12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
Equity

Note 11 – Equity

 

Our authorized capital stock consists of an aggregate of 3,505,000,000 shares, comprised of 3,500,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, which may be issued in various series from time to time and the rights, preferences, privileges and restrictions of which shall be established by our board of directors. As of December 31, 2022, we have 2,617,390,830 shares of common stock and 2 preferred shares issued and outstanding.

 

In 2021, we issued 4,850,075 shares of common stock for an investment in the Company’s Private Placement of $285,500.

 

In 2021, we issued 21,000,000 shares of common stock, valued at $858,900 for consulting services.

 

In 2021, we issued 8,341,723 shares of common stock, valued at $239,799 for salaries.

 

In 2021, we issued 1,500,000 shares of common stock, valued at $58,900 for land development.

 

In 2021, we issued 21,690,671 shares of common stock for the conversion of convertible notes of $1,019,014.

 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Notes to Financial Statements

December 31, 2022

 

Note 11 – Equity (continued)

 

In 2022, we issued 44,500,000 shares of common stock for an investment in the Company’s Private Placement of $445,000.

 

In 2022, we issued 32,412,577 shares of common stock, valued at $691,520 for consulting services.

 

In 2022, we committed to issue 3,000,000 shares of common stock, valued at $18,000 for consulting services, which were issued on January 3, 2023.

 

In 2022, we issued 4,812,259 shares of common stock, valued at $67,399 for salaries.

 

In 2022, we issued 149,402,390 shares of common stock, valued at $3,107,570 for a license.

 

In 2022, we issued 11,000,000 shares of common stock, valued at $242,320 for prepaid fees.

 

In 2022, we issued 64,139,744 shares of common stock for the conversion of convertible notes of $1,313,772.

 

In 2022, we committed to issue 4,054,054 shares of common stock for the conversion of convertible notes of $15,000, which were issued on January 3, 2023.

 
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Legal proceedings
 12 Months Ended
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Legal proceedings

Note 12 – Legal proceedings

 

From time to time, claims are made against us in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from selling one or more products or engaging in other activities. The occurrence of an unfavorable outcome in any specific period could have a material adverse effect on our results of operations for that period or future periods.

 

However, as of the date of this report, management believes the outcome of currently identified potential claims and lawsuits will not have a material adverse effect on our financial condition or results of operations.

 
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 13 – Commitments and Contingencies

 

Effective March 1, 2020, the Company entered into a fifth amendment to a Lease Agreement for property located in Oceanside, CA. The lease consists of approximately 1,700 square feet and the amendment is for a term of 36 months and expires on April 30, 2023.

 

During the year ended December 31, 2022 and 2021, the Company incurred rent expense of $25,044 and $22,768.

 

The lease will expire in 2023. The weighted average discount rate used for this lease is 5% (average borrowing rate of the Company). Maturities of Leases were:

 

Future minimum lease payments as of December 31, 2022 are as follows:

 

For the year ending December 31,    
      
2023  $8,612 

 

Effective November 8, 2019, the Company entered into a royalty agreement with one of the officers, refer to Note 9.

 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent events
 12 Months Ended
Dec. 31, 2022
Subsequent Events [Abstract]  
Subsequent events

Note 14 – Subsequent events

 

On January 3, 2023, we issued 4,054,054 shares of common stock for the partial conversion of $15,000 for convertible note dated June 27, 2022.

 

On January 3, 2023, we issued 17,000,000 shares of common stock, valued at $0.006 per share, for consulting services.

 

On January 4, 2023, we issued 10,052,083 shares of common stock for the complete conversion of $36,188 for convertible note dated June 27, 2022.

 

On January 9, 2023, we issued 4,081,632 shares of common stock for $20,000 of accrued salaries.

 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Notes to Financial Statements

December 31, 2022

 

Note 14 – Subsequent events (continued)

 

On January 9, 2023, we issued 4,000,000 shares of common stock, valued at $0.049 per share, for consulting services.

 

On February 6, 2023, we issued 6,060,606 shares of common stock for the partial conversion of $20,000 for convertible note dated August 2, 2022.

 

On February 7, 2023, we issued 11,386,719 shares of common stock for the complete conversion of $36,438 for convertible note dated August 2, 2022.

 

On February 21, 2023, we issued 60,224,825 shares of common stock, valued at $0.00216 per share, for an investment in the Company’s Private Placement.

 

On or about March 21, 2023, the Board of Directors of Therapeutic Solutions International, Inc. (“TSOI”), by unanimous approval, and with the unanimous approval of the Preferred A Stock holders representing at least 51% of all shareholders with the right to vote, pursuant to Nevada Revised Statutes Section NRS 78.215, has approved a one-time dividend, to be awarded to stockholders of TSOI in subsidiary Campbell Neurosciences, Inc., a Delaware corporation (“CNSI”). To receive the dividend by future election you must hold TSOI common at the market close of April 7, 2023. The dividend rate of conversion shall be for every share of TSOI common you will receive 0.0034 shares of CNSI.

 

TSOI, which owns 15,660,000 (31%) of the shares of CNSI common stock, would like to issue a dividend consisting of 10,000,000 shares of its holdings in CNSI to TSOI shareholders at a ratio of 0.00365 shares of CNSI stock for each one (1) share owned in TSOI stock as of April 7, 2023 (“Dividend Offer”) on April 8, 2023 (“Dividend Offer Date”). The Dividend Offer will remain open for Ninety (90) days from the Dividend Offer Date.

 

A letter will be mailed to every shareholder of record details of how to accept the Dividend Offer and a fully pre-paid return acceptance letter containing the necessary information for issuance. In addition, a Shareholder’s Rights Agreement will be enclosed, an executed copy to be returned with acceptance.

 

Required forms and documents shall be filed with FINRA describing the identity of the parties and the Dividend Offer timely.

 

In accordance with ASC 855, the Company has analyzed its operations subsequent to December 31, 2022 through the date these financial statements were issued, and has determined that it does not have any other material subsequent events to disclose in these financial statements.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Basis of presentation and significant accounting policies (Policies)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented.

 
Principles of Consolidation

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. No material activity in any subsidiaries.

 
Accounts Receivable

Accounts Receivable

 

Accounts receivable are stated at amounts due from customers, net of an allowance for doubtful accounts, and the Company generally does not require collateral. As a general policy, the Company determines an allowance for doubtful accounts by considering a number of factors, including the length of time trade accounts receivable are past due, the Company’s previous loss history, the customer’s current ability to pay its obligation to the Company, and the condition of the general economy and industry as a whole. The Company writes off accounts receivable when they become uncollectible, and payments subsequently received on such receivables are credited to the allowance for doubtful accounts.

 

The Company recorded an allowance for doubtful accounts of $6,807 as of both December 31, 2022 and 2021, respectively.

 
Revenue Recognition

Revenue Recognition

 

The Company recognizes revenue in accordance with ASC 606,”Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the Company applies the following methodology to recognize revenue:

 

1)Identify the contract with a customer.
2)Identify the performance obligations in the contract.
3)Determine the transaction price.
4)Allocate the transaction price to the performance obligations in the contract.
5)Recognize revenue when (or as) the entity satisfies a performance obligation.

 

ASC 606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which the customer obtains control of the product or service.

 

Returns. We will gladly accept the return of products that are defective due to defects in manufacturing and/or workmanship.

 

Wholesale policies:

 

Delivery. The Goods shall be deemed delivered when Buyer has accepted delivery at the above-referenced location. The shipping method shall be determined by Seller, but Buyer will not be responsible for shipping costs.

 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Notes to Financial Statements

December 31, 2022

 

Note 2 – Basis of presentation and significant accounting policies (Continued)

 

Purchase Price & Payments. Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail.

 

Inspection of Goods & Rejection. Buyer is entitled to inspect the Goods upon delivery. If the Goods are unacceptable for any reason, Buyer must reject them at the time of delivery up to five (5) business days from the date of delivery. If Buyer has not rejected the Goods within five (5) business days from the date of delivery, Buyer shall have waived any right to reject that specific delivery of Goods. In the event Buyer rejects the Goods, Buyer shall allow Seller a reasonable time to cure the deficiency. A reasonable time period shall be determined by industry standards for the particular Goods, as well as the Seller and Buyer.

 

Risk of Loss. Risk of loss will be on the Seller until the time when the Buyer accepts delivery. Seller shall maintain any and all necessary insurance in order to insure the Goods against loss at Seller’s own expense

 

Retail policies of e-commerce:

 

Returns. We will gladly accept the return of products that are defective due to defects in manufacturing and/or workmanship. Fulfillment mistakes that may be made which result in the shipment of incorrect products to you will also be accepted for return.

 

Shipping. Shipping Time –Most orders will ship the next business day, provided the product ordered is in stock. Orders are not processed or shipped on Saturday or Sunday, except by prior arrangement. We cannot guarantee when an order will arrive. Consider any shipping or transit time offered to you by this site or other parties only as an estimate. We encourage you to order in a timely fashion to avoid delays caused by shipping or product availability. Shipping for Amazon and Walmart are shipped to the fullfillment centers based on inventory amounts. Orders are shipped to customers by the companies as ordered on their websites.

 

Out of Stock. We will ship your product as it becomes available. Usually, products ship by the next business day. However, there may be times when the product you have ordered is out-of-stock, which will delay fulfilling your order. We will keep you informed of any products that you have ordered that are out-of-stock and unavailable for immediate shipment. You may cancel your order at any time prior to shipping.

 
Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.

Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At December 31, 2022 and 2021, the Company had $0 in excess of the FDIC insured limit.

 
Inventories

Inventories

 

Inventories are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials and assembly items.

 
Derivative Liabilities

Derivative Liabilities

 

A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities.

 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Notes to Financial Statements

December 31, 2022

 

Note 2 – Basis of presentation and significant accounting policies (Continued)

 

As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2022 and 2021, as disclosed in Note 5, containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis.

 

The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified.

 

Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $202,144 and $531,525 at December 31, 2022 and 2021, respectively.

 
Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items.

 

Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy:

 

Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.

 

Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.

 

Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.

 

When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of December 31, 2021 and 2020, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations:

 

The following is the change in derivative liability for the years ended December 31, 2022 and 2021:

 

Balance, December 31, 2020  $437,549 
      
Issuance of new derivative liabilities   1,077,756 
Conversions   (489,279)
Change in fair market value of derivative liabilities   (494,501)
      
Balance, December 31, 2021   531,525 
      
Issuance of new derivative liabilities   674,971 
Conversions   (713,229)
Change in fair market value of derivative liabilities   (291,123)
Balance, December 31, 2022  $202,144 

 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Notes to Financial Statements

December 31, 2022

 
Use of Estimates

Use of Estimates

 

Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates.

 
Comprehensive Loss

Comprehensive Loss

 

Comprehensive loss for the periods reported was comprised solely of the Company’s net loss.

 
Net Loss Per Share

Net Loss Per Share

 

Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive.

 

As of December 31, 2022 and 2021, a total of 267,136,056 and 95,273,690, respectively, potential common shares, consisting of shares underlying outstanding convertible notes payable were excluded as their inclusion would be antidilutive.

 
Depreciation and Amortization

Depreciation and Amortization

 

Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. Depreciation expense for the years ended December 31, 2022 and 2021 was $10,946 and $6,772, respectively.

 
Intangible Assets

Intangible Assets

 

Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Amortization expense for the years ended December 31, 2022 and 2021 was $233,685 and $11,295, respectively.

 
Long-lived Assets

Long-lived Assets

 

In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value.

 
Shipping and Handling

Shipping and Handling

 

The Company recognizes shipping and handling billed to customers as a component of net revenues, and the cost of shipping and handling within general administrative expenses.

 
Advertising

Advertising

 

Advertising costs are expensed as incurred. Advertising expense for the years ended December 31, 2022 and 2021 were $4,132 and $0, respectively.

 
Research and Development

Research and Development

 

Research and Development costs are expensed as incurred. Research and Development expenses were $1,441,128 and $794,750 for the years ended December 31, 2022 and 2021, respectively.

 
Income Taxes

Income Taxes

 

The Company accounts for income taxes under ASC 7”0 “Income Tax”s,” which codified SFAS 10”, “Accounting for Income Ta”es” and FIN 48 “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.

 

 

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Consolidated Notes to Financial Statements

December 31, 2022

 

Note 2 – Basis of presentation and significant accounting policies (Continued)

 
Stock-Based Compensation

Stock-Based Compensation

 

Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted and nonrefundable shares.

 
Leases

Leases

 

On February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company recorded a Right-of-use asset and a Lease Liability of $8,612 as of December 31, 2022.
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Basis of presentation and significant accounting policies (Tables)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Schedule of Change in Derivative Liability

The following is the change in derivative liability for the years ended December 31, 2022 and 2021:

 

Balance, December 31, 2020  $437,549 
      
Issuance of new derivative liabilities   1,077,756 
Conversions   (489,279)
Change in fair market value of derivative liabilities   (494,501)
      
Balance, December 31, 2021   531,525 
      
Issuance of new derivative liabilities   674,971 
Conversions   (713,229)
Change in fair market value of derivative liabilities   (291,123)
Balance, December 31, 2022  $202,144 
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Prepaid expense and other current assets (Tables)
 12 Months Ended
Dec. 31, 2022
Prepaid Expense And Other Current Assets  
Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:

 

   December 31, 2022   December 31, 2021 
         
Prepaid consulting  $148,550   $930,893 
Insurance   1,141    987 
Prepaid costs   62,661    27,427 
Total  $212,352   $959,307 
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Fixed assets (Tables)
 12 Months Ended
Dec. 31, 2022
Property, Plant and Equipment [Abstract]  
Schedule of Fixed Assets

Fixed assets consist of the following:

 

   December 31, 2022   December 31, 2021 
         
Land  $235,223   $235,223 
Vehicles   50,514    50,514 
Computer hardware   6,135    5,935 
Office furniture and equipment   7,912    7,912 
Shipping and other equipment   1,575    1,575 
Total   301,359    301,159 
Accumulated depreciation   (28,281)   (17,135)
Property and equipment, net  $273,078   $284,024 
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Other assets (Tables)
 12 Months Ended
Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Schedule of Other Assets

Other assets consist of the following:

 

   December 31, 2022   December 31, 2021 
         
Prepaid consulting  $7,537   $108,673 
Deposit   4,123    39,823 
Licenses, net   3,002,960    129,075 
Total  $3,014,620   $277,571 
Schedule of Net Licenses

Prepaid consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above consists of the following:

 

   December 31, 2022   December 31, 2021 
         
Licenses  $3,261,122   $153,552 
Accumulated amortization   (258,162)   (24,477)
Licenses, net  $3,002,960   $129,075 
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Notes payable-related parties (Tables)
 12 Months Ended
Dec. 31, 2022
Debt Disclosure [Abstract]  
Schedule of Notes Payable Related Parties

Notes payable-related parties consist of:

 

  

December 31,

2022

  

December 31,

2021

 
         
  $-   $2,356 
Note payable – Scientific Advisory Board Member, unsecured, including interest at 10% per annum, with a maturity date of December 31, 2019  $-   $2,356 
           
One notes payable – Chief Executive Officer, unsecured, including interest at 8% and 10% per annum, respectively, with maturity date of December 31, 2019   29,090    27,577 
           
One note payable – Chief Executive Officer, unsecured, no interest, paid from a % of revenues   534,448    534,544 
           
Note payable – Chief Financial Officer, unsecured, including interest at 8% per annum, with a maturity date of December 31, 2019   124,800    118,400 
           
Three notes payable – Business Advisory Board Member, unsecured, including interest at 8% and 10% per annum, convertible into common stock at $0.005 and $0.004, respectively, with maturity date of April 20, 2019   30,334    282,334 
    988,672    965,211 
           
   $988,672   $965,211 
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Income taxes (Tables)
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Schedule of Income tax Expense

 

   December 31, 2022   December 31, 2021 
         
Expected income tax at statutory rate  $(709,666)  $(621,735)
State tax   (101,347)   168 
Permanent differences   405,376    404,872 
Other   -    (71,992)
Change in valuation allowance   406,437    289,487 
Provision for income taxes  $800   $800 
Schedule of Deferred Tax Assets and Liabilities

The significant components of deferred income tax assets and liabilities at December 31, 2022 and 2021 are as follows:

 

   December 31, 2022   December 31, 2021 
         
Net operating loss carry-forward  $2,364,249   $1,957,812 
Valuation allowance   (2,364,249)   (1,957,812)
Net deferred tax asset  $-   $- 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies (Tables)
 12 Months Ended
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Future Minimum Lease Payments

Future minimum lease payments as of December 31, 2022 are as follows:

 

For the year ending December 31,    
      
2023  $8,612 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Organization and Business Description (Details Narrative) - USD ($)
$ in Millions
 12 Months Ended
Aug. 04, 2021
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Entity incorporation date   Aug. 06, 2007
Unusual or infrequent item, description the JadiCell™ was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91%.  
Net loss   $ 17.3
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Change in Derivative Liability (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Accounting Policies [Abstract]    
Beginning Balance $ 531,525 $ 437,549
Issuance of new derivative liabilities 674,971 1,077,756
Conversions (713,229) (489,279)
Change in fair market value of derivative liabilities (291,123) (494,501)
Ending Balance $ 202,144 $ 531,525
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Basis of presentation and significant accounting policies (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Property, Plant and Equipment [Line Items]    
Allowance for doubtful accounts $ 6,807 $ 6,807
Payments description Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail.  
Cash, FDIC insured amount $ 0 0
Derivative liabilities $ 202,144 $ 531,525
Antidilutive securities excluded from computation of earnings per share 267,136,056 95,273,690
Depreciation expense $ 10,946 $ 6,772
Amortization expense 233,685 11,295
Advertising expense 4,132 0
Research and development expense 1,441,128 794,750
Lease liability 8,612  
Right-of-use asset 8,612 $ 34,184
Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Cash, FDIC insured amount $ 250,000  
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Restricted cash (Details Narrative)
 12 Months Ended
Dec. 31, 2022
USD ($)
Cash and Cash Equivalents [Abstract]  
Restricted cash and non-cash equivalents $ 10,000
Annual interest rate 0.60%
Restricted cash description This certificate matures on June 17, 2023, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011.
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Prepaid Expense And Other Current Assets    
Prepaid consulting $ 148,550 $ 930,893
Insurance 1,141 987
Prepaid costs 62,661 27,427
Total $ 212,352 $ 959,307
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Fixed Assets (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Property, Plant and Equipment [Line Items]    
Total $ 301,359 $ 301,159
Accumulated depreciation (28,281) (17,135)
Property and equipment, net 273,078 284,024
Land [Member]    
Property, Plant and Equipment [Line Items]    
Total 235,223 235,223
Vehicles [Member]    
Property, Plant and Equipment [Line Items]    
Total 50,514 50,514
Computer Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Total 6,135 5,935
Office Furniture and Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Total 7,912 7,912
Shipping and Other Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Total $ 1,575 $ 1,575
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Fixed assets (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Property, Plant and Equipment [Abstract]    
Depreciation expense $ 10,946 $ 6,772
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Other Assets (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Prepaid consulting $ 7,537 $ 108,673
Deposit 4,123 39,823
Licenses, net 3,002,960 129,075
Total $ 3,014,620 $ 277,571
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Net Licenses (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Licenses $ 3,261,122 $ 153,552
Accumulated amortization (258,162) (24,477)
Licenses, net $ 3,002,960 $ 129,075
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Other assets (Details Narrative) - USD ($)
 12 Months Ended
Mar. 25, 2022
Feb. 23, 2022
Dec. 31, 2022
Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Amortization expenses     $ 233,685 $ 24,477
Stock Issued During Period, Value, New Issues     $ 445,000 $ 285,499
Exclusive patent license agreement [Member] | Convertible Promissory Note [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Stock Issued During Period, Shares, New Issues   149,402,390    
Share Price   $ 0.0208    
Stock Issued During Period, Value, New Issues   $ 3,107,570    
[custom:PatentExpiresAgreementDate]   Dec. 31, 2032    
Finite-Lived Intangible Assets, Remaining Amortization Period   10 years    
Assets Transfer and License Agreement [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Amortized life of agreement Mar. 24, 2027      
Assets Transfer and License Agreement [Member] | Initial Payment [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Payments to Acquire Intangible Assets $ 200,000      
Assets Transfer and License Agreement [Member] | Second Payment [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Payments to Acquire Intangible Assets $ 1,800,000      
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Convertible notes payable (Details Narrative)
 12 Months Ended
Dec. 31, 2022
USD ($)
$ / shares
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Debt Instrument [Line Items]    
Debt original issuance discount $ 505,000 $ 538,750
Loss on derivative liability 131,475 539,006
Derivative liabilities 202,144 531,525
Gain loss on derivative liabilities 291,123 494,501
Convertible Notes Payable [Member]    
Debt Instrument [Line Items]    
Debt discount 175,063  
Interest expenses 593,463 541,612
Derivative [Member]    
Debt Instrument [Line Items]    
Derivative issuance liability 674,971 1,077,756
Loss on derivative liability $ 171,245 $ 539,006
Derivative [Member] | Measurement Input, Expected Dividend Rate [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input 0 0
Derivative [Member] | Measurement Input, Expected Term [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input term 1 year 1 year
Minimum [Member] | Derivative [Member] | Measurement Input, Conversion Price [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input | $ / shares 0.0058 0.0039
Minimum [Member] | Derivative [Member] | Measurement Input, Share Price [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input | $ / shares 0.008 0.0217
Minimum [Member] | Derivative [Member] | Measurement Input, Price Volatility [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input 148 197
Minimum [Member] | Derivative [Member] | Measurement Input, Risk Free Interest Rate [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input 0.48 0.05
Maximum [Member] | Derivative [Member] | Measurement Input, Conversion Price [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input | $ / shares 0.0143 0.0351
Maximum [Member] | Derivative [Member] | Measurement Input, Share Price [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input | $ / shares 0.0272 0.0540
Maximum [Member] | Derivative [Member] | Measurement Input, Price Volatility [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input 216 264
Maximum [Member] | Derivative [Member] | Measurement Input, Risk Free Interest Rate [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input 4.77 0.29
Convertible Promissory Note [Member]    
Debt Instrument [Line Items]    
Debt principal amount $ 544,000 $ 572,250
Debt original issuance discount 505,000 538,750
Debt discount $ 39,000 $ 33,500
Interest rate percentage 10.00%  
Debt maturity date description mature on dates ranging from January 1, 2023 to December 5, 2023 mature on dates ranging from January 25, 2022 to December 15, 2022
Debt conversion description The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to a percentage of 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable con’ersion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%. The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to apercentage ranging from 61% to 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%.
Common shares reserve | shares 267,136,056 95,273,690
Convertible Promissory Note [Member] | Minimum [Member]    
Debt Instrument [Line Items]    
Interest rate percentage   10.00%
Convertible Promissory Note [Member] | Maximum [Member]    
Debt Instrument [Line Items]    
Interest rate percentage   12.00%
Convertible Notes [Member]    
Debt Instrument [Line Items]    
Loss on derivative liability $ 39,770  
Debt conversion of convertible shares, value $ 774,176 $ 529,735
Debt conversion of convertible shares | shares 68,193,798 21,690,671
Common stock, subscribed and issued | shares 4,054,054  
Additional paid in capital on convertible debt features   $ 489,279
Convertible Notes [Member] | Measurement Input, Expected Dividend Rate [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input   0
Convertible Notes [Member] | Minimum [Member] | Measurement Input, Conversion Price [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input | $ / shares 0.0038 0.0136
Convertible Notes [Member] | Minimum [Member] | Measurement Input, Share Price [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input | $ / shares 0.006 0.022
Convertible Notes [Member] | Minimum [Member] | Measurement Input, Price Volatility [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input 63 125
Convertible Notes [Member] | Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input 0.51 0.06
Convertible Notes [Member] | Minimum [Member] | Measurement Input, Expected Term [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input term 5 months 8 days 5 months 23 days
Convertible Notes [Member] | Maximum [Member] | Measurement Input, Conversion Price [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input | $ / shares 0.016 0.035
Convertible Notes [Member] | Maximum [Member] | Measurement Input, Share Price [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input | $ / shares 0.026 0.057
Convertible Notes [Member] | Maximum [Member] | Measurement Input, Price Volatility [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input 191 251
Convertible Notes [Member] | Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input 4.74 0.29
Convertible Notes [Member] | Maximum [Member] | Measurement Input, Expected Term [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input term 6 months 6 months
Convertible Notes Payable [Member] | Derivative [Member] | Measurement Input, Expected Dividend Rate [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input 0  
Remaining Convertible Notes [Member]    
Debt Instrument [Line Items]    
Derivative liabilities $ 202,144 $ 531,525
Gain loss on derivative liabilities $ 291,123 $ 494,501
Remaining Convertible Notes [Member] | Measurement Input, Share Price [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input | $ / shares 0.006 0.029
Remaining Convertible Notes [Member] | Measurement Input, Expected Dividend Rate [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input 0 0
Remaining Convertible Notes [Member] | Measurement Input, Risk Free Interest Rate [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input 4.71 0.39
Remaining Convertible Notes [Member] | Measurement Input, Exercise Price [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input | $ / shares 0.0038  
Remaining Convertible Notes [Member] | Minimum [Member] | Measurement Input, Conversion Price [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input | $ / shares   0.0123
Remaining Convertible Notes [Member] | Minimum [Member] | Measurement Input, Price Volatility [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input 96 165
Remaining Convertible Notes [Member] | Minimum [Member] | Measurement Input, Expected Term [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input term 5 months 26 days 6 months 10 days
Remaining Convertible Notes [Member] | Maximum [Member] | Measurement Input, Conversion Price [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input | $ / shares   0.0127
Remaining Convertible Notes [Member] | Maximum [Member] | Measurement Input, Price Volatility [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input 120 218
Remaining Convertible Notes [Member] | Maximum [Member] | Measurement Input, Expected Term [Member]    
Debt Instrument [Line Items]    
Derivative liability, measurement input term 11 months 4 days 11 months 15 days
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Notes Payable Related Parties (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Short-Term Debt [Line Items]    
Notes payable related party, current $ 988,672 $ 965,211
Notes payable related party, non-current 988,672 965,211
Notes Payable One [Member]    
Short-Term Debt [Line Items]    
Notes payable related party, current 2,356
Notes Payable Two [Member]    
Short-Term Debt [Line Items]    
Notes payable related party, current 29,090 27,577
Notes Payable Three [Member]    
Short-Term Debt [Line Items]    
Notes payable related party, current 534,448 534,544
Notes Payable Four [Member]    
Short-Term Debt [Line Items]    
Notes payable related party, current 124,800 118,400
Notes Payable Five [Membe]    
Short-Term Debt [Line Items]    
Notes payable related party, current $ 30,334 $ 282,334
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Notes Payable Related Parties (Details) (Parenthetical) - $ / shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Scientific Advisory Board [Member] | Notes Payable One [Member]    
Short-Term Debt [Line Items]    
Debt interest percentage 10.00% 10.00%
Debt maturity date Dec. 31, 2019 Dec. 31, 2019
Chief Executive Officer [Member] | Notes Payable Two [Member]    
Short-Term Debt [Line Items]    
Debt maturity date Dec. 31, 2019 Dec. 31, 2019
Chief Executive Officer [Member] | Notes Payable Two [Member] | Minimum [Member]    
Short-Term Debt [Line Items]    
Debt interest percentage 8.00% 8.00%
Chief Executive Officer [Member] | Notes Payable Two [Member] | Maximum [Member]    
Short-Term Debt [Line Items]    
Debt interest percentage 10.00% 10.00%
Chief Financial Officer [Member] | Notes Payable Four [Member]    
Short-Term Debt [Line Items]    
Debt interest percentage 8.00% 8.00%
Debt maturity date Dec. 31, 2019 Dec. 31, 2019
Business Advisory Board [Member] | Notes Payable Five [Membe]    
Short-Term Debt [Line Items]    
Debt maturity date Apr. 20, 2019 Apr. 20, 2019
Business Advisory Board [Member] | Notes Payable Five [Membe] | Minimum [Member]    
Short-Term Debt [Line Items]    
Debt interest percentage 8.00% 8.00%
Share price $ 0.004 $ 0.004
Business Advisory Board [Member] | Notes Payable Five [Membe] | Maximum [Member]    
Short-Term Debt [Line Items]    
Debt interest percentage 10.00% 10.00%
Share price $ 0.005 $ 0.005
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.23.1
Related party transactions (Details Narrative) - USD ($)
 12 Months Ended
Dec. 30, 2022
Nov. 02, 2022
Sep. 08, 2022
Apr. 05, 2022
Nov. 30, 2021
Jun. 18, 2021
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2019
Dec. 31, 2018
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]                    
Related Party Transaction, Rate             0.50%      
Payments             $ 97 $ 101    
Number of common stock issued, value             $ 445,000 $ 285,499    
Officer [Member]                    
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]                    
Accrued Salaries, Current                 $ 439,534 $ 663,100
One Officers [Member] | Restricted Stock [Member] | Accrued Salaries [Member]                    
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]                    
Number of common stock issued             4,812,259 7,544,848    
Number of common stock issued, value             $ 67,399 $ 239,800    
One Officer and One Director [Member] | Restricted Stock [Member]                    
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]                    
Number of common stock issued     4,000,000     2,000,000        
Number of common stock issued, value     $ 46,400     $ 94,600        
Four Officer and One Director [Member] | Restricted Stock [Member]                    
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]                    
Number of common stock issued 14,000,000     7,000,000 7,000,000          
Number of common stock issued, value $ 84,000     $ 175,700 $ 224,000          
Four Officer One Director [Member] | Restricted Stock [Member]                    
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]                    
Number of common stock issued   3,000,000                
Number of common stock issued, value   $ 29,700                
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Income tax Expense (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Expected income tax at statutory rate $ (709,666) $ (621,735)
State tax (101,347) 168
Permanent differences 405,376 404,872
Other (71,992)
Change in valuation allowance 406,437 289,487
Provision for income taxes $ 800 $ 800
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Net operating loss carry-forward $ 2,364,249 $ 1,957,812
Valuation allowance (2,364,249) (1,957,812)
Net deferred tax asset
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.1
Income taxes (Details Narrative) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Federal and state income taxes rate 30.00%  
Federal net operating loss carryfowards $ 9.4 $ 7.5
State net operating loss carryfowards 7.4 $ 5.5
Net operating loss carryforwards are available to offset taxable income $ 5.0  
Net operating loss carryforwards, expiration, description expires beginning in fiscal 2032  
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.1
Equity (Details Narrative) - USD ($)
 12 Months Ended
Mar. 21, 2023
Feb. 21, 2023
Feb. 07, 2023
Feb. 06, 2023
Jan. 04, 2023
Jan. 03, 2023
Dec. 31, 2022
Dec. 31, 2021
Subsidiary, Sale of Stock [Line Items]                
Aggregate authorized capital             3,505,000,000  
Common stock, shares authorized             3,500,000,000 3,500,000,000
Common stock, par value             $ 0.001 $ 0.001
Preferred Stock, Shares Authorized             5,000,000 5,000,000
Common stock, shares outstanding             2,617,390,830 2,311,123,860
Preferred stock, shares outstanding             2 0
Preferred stock, shares issued             2 0
Common stock issued for cash             $ 445,000 $ 285,499
Common stock issued for cash, shares             1,313,772 529,735
Common stock issued for cash, shares             $ 691,520 $ 858,900
Prepaid Fees [Member]                
Subsidiary, Sale of Stock [Line Items]                
Common stock issued for cash, shares             11,000,000  
Common stock issued for cash             $ 242,320  
Subsequent Event [Member]                
Subsidiary, Sale of Stock [Line Items]                
Common stock issued for cash, shares 15,660,000              
Convertible Notes Payable [Member]                
Subsidiary, Sale of Stock [Line Items]                
Conversion of convertible notes             64,139,744 21,690,671
Common stock issued for cash, shares             $ 1,313,772 $ 1,019,014
Convertible Notes Payable [Member] | Subsequent Event [Member]                
Subsidiary, Sale of Stock [Line Items]                
Conversion of convertible notes     11,386,719 6,060,606 10,052,083 4,054,054    
Common stock issued for cash, shares     $ 36,438 $ 20,000 $ 36,188 $ 15,000    
Land Development [Member]                
Subsidiary, Sale of Stock [Line Items]                
Common stock issued for cash, shares               1,500,000
Common stock issued for cash               $ 58,900
Salaries [Member]                
Subsidiary, Sale of Stock [Line Items]                
Common stock issued for cash, shares             4,812,259 8,341,723
Common stock issued for cash             $ 67,399 $ 239,799
Consulting Services [Member]                
Subsidiary, Sale of Stock [Line Items]                
Common stock issued for cash, shares             32,412,577 21,000,000
Common stock issued for cash             $ 691,520 $ 858,900
Consulting Services [Member] | Subsequent Event [Member]                
Subsidiary, Sale of Stock [Line Items]                
Common stock issued for cash           18,000    
Common stock issued for cash, shares           $ 3,000,000    
License [Member]                
Subsidiary, Sale of Stock [Line Items]                
Common stock issued for cash, shares             149,402,390  
Common stock issued for cash             $ 3,107,570  
Private Placement [Member]                
Subsidiary, Sale of Stock [Line Items]                
Common stock issued for cash, shares             44,500,000 4,850,075
Common stock issued for cash             $ 445,000 $ 285,500
Private Placement [Member] | Subsequent Event [Member]                
Subsidiary, Sale of Stock [Line Items]                
Common stock issued for cash, shares   60,224,825            
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Future Minimum Lease Payments (Details)
Dec. 31, 2022
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
2023 $ 8,612
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies (Details Narrative)
 12 Months Ended
Dec. 31, 2022
USD ($)
ft²
Dec. 31, 2021
USD ($)
Commitments and Contingencies Disclosure [Abstract]    
Area of land | ft² 1,700  
Lease contract term 36 months  
Lease expiration date Apr. 30, 2023  
Payment for rent | $ $ 25,044 $ 22,768
Operating lease discount rate 5.00%  
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent events (Details Narrative)
 12 Months Ended
Mar. 21, 2023
shares
Feb. 21, 2023
$ / shares
shares
Feb. 07, 2023
USD ($)
shares
Feb. 06, 2023
USD ($)
shares
Jan. 09, 2023
USD ($)
$ / shares
shares
Jan. 04, 2023
USD ($)
shares
Jan. 03, 2023
USD ($)
$ / shares
shares
Dec. 31, 2022
USD ($)
shares
Dec. 31, 2021
USD ($)
shares
Subsequent Event [Line Items]                  
Conversion of common stock | $               $ 1,313,772 $ 529,735
Common stock issued for cash | $               $ 445,000 $ 285,499
Private Placement [Member]                  
Subsequent Event [Line Items]                  
Common stock issued for cash, shares               44,500,000 4,850,075
Common stock issued for cash | $               $ 445,000 $ 285,500
Subsequent Event [Member]                  
Subsequent Event [Line Items]                  
Shares issued for consulting services         4,000,000   17,000,000    
Shares issued price per share | $ / shares         $ 0.049   $ 0.006    
Common stock issued for cash, shares 15,660,000                
Subsequent Event [Member] | Campbell Neurosciences Inc [Member]                  
Subsequent Event [Line Items]                  
Dividend conversion rate 0.0034                
Common stock shares percentage 31.00%                
Common stock divident 10,000,000                
Dividend, description TSOI shareholders at a ratio of 0.00365 shares of CNSI stock for each one (1) share owned in TSOI stock as of April 7, 2023 (“Dividend Offer”) on April 8, 2023 (“Dividend Offer Date”). The Dividend Offer will remain open for Ninety (90) days from the Dividend Offer Date                
Dividend offer date Apr. 07, 2023                
Subsequent Event [Member] | Preferred Class A [Member] | Director [Member]                  
Subsequent Event [Line Items]                  
Right of voting Preferred A Stock holders representing at least 51% of all shareholders with the right to vote                
Subsequent Event [Member] | Private Placement [Member]                  
Subsequent Event [Line Items]                  
Shares issued price per share | $ / shares   $ 0.00216              
Common stock issued for cash, shares   60,224,825              
Subsequent Event [Member] | Accrued Salaries [Member]                  
Subsequent Event [Line Items]                  
Common stock issued for cash, shares         4,081,632        
Common stock issued for cash | $         $ 20,000        
Convertible Notes Payable [Member]                  
Subsequent Event [Line Items]                  
Conversion of common stock, shares               64,139,744 21,690,671
Conversion of common stock | $               $ 1,313,772 $ 1,019,014
Convertible Notes Payable [Member] | Subsequent Event [Member]                  
Subsequent Event [Line Items]                  
Conversion of common stock, shares     11,386,719 6,060,606   10,052,083 4,054,054    
Conversion of common stock | $     $ 36,438 $ 20,000   $ 36,188 $ 15,000    
XML 60 form10-k_htm.xml IDEA: XBRL DOCUMENT 0001419051 2022-01-01 2022-12-31 0001419051 2022-06-30 0001419051 2023-03-29 0001419051 2022-12-31 0001419051 2021-12-31 0001419051 2021-01-01 2021-12-31 0001419051 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001419051 us-gaap:CommonStockMember 2020-12-31 0001419051 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001419051 TSOI:SharesToBeIssuedMember 2020-12-31 0001419051 TSOI:SubscriptionReceivableMember 2020-12-31 0001419051 us-gaap:RetainedEarningsMember 2020-12-31 0001419051 2020-12-31 0001419051 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001419051 us-gaap:CommonStockMember 2021-12-31 0001419051 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001419051 TSOI:SharesToBeIssuedMember 2021-12-31 0001419051 TSOI:SubscriptionReceivableMember 2021-12-31 0001419051 us-gaap:RetainedEarningsMember 2021-12-31 0001419051 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001419051 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001419051 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001419051 TSOI:SharesToBeIssuedMember 2021-01-01 2021-12-31 0001419051 TSOI:SubscriptionReceivableMember 2021-01-01 2021-12-31 0001419051 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001419051 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001419051 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001419051 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001419051 TSOI:SharesToBeIssuedMember 2022-01-01 2022-12-31 0001419051 TSOI:SubscriptionReceivableMember 2022-01-01 2022-12-31 0001419051 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001419051 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001419051 us-gaap:CommonStockMember 2022-12-31 0001419051 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001419051 TSOI:SharesToBeIssuedMember 2022-12-31 0001419051 TSOI:SubscriptionReceivableMember 2022-12-31 0001419051 us-gaap:RetainedEarningsMember 2022-12-31 0001419051 2021-08-03 2021-08-04 0001419051 srt:MaximumMember 2022-12-31 0001419051 us-gaap:LandMember 2022-12-31 0001419051 us-gaap:LandMember 2021-12-31 0001419051 us-gaap:VehiclesMember 2022-12-31 0001419051 us-gaap:VehiclesMember 2021-12-31 0001419051 us-gaap:ComputerEquipmentMember 2022-12-31 0001419051 us-gaap:ComputerEquipmentMember 2021-12-31 0001419051 TSOI:OfficeFurnitureAndEquipmentMember 2022-12-31 0001419051 TSOI:OfficeFurnitureAndEquipmentMember 2021-12-31 0001419051 TSOI:ShippingAndOtherEquipmentMember 2022-12-31 0001419051 TSOI:ShippingAndOtherEquipmentMember 2021-12-31 0001419051 TSOI:ConvertiblePromissoryNoteMember TSOI:ExclusivePatentLicenseAgreementMember 2022-02-21 2022-02-23 0001419051 TSOI:ConvertiblePromissoryNoteMember TSOI:ExclusivePatentLicenseAgreementMember 2022-02-23 0001419051 TSOI:AssetsTransferAndLicenseAgreementMember 2022-03-24 2022-03-25 0001419051 TSOI:InitialPaymentMember TSOI:AssetsTransferAndLicenseAgreementMember 2022-03-24 2022-03-25 0001419051 TSOI:SecondPaymentMember TSOI:AssetsTransferAndLicenseAgreementMember 2022-03-24 2022-03-25 0001419051 TSOI:ConvertiblePromissoryNoteMember 2022-12-31 0001419051 TSOI:ConvertiblePromissoryNoteMember 2022-01-01 2022-12-31 0001419051 TSOI:ConvertiblePromissoryNoteMember 2021-12-31 0001419051 TSOI:ConvertiblePromissoryNoteMember 2021-01-01 2021-12-31 0001419051 srt:MinimumMember TSOI:ConvertiblePromissoryNoteMember 2021-12-31 0001419051 srt:MaximumMember TSOI:ConvertiblePromissoryNoteMember 2021-12-31 0001419051 us-gaap:DerivativeMember 2022-01-01 2022-12-31 0001419051 srt:MinimumMember us-gaap:DerivativeMember us-gaap:MeasurementInputConversionPriceMember 2022-12-31 0001419051 srt:MaximumMember us-gaap:DerivativeMember us-gaap:MeasurementInputConversionPriceMember 2022-12-31 0001419051 srt:MinimumMember us-gaap:DerivativeMember us-gaap:MeasurementInputSharePriceMember 2022-12-31 0001419051 srt:MaximumMember us-gaap:DerivativeMember us-gaap:MeasurementInputSharePriceMember 2022-12-31 0001419051 us-gaap:DerivativeMember us-gaap:MeasurementInputExpectedDividendRateMember 2022-12-31 0001419051 srt:MinimumMember us-gaap:DerivativeMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001419051 srt:MaximumMember us-gaap:DerivativeMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001419051 srt:MinimumMember us-gaap:DerivativeMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001419051 srt:MaximumMember us-gaap:DerivativeMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001419051 us-gaap:DerivativeMember us-gaap:MeasurementInputExpectedTermMember 2022-01-01 2022-12-31 0001419051 TSOI:ConvertibleNotesMember 2022-01-01 2022-12-31 0001419051 TSOI:ConvertibleNotesMember 2022-12-31 0001419051 srt:MinimumMember TSOI:ConvertibleNotesMember us-gaap:MeasurementInputConversionPriceMember 2022-12-31 0001419051 srt:MaximumMember TSOI:ConvertibleNotesMember us-gaap:MeasurementInputConversionPriceMember 2022-12-31 0001419051 srt:MinimumMember TSOI:ConvertibleNotesMember us-gaap:MeasurementInputSharePriceMember 2022-12-31 0001419051 srt:MaximumMember TSOI:ConvertibleNotesMember us-gaap:MeasurementInputSharePriceMember 2022-12-31 0001419051 us-gaap:DerivativeMember us-gaap:ConvertibleNotesPayableMember us-gaap:MeasurementInputExpectedDividendRateMember 2022-12-31 0001419051 srt:MinimumMember TSOI:ConvertibleNotesMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001419051 srt:MaximumMember TSOI:ConvertibleNotesMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001419051 srt:MinimumMember TSOI:ConvertibleNotesMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001419051 srt:MaximumMember TSOI:ConvertibleNotesMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001419051 srt:MinimumMember TSOI:ConvertibleNotesMember us-gaap:MeasurementInputExpectedTermMember 2022-01-01 2022-12-31 0001419051 srt:MaximumMember TSOI:ConvertibleNotesMember us-gaap:MeasurementInputExpectedTermMember 2022-01-01 2022-12-31 0001419051 TSOI:RemainingConvertibleNotesMember 2022-12-31 0001419051 TSOI:RemainingConvertibleNotesMember 2022-01-01 2022-12-31 0001419051 TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputExercisePriceMember 2022-12-31 0001419051 TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputSharePriceMember 2022-12-31 0001419051 TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputExpectedDividendRateMember 2022-12-31 0001419051 srt:MinimumMember TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001419051 srt:MaximumMember TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001419051 TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001419051 srt:MinimumMember TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputExpectedTermMember 2022-01-01 2022-12-31 0001419051 srt:MaximumMember TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputExpectedTermMember 2022-01-01 2022-12-31 0001419051 us-gaap:DerivativeMember 2021-01-01 2021-12-31 0001419051 srt:MinimumMember us-gaap:DerivativeMember us-gaap:MeasurementInputConversionPriceMember 2021-12-31 0001419051 srt:MaximumMember us-gaap:DerivativeMember us-gaap:MeasurementInputConversionPriceMember 2021-12-31 0001419051 srt:MinimumMember us-gaap:DerivativeMember us-gaap:MeasurementInputSharePriceMember 2021-12-31 0001419051 srt:MaximumMember us-gaap:DerivativeMember us-gaap:MeasurementInputSharePriceMember 2021-12-31 0001419051 us-gaap:DerivativeMember us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0001419051 srt:MinimumMember us-gaap:DerivativeMember us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001419051 srt:MaximumMember us-gaap:DerivativeMember us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001419051 srt:MinimumMember us-gaap:DerivativeMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001419051 srt:MaximumMember us-gaap:DerivativeMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001419051 us-gaap:DerivativeMember us-gaap:MeasurementInputExpectedTermMember 2021-01-01 2021-12-31 0001419051 TSOI:ConvertibleNotesMember 2021-01-01 2021-12-31 0001419051 srt:MinimumMember TSOI:ConvertibleNotesMember us-gaap:MeasurementInputConversionPriceMember 2021-12-31 0001419051 srt:MaximumMember TSOI:ConvertibleNotesMember us-gaap:MeasurementInputConversionPriceMember 2021-12-31 0001419051 srt:MinimumMember TSOI:ConvertibleNotesMember us-gaap:MeasurementInputSharePriceMember 2021-12-31 0001419051 srt:MaximumMember TSOI:ConvertibleNotesMember us-gaap:MeasurementInputSharePriceMember 2021-12-31 0001419051 TSOI:ConvertibleNotesMember us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0001419051 srt:MinimumMember TSOI:ConvertibleNotesMember us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001419051 srt:MaximumMember TSOI:ConvertibleNotesMember us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001419051 srt:MinimumMember TSOI:ConvertibleNotesMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001419051 srt:MaximumMember TSOI:ConvertibleNotesMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001419051 srt:MinimumMember TSOI:ConvertibleNotesMember us-gaap:MeasurementInputExpectedTermMember 2021-01-01 2021-12-31 0001419051 srt:MaximumMember TSOI:ConvertibleNotesMember us-gaap:MeasurementInputExpectedTermMember 2021-01-01 2021-12-31 0001419051 TSOI:RemainingConvertibleNotesMember 2021-12-31 0001419051 TSOI:RemainingConvertibleNotesMember 2021-01-01 2021-12-31 0001419051 srt:MinimumMember TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputConversionPriceMember 2021-12-31 0001419051 srt:MaximumMember TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputConversionPriceMember 2021-12-31 0001419051 TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputSharePriceMember 2021-12-31 0001419051 TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0001419051 srt:MinimumMember TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001419051 srt:MaximumMember TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001419051 TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001419051 srt:MinimumMember TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputExpectedTermMember 2021-01-01 2021-12-31 0001419051 srt:MaximumMember TSOI:RemainingConvertibleNotesMember us-gaap:MeasurementInputExpectedTermMember 2021-01-01 2021-12-31 0001419051 us-gaap:ConvertibleNotesPayableMember 2022-01-01 2022-12-31 0001419051 us-gaap:ConvertibleNotesPayableMember 2021-01-01 2021-12-31 0001419051 us-gaap:ConvertibleNotesPayableMember 2022-12-31 0001419051 TSOI:NotesPayableOneMember 2022-12-31 0001419051 TSOI:NotesPayableOneMember 2021-12-31 0001419051 TSOI:NotesPayableTwoMember 2022-12-31 0001419051 TSOI:NotesPayableTwoMember 2021-12-31 0001419051 TSOI:NotesPayableThreeMember 2022-12-31 0001419051 TSOI:NotesPayableThreeMember 2021-12-31 0001419051 TSOI:NotesPayableFourMember 2022-12-31 0001419051 TSOI:NotesPayableFourMember 2021-12-31 0001419051 TSOI:NotesPayableFiveMember 2022-12-31 0001419051 TSOI:NotesPayableFiveMember 2021-12-31 0001419051 TSOI:ScientificAdvisoryBoardMember TSOI:NotesPayableOneMember 2022-12-31 0001419051 TSOI:ScientificAdvisoryBoardMember TSOI:NotesPayableOneMember 2021-12-31 0001419051 TSOI:ScientificAdvisoryBoardMember TSOI:NotesPayableOneMember 2022-01-01 2022-12-31 0001419051 TSOI:ScientificAdvisoryBoardMember TSOI:NotesPayableOneMember 2021-01-01 2021-12-31 0001419051 srt:MinimumMember srt:ChiefExecutiveOfficerMember TSOI:NotesPayableTwoMember 2022-12-31 0001419051 srt:MinimumMember srt:ChiefExecutiveOfficerMember TSOI:NotesPayableTwoMember 2021-12-31 0001419051 srt:MaximumMember srt:ChiefExecutiveOfficerMember TSOI:NotesPayableTwoMember 2022-12-31 0001419051 srt:MaximumMember srt:ChiefExecutiveOfficerMember TSOI:NotesPayableTwoMember 2021-12-31 0001419051 srt:ChiefExecutiveOfficerMember TSOI:NotesPayableTwoMember 2022-01-01 2022-12-31 0001419051 srt:ChiefExecutiveOfficerMember TSOI:NotesPayableTwoMember 2021-01-01 2021-12-31 0001419051 srt:ChiefFinancialOfficerMember TSOI:NotesPayableFourMember 2022-12-31 0001419051 srt:ChiefFinancialOfficerMember TSOI:NotesPayableFourMember 2021-12-31 0001419051 srt:ChiefFinancialOfficerMember TSOI:NotesPayableFourMember 2022-01-01 2022-12-31 0001419051 srt:ChiefFinancialOfficerMember TSOI:NotesPayableFourMember 2021-01-01 2021-12-31 0001419051 srt:MinimumMember TSOI:BusinessAdvisoryBoardMember TSOI:NotesPayableFiveMember 2022-12-31 0001419051 srt:MinimumMember TSOI:BusinessAdvisoryBoardMember TSOI:NotesPayableFiveMember 2021-12-31 0001419051 srt:MaximumMember TSOI:BusinessAdvisoryBoardMember TSOI:NotesPayableFiveMember 2022-12-31 0001419051 srt:MaximumMember TSOI:BusinessAdvisoryBoardMember TSOI:NotesPayableFiveMember 2021-12-31 0001419051 TSOI:BusinessAdvisoryBoardMember TSOI:NotesPayableFiveMember 2022-01-01 2022-12-31 0001419051 TSOI:BusinessAdvisoryBoardMember TSOI:NotesPayableFiveMember 2021-01-01 2021-12-31 0001419051 srt:OfficerMember 2019-12-31 0001419051 srt:OfficerMember 2018-12-31 0001419051 TSOI:OneOfficersMember us-gaap:RestrictedStockMember TSOI:AccruedSalariesMember 2021-01-01 2021-12-31 0001419051 TSOI:OneOfficerAndOneDirectorMember us-gaap:RestrictedStockMember 2021-06-17 2021-06-18 0001419051 TSOI:FourOfficerAndOneDirectorMember us-gaap:RestrictedStockMember 2021-11-30 2021-11-30 0001419051 TSOI:OneOfficersMember us-gaap:RestrictedStockMember TSOI:AccruedSalariesMember 2022-01-01 2022-12-31 0001419051 TSOI:FourOfficerAndOneDirectorMember us-gaap:RestrictedStockMember 2022-04-05 2022-04-05 0001419051 TSOI:OneOfficerAndOneDirectorMember us-gaap:RestrictedStockMember 2022-09-08 2022-09-08 0001419051 TSOI:FourOfficerOneDirectorMember us-gaap:RestrictedStockMember 2022-11-02 2022-11-02 0001419051 TSOI:FourOfficerAndOneDirectorMember us-gaap:RestrictedStockMember 2022-12-30 2022-12-30 0001419051 us-gaap:PrivatePlacementMember 2021-01-01 2021-12-31 0001419051 TSOI:ConsultingServicesMember 2021-01-01 2021-12-31 0001419051 TSOI:SalariesMember 2021-01-01 2021-12-31 0001419051 TSOI:LandDevelopmentMember 2021-01-01 2021-12-31 0001419051 us-gaap:PrivatePlacementMember 2022-01-01 2022-12-31 0001419051 TSOI:ConsultingServicesMember 2022-01-01 2022-12-31 0001419051 TSOI:ConsultingServicesMember us-gaap:SubsequentEventMember 2023-01-03 2023-01-03 0001419051 TSOI:SalariesMember 2022-01-01 2022-12-31 0001419051 us-gaap:LicenseMember 2022-01-01 2022-12-31 0001419051 TSOI:PrepaidFeesMember 2022-01-01 2022-12-31 0001419051 us-gaap:ConvertibleNotesPayableMember us-gaap:SubsequentEventMember 2023-01-03 2023-01-03 0001419051 us-gaap:SubsequentEventMember 2023-01-03 2023-01-03 0001419051 us-gaap:SubsequentEventMember 2023-01-03 0001419051 us-gaap:ConvertibleNotesPayableMember us-gaap:SubsequentEventMember 2023-01-04 2023-01-04 0001419051 TSOI:AccruedSalariesMember us-gaap:SubsequentEventMember 2023-01-09 2023-01-09 0001419051 us-gaap:SubsequentEventMember 2023-01-09 2023-01-09 0001419051 us-gaap:SubsequentEventMember 2023-01-09 0001419051 us-gaap:ConvertibleNotesPayableMember us-gaap:SubsequentEventMember 2023-02-06 2023-02-06 0001419051 us-gaap:ConvertibleNotesPayableMember us-gaap:SubsequentEventMember 2023-02-07 2023-02-07 0001419051 us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2023-02-21 2023-02-21 0001419051 us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2023-02-21 0001419051 srt:DirectorMember us-gaap:PreferredClassAMember us-gaap:SubsequentEventMember 2023-03-21 2023-03-21 0001419051 TSOI:CampbellNeurosciencesIncMember us-gaap:SubsequentEventMember 2023-03-21 2023-03-21 0001419051 us-gaap:SubsequentEventMember 2023-03-21 2023-03-21 0001419051 TSOI:CampbellNeurosciencesIncMember us-gaap:SubsequentEventMember 2023-03-21 iso4217:USD shares iso4217:USD shares utr:sqft pure 0001419051 false FY 10-K true 2022-12-31 --12-31 2022 false 000-54554 Therapeutic Solutions International, Inc. NV 45-1226465 701 Wild Rose Lane Elk City ID 83525 760 295-7208 Common Stock, $0.001 par value per share No No Yes No Non-accelerated Filer true false false 1296570604 2734250749 5525 Fruci & Associates II, PLLC Spokane, Washington 18040 94036 11003 10223 25398 16613 42428 39817 212352 959307 309221 1119996 273078 284024 8612 34184 3014620 277571 3605531 1715775 401992 394035 7209 9791 531783 487208 8612 25374 4638 4071 175063 225800 65187 79200 988672 965211 202144 531525 2210237 2496415 10507 15532 8810 2220744 2520757 0.001 0.001 5000000 5000000 2 2 0 0 0.001 0.001 3500000000 3500000000 2617390830 2617390830 2311123860 2311123860 2617392 2311125 16334129 10899139 126324 21000 21000 -17672058 -13994246 1384787 -804982 3605531 1715775 206767 145956 79440 42544 127327 103412 491928 138710 444865 436555 432033 264540 397302 773203 1441128 794750 3207256 2407758 -3079929 -2304346 131475 539006 291123 494501 646089 611794 -110642 -597083 -656299 -3677012 -2960645 800 800 -3677812 -2961445 -0.00 -0.00 2528062958 2263126970 2233741391 2233742 7041960 -21000 -11032801 -1778099 21000000 21000 837900 858900 20000000 20000 1452450 1472450 8341723 8342 231457 239799 4850075 4850 280649 285499 1500000 1500 57400 58900 21690671 21691 508044 529735 489279 489279 -2961445 -2961445 2311123860 2311125 10899139 -21000 -13994246 -804982 2311123860 2311125 10899139 -21000 -13994246 -804982 32412577 32413 557107 102000 691520 11000000 11000 231320 242320 4812259 4812 62587 67399 44500000 44500 400500 445000 149402390 149402 2958168 3107570 64139744 64140 1225308 24324 1313772 2 -3677812 -3677812 2 2617390830 2617392 16334129 126324 -21000 -17672058 1384787 2 2617390830 2617392 16334129 126324 -21000 -17672058 1384787 -3677812 -2961445 380820 397750 310700 461150 131475 539006 291123 494501 951748 480135 593463 541612 233685 11295 10946 6772 8785 14172 2611 34418 -174364 -64777 25572 24792 15166 91557 -9791 2581 169451 188979 -25572 -24792 -1018304 -718922 260565 4015 -256550 2453 4799 505000 538750 4459 2068 445000 285499 943088 817382 -75216 -158090 104259 262349 29043 104259 3173 3312 800 800 39000 33500 503726 538750 1313772 1019014 21671 242320 1472450 67399 239799 25914 25912 3107570 58900 18040 94036 11003 10223 29043 104259 <p id="xdx_80A_eus-gaap--NatureOfOperations_zHMMXb3Ty6i2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 – <span id="xdx_82D_zHl7RuiaS747">Organization and Business Description</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therapeutic Solutions International, Inc. (“TSI” or the “Company”) was organized <span id="xdx_902_edei--EntityIncorporationDateOfIncorporation_c20220101__20221231_zqhIZswywuqh" title="Entity incorporation date">August 6, 2007</span> under the name Friendly Auto Dealers, Inc., under the laws of the State of Nevada. In the first quarter of 2011 the Company changed its name from Friendly Auto Dealers, Inc. to Therapeutic Solutions International, Inc., and acquired Splint Decisions, Inc., a California corporation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business Description</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently, the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Activating one’s immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TSOI is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, traumatic brain injury, lung pathologies, and for daily health.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cellular Division</b> – TSOI obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and Lung Pathology (LP).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The stem cell licensed, termed “JadiCell” is unique in that it possesses features of mesenchymal stem cells, however, outperforms these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and neurogenic ability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chronic Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe. TSOI has previously filed several patents in the area of CTE based on modulating the brain microenvironment to enhance receptivity of regenerative cells such as stem cells. On March 4, 2021 the Company received an IND Serial # 27377 for a clinical trial of 10 patients with CTE.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On Augus<sup>t </sup>4th, 2021, the Company announced clearance from the Food and Drug Administration (FDA) to initiate a Phase III pivotal trial for registration of the Company’s JadiCell™ universal donor stem cell as a treatment for COVID-19 associated lung failure under IND # 19757. In previous studies the Company has demonstrated the superior activity of JadiCell™ to other types of stem cells including bone marrow, adipose, cord blood, and placenta. Furthermore, <span id="xdx_900_eus-gaap--UnusualOrInfrequentItemNatureOfEventOrTransaction_c20210803__20210804_zAUCUWek9SM7" title="Unusual or infrequent item, description">the JadiCell™ was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91%.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, the Company has filed data with the FDA, as part of IND #17448, which demonstrated that treatment of cancer patients with StemVacs™ resulted in enhanced activity of a type of immunological cell called “natural killer” cells, otherwise known as “NK cells.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has also developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body’s NK cells.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most recently the Company announced filing of a patent for a new hybrid cell created by the Company capable of training the immune system to kill blood vessels feeding cancer, but sparing healthy blood vessels. These discoveries are an extension of previous findings from the Company showing that StemVacs is capable of suppressing new blood vessel production.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 9, 2022, the Company filed an Investigational New Drug Application for Treatment of Chronic Obstructive Pulmonary Disease (COPD) Using JadiCell™ Universal Donor Adult Stem Cells under IND Serial # 28508.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Notes to Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management does not expect existing cash as of December 31, 2022 or as of March 31, 2023 to be sufficient to fund the Company’s operations for at least twelve months from the issuance date of these financial statements. These financial statements have been prepared on a going concern basis which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of December 31, 2022, the Company has incurred losses totaling $<span id="xdx_905_eus-gaap--ProfitLoss_pn5n6_c20220101__20221231_zTGm8Oxg81Kh" title="Net loss">17.3</span> million since inception, has not yet generated material revenue from operations, and will require additional funds to maintain its operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern within one year after the consolidated financial statements are issued. The Company’s ability to continue as a going concern is dependent upon its ability to generate future profitable operations and obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. The Company intends to finance operating costs over the next twelve months through its existing financial resources and we may also raise additional capital through equity offerings, debt financings, collaborations and/or licensing arrangements. If adequate funds are not available on acceptable terms, we may be required to delay, reduce the scope of, or curtail, our operations. The accompanying consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 2007-08-06 the JadiCell™ was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91%. 17300000 <p id="xdx_80D_eus-gaap--SignificantAccountingPoliciesTextBlock_zP9aNqA7zLVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 – <span id="xdx_82F_zyaZ64B7Zigd">Basis of presentation and significant accounting policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zSUikSaPHH4g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zGFVbBwzO9v8">Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_zFCATdNRGQVd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zpYw9vOIkida">Principles of Consolidation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. No material activity in any subsidiaries.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zyaUilyX48nc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zAUMon69hLOa">Accounts Receivable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span> </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable are stated at amounts due from customers, net of an allowance for doubtful accounts, and the Company generally does not require collateral. As a general policy, the Company determines an allowance for doubtful accounts by considering a number of factors, including the length of time trade accounts receivable are past due, the Company’s previous loss history, the customer’s current ability to pay its obligation to the Company, and the condition of the general economy and industry as a whole. The Company writes off accounts receivable when they become uncollectible, and payments subsequently received on such receivables are credited to the allowance for doubtful accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recorded an allowance for doubtful accounts of $<span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20221231_z2UFaiTt80xi" title="Allowance for doubtful accounts"><span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20211231_z6RLettK2Pa4" title="Allowance for doubtful accounts">6,807</span></span> as of both December 31, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p id="xdx_845_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zwLkqzSMnpGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_z2PNfFStFWI4">Revenue Recognition</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue in accordance with ASC 606,”Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the Company applies the following methodology to recognize revenue:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify the contract with a customer.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify the performance obligations in the contract.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determine the transaction price.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocate the transaction price to the performance obligations in the contract.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognize revenue when (or as) the entity satisfies a performance obligation.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">ASC 606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which the customer obtains control of the product or service.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Returns. </b>We will gladly accept the return of products that are defective due to defects in manufacturing and/or workmanship.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Wholesale policies:</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delivery. </b>The Goods shall be deemed delivered when Buyer has accepted delivery at the above-referenced location. The shipping method shall be determined by Seller, but Buyer will not be responsible for shipping costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Notes to Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 – Basis of presentation and significant accounting policies (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Purchase Price &amp; Payments.</b> <span id="xdx_902_ecustom--WholesalePurchasePriceAndPaymentsDescription_c20220101__20221231_zVeNokZ4pEng" title="Payments description">Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inspection of Goods &amp; Rejection.</b> Buyer is entitled to inspect the Goods upon delivery. If the Goods are unacceptable for any reason, Buyer must reject them at the time of delivery up to five (5) business days from the date of delivery. If Buyer has not rejected the Goods within five (5) business days from the date of delivery, Buyer shall have waived any right to reject that specific delivery of Goods. In the event Buyer rejects the Goods, Buyer shall allow Seller a reasonable time to cure the deficiency. A reasonable time period shall be determined by industry standards for the particular Goods, as well as the Seller and Buyer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk of Loss.</b> Risk of loss will be on the Seller until the time when the Buyer accepts delivery. Seller shall maintain any and all necessary insurance in order to insure the Goods against loss at Seller’s own expense</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Retail policies of e-commerce:</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Returns. </b>We will gladly accept the return of products that are defective due to defects in manufacturing and/or workmanship. Fulfillment mistakes that may be made which result in the shipment of incorrect products to you will also be accepted for return.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shipping. </b>Shipping Time –Most orders will ship the next business day, provided the product ordered is in stock. Orders are not processed or shipped on Saturday or Sunday, except by prior arrangement. We cannot guarantee when an order will arrive. Consider any shipping or transit time offered to you by this site or other parties only as an estimate. We encourage you to order in a timely fashion to avoid delays caused by shipping or product availability. Shipping for Amazon and Walmart are shipped to the fullfillment centers based on inventory amounts. Orders are shipped to customers by the companies as ordered on their websites.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Out of Stock.</b> We will ship your product as it becomes available. Usually, products ship by the next business day. However, there may be times when the product you have ordered is out-of-stock, which will delay fulfilling your order. We will keep you informed of any products that you have ordered that are out-of-stock and unavailable for immediate shipment. You may cancel your order at any time prior to shipping.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z3LiHAmBORrb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zJ9TPvkB8Tk4">Cash and Cash Equivalents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20221231__srt--RangeAxis__srt--MaximumMember_zVGF60A2VEe" title="Cash, FDIC insured amount">250,000</span>. At December 31, 2022 and 2021, the Company had $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20221231_zTAuRanP6rbj" title="Cash, FDIC insured amount"><span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20211231_zpd5z1y7rQP8" title="Cash, FDIC insured amount">0</span></span> in excess of the FDIC insured limit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--InventoryPolicyTextBlock_zK8Ci85gpUe9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zKUjdX3uUK4e">Inventories</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials and assembly items.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--DerivativesPolicyTextBlock_z2VeTu1aPrc7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_ziJjoVKpUsae">Derivative Liabilities</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Notes to Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 – Basis of presentation and significant accounting policies (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2022 and 2021, as disclosed in Note 5, containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $<span id="xdx_900_eus-gaap--DerivativeLiabilitiesCurrent_iI_pp0p0_c20221231_z8jr9WRNVuJ8" title="Derivative liabilities">202,144</span> and $<span id="xdx_902_eus-gaap--DerivativeLiabilitiesCurrent_iI_pp0p0_c20211231_zCUocV1KNBte" title="Derivative liabilities">531,525</span> at December 31, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zmSUDci4OHR7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zU9OdrKYSdM4">Fair Value of Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of December 31, 2021 and 2020, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_z6ub9oQvLXXa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is the change in derivative liability for the years ended December 31, 2022 and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B3_zyCxme6metyk" style="display: none">Schedule of Change in Derivative Liability</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance, December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_c20210101__20211231_zbFszv10Nsud" style="width: 16%; text-align: right" title="Beginning Balance">437,549</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Issuance of new derivative liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_pp0p0_c20210101__20211231_zdtoJqQRqjvl" style="text-align: right" title="Issuance of new derivative liabilities">1,077,756</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Conversions</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet_pp0p0_c20210101__20211231_zXc3Kf16X0Oc" style="text-align: right" title="Conversions">(489,279</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair market value of derivative liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_pp0p0_c20210101__20211231_zw6m3X0GAQb3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair market value of derivative liabilities">(494,501</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance, December 31, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_c20220101__20221231_zZ4HmXi1QB41" style="text-align: right" title="Beginning Balance">531,525</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Issuance of new derivative liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_pp0p0_c20220101__20221231_zuDvgznaV7ge" style="text-align: right" title="Issuance of new derivative liabilities">674,971</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Conversions</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet_pp0p0_c20220101__20221231_zqG5FYD3MnMb" style="text-align: right" title="Conversions">(713,229</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair market value of derivative liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_pp0p0_c20220101__20221231_zrvU5Js1X7B3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair market value of derivative liabilities">(291,123</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance, December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_c20220101__20221231_zzHL0Lc5oTO4" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">202,144</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zHSD6CGPj7B2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Notes to Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_847_eus-gaap--UseOfEstimates_zOZYgg1gZZTj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zNo3hEJbYQF3">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zbyEPXMqju86" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zBtwdjBd9Ws5">Comprehensive Loss</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive loss for the periods reported was comprised solely of the Company’s net loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--EarningsPerShareTextBlock_zaVsR4TyCEmh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zjVanUw4pwe2">Net Loss Per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022 and 2021, a total of <span style="background-color: white"><span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231_zdV1p0zuYEu" title="Antidilutive securities excluded from computation of earnings per share">267,136,056</span> and <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231_zGs18M8nEqKg" title="Antidilutive securities excluded from computation of earnings per share">95,273,690</span>,</span> respectively, potential common shares, consisting of shares underlying outstanding convertible notes payable were excluded as their inclusion would be antidilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84D_eus-gaap--DepreciationDepletionAndAmortizationPolicyTextBlock_zVLBd1yQtl9e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_z0qaUgMipb27">Depreciation and Amortization</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. Depreciation expense for the years ended December 31, 2022 and 2021 was $<span id="xdx_903_eus-gaap--Depreciation_pp0p0_c20220101__20221231_zNngFR0uAbtl" title="Depreciation expense">10,946</span> and $<span id="xdx_90C_eus-gaap--Depreciation_pp0p0_c20210101__20211231_zM2pJcYlU0Y2" title="Depreciation expense">6,772</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zwsP4pbOskpe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zSys55t3OhTc">Intangible Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Amortization expense for the years ended December 31, 2022 and 2021 was $<span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20220101__20221231_zPRJYk46QoPi" title="Amortization expense">233,685</span> and $<span id="xdx_90C_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20210101__20211231_z3ZbT0KXU16h" title="Amortization expense">11,295</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_z5NB65A9qvG9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zbyphpw6xChd">Long-lived Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_ecustom--ShippingAndHandlingCostsPolicyTextBlock_zMkUMxetQNM6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zVK0fDSU1k2k">Shipping and Handling</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes shipping and handling billed to customers as a component of net revenues, and the cost of shipping and handling within general administrative expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--AdvertisingCostsPolicyTextBlock_zpzWScbKFyq4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zqlCo5ph4n1h">Advertising</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising costs are expensed as incurred. Advertising expense for the years ended December 31, 2022 and 2021 were $<span id="xdx_90D_eus-gaap--AdvertisingExpense_c20220101__20221231_zOGbt2mMgMyi" title="Advertising expense">4,132</span> and $<span id="xdx_900_eus-gaap--AdvertisingExpense_c20210101__20211231_zwK6DdBkTcd9" title="Advertising expense">0</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--ResearchAndDevelopmentExpensePolicy_zQ2GUYfl82s2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_z55QFJ9mLtOg">Research and Development</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and Development costs are expensed as incurred. Research and Development expenses were $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220101__20221231_zkshfyMwRIS7" title="Research and development expense">1,441,128</span> and $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210101__20211231_zibqnGpzUbdc" title="Research and development expense">794,750</span> for the years ended December 31, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--IncomeTaxPolicyTextBlock_z5vVAGbaCH5e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zGbt00mvB7Sd">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes under ASC 7”0 <i>“Income Tax”s,” </i>which codified SFAS 10”, <i>“Accounting for Income Ta”es” </i>and FIN 48 <i>“Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.” </i>Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Notes to Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 – Basis of presentation and significant accounting policies (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z8i5dlLHlLN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z699CFTNPgw">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted and nonrefundable shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--LesseeLeasesPolicyTextBlock_zf5GxhcwvTg1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zcMphhY44VUa">Leases</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company recorded a Right-of-use asset and a Lease Liability of $<span id="xdx_909_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20221231_zPCOgyy2EU2l" title="Lease liability"><span id="xdx_90F_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20221231_z3YfLlVARI51" title="Right-of-use asset">8,612</span></span> as of December 31, 2022.</span></p> <p id="xdx_851_ztba5GRoRe8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zSUikSaPHH4g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zGFVbBwzO9v8">Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_zFCATdNRGQVd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zpYw9vOIkida">Principles of Consolidation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. No material activity in any subsidiaries.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zyaUilyX48nc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zAUMon69hLOa">Accounts Receivable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span> </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable are stated at amounts due from customers, net of an allowance for doubtful accounts, and the Company generally does not require collateral. As a general policy, the Company determines an allowance for doubtful accounts by considering a number of factors, including the length of time trade accounts receivable are past due, the Company’s previous loss history, the customer’s current ability to pay its obligation to the Company, and the condition of the general economy and industry as a whole. The Company writes off accounts receivable when they become uncollectible, and payments subsequently received on such receivables are credited to the allowance for doubtful accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recorded an allowance for doubtful accounts of $<span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20221231_z2UFaiTt80xi" title="Allowance for doubtful accounts"><span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20211231_z6RLettK2Pa4" title="Allowance for doubtful accounts">6,807</span></span> as of both December 31, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> 6807 6807 <p id="xdx_845_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zwLkqzSMnpGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_z2PNfFStFWI4">Revenue Recognition</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue in accordance with ASC 606,”Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the Company applies the following methodology to recognize revenue:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify the contract with a customer.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify the performance obligations in the contract.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determine the transaction price.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocate the transaction price to the performance obligations in the contract.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognize revenue when (or as) the entity satisfies a performance obligation.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">ASC 606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which the customer obtains control of the product or service.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Returns. </b>We will gladly accept the return of products that are defective due to defects in manufacturing and/or workmanship.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Wholesale policies:</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delivery. </b>The Goods shall be deemed delivered when Buyer has accepted delivery at the above-referenced location. The shipping method shall be determined by Seller, but Buyer will not be responsible for shipping costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Notes to Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 – Basis of presentation and significant accounting policies (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Purchase Price &amp; Payments.</b> <span id="xdx_902_ecustom--WholesalePurchasePriceAndPaymentsDescription_c20220101__20221231_zVeNokZ4pEng" title="Payments description">Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inspection of Goods &amp; Rejection.</b> Buyer is entitled to inspect the Goods upon delivery. If the Goods are unacceptable for any reason, Buyer must reject them at the time of delivery up to five (5) business days from the date of delivery. If Buyer has not rejected the Goods within five (5) business days from the date of delivery, Buyer shall have waived any right to reject that specific delivery of Goods. In the event Buyer rejects the Goods, Buyer shall allow Seller a reasonable time to cure the deficiency. A reasonable time period shall be determined by industry standards for the particular Goods, as well as the Seller and Buyer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk of Loss.</b> Risk of loss will be on the Seller until the time when the Buyer accepts delivery. Seller shall maintain any and all necessary insurance in order to insure the Goods against loss at Seller’s own expense</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Retail policies of e-commerce:</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Returns. </b>We will gladly accept the return of products that are defective due to defects in manufacturing and/or workmanship. Fulfillment mistakes that may be made which result in the shipment of incorrect products to you will also be accepted for return.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shipping. </b>Shipping Time –Most orders will ship the next business day, provided the product ordered is in stock. Orders are not processed or shipped on Saturday or Sunday, except by prior arrangement. We cannot guarantee when an order will arrive. Consider any shipping or transit time offered to you by this site or other parties only as an estimate. We encourage you to order in a timely fashion to avoid delays caused by shipping or product availability. Shipping for Amazon and Walmart are shipped to the fullfillment centers based on inventory amounts. Orders are shipped to customers by the companies as ordered on their websites.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Out of Stock.</b> We will ship your product as it becomes available. Usually, products ship by the next business day. However, there may be times when the product you have ordered is out-of-stock, which will delay fulfilling your order. We will keep you informed of any products that you have ordered that are out-of-stock and unavailable for immediate shipment. You may cancel your order at any time prior to shipping.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail. <p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z3LiHAmBORrb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zJ9TPvkB8Tk4">Cash and Cash Equivalents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20221231__srt--RangeAxis__srt--MaximumMember_zVGF60A2VEe" title="Cash, FDIC insured amount">250,000</span>. At December 31, 2022 and 2021, the Company had $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20221231_zTAuRanP6rbj" title="Cash, FDIC insured amount"><span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20211231_zpd5z1y7rQP8" title="Cash, FDIC insured amount">0</span></span> in excess of the FDIC insured limit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 250000 0 0 <p id="xdx_842_eus-gaap--InventoryPolicyTextBlock_zK8Ci85gpUe9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zKUjdX3uUK4e">Inventories</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials and assembly items.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--DerivativesPolicyTextBlock_z2VeTu1aPrc7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_ziJjoVKpUsae">Derivative Liabilities</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Notes to Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 – Basis of presentation and significant accounting policies (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2022 and 2021, as disclosed in Note 5, containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $<span id="xdx_900_eus-gaap--DerivativeLiabilitiesCurrent_iI_pp0p0_c20221231_z8jr9WRNVuJ8" title="Derivative liabilities">202,144</span> and $<span id="xdx_902_eus-gaap--DerivativeLiabilitiesCurrent_iI_pp0p0_c20211231_zCUocV1KNBte" title="Derivative liabilities">531,525</span> at December 31, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 202144 531525 <p id="xdx_844_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zmSUDci4OHR7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zU9OdrKYSdM4">Fair Value of Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of December 31, 2021 and 2020, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_z6ub9oQvLXXa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is the change in derivative liability for the years ended December 31, 2022 and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B3_zyCxme6metyk" style="display: none">Schedule of Change in Derivative Liability</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance, December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_c20210101__20211231_zbFszv10Nsud" style="width: 16%; text-align: right" title="Beginning Balance">437,549</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Issuance of new derivative liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_pp0p0_c20210101__20211231_zdtoJqQRqjvl" style="text-align: right" title="Issuance of new derivative liabilities">1,077,756</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Conversions</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet_pp0p0_c20210101__20211231_zXc3Kf16X0Oc" style="text-align: right" title="Conversions">(489,279</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair market value of derivative liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_pp0p0_c20210101__20211231_zw6m3X0GAQb3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair market value of derivative liabilities">(494,501</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance, December 31, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_c20220101__20221231_zZ4HmXi1QB41" style="text-align: right" title="Beginning Balance">531,525</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Issuance of new derivative liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_pp0p0_c20220101__20221231_zuDvgznaV7ge" style="text-align: right" title="Issuance of new derivative liabilities">674,971</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Conversions</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet_pp0p0_c20220101__20221231_zqG5FYD3MnMb" style="text-align: right" title="Conversions">(713,229</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair market value of derivative liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_pp0p0_c20220101__20221231_zrvU5Js1X7B3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair market value of derivative liabilities">(291,123</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance, December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_c20220101__20221231_zzHL0Lc5oTO4" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">202,144</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zHSD6CGPj7B2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Notes to Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_892_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_z6ub9oQvLXXa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is the change in derivative liability for the years ended December 31, 2022 and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B3_zyCxme6metyk" style="display: none">Schedule of Change in Derivative Liability</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance, December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_c20210101__20211231_zbFszv10Nsud" style="width: 16%; text-align: right" title="Beginning Balance">437,549</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Issuance of new derivative liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_pp0p0_c20210101__20211231_zdtoJqQRqjvl" style="text-align: right" title="Issuance of new derivative liabilities">1,077,756</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Conversions</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet_pp0p0_c20210101__20211231_zXc3Kf16X0Oc" style="text-align: right" title="Conversions">(489,279</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair market value of derivative liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_pp0p0_c20210101__20211231_zw6m3X0GAQb3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair market value of derivative liabilities">(494,501</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance, December 31, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_c20220101__20221231_zZ4HmXi1QB41" style="text-align: right" title="Beginning Balance">531,525</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Issuance of new derivative liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_pp0p0_c20220101__20221231_zuDvgznaV7ge" style="text-align: right" title="Issuance of new derivative liabilities">674,971</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Conversions</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet_pp0p0_c20220101__20221231_zqG5FYD3MnMb" style="text-align: right" title="Conversions">(713,229</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair market value of derivative liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_pp0p0_c20220101__20221231_zrvU5Js1X7B3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair market value of derivative liabilities">(291,123</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance, December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_c20220101__20221231_zzHL0Lc5oTO4" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">202,144</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 437549 1077756 -489279 -494501 531525 674971 -713229 -291123 202144 <p id="xdx_847_eus-gaap--UseOfEstimates_zOZYgg1gZZTj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zNo3hEJbYQF3">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zbyEPXMqju86" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zBtwdjBd9Ws5">Comprehensive Loss</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive loss for the periods reported was comprised solely of the Company’s net loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--EarningsPerShareTextBlock_zaVsR4TyCEmh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zjVanUw4pwe2">Net Loss Per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022 and 2021, a total of <span style="background-color: white"><span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231_zdV1p0zuYEu" title="Antidilutive securities excluded from computation of earnings per share">267,136,056</span> and <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20211231_zGs18M8nEqKg" title="Antidilutive securities excluded from computation of earnings per share">95,273,690</span>,</span> respectively, potential common shares, consisting of shares underlying outstanding convertible notes payable were excluded as their inclusion would be antidilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 267136056 95273690 <p id="xdx_84D_eus-gaap--DepreciationDepletionAndAmortizationPolicyTextBlock_zVLBd1yQtl9e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_z0qaUgMipb27">Depreciation and Amortization</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. Depreciation expense for the years ended December 31, 2022 and 2021 was $<span id="xdx_903_eus-gaap--Depreciation_pp0p0_c20220101__20221231_zNngFR0uAbtl" title="Depreciation expense">10,946</span> and $<span id="xdx_90C_eus-gaap--Depreciation_pp0p0_c20210101__20211231_zM2pJcYlU0Y2" title="Depreciation expense">6,772</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 10946 6772 <p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zwsP4pbOskpe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zSys55t3OhTc">Intangible Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Amortization expense for the years ended December 31, 2022 and 2021 was $<span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20220101__20221231_zPRJYk46QoPi" title="Amortization expense">233,685</span> and $<span id="xdx_90C_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20210101__20211231_z3ZbT0KXU16h" title="Amortization expense">11,295</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 233685 11295 <p id="xdx_84A_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_z5NB65A9qvG9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zbyphpw6xChd">Long-lived Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_ecustom--ShippingAndHandlingCostsPolicyTextBlock_zMkUMxetQNM6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zVK0fDSU1k2k">Shipping and Handling</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes shipping and handling billed to customers as a component of net revenues, and the cost of shipping and handling within general administrative expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--AdvertisingCostsPolicyTextBlock_zpzWScbKFyq4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zqlCo5ph4n1h">Advertising</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising costs are expensed as incurred. Advertising expense for the years ended December 31, 2022 and 2021 were $<span id="xdx_90D_eus-gaap--AdvertisingExpense_c20220101__20221231_zOGbt2mMgMyi" title="Advertising expense">4,132</span> and $<span id="xdx_900_eus-gaap--AdvertisingExpense_c20210101__20211231_zwK6DdBkTcd9" title="Advertising expense">0</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 4132 0 <p id="xdx_848_eus-gaap--ResearchAndDevelopmentExpensePolicy_zQ2GUYfl82s2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_z55QFJ9mLtOg">Research and Development</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and Development costs are expensed as incurred. Research and Development expenses were $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220101__20221231_zkshfyMwRIS7" title="Research and development expense">1,441,128</span> and $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210101__20211231_zibqnGpzUbdc" title="Research and development expense">794,750</span> for the years ended December 31, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1441128 794750 <p id="xdx_843_eus-gaap--IncomeTaxPolicyTextBlock_z5vVAGbaCH5e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zGbt00mvB7Sd">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes under ASC 7”0 <i>“Income Tax”s,” </i>which codified SFAS 10”, <i>“Accounting for Income Ta”es” </i>and FIN 48 <i>“Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.” </i>Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Notes to Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 – Basis of presentation and significant accounting policies (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z8i5dlLHlLN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z699CFTNPgw">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted and nonrefundable shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--LesseeLeasesPolicyTextBlock_zf5GxhcwvTg1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zcMphhY44VUa">Leases</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company recorded a Right-of-use asset and a Lease Liability of $<span id="xdx_909_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20221231_zPCOgyy2EU2l" title="Lease liability"><span id="xdx_90F_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20221231_z3YfLlVARI51" title="Right-of-use asset">8,612</span></span> as of December 31, 2022.</span></p> 8612 8612 <p id="xdx_80C_eus-gaap--CashAndCashEquivalentsDisclosureTextBlock_zTQACVbUJlWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 3 – <span id="xdx_821_zW1mRz2gLC68">Restricted cash</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included in current assets is a $<span id="xdx_90E_eus-gaap--RestrictedCashAndCashEquivalents_iI_pp0p0_c20221231_z8GaLTjsYbl3" title="Restricted cash and non-cash equivalents">10,000</span> certificate of deposit with an annual interest rate of <span id="xdx_90F_ecustom--AnnualInterestRate_pid_dp_c20220101__20221231_zp2wD6WEFOz" title="Annual interest rate">0.6%</span>. <span id="xdx_90E_eus-gaap--RestrictedCashCurrentNatureOfRestrictionDescription_c20220101__20221231_zOHvikDRnGs1" title="Restricted cash description">This certificate matures on June 17, 2023, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 10000 0.006 This certificate matures on June 17, 2023, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011. <p id="xdx_80B_ecustom--DeferredCostsCapitalizedPrepaidAndOtherAssetsTextBlock_z1r5RqErtSTc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4 – <span id="xdx_821_zFFjogrsHwdd">Prepaid expense and other current assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_894_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_z1rwSmCZ4E18" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and other current assets consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B9_zFHHhTNfUuR9" style="display: none">Schedule of Prepaid Expenses and Other Current Assets</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20221231_zWlumOMj3G6c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20211231_z3t3OFklh5eh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_402_ecustom--PrepaidConsultingCurrent_iI_maPEAOAzRPT_zYwUgfJvvhWl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Prepaid consulting</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">148,550</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">930,893</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--PrepaidInsurance_iI_maPEAOAzRPT_z5NE29x8IXZ7" style="vertical-align: bottom; background-color: White"> <td>Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,141</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">987</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PrepaidExpenseCurrent_iI_maPEAOAzRPT_zMxCgTgC5i9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Prepaid costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">62,661</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,427</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzRPT_z0051tUe1Dv9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">212,352</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">959,307</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zXw0Tltfxleh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_894_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_z1rwSmCZ4E18" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and other current assets consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B9_zFHHhTNfUuR9" style="display: none">Schedule of Prepaid Expenses and Other Current Assets</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20221231_zWlumOMj3G6c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20211231_z3t3OFklh5eh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_402_ecustom--PrepaidConsultingCurrent_iI_maPEAOAzRPT_zYwUgfJvvhWl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Prepaid consulting</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">148,550</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">930,893</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--PrepaidInsurance_iI_maPEAOAzRPT_z5NE29x8IXZ7" style="vertical-align: bottom; background-color: White"> <td>Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,141</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">987</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PrepaidExpenseCurrent_iI_maPEAOAzRPT_zMxCgTgC5i9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Prepaid costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">62,661</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,427</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzRPT_z0051tUe1Dv9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">212,352</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">959,307</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 148550 930893 1141 987 62661 27427 212352 959307 <p id="xdx_80B_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zo8l45GcKFj6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 5 – <span id="xdx_826_zmIhWvEmnB2a">Fixed assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_zHqZO6lf488e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixed assets consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BC_zMwkm72sePTh" style="display: none">Schedule of Fixed Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20221231_zNK2FvIEtOA5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20211231_zwOmMik3D2g8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zmIuH8IIr5M2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Land</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">235,223</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">235,223</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zJwbTuTpJ2il" style="vertical-align: bottom; background-color: White"> <td>Vehicles</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,514</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,514</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zGDLxen0PNhl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Computer hardware</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,135</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,935</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zRM7CLtFwS23" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Office furniture and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,912</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,912</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ShippingAndOtherEquipmentMember_zjEbaVUWiSCk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Shipping and other equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,575</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,575</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzhfQ_z2gNgzkteZK" style="vertical-align: bottom; background-color: White"> <td>Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">301,359</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">301,159</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzhfQ_zzz2XP8H5zZg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28,281</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,135</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzhfQ_z2rI6e0WQUSe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">273,078</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">284,024</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zdz6DX0fQrJk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation expense was $<span id="xdx_908_eus-gaap--Depreciation_pp0p0_c20220101__20221231_zFC36UZMXiB7" title="Depreciation expense">10,946</span> and $<span id="xdx_90A_eus-gaap--Depreciation_pp0p0_c20210101__20211231_zeYufJD5ENV2" title="Depreciation expense">6,772</span> for the years ended December 31, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_zHqZO6lf488e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixed assets consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BC_zMwkm72sePTh" style="display: none">Schedule of Fixed Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20221231_zNK2FvIEtOA5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20211231_zwOmMik3D2g8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zmIuH8IIr5M2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Land</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">235,223</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">235,223</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zJwbTuTpJ2il" style="vertical-align: bottom; background-color: White"> <td>Vehicles</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,514</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,514</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zGDLxen0PNhl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Computer hardware</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,135</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,935</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zRM7CLtFwS23" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Office furniture and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,912</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,912</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ShippingAndOtherEquipmentMember_zjEbaVUWiSCk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Shipping and other equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,575</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,575</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzhfQ_z2gNgzkteZK" style="vertical-align: bottom; background-color: White"> <td>Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">301,359</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">301,159</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzhfQ_zzz2XP8H5zZg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28,281</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,135</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzhfQ_z2rI6e0WQUSe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">273,078</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">284,024</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 235223 235223 50514 50514 6135 5935 7912 7912 1575 1575 301359 301159 28281 17135 273078 284024 10946 6772 <p id="xdx_804_eus-gaap--OtherAssetsDisclosureTextBlock_ztR66ifn7e31" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 6 – <span id="xdx_822_zZnntJtBPVE8">Other assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_896_eus-gaap--ScheduleOfOtherAssetsTableTextBlock_z8WDEiqGSv0l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other assets consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B4_znln34Nokf3b" style="display: none">Schedule of Other Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20221231_zqckgTHteZ3k" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20211231_zbnP6YfVfJ3l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40C_ecustom--PrepaidConsultingNoncurrent_iI_maOANzU1C_zXMv2WfvZjT2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Prepaid consulting</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">7,537</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">108,673</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DepositsAssetsNoncurrent_iI_maOANzU1C_zjsLoMI0UFT3" style="vertical-align: bottom; background-color: White"> <td>Deposit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,123</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,823</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--LicensesNoncurrent_iI_maOANzU1C_z4btBKy0S9Jc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Licenses, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,002,960</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">129,075</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OtherAssetsNoncurrent_iTI_mtOANzU1C_z3xViQOg0Y19" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,014,620</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">277,571</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zFIQmUBxxjQ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Notes to Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_892_ecustom--ScheduleOfNetLicensesTableTextBlock_zvbsbFfZniQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BD_zWCtLgJMwBB3" style="display: none">Schedule of Net Licenses</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20221231_zOLt8Z2PPc37" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20211231_zTWCZjvuh57i" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maFLIANz8nc_z0mrx98a27il" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Licenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,261,122</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">153,552</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msFLIANz8nc_zIeENXAd0Bl2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(258,162</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24,477</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANz8nc_zyDXT9fBEO1d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Licenses, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,002,960</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">129,075</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zbHKddyvYS1i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization expense for the years ended December 31, 2022 and 2021 was $<span id="xdx_900_eus-gaap--DepreciationAndAmortization_pp0p0_c20220101__20221231_zjEAFUkFv0c6" title="Amortization expenses">233,685</span> and $<span id="xdx_906_eus-gaap--DepreciationAndAmortization_pp0p0_c20210101__20211231_zlceZtELPJS7" title="Amortization expenses">24,477</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As of June 1, 2019, we entered into a license agreement, which will be amortized over the life of the Patent. The Patent expires December 31, 2032. The Exclusive Patent License to the Jadi Cell is for use under the designated areas of CTE (Chronic Traumatic Encephalopathy), and TBI (Traumatic Brain Injury). The Jadi Cell is an cGMP grade and Research grade manufactured allogenic mesenchymal stem cells derived from US Patent No.: 9,803,176 B2. Forward looking the Company intends to file an Investigational New Drug Application (IND) for brain injured patients who have been intensively cared for and mechanically ventilated due to covid-19 illness and a second IND for CTE/TBI as well in keeping with the spirit of the licensing agreement to advance the Jadi Cell through to FDA Approval for CTE/TBI.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On February 9, 2021, the Company issued a Convertible Promissory Note (CPN) to JadiCell LLC that was never fully executed while the parties worked to finalize the agreement that resulted in an Exclusive Patent License Agreement (EPLA) being executed on September 15, 2021. Finally, a Settlement Agreement was entered into on February 23, 2022. On February 23, 2022, we issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220221__20220223__us-gaap--TypeOfArrangementAxis__custom--ExclusivePatentLicenseAgreementMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNoteMember_z5TbH8xMx2n9">149,402,390 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">shares of common stock, valued at $<span id="xdx_901_eus-gaap--SharePrice_iI_c20220223__us-gaap--TypeOfArrangementAxis__custom--ExclusivePatentLicenseAgreementMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNoteMember_zkozucd8Usci">0.0208 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">per share, for the EPLA, with a final value of the license being recorded at $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp2p0_c20220221__20220223__us-gaap--TypeOfArrangementAxis__custom--ExclusivePatentLicenseAgreementMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNoteMember_zWw1VbpgbNMi">3,107,570</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">. The Patent expires <span id="xdx_905_ecustom--PatentExpiresAgreementDate_c20220221__20220223__us-gaap--TypeOfArrangementAxis__custom--ExclusivePatentLicenseAgreementMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNoteMember_z0wJGszyELch">December 31, 2032</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">. The Exclusive Patent License to the Jadi Cell is for use under the designated areas of all applicable Lung Pathology. The Jadi Cell is an cGMP grade and Research grade manufactured allogenic mesenchymal stem cells derived from US Patent No.: 9,803,176 B2 and will be amortized over the <span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20220221__20220223__us-gaap--TypeOfArrangementAxis__custom--ExclusivePatentLicenseAgreementMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNoteMember_ztjvBR9QDUBi">10 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">year life of the Patent. As of March 25, 2022, we entered into a asset transfer and license agreement, which will be amortized over the life of the agreement. The agreement is until <span id="xdx_909_ecustom--AmortizedLifeOfAgreement_dc_c20220324__20220325__us-gaap--TypeOfArrangementAxis__custom--AssetsTransferAndLicenseAgreementMember_zdaXsjbokcZk">March 24, 2027</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">. The Company has made an initial payment of $<span id="xdx_909_eus-gaap--PaymentsToAcquireIntangibleAssets_pp2p0_c20220324__20220325__us-gaap--TypeOfArrangementAxis__custom--AssetsTransferAndLicenseAgreementMember__srt--StatementScenarioAxis__custom--InitialPaymentMember_zP1fRSryLqh7">200,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">. Within six months, the Company will make a second payment of $<span id="xdx_904_eus-gaap--PaymentsToAcquireIntangibleAssets_pn5n6_c20220324__20220325__us-gaap--TypeOfArrangementAxis__custom--AssetsTransferAndLicenseAgreementMember__srt--StatementScenarioAxis__custom--SecondPaymentMember_zNsx05SJWci8">1.8 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">million. The agreement is in default and the initial paymentof $200,000 was expensed to research &amp; development.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_896_eus-gaap--ScheduleOfOtherAssetsTableTextBlock_z8WDEiqGSv0l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other assets consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B4_znln34Nokf3b" style="display: none">Schedule of Other Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20221231_zqckgTHteZ3k" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20211231_zbnP6YfVfJ3l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40C_ecustom--PrepaidConsultingNoncurrent_iI_maOANzU1C_zXMv2WfvZjT2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Prepaid consulting</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">7,537</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">108,673</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DepositsAssetsNoncurrent_iI_maOANzU1C_zjsLoMI0UFT3" style="vertical-align: bottom; background-color: White"> <td>Deposit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,123</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,823</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--LicensesNoncurrent_iI_maOANzU1C_z4btBKy0S9Jc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Licenses, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,002,960</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">129,075</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OtherAssetsNoncurrent_iTI_mtOANzU1C_z3xViQOg0Y19" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,014,620</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">277,571</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 7537 108673 4123 39823 3002960 129075 3014620 277571 <p id="xdx_892_ecustom--ScheduleOfNetLicensesTableTextBlock_zvbsbFfZniQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BD_zWCtLgJMwBB3" style="display: none">Schedule of Net Licenses</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20221231_zOLt8Z2PPc37" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20211231_zTWCZjvuh57i" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maFLIANz8nc_z0mrx98a27il" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Licenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,261,122</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">153,552</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msFLIANz8nc_zIeENXAd0Bl2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(258,162</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24,477</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANz8nc_zyDXT9fBEO1d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Licenses, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,002,960</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">129,075</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 3261122 153552 258162 24477 3002960 129075 233685 24477 149402390 0.0208 3107570 2032-12-31 P10Y 2027-03-24 200000 1800000 <p id="xdx_801_eus-gaap--LongTermDebtTextBlock_zaSKNYMMxvBb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 7 – <span id="xdx_825_zn8YQUWXjQjj">Convertible notes payable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">At various times during the year ended December 31, 2022, the Company entered into convertible promissory notes with principal amounts totaling $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20221231__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNoteMember_zVt8s6UFSzLi" title="Debt principal amount">544,000</span> with third parties for which the proceeds were used for operations. The Company received net proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20220101__20221231__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNoteMember_zH2Pt9ZJMztl" title="Proceeds from convertible debt">505,000</span>, and a $<span id="xdx_905_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20221231__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNoteMember_zrZCAoWihMhd" title="Debt discount">39,000</span> original issuance discount was recorded. The convertible promissory notes incur interest at a rate of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNoteMember_zGDxwO8YT8Wl" title="Interest rate percentage">10</span>% per annum and <span id="xdx_906_eus-gaap--DebtInstrumentMaturityDateDescription_c20220101__20221231__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNoteMember_zR4MUqs9jVrj" title="Debt maturity date description">mature on dates ranging from January 1, 2023 to December 5, 2023</span>. <span id="xdx_902_eus-gaap--DebtConversionDescription_c20220101__20221231__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNoteMember_zIOWoq5JYVF4" title="Debt conversion description">The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to a percentage of 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable con’ersion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%.</span> The Company was required to reserve at December 31, 2022 a total of <span id="xdx_90A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20221231__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNoteMember_zunzLZyUkPr9" title="Common shares reserve for future issuance">267,136,056</span> common shares in connection with these promissory notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Notes to Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 7 – Convertible notes payable (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">At various times during the year ended December 31, 2021, the Company entered into convertible promissory notes with principal amounts totaling $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNoteMember_zH41SIaW9Etb" title="Debt principal amount">572,250</span> with third parties for which the proceeds were used for operations. The Company received net proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromConvertibleDebt_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNoteMember_zbYtuqXMdOk2" title="Debt original issuance discount">538,750</span>, and a $<span id="xdx_904_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNoteMember_zQOYIP5Uyyki" title="Debt original issuance discount">33,500</span> original issuance discount was recorded. The convertible promissory notes incur interest at rates ranging from <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNoteMember__srt--RangeAxis__srt--MinimumMember_zNE2e0iuQpd5" title="Interest rate percentage">10</span>% to <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNoteMember__srt--RangeAxis__srt--MaximumMember_zshqgTVGLI0i" title="Interest rate percentage">12</span>% per annum and <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDateDescription_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNoteMember_zFh2ZahZaeih" title="Debt maturity date description">mature on dates ranging from January 25, 2022 to December 15, 2022</span>. <span id="xdx_90C_eus-gaap--DebtConversionDescription_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNoteMember_zCN88TENxebf" title="Debt conversion description">The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to apercentage ranging from 61% to 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%.</span> The Company was required to reserve at December 31, 2021 total of <span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNoteMember_zJs3ExJqDpYc" title="Common shares reserve">95,273,690</span> common shares in connection with these promissory notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative liabilities</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These convertible promissory notes are convertible into a variable number of shares of common stock for which there is not a floor to the number of common stock we might be required to issue. Based on the requirements of ASC 815 Derivatives and Hedging, the conversion feature represented an embedded derivative that is required to be bifurcated and accounted for as a separate derivative liability. The derivative liability is originally recorded at its estimated fair value and is required to be revalued at each conversion event and reporting period. Changes in the derivative liability fair value are reported in operating results each reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the notes issued during the year ended December 31, 2022, the Company valued the conversion features on the date of issuance resulting in initial liabilities totaling $<span id="xdx_902_eus-gaap--PaymentsOfDerivativeIssuanceCosts_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember_zBfn0B9vxgn4" title="Derivative issuance liability">674,971</span>. Since the fair value of the derivative was in excess of the proceeds received, a full discount to convertible notes payable and a day one loss on derivative liabilities of $<span id="xdx_904_eus-gaap--DerivativeLossOnDerivative_pp0p0_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember_zQ5E0aaS1wlb" title="Loss on derivative liability">171,245</span> was recorded during the year ended December 31, 2022. The Company valued the conversion feature using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $<span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember__srt--RangeAxis__srt--MinimumMember_zZddgaH5Y09i" title="Derivative liability, measurement input">0.0058</span> to $<span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember__srt--RangeAxis__srt--MaximumMember_zVcwtuEyQZY9" title="Derivative liability, measurement input">0.0143</span>, the closing stock price of the Company’s common stock on the dates of valuation ranging from $<span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_znbENZfAKnR1" title="Derivative liability, measurement input">0.008</span> to $<span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zUfPqnCw4rTc" title="Derivative liability, measurement input">0.0272</span>, an expected dividend yield of <span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zzojK7YsuOCi" title="Derivative liability, measurement input">0</span>%, expected volatilities ranging from <span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zCBz1bVEHUsd" title="Derivative liability, measurement input">148</span>%-<span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zWaPggbAOyX2" title="Derivative liability, measurement input">216</span>%, risk-free interest rate ranging from <span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zmZNLNOsM3X4" title="Derivative liability, measurement input">0.48</span>% to <span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zfTaiho2xoHk" title="Derivative liability, measurement input">4.77</span>%, and an expected term of <span id="xdx_906_ecustom--DerivativeLiabilityMeasurementInputTerm_dc_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z0IxOaQ2JAPh" title="Derivative liability, measurement input term">one year</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, convertible notes principal plus their accrued interest totaling $<span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20220101__20221231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember_zFqdZQO8mHV8" title="Debt conversion of convertible shares, value">774,176</span> were converted into <span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20220101__20221231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember_zIyEiihaRvg7" title="Debt conversion of convertible shares">68,193,798</span> shares of common stock, of which <span id="xdx_904_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_c20221231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember_z2k1PRkgZSJ8" title="Common stock, subscribed and issued">4,054,054</span> are yet to be issued as of December 31, 2022. At each conversion date, the Company recalculated the value of the derivative liability associated with the convertible note recording a gain (loss) in connection with the change in fair market value. In addition, the fair value of the shares of common stock issued in excess or deficit of the pro-rata portion of the derivative liability as compared to the portio of the convertible note converted was recorded as a loss or gain on derivative liabilities. During the year ended December 31, 2022, the Company recorded $<span id="xdx_905_eus-gaap--DerivativeLossOnDerivative_c20220101__20221231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember_zQ1mQTMFjaZi" title="Gain on derivative liabilities">39,770</span> to gain on derivative liabilities. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $<span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20221231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember__srt--RangeAxis__srt--MinimumMember_zeyuQdPlwJL2" title="Derivative liability, measurement input">0.0038</span> to $<span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20221231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember__srt--RangeAxis__srt--MaximumMember_zeTKZpX8el1k" title="Derivative liability, measurement input">0.016</span>, the closing stock price of the Company’s common stock on the dates of valuation ranging from $<span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20221231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_zDXTzBP1mbwc" title="Derivative liability, measurement input">0.006</span> to $<span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20221231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zhLNRKlm537" title="Derivative liability, measurement input">0.026</span>, an expected dividend yield of <span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z5zc6y07izJ2" title="Derivative liability, measurement input">0</span>%, expected volatility ranging from <span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zhxCDrS0Afv7" title="Derivative liability, measurement input">63</span>% to <span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zR8UbFFDAsJb" title="Derivative liability, measurement input">191</span>%, risk-free interest rates ranging from <span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_z457dVVZSQda" title="Derivative liability, measurement input">0.51</span>% to <span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zYT0YPbnf7ak" title="Derivative liability, measurement input">4.74</span>%, and expected terms ranging from <span id="xdx_909_ecustom--DerivativeLiabilityMeasurementInputTerm_dtY_c20220101__20221231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zvYGS1VUMO68" title="Derivative liability, measurement input term">0.44</span> to <span id="xdx_905_ecustom--DerivativeLiabilityMeasurementInputTerm_dtY_c20220101__20221231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zI9SqCZ6Vejh" title="Derivative liability, measurement input term">0.50</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 31, 2022, the derivative liabilities on the remaining convertible notes were revalued at $<span id="xdx_902_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20221231__us-gaap--LongtermDebtTypeAxis__custom--RemainingConvertibleNotesMember_z1ORu65J18Fj" title="Derivative liabilities">202,144</span> resulting in a gain of $<span id="xdx_90A_eus-gaap--GainLossOnDerivativeInstrumentsNetPretax_pp0p0_c20220101__20221231__us-gaap--LongtermDebtTypeAxis__custom--RemainingConvertibleNotesMember_zjXwnzad4Rbl" title="Gain on derivative liabilities">291,123</span> for the year ended December 31, 2022 related to the change in fair value of the derivative liabilities. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following assumptions: exercise price of $<span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20221231__us-gaap--LongtermDebtTypeAxis__custom--RemainingConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zVUWzAhlmwOk" title="Stock option, exercise price">0.0038</span>, the closing stock price of the Company’s common stock on the date of valuation of $<span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20221231__us-gaap--LongtermDebtTypeAxis__custom--RemainingConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zVLXrrwWpSaj" title="Derivative liability, measurement input">0.006</span>, an expected dividend yield of <span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--LongtermDebtTypeAxis__custom--RemainingConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zqvg0dk5Hzhk" title="Derivative liability, measurement input">0</span>%, expected volatility ranging from <span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--LongtermDebtTypeAxis__custom--RemainingConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zpzBSE9qCDdf" title="Derivative liability, measurement input">96</span>% to <span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--LongtermDebtTypeAxis__custom--RemainingConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zwN6otqoEGM9" title="Derivative liability, measurement input">120</span>%, risk-free interest rate of <span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--LongtermDebtTypeAxis__custom--RemainingConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z8PkvAK8aRN5" title="Derivative liability, measurement input">4.71</span>%, and an expected term ranging from <span id="xdx_902_ecustom--DerivativeLiabilityMeasurementInputTerm_dtY_c20220101__20221231__us-gaap--LongtermDebtTypeAxis__custom--RemainingConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zmw8OQ5mhrD" title="Derivative liability, measurement input term">0.49</span> to <span id="xdx_901_ecustom--DerivativeLiabilityMeasurementInputTerm_dtY_c20220101__20221231__us-gaap--LongtermDebtTypeAxis__custom--RemainingConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zCXrOn34Pc57" title="Derivative liability, measurement input term">0.93</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the notes issued during the year ended December 31, 2021, the Company valued the conversion features on the date of issuance resulting in initial liabilities totaling $<span id="xdx_908_eus-gaap--PaymentsOfDerivativeIssuanceCosts_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember_z9ByR8WoZFMb" title="Derivative issuance liability">1,077,756</span>. Since the fair value of the derivative was in excess of the proceeds received, a full discount to convertible notes payable and a day one loss on derivative liabilities of $<span id="xdx_909_eus-gaap--DerivativeLossOnDerivative_pp0p0_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember_zuYtpPHsT7Tg" title="Loss on derivative liability">539,006</span> was recorded during the year ended December 31, 2021. The Company valued the conversion feature using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $<span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember__srt--RangeAxis__srt--MinimumMember_z7qvReDh0tpk" title="Derivative liability, measurement input">0.0039</span> to $<span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember__srt--RangeAxis__srt--MaximumMember_zUGrt5zshGE2" title="Derivative liability, measurement input">0.0351</span>, the closing stock price of the Company’s common stock on the dates of valuation ranging from $<span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_zA3H4u9U4jmh" title="Derivative liability, measurement input">0.0217</span> to $<span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zZdFOXT0Kt9f" title="Derivative liability, measurement input">0.0540</span>, an expected dividend yield of <span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z5ekdGgq2Bfa" title="Derivative liability, measurement input">0</span>%, expected volatilities ranging from <span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zM8xfxMfNLBf" title="Derivative liability, measurement input">197</span>%-<span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zSXGBpallflb" title="Derivative liability, measurement input">264</span>%, risk-free interest rate ranging from <span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zHt95nQskJ7d" title="Derivative liability, measurement input">0.05</span>% to <span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zQX2E0tgVSb7" title="Derivative liability, measurement input">0.29</span>%, and an expected term of <span id="xdx_908_ecustom--DerivativeLiabilityMeasurementInputTerm_dc_c20210101__20211231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zi6k6hGyySWl" title="Derivative liability, measurement input term">one year</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Notes to Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 7 – Convertible notes payable (Continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, convertible notes principal plus their accrued interest totaling $<span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember_zJ2nBI3VmF63" title="Debt conversion of convertible shares, value">529,735</span> were converted into <span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember_zBrWGnB9hse4" title="Debt conversion of convertible shares">21,690,671</span> shares of common stock. At each conversion date, the Company recalculated the value of the derivative liability associated with the convertible note recording a gain (loss) in connection with the change in fair market value. In addition, the pro-rata portion of the derivative liability as compared to the portion of the convertible note converted was reclassed to additional paid-in capital. During the year ended December 31, 2021, the Company recorded $<span id="xdx_90F_eus-gaap--AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember_zN9HCLmfSn2b" title="Additional paid in capital on convertible debt features">489,279</span> to additional paid-in capital. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $<span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember__srt--RangeAxis__srt--MinimumMember_zv3yfjsJBeIb" title="Derivative liability, measurement input">0.0136</span> to $<span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember__srt--RangeAxis__srt--MaximumMember_zQaYP0yCyv6b" title="Derivative liability, measurement input">0.035</span>, the closing stock price of the Company’s common stock on the dates of valuation ranging from $<span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_zSfeMaDYcnbj" title="Derivative liability, measurement input">0.022</span> to $<span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_z3OgMjsGKeAf" title="Derivative liability, measurement input">0.057</span>, an expected dividend yield of <span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z5EOyCJWmOJi" title="Derivative liability, measurement input">0</span>%, expected volatility ranging from <span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zAHkCpGv6xTj" title="Derivative liability, measurement input">125</span>% to <span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zddyQWvhr4yk" title="Derivative liability, measurement input">251</span>%, risk-free interest rates ranging from <span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zEGGXjS0eYih" title="Derivative liability, measurement input">0.06</span>% to <span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zvJE1MuYAbKb" title="Derivative liability, measurement input">0.29</span>%, and expected terms ranging from <span id="xdx_90F_ecustom--DerivativeLiabilityMeasurementInputTerm_dtY_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zvbxuyiOAI1i" title="Derivative liability, measurement input term">0.48</span> to <span id="xdx_907_ecustom--DerivativeLiabilityMeasurementInputTerm_dtY_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zPM7dgnVJb75" title="Derivative liability, measurement input term">0.50</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 31, 2021, the derivative liabilities on the remaining five convertible notes were revalued at $<span id="xdx_90D_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20211231__us-gaap--LongtermDebtTypeAxis__custom--RemainingConvertibleNotesMember_zeCUc245lap8" title="Derivative liabilities">531,525</span> resulting in a gain of $<span id="xdx_90F_eus-gaap--GainLossOnDerivativeInstrumentsNetPretax_pp0p0_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--RemainingConvertibleNotesMember_zGfTcDvSNLvg" title="Gain loss on derivative liabilities">494,501</span> for the year ended December 31, 2021 related to the change in fair value of the derivative liabilities. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $<span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20211231__us-gaap--LongtermDebtTypeAxis__custom--RemainingConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember__srt--RangeAxis__srt--MinimumMember_zk20k6RFn3el" title="Derivative liability, measurement input">0.0123</span> to $<span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20211231__us-gaap--LongtermDebtTypeAxis__custom--RemainingConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember__srt--RangeAxis__srt--MaximumMember_zt7MFFLEUs4c" title="Derivative liability, measurement input">0.0127</span>, the closing stock price of the Company’s common stock on the date of valuation of $<span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uUSDPShares_c20211231__us-gaap--LongtermDebtTypeAxis__custom--RemainingConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zdWw9ToGajj2" title="Derivative liability, measurement input">0.029</span>, an expected dividend yield of <span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--LongtermDebtTypeAxis__custom--RemainingConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zcgtvqp0vwzh" title="Derivative liability, measurement input">0</span>%, expected volatility ranging from <span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--LongtermDebtTypeAxis__custom--RemainingConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zSAB14dSfqT6" title="Derivative liability, measurement input">165</span>% to <span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--LongtermDebtTypeAxis__custom--RemainingConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zibcOZWHqZDk" title="Derivative liability, measurement input">218</span>%, risk-free interest rate of <span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--LongtermDebtTypeAxis__custom--RemainingConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zoO2YCuiV23" title="Derivative liability, measurement input">0.39</span>%, and an expected term ranging from <span id="xdx_908_ecustom--DerivativeLiabilityMeasurementInputTerm_dtY_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--RemainingConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_ztxh6Ue5tcJ9" title="Derivative liability, measurement input term">0.53</span> to <span id="xdx_90A_ecustom--DerivativeLiabilityMeasurementInputTerm_dtY_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--RemainingConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zMQKtDHaTL88" title="Derivative liability, measurement input term">0.96</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company amortizes the discounts over the term of the convertible promissory notes using the straight line method which is similar to the effective interest method. During the years ended December 31, 2022 and 2021, the Company amortized $<span id="xdx_909_eus-gaap--InterestExpenseDebt_pp0p0_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zvFbpqQ6fazg" title="Interest expenses">593,463</span> and $<span id="xdx_902_eus-gaap--InterestExpenseDebt_pp0p0_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zUT5Vdhaz13h" title="Interest expenses">541,612</span> to interest expense, respectively. As of December 31, 2022, discounts of $<span id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zZcIsKY415rl" title="Debt discount">175,063</span> remained for which will be amortized through December 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 544000 505000 39000 0.10 mature on dates ranging from January 1, 2023 to December 5, 2023 The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to a percentage of 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable con’ersion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%. 267136056 572250 538750 33500 0.10 0.12 mature on dates ranging from January 25, 2022 to December 15, 2022 The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to apercentage ranging from 61% to 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%. 95273690 674971 171245 0.0058 0.0143 0.008 0.0272 0 148 216 0.48 4.77 P1Y 774176 68193798 4054054 39770 0.0038 0.016 0.006 0.026 0 63 191 0.51 4.74 P0Y5M8D P0Y6M 202144 291123 0.0038 0.006 0 96 120 4.71 P0Y5M26D P0Y11M4D 1077756 539006 0.0039 0.0351 0.0217 0.0540 0 197 264 0.05 0.29 P1Y 529735 21690671 489279 0.0136 0.035 0.022 0.057 0 125 251 0.06 0.29 P0Y5M23D P0Y6M 531525 494501 0.0123 0.0127 0.029 0 165 218 0.39 P0Y6M10D P0Y11M15D 593463 541612 175063 <p id="xdx_80E_eus-gaap--DebtDisclosureTextBlock_zcgyQKrEClB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 8 – <span id="xdx_829_zsipambyuPS4">Notes payable-related parties</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_ecustom--NotesPayableRelatedPartiesTableTextBlock_zmRaW1FqO6La" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable-related parties consist of:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BA_zMisRgXTZ9r2" style="display: none">Schedule of Notes Payable Related Parties</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"/><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableOneMember_zQCbAK7RB1ua" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1044">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--NotesPayableOneMember_zp7L9JVQFclk" style="text-align: right">2,356</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Note payable – Scientific Advisory Board Member, unsecured, including interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__srt--TitleOfIndividualAxis__custom--ScientificAdvisoryBoardMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableOneMember_zu5W2hWeWlXj" title="Debt interest percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__srt--TitleOfIndividualAxis__custom--ScientificAdvisoryBoardMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableOneMember_zALH0cux4cc7" title="Debt interest percentage">10</span></span>% per annum, with a maturity date of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_pid_dd_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ScientificAdvisoryBoardMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableOneMember_zcvf39UQNYU" title="Debt maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_pid_dd_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ScientificAdvisoryBoardMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableOneMember_zXXbqt07Evte" title="Debt maturity date">December 31, 2019</span></span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableOneMember_zK7i3Wn6F5aj" style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1054">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--NotesPayableOneMember_zxxsCearCj3i" style="width: 16%; text-align: right">2,356</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">One notes payable – Chief Executive Officer, unsecured, including interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableTwoMember__srt--RangeAxis__srt--MinimumMember_zkJllGBFIijg"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableTwoMember__srt--RangeAxis__srt--MinimumMember_z1FkcXbNHlrk">8</span></span>% and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableTwoMember__srt--RangeAxis__srt--MaximumMember_zItHnKLtzAfe"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableTwoMember__srt--RangeAxis__srt--MaximumMember_ziFf4wv0ges4">10</span></span>% per annum, respectively, with maturity date of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_pid_dd_c20220101__20221231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableTwoMember_z09lhxR8sQ58" title="Debt maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_pid_dd_c20210101__20211231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableTwoMember_zIuDaoUiGaBg" title="Debt maturity date">December 31, 2019</span></span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableTwoMember_z8OIqkSF2TM" style="text-align: right">29,090</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--NotesPayableTwoMember_zau6nmvQGQk9" style="text-align: right">27,577</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">One note payable – Chief Executive Officer, unsecured, no interest, paid from a % of revenues</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableThreeMember_zQx57PZmbnzd" style="text-align: right">534,448</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--NotesPayableThreeMember_zXgzYuo3Dlmg" style="text-align: right">534,544</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Note payable – Chief Financial Officer, unsecured, including interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableFourMember_zgYoHq8kjsRh"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableFourMember_zzYhR3uphasi">8</span></span>% per annum, with a maturity date of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_pid_dd_c20220101__20221231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableFourMember_zxzksjmZ0lk6" title="Debt maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_pid_dd_c20210101__20211231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableFourMember_zgIxFSOF5Ldb" title="Debt maturity date">December 31, 2019</span></span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableFourMember_zoqYGDufKFWj" style="text-align: right">124,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--NotesPayableFourMember_zh07tO8pkVjl" style="text-align: right">118,400</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Three notes payable – Business Advisory Board Member, unsecured, including interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__srt--TitleOfIndividualAxis__custom--BusinessAdvisoryBoardMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableFiveMember__srt--RangeAxis__srt--MinimumMember_zUj7uQxV3INk" title="Debt interest percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__srt--TitleOfIndividualAxis__custom--BusinessAdvisoryBoardMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableFiveMember__srt--RangeAxis__srt--MinimumMember_z6vp7F9XSei3" title="Debt interest percentage">8</span></span>% and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__srt--TitleOfIndividualAxis__custom--BusinessAdvisoryBoardMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableFiveMember__srt--RangeAxis__srt--MaximumMember_zFCPh6Vthjcg" title="Debt interest percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__srt--TitleOfIndividualAxis__custom--BusinessAdvisoryBoardMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableFiveMember__srt--RangeAxis__srt--MaximumMember_z4gh3RvzplRf" title="Debt interest percentage">10</span></span>% per annum, convertible into common stock at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--BusinessAdvisoryBoardMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableFiveMember__srt--RangeAxis__srt--MaximumMember_zHKQFK4And24" title="Share price"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--SharePrice_iI_pid_c20211231__srt--TitleOfIndividualAxis__custom--BusinessAdvisoryBoardMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableFiveMember__srt--RangeAxis__srt--MaximumMember_zX1599z6Ye1b" title="Share price">0.005</span></span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--BusinessAdvisoryBoardMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableFiveMember__srt--RangeAxis__srt--MinimumMember_zgVRLz4PDfh4" title="Share price"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20211231__srt--TitleOfIndividualAxis__custom--BusinessAdvisoryBoardMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableFiveMember__srt--RangeAxis__srt--MinimumMember_zAKdkDJ9IFc1" title="Share price">0.004</span></span>, respectively, with maturity date of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_pid_dd_c20220101__20221231__srt--TitleOfIndividualAxis__custom--BusinessAdvisoryBoardMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableFiveMember_zatee5kSJue1" title="Debt maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_pid_dd_c20210101__20211231__srt--TitleOfIndividualAxis__custom--BusinessAdvisoryBoardMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableFiveMember_zlSqpix0gmi8" title="Debt maturity date">April 20, 2019</span></span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableFiveMember_zfmGyWl1Eyyi" style="border-bottom: Black 1.5pt solid; text-align: right">30,334</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--NotesPayableFiveMember_zLfFuvceVCU9" style="border-bottom: Black 1.5pt solid; text-align: right">282,334</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20221231_zDFI3brcbh43" style="border-bottom: Black 1.5pt solid; text-align: right" title="Notes payable related party, current">988,672</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20211231_zgSIpOWejmIk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Notes payable related party, current">965,211</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--NotesPayableRelatedPartiesCurrentAndNoncurrent_iI_c20221231_z8oUbd57ljsd" style="border-bottom: Black 2.5pt double; text-align: right" title="Notes payable related party, non-current">988,672</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--NotesPayableRelatedPartiesCurrentAndNoncurrent_iI_c20211231_zoQCetbeqlP5" style="border-bottom: Black 2.5pt double; text-align: right" title="Notes payable related party, non-current">965,211</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zQiJnpzZyG49" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Notes to Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_89F_ecustom--NotesPayableRelatedPartiesTableTextBlock_zmRaW1FqO6La" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable-related parties consist of:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BA_zMisRgXTZ9r2" style="display: none">Schedule of Notes Payable Related Parties</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"/><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableOneMember_zQCbAK7RB1ua" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1044">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--NotesPayableOneMember_zp7L9JVQFclk" style="text-align: right">2,356</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Note payable – Scientific Advisory Board Member, unsecured, including interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__srt--TitleOfIndividualAxis__custom--ScientificAdvisoryBoardMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableOneMember_zu5W2hWeWlXj" title="Debt interest percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__srt--TitleOfIndividualAxis__custom--ScientificAdvisoryBoardMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableOneMember_zALH0cux4cc7" title="Debt interest percentage">10</span></span>% per annum, with a maturity date of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_pid_dd_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ScientificAdvisoryBoardMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableOneMember_zcvf39UQNYU" title="Debt maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_pid_dd_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ScientificAdvisoryBoardMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableOneMember_zXXbqt07Evte" title="Debt maturity date">December 31, 2019</span></span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableOneMember_zK7i3Wn6F5aj" style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1054">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--NotesPayableOneMember_zxxsCearCj3i" style="width: 16%; text-align: right">2,356</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">One notes payable – Chief Executive Officer, unsecured, including interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableTwoMember__srt--RangeAxis__srt--MinimumMember_zkJllGBFIijg"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableTwoMember__srt--RangeAxis__srt--MinimumMember_z1FkcXbNHlrk">8</span></span>% and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableTwoMember__srt--RangeAxis__srt--MaximumMember_zItHnKLtzAfe"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableTwoMember__srt--RangeAxis__srt--MaximumMember_ziFf4wv0ges4">10</span></span>% per annum, respectively, with maturity date of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_pid_dd_c20220101__20221231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableTwoMember_z09lhxR8sQ58" title="Debt maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_pid_dd_c20210101__20211231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableTwoMember_zIuDaoUiGaBg" title="Debt maturity date">December 31, 2019</span></span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableTwoMember_z8OIqkSF2TM" style="text-align: right">29,090</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--NotesPayableTwoMember_zau6nmvQGQk9" style="text-align: right">27,577</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">One note payable – Chief Executive Officer, unsecured, no interest, paid from a % of revenues</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableThreeMember_zQx57PZmbnzd" style="text-align: right">534,448</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--NotesPayableThreeMember_zXgzYuo3Dlmg" style="text-align: right">534,544</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Note payable – Chief Financial Officer, unsecured, including interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableFourMember_zgYoHq8kjsRh"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableFourMember_zzYhR3uphasi">8</span></span>% per annum, with a maturity date of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_pid_dd_c20220101__20221231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableFourMember_zxzksjmZ0lk6" title="Debt maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_pid_dd_c20210101__20211231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableFourMember_zgIxFSOF5Ldb" title="Debt maturity date">December 31, 2019</span></span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableFourMember_zoqYGDufKFWj" style="text-align: right">124,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--NotesPayableFourMember_zh07tO8pkVjl" style="text-align: right">118,400</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Three notes payable – Business Advisory Board Member, unsecured, including interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__srt--TitleOfIndividualAxis__custom--BusinessAdvisoryBoardMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableFiveMember__srt--RangeAxis__srt--MinimumMember_zUj7uQxV3INk" title="Debt interest percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__srt--TitleOfIndividualAxis__custom--BusinessAdvisoryBoardMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableFiveMember__srt--RangeAxis__srt--MinimumMember_z6vp7F9XSei3" title="Debt interest percentage">8</span></span>% and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__srt--TitleOfIndividualAxis__custom--BusinessAdvisoryBoardMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableFiveMember__srt--RangeAxis__srt--MaximumMember_zFCPh6Vthjcg" title="Debt interest percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__srt--TitleOfIndividualAxis__custom--BusinessAdvisoryBoardMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableFiveMember__srt--RangeAxis__srt--MaximumMember_z4gh3RvzplRf" title="Debt interest percentage">10</span></span>% per annum, convertible into common stock at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--BusinessAdvisoryBoardMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableFiveMember__srt--RangeAxis__srt--MaximumMember_zHKQFK4And24" title="Share price"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--SharePrice_iI_pid_c20211231__srt--TitleOfIndividualAxis__custom--BusinessAdvisoryBoardMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableFiveMember__srt--RangeAxis__srt--MaximumMember_zX1599z6Ye1b" title="Share price">0.005</span></span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--BusinessAdvisoryBoardMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableFiveMember__srt--RangeAxis__srt--MinimumMember_zgVRLz4PDfh4" title="Share price"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20211231__srt--TitleOfIndividualAxis__custom--BusinessAdvisoryBoardMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableFiveMember__srt--RangeAxis__srt--MinimumMember_zAKdkDJ9IFc1" title="Share price">0.004</span></span>, respectively, with maturity date of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_pid_dd_c20220101__20221231__srt--TitleOfIndividualAxis__custom--BusinessAdvisoryBoardMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableFiveMember_zatee5kSJue1" title="Debt maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_pid_dd_c20210101__20211231__srt--TitleOfIndividualAxis__custom--BusinessAdvisoryBoardMember__us-gaap--DebtInstrumentAxis__custom--NotesPayableFiveMember_zlSqpix0gmi8" title="Debt maturity date">April 20, 2019</span></span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--NotesPayableFiveMember_zfmGyWl1Eyyi" style="border-bottom: Black 1.5pt solid; text-align: right">30,334</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--NotesPayableFiveMember_zLfFuvceVCU9" style="border-bottom: Black 1.5pt solid; text-align: right">282,334</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20221231_zDFI3brcbh43" style="border-bottom: Black 1.5pt solid; text-align: right" title="Notes payable related party, current">988,672</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20211231_zgSIpOWejmIk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Notes payable related party, current">965,211</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--NotesPayableRelatedPartiesCurrentAndNoncurrent_iI_c20221231_z8oUbd57ljsd" style="border-bottom: Black 2.5pt double; text-align: right" title="Notes payable related party, non-current">988,672</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--NotesPayableRelatedPartiesCurrentAndNoncurrent_iI_c20211231_zoQCetbeqlP5" style="border-bottom: Black 2.5pt double; text-align: right" title="Notes payable related party, non-current">965,211</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2356 0.10 0.10 2019-12-31 2019-12-31 2356 0.08 0.08 0.10 0.10 2019-12-31 2019-12-31 29090 27577 534448 534544 0.08 0.08 2019-12-31 2019-12-31 124800 118400 0.08 0.08 0.10 0.10 0.005 0.005 0.004 0.004 2019-04-20 2019-04-20 30334 282334 988672 965211 988672 965211 <p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z81hupt3P4Ve" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9 – <span id="xdx_828_zbH3ckoI9KT1">Related party transactions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2019 and 2018, the Company had accrued officers’ salary of $<span id="xdx_907_eus-gaap--AccruedSalariesCurrent_iI_c20191231__srt--TitleOfIndividualAxis__srt--OfficerMember_ztTvnMVc1j5k">439,534 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_904_eus-gaap--AccruedSalariesCurrent_iI_c20181231__srt--TitleOfIndividualAxis__srt--OfficerMember_zEhTFjnHtwP2">663,100</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively. One of the officers settled with the company for a note payable that is unsecured on November 8, 2019 and doesn’t accrue interest and will be paid as <span id="xdx_902_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20220101__20221231_zU5nwqpqynA2">0.5</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of revenues. This decreased accrued officers’ salary. The note is still outstanding as of December 31, 2022 and 2021. Payments for the years ended December 31, 2022 and 2021 was $<span id="xdx_907_eus-gaap--RelatedPartyTransactionDueFromToRelatedParty_iI_c20221231_zB5zw5zkKNze" title="Payments">97</span> and $<span id="xdx_90D_eus-gaap--RelatedPartyTransactionDueFromToRelatedParty_iI_c20211231_zzYQkJ2LFq2c" title="Payments">101</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2021, we issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__srt--TitleOfIndividualAxis__custom--OneOfficersMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__custom--AccruedSalariesMember_z7AMruvfWZw2" title="Number of common stock issued">7,544,848</span> shares of common stock for $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20211231__srt--TitleOfIndividualAxis__custom--OneOfficersMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__custom--AccruedSalariesMember_z5yJHO9kRrB4" title="Number of common stock issued, value">239,800</span> of accrued salaries to one officer of the Company under a Restricted Stock Award.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 18, 2021, we issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210617__20210618__srt--TitleOfIndividualAxis__custom--OneOfficerAndOneDirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zVr41vKoMu38" title="Number of common stock issued">2,000,000</span> shares of common stock, to one officer and one director of the Company under a Restricted Stock Award for $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210617__20210618__srt--TitleOfIndividualAxis__custom--OneOfficerAndOneDirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zlmbnZSl6WTi" title="Number of common stock issued, value">94,600</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 30, 2021, we issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211130__20211130__srt--TitleOfIndividualAxis__custom--FourOfficerAndOneDirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zO6zd8jbceK8" title="Number of common stock issued">7,000,000</span> shares of common stock to four officers and one director under a Restricted Stock Award for $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20211130__20211130__srt--TitleOfIndividualAxis__custom--FourOfficerAndOneDirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zuahZYlRAUqd" title="Number of common stock issued, value">224,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2022, we issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__srt--TitleOfIndividualAxis__custom--OneOfficersMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__custom--AccruedSalariesMember_zhMstSNfgP8g" title="Number of common stock issued">4,812,259</span> shares of common stock for $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20221231__srt--TitleOfIndividualAxis__custom--OneOfficersMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__custom--AccruedSalariesMember_zaNU4rh6pKl4" title="Number of common stock issued, value">67,399</span> of accrued salaries to one officer of the Company under a Restricted Stock Award.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 5, 2022, we issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220405__20220405__srt--TitleOfIndividualAxis__custom--FourOfficerAndOneDirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z7c8kxvDGaoj" title="Number of common stock issued">7,000,000</span> shares of common stock, to four officers and one director of the Company under a Restricted Stock Award for $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220405__20220405__srt--TitleOfIndividualAxis__custom--FourOfficerAndOneDirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zentW2Jj2d24" title="Number of common stock issued, value">175,700</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 8, 2022, we issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220908__20220908__srt--TitleOfIndividualAxis__custom--OneOfficerAndOneDirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zBGhyqzDh2X3" title="Number of common stock issued">4,000,000</span> shares of common stock to one officer and one director under a Restricted Stock Award for $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220908__20220908__srt--TitleOfIndividualAxis__custom--OneOfficerAndOneDirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zAmUEs6o5Qje" title="Number of common stock issued, value">46,400</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 2, 2022, we issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221102__20221102__srt--TitleOfIndividualAxis__custom--FourOfficerOneDirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zTsG1J2OGv6i" title="Number of common stock issued">3,000,000</span> shares of common stock to one director under a Restricted Stock Award for $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221102__20221102__srt--TitleOfIndividualAxis__custom--FourOfficerOneDirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zwk3ljRNXiDb" title="Number of common stock issued, value">29,700</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 30, 2022, we committed to issue <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221230__20221230__srt--TitleOfIndividualAxis__custom--FourOfficerAndOneDirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zxpkAgpa1Eoe" title="Number of common stock issued">14,000,000</span> shares of common stock, to four officers and one director of the Company under a Restricted Stock Award for <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221230__20221230__srt--TitleOfIndividualAxis__custom--FourOfficerAndOneDirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z8yXqftdG1Te" title="Number of common stock issued, value">$84,000</span>, which were subsequently issued on January 3, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Notes to Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 439534 663100 0.005 97 101 7544848 239800 2000000 94600 7000000 224000 4812259 67399 7000000 175700 4000000 46400 3000000 29700 14000000 84000 <p id="xdx_802_eus-gaap--IncomeTaxDisclosureTextBlock_zWHvnKaP44fg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 10 – <span id="xdx_826_z9ioZ6DhcqC8">Income taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to United States federal and state income taxes at an approximate rate of <span id="xdx_901_ecustom--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxAndStateAndLocalIncomeTaxesRate_pid_dp_uPure_c20220101__20221231_zHL6veaW19ac" title="Federal and state income taxes rate">30</span>%. The reconciliation of the provision for income taxes at the United States federal statutory rate compared to the Company’s income tax expense as reported is as follows:</span></p> <p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zGX02WWHrXH3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B6_zw6IiU8Xgdj5" style="display: none">Schedule of Income tax Expense</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20220101__20221231_z9RxLJ4bBUl7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20210101__20211231_zLVSM8pgAbch" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzVu3_zFoO8iAFpyck" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Expected income tax at statutory rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(709,666</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(621,735</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzVu3_zdQDrH75Usdf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State tax</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(101,347</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">168</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maITEBzVu3_zyoDtsL1U278" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Permanent differences</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">405,376</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">404,872</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_maITEBzVu3_z7vXjCa8cSZ1" style="vertical-align: bottom; background-color: White"> <td>Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1163">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(71,992</td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_di_msITEBzVu3_zwthUARrHNwg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">406,437</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">289,487</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzVu3_zLKQ8QZxqe0c" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Provision for income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">800</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">800</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zEncZz1V36Z" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zN8i5FEf0hW" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The significant components of deferred income tax assets and liabilities at December 31, 2022 and 2021 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B8_zwMrqux0OSy3" style="display: none">Schedule of Deferred Tax Assets and Liabilities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20221231_zH19gfWMMg81" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20211231_zOe3E5MC1ajk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTANz9Wl_zuAj90Y0Z5j1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Net operating loss carry-forward</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,364,249</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,957,812</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANz9Wl_zqxku632coVj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,364,249</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,957,812</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANz9Wl_zkXW6xgMQrY2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax asset</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1180">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1181">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zVgyr6BTYEq1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has Federal net operating loss carryforwards of approximately $<span id="xdx_907_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20221231_zDlE2BkJnx3" title="Federal net operating loss carryfowards">9.4</span> million and $<span id="xdx_90F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn5n6_c20211231_zem8k0dOLKzi" title="Federal net operating loss carryfowards">7.5</span> million as of December 31, 2022 and 2021, respectively. The Company has state net operating loss carryforwards of approximately $<span id="xdx_902_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20221231_z4YbgY6Sdl87" title="State net operating loss carryfowards">7.4</span> million and $<span id="xdx_902_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20211231_zLnhuydOARt1" title="State net operating loss carryfowards">5.5</span> million as of December 31, 2022 and 2021, respectively. The net operating loss carryforwards are available to offset taxable income in future years, of which approximately $<span id="xdx_90E_ecustom--NetOperatingLossCarryforwardsAreAvailableToOffsetTaxableIncome_pn6n6_c20220101__20221231_z2KeDre1GXDd" title="Net operating loss carryforwards are available to offset taxable income">5</span> million <span id="xdx_906_ecustom--NetOperatingLossCarryforwardsExpirationDescription_c20220101__20221231_zFJmjcsGl5L6" title="Net operating loss carryforwards, expiration, description">expires beginning in fiscal 2032</span>. Net operating loss carrforwards incurred after 2018 are carried on indefinitely.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of and for the years ended December 31, 2022 and 2021, management does not believe the Company has any uncertain tax positions. Accordingly, there are no recognized tax benefits at December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to tax in the United States and files tax returns in the U.S. Federal jurisdiction and California state jurisdiction. The Company is subject to U.S. Federal, state and local income tax examinations by tax authorities starting in 2019. The Company currently is not under examination by any tax authority.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 0.30 <p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zGX02WWHrXH3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B6_zw6IiU8Xgdj5" style="display: none">Schedule of Income tax Expense</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20220101__20221231_z9RxLJ4bBUl7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20210101__20211231_zLVSM8pgAbch" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzVu3_zFoO8iAFpyck" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Expected income tax at statutory rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(709,666</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(621,735</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzVu3_zdQDrH75Usdf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State tax</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(101,347</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">168</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maITEBzVu3_zyoDtsL1U278" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Permanent differences</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">405,376</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">404,872</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_maITEBzVu3_z7vXjCa8cSZ1" style="vertical-align: bottom; background-color: White"> <td>Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1163">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(71,992</td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_di_msITEBzVu3_zwthUARrHNwg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">406,437</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">289,487</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzVu3_zLKQ8QZxqe0c" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Provision for income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">800</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">800</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> -709666 -621735 -101347 168 405376 404872 -71992 -406437 -289487 800 800 <p id="xdx_894_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zN8i5FEf0hW" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The significant components of deferred income tax assets and liabilities at December 31, 2022 and 2021 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B8_zwMrqux0OSy3" style="display: none">Schedule of Deferred Tax Assets and Liabilities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20221231_zH19gfWMMg81" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20211231_zOe3E5MC1ajk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTANz9Wl_zuAj90Y0Z5j1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Net operating loss carry-forward</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,364,249</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,957,812</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANz9Wl_zqxku632coVj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,364,249</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,957,812</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANz9Wl_zkXW6xgMQrY2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax asset</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1180">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1181">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2364249 1957812 2364249 1957812 9400000 7500000 7400000 5500000 5000000 expires beginning in fiscal 2032 <p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zyyEayZccFCh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 11 – <span id="xdx_82E_z0BbpNi0AXob">Equity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our authorized capital stock consists of an aggregate of <span id="xdx_90A_eus-gaap--CapitalUnitsAuthorized_iI_c20221231_zxXqpuGiootj" title="Aggregate authorized capital">3,505,000,000</span> shares, comprised of <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zRKmo0YIkfUg" title="Common stock, shares authorized">3,500,000,000</span> shares of common stock, par value $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231_zi2EvK8VNEsd" title="Common stock, par value">0.001</span> per share, and <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231_z4U1lzixqui5">5,000,000</span> shares of preferred stock, which may be issued in various series from time to time and the rights, preferences, privileges and restrictions of which shall be established by our board of directors. As of December 31, 2022, we have <span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zqfc4prgohx9" title="Common stock, shares outstanding">2,617,390,830</span> shares of common stock and <span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231_zYTI65xnoNi7" title="Preferred stock, shares outstanding"><span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_do_c20221231_zdb5phsSg4S4" title="Preferred stock, shares issued">2</span></span> preferred shares issued and outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2021, we issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zo5sZYtnLAB" title="Common stock issued for cash, shares">4,850,075</span> shares of common stock for an investment in the Company’s Private Placement of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zZsutoxbMri7" title="Common stock issued for cash">285,500</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2021, we issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__srt--ProductOrServiceAxis__custom--ConsultingServicesMember_znvl5W2vOBk7" title="Common stock issued for cash, shares">21,000,000</span> shares of common stock, valued at $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20211231__srt--ProductOrServiceAxis__custom--ConsultingServicesMember_zhN58kx6zv58" title="Common stock issued for cash, shares">858,900</span> for consulting services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2021, we issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__custom--SalariesMember_zfAJeeRqYoxe" title="Common stock issued for cash, shares">8,341,723</span> shares of common stock, valued at $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__custom--SalariesMember_zVF8hsGTUg51" title="Common stock issued for cash">239,799</span> for salaries.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2021, we issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--AwardTypeAxis__custom--LandDevelopmentMember_zuYUihjsWnpd" title="Common stock issued for cash for purchase of assets, shares">1,500,000</span> shares of common stock, valued at $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20210101__20211231__us-gaap--AwardTypeAxis__custom--LandDevelopmentMember_zQ2MQeHc53s3" title="Common stock issued for cash for purchase of assets">58,900</span> for land development.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2021, we issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zQl8Fp4INhN6" title="Conversion of convertible notes">21,690,671</span> shares of common stock for the conversion of convertible notes of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pp0p0_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zETZGCVixMS1" title="conversion of convertible notes, value">1,019,014</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Notes to Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 11 – Equity (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2022, we issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zjXsSljWgutc" title="Common stock issued for cash, shares">44,500,000</span> shares of common stock for an investment in the Company’s Private Placement of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zImgpNN2kGjd" title="Common stock issued for cash">445,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2022, we issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__srt--ProductOrServiceAxis__custom--ConsultingServicesMember_zz3XgsQPqSAg" title="Common stock issued for cash, shares">32,412,577</span> shares of common stock, valued at $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20221231__srt--ProductOrServiceAxis__custom--ConsultingServicesMember_zKTRX6VEpnR3" title="Common stock issued for cash, shares">691,520</span> for consulting services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2022, we committed to issue <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230103__20230103__srt--ProductOrServiceAxis__custom--ConsultingServicesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpXwlzntoDci" title="Common stock issued for cash, shares">3,000,000</span> shares of common stock, valued at $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230103__20230103__srt--ProductOrServiceAxis__custom--ConsultingServicesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zJR8gvO8SWVh" title="Common stock issued for cash, shares">18,000</span> for consulting services, which were issued on January 3, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2022, we issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--SalariesMember_zOPqeD6ChHE3" title="Common stock issued for cash, shares">4,812,259</span> shares of common stock, valued at $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--SalariesMember_zPbt2THVUU8" title="Common stock issued for cash">67,399</span> for salaries.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2022, we issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zSbCu1JzYJx9" title="Common stock issued for cash, shares">149,402,390</span> shares of common stock, valued at $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20220101__20221231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zmOPuRJwSXW9" title="Common stock issued for cash">3,107,570</span> for a license.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2022, we issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidFeesMember_zDnWUccAqbck" title="Common stock issued for cash, shares">11,000,000</span> shares of common stock, valued at $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20220101__20221231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidFeesMember_zNH4az4sfpp9" title="Common stock issued for cash">242,320</span> for prepaid fees.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2022, we issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zkeYG3ejekh8" title="Conversion of convertible notes">64,139,744</span> shares of common stock for the conversion of convertible notes of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pp0p0_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zpw3eJkLa6he" title="conversion of convertible notes, value">1,313,772</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2022, we committed to issue <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230103__20230103__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zuTZDgb38k1h" title="Conversion of convertible notes">4,054,054</span> shares of common stock for the conversion of convertible notes of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20230103__20230103__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zMrFrSMhEY9l" title="Common stock issued for cash, shares">15,000</span>, which were issued on January 3, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 3505000000 3500000000 0.001 5000000 2617390830 2 2 4850075 285500 21000000 858900 8341723 239799 1500000 58900 21690671 1019014 44500000 445000 32412577 691520 3000000 18000 4812259 67399 149402390 3107570 11000000 242320 64139744 1313772 4054054 15000 <p id="xdx_805_eus-gaap--LegalMattersAndContingenciesTextBlock_z8iRUqwTuRT3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 12 – <span id="xdx_828_zxtGtC6fNOBc">Legal proceedings</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, claims are made against us in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from selling one or more products or engaging in other activities. The occurrence of an unfavorable outcome in any specific period could have a material adverse effect on our results of operations for that period or future periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However, as of the date of this report, management believes the outcome of currently identified potential claims and lawsuits will not have a material adverse effect on our financial condition or results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zq7ZMic4ZTRg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 13 – <span id="xdx_825_zZaL99UJegl8">Commitments and Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective March 1, 2020, the Company entered into a fifth amendment to a Lease Agreement for property located in Oceanside, CA. The lease consists of approximately <span id="xdx_903_eus-gaap--AreaOfLand_iI_uSqft_c20221231_zvJpFzxM9adj" title="Area of land">1,700</span> square feet and the amendment is for a term of <span id="xdx_906_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20221231_zbm1IS8c8dN1" title="Lease contract term">36</span> months and expires on <span id="xdx_901_eus-gaap--LeaseExpirationDate1_dd_c20220101__20221231_zx21IQ2yTK1a" title="Lease expiration date">April 30, 2023</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022 and 2021, the Company incurred rent expense of $<span id="xdx_902_eus-gaap--PaymentsForRent_pp0p0_c20220101__20221231_zo2Y43jW0ugj" title="Payment for rent">25,044</span> and $<span id="xdx_90C_eus-gaap--PaymentsForRent_pp0p0_c20210101__20211231_zZoWnURPJHFk" title="Payment for rent">22,768</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The lease will expire in 2023. The weighted average discount rate used for this lease is <span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20221231_zXUeNg56r6xe" title="Operating lease discount rate">5</span>% (average borrowing rate of the Company). Maturities of Leases were:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zRqOk0o5gDx1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future minimum lease payments as of December 31, 2022 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BA_zgxxAoSKqWOg" style="display: none">Schedule of Future Minimum Lease Payments</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"> <tr style="vertical-align: bottom"> <td>For the year ending December 31,</td><td> </td> <td colspan="2" id="xdx_496_20221231_zq4DvSp7LHhf"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 80%"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzKHl_zWikzEeDsZKg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,612</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A4_zRDyYI4IfQ0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective November 8, 2019, the Company entered into a royalty agreement with one of the officers, refer to Note 9.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 1700 P36M 2023-04-30 25044 22768 0.05 <p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zRqOk0o5gDx1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future minimum lease payments as of December 31, 2022 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BA_zgxxAoSKqWOg" style="display: none">Schedule of Future Minimum Lease Payments</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"> <tr style="vertical-align: bottom"> <td>For the year ending December 31,</td><td> </td> <td colspan="2" id="xdx_496_20221231_zq4DvSp7LHhf"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 80%"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzKHl_zWikzEeDsZKg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,612</td><td style="text-align: left"> </td></tr> </table> 8612 <p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_z6mEafjij20c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 14 – <span id="xdx_822_znZf1TkY9hqf">Subsequent events</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 3, 2023, we issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230103__20230103__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zlHADrpQt9yf" title="Conversion of common stock, shares">4,054,054</span> shares of common stock for the partial conversion of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20230103__20230103__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBdR5KAgU287" title="Conversion of common stock">15,000</span> for convertible note dated June 27, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 3, 2023, we issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230103__20230103__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0yF0IgBR6tb" title="Shares issued for consulting services">17,000,000</span> shares of common stock, valued at $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230103__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zw23ZMf9v0n" title="Share issued price per share">0.006</span> per share, for consulting services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 4, 2023, we issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230104__20230104__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zr1vuDKpDC7j" title="Conversion of common stock, shares">10,052,083</span> shares of common stock for the complete conversion of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20230104__20230104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zUYgRkJDBSih" title="Conversion of common stock">36,188</span> for convertible note dated June 27, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 9, 2023, we issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230109__20230109__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--IncomeStatementLocationAxis__custom--AccruedSalariesMember_zCtquK0F66Bb" title="Common stock issued for cash, shares">4,081,632</span> shares of common stock for $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20230109__20230109__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--IncomeStatementLocationAxis__custom--AccruedSalariesMember_zOcUBDJOeZ01" title="Common stock issued for cash">20,000</span> of accrued salaries.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Notes to Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 14 – Subsequent events (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 9, 2023, we issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230109__20230109__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHpHH599keXe" title="Shares issued for consulting services">4,000,000</span> shares of common stock, valued at $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230109__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpd3g1A68rR3" title="Share issued price per share">0.049</span> per share, for consulting services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 6, 2023, we issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230206__20230206__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zwIhxoIB3mjf" title="Conversion of common stock, shares">6,060,606</span> shares of common stock for the partial conversion of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20230206__20230206__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zp6lXj3IzSdj" title="Conversion of common stock">20,000</span> for convertible note dated August 2, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 7, 2023, we issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230207__20230207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zACM22w3s0Tf" title="Conversion of common stock, shares">11,386,719</span> shares of common stock for the complete conversion of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20230207__20230207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zf7uHUt6E7Pc" title="Conversion of common stock">36,438</span> for convertible note dated August 2, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 21, 2023, we issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230221__20230221__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgcdO649rMA7" title="Common stock issued for cash, shares">60,224,825</span> shares of common stock, valued at $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230221__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zjQjD3hjosPj" title="Shares issued price per share">0.00216</span> per share, for an investment in the Company’s Private Placement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On or about March 21, 2023, the Board of Directors of Therapeutic Solutions International, Inc. (“TSOI”), by unanimous approval, and with the unanimous approval of the <span id="xdx_907_eus-gaap--PreferredStockVotingRights_c20230321__20230321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredClassAMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zXnmRuzdCvr6" title="Right of voting">Preferred A Stock holders representing at least 51% of all shareholders with the right to vote</span>, pursuant to Nevada Revised Statutes Section NRS 78.215, has approved a one-time dividend, to be awarded to stockholders of TSOI in subsidiary Campbell Neurosciences, Inc., a Delaware corporation (“CNSI”). To receive the dividend by future election you must hold TSOI common at the market close of April 7, 2023. The dividend rate of conversion shall be for every share of TSOI common you will receive <span id="xdx_907_ecustom--DividendConversionRate_pid_c20230321__20230321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CampbellNeurosciencesIncMember_zPLwMRVwZRV4" title="Dividend conversion rate">0.0034</span> shares of CNSI.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TSOI, which owns <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230321__20230321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLfOPk5yIb32" title="Common stock issued for cash, shares">15,660,000</span> (<span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20230321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CampbellNeurosciencesIncMember_zJhU6OBE9k89" title="Common stock shares percentage">31%</span>) of the shares of CNSI common stock, would like to issue a dividend consisting of <span id="xdx_906_eus-gaap--CommonStockDividendsShares_c20230321__20230321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CampbellNeurosciencesIncMember_z5PWoQ653Im4" title="Common stock divident">10,000,000</span> shares of its holdings in CNSI to <span id="xdx_904_eus-gaap--DividendsPayableNature_pid_dp_c20230321__20230321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CampbellNeurosciencesIncMember_zNSxBq1KiyVj" title="Dividend, description">TSOI shareholders at a ratio of 0.00365 shares of CNSI stock for each one (1) share owned in TSOI stock as of <span id="xdx_907_eus-gaap--DividendsPayableDateDeclaredDayMonthAndYear_pid_dp_c20230321__20230321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CampbellNeurosciencesIncMember_zrWcDQ5zymmc" title="Dividend offer date">April 7, 2023</span> (“Dividend Offer”) on April 8, 2023 (“Dividend Offer Date”). The Dividend Offer will remain open for Ninety (90) days from the Dividend Offer Date</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A letter will be mailed to every shareholder of record details of how to accept the Dividend Offer and a fully pre-paid return acceptance letter containing the necessary information for issuance. In addition, a Shareholder’s Rights Agreement will be enclosed, an executed copy to be returned with acceptance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Required forms and documents shall be filed with FINRA describing the identity of the parties and the Dividend Offer timely.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In accordance with ASC 855, the Company has analyzed its operations subsequent to December 31, 2022 through the date these financial statements were issued, and has determined that it does not have any other material subsequent events to disclose in these financial statements.</span></p> 4054054 15000 17000000 0.006 10052083 36188 4081632 20000 4000000 0.049 6060606 20000 11386719 36438 60224825 0.00216 Preferred A Stock holders representing at least 51% of all shareholders with the right to vote 0.0034 15660000 0.31 10000000 TSOI shareholders at a ratio of 0.00365 shares of CNSI stock for each one (1) share owned in TSOI stock as of April 7, 2023 (“Dividend Offer”) on April 8, 2023 (“Dividend Offer Date”). The Dividend Offer will remain open for Ninety (90) days from the Dividend Offer Date 2023-04-07 EXCEL 61 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 63 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 196 270 1 false 58 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://therapeuticsolutionsint.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://therapeuticsolutionsint.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://therapeuticsolutionsint.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations Sheet http://therapeuticsolutionsint.com/role/StatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Changes in Shareholders' Deficit Sheet http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit Consolidated Statements of Changes in Shareholders' Deficit Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows Sheet http://therapeuticsolutionsint.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - Organization and Business Description Sheet http://therapeuticsolutionsint.com/role/OrganizationAndBusinessDescription Organization and Business Description Notes 7 false false R8.htm 00000008 - Disclosure - Basis of presentation and significant accounting policies Sheet http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPolicies Basis of presentation and significant accounting policies Notes 8 false false R9.htm 00000009 - Disclosure - Restricted cash Sheet http://therapeuticsolutionsint.com/role/RestrictedCash Restricted cash Notes 9 false false R10.htm 00000010 - Disclosure - Prepaid expense and other current assets Sheet http://therapeuticsolutionsint.com/role/PrepaidExpenseAndOtherCurrentAssets Prepaid expense and other current assets Notes 10 false false R11.htm 00000011 - Disclosure - Fixed assets Sheet http://therapeuticsolutionsint.com/role/FixedAssets Fixed assets Notes 11 false false R12.htm 00000012 - Disclosure - Other assets Sheet http://therapeuticsolutionsint.com/role/OtherAssets Other assets Notes 12 false false R13.htm 00000013 - Disclosure - Convertible notes payable Notes http://therapeuticsolutionsint.com/role/ConvertibleNotesPayable Convertible notes payable Notes 13 false false R14.htm 00000014 - Disclosure - Notes payable-related parties Notes http://therapeuticsolutionsint.com/role/NotesPayable-relatedParties Notes payable-related parties Notes 14 false false R15.htm 00000015 - Disclosure - Related party transactions Sheet http://therapeuticsolutionsint.com/role/RelatedPartyTransactions Related party transactions Notes 15 false false R16.htm 00000016 - Disclosure - Income taxes Sheet http://therapeuticsolutionsint.com/role/IncomeTaxes Income taxes Notes 16 false false R17.htm 00000017 - Disclosure - Equity Sheet http://therapeuticsolutionsint.com/role/Equity Equity Notes 17 false false R18.htm 00000018 - Disclosure - Legal proceedings Sheet http://therapeuticsolutionsint.com/role/LegalProceedings Legal proceedings Notes 18 false false R19.htm 00000019 - Disclosure - Commitments and Contingencies Sheet http://therapeuticsolutionsint.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 19 false false R20.htm 00000020 - Disclosure - Subsequent events Sheet http://therapeuticsolutionsint.com/role/SubsequentEvents Subsequent events Notes 20 false false R21.htm 00000021 - Disclosure - Basis of presentation and significant accounting policies (Policies) Sheet http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies Basis of presentation and significant accounting policies (Policies) Policies 21 false false R22.htm 00000022 - Disclosure - Basis of presentation and significant accounting policies (Tables) Sheet http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables Basis of presentation and significant accounting policies (Tables) Tables http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPolicies 22 false false R23.htm 00000023 - Disclosure - Prepaid expense and other current assets (Tables) Sheet http://therapeuticsolutionsint.com/role/PrepaidExpenseAndOtherCurrentAssetsTables Prepaid expense and other current assets (Tables) Tables http://therapeuticsolutionsint.com/role/PrepaidExpenseAndOtherCurrentAssets 23 false false R24.htm 00000024 - Disclosure - Fixed assets (Tables) Sheet http://therapeuticsolutionsint.com/role/FixedAssetsTables Fixed assets (Tables) Tables http://therapeuticsolutionsint.com/role/FixedAssets 24 false false R25.htm 00000025 - Disclosure - Other assets (Tables) Sheet http://therapeuticsolutionsint.com/role/OtherAssetsTables Other assets (Tables) Tables http://therapeuticsolutionsint.com/role/OtherAssets 25 false false R26.htm 00000026 - Disclosure - Notes payable-related parties (Tables) Notes http://therapeuticsolutionsint.com/role/NotesPayable-relatedPartiesTables Notes payable-related parties (Tables) Tables http://therapeuticsolutionsint.com/role/NotesPayable-relatedParties 26 false false R27.htm 00000027 - Disclosure - Income taxes (Tables) Sheet http://therapeuticsolutionsint.com/role/IncomeTaxesTables Income taxes (Tables) Tables http://therapeuticsolutionsint.com/role/IncomeTaxes 27 false false R28.htm 00000028 - Disclosure - Commitments and Contingencies (Tables) Sheet http://therapeuticsolutionsint.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://therapeuticsolutionsint.com/role/CommitmentsAndContingencies 28 false false R29.htm 00000029 - Disclosure - Organization and Business Description (Details Narrative) Sheet http://therapeuticsolutionsint.com/role/OrganizationAndBusinessDescriptionDetailsNarrative Organization and Business Description (Details Narrative) Details http://therapeuticsolutionsint.com/role/OrganizationAndBusinessDescription 29 false false R30.htm 00000030 - Disclosure - Schedule of Change in Derivative Liability (Details) Sheet http://therapeuticsolutionsint.com/role/ScheduleOfChangeInDerivativeLiabilityDetails Schedule of Change in Derivative Liability (Details) Details 30 false false R31.htm 00000031 - Disclosure - Basis of presentation and significant accounting policies (Details Narrative) Sheet http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative Basis of presentation and significant accounting policies (Details Narrative) Details http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables 31 false false R32.htm 00000032 - Disclosure - Restricted cash (Details Narrative) Sheet http://therapeuticsolutionsint.com/role/RestrictedCashDetailsNarrative Restricted cash (Details Narrative) Details http://therapeuticsolutionsint.com/role/RestrictedCash 32 false false R33.htm 00000033 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details) Sheet http://therapeuticsolutionsint.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails Schedule of Prepaid Expenses and Other Current Assets (Details) Details 33 false false R34.htm 00000034 - Disclosure - Schedule of Fixed Assets (Details) Sheet http://therapeuticsolutionsint.com/role/ScheduleOfFixedAssetsDetails Schedule of Fixed Assets (Details) Details 34 false false R35.htm 00000035 - Disclosure - Fixed assets (Details Narrative) Sheet http://therapeuticsolutionsint.com/role/FixedAssetsDetailsNarrative Fixed assets (Details Narrative) Details http://therapeuticsolutionsint.com/role/FixedAssetsTables 35 false false R36.htm 00000036 - Disclosure - Schedule of Other Assets (Details) Sheet http://therapeuticsolutionsint.com/role/ScheduleOfOtherAssetsDetails Schedule of Other Assets (Details) Details 36 false false R37.htm 00000037 - Disclosure - Schedule of Net Licenses (Details) Sheet http://therapeuticsolutionsint.com/role/ScheduleOfNetLicensesDetails Schedule of Net Licenses (Details) Details 37 false false R38.htm 00000038 - Disclosure - Other assets (Details Narrative) Sheet http://therapeuticsolutionsint.com/role/OtherAssetsDetailsNarrative Other assets (Details Narrative) Details http://therapeuticsolutionsint.com/role/OtherAssetsTables 38 false false R39.htm 00000039 - Disclosure - Convertible notes payable (Details Narrative) Notes http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative Convertible notes payable (Details Narrative) Details http://therapeuticsolutionsint.com/role/ConvertibleNotesPayable 39 false false R40.htm 00000040 - Disclosure - Schedule of Notes Payable Related Parties (Details) Notes http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetails Schedule of Notes Payable Related Parties (Details) Details 40 false false R41.htm 00000041 - Disclosure - Schedule of Notes Payable Related Parties (Details) (Parenthetical) Notes http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetailsParenthetical Schedule of Notes Payable Related Parties (Details) (Parenthetical) Details 41 false false R42.htm 00000042 - Disclosure - Related party transactions (Details Narrative) Sheet http://therapeuticsolutionsint.com/role/RelatedPartyTransactionsDetailsNarrative Related party transactions (Details Narrative) Details http://therapeuticsolutionsint.com/role/RelatedPartyTransactions 42 false false R43.htm 00000043 - Disclosure - Schedule of Income tax Expense (Details) Sheet http://therapeuticsolutionsint.com/role/ScheduleOfIncomeTaxExpenseDetails Schedule of Income tax Expense (Details) Details 43 false false R44.htm 00000044 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details) Sheet http://therapeuticsolutionsint.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails Schedule of Deferred Tax Assets and Liabilities (Details) Details 44 false false R45.htm 00000045 - Disclosure - Income taxes (Details Narrative) Sheet http://therapeuticsolutionsint.com/role/IncomeTaxesDetailsNarrative Income taxes (Details Narrative) Details http://therapeuticsolutionsint.com/role/IncomeTaxesTables 45 false false R46.htm 00000046 - Disclosure - Equity (Details Narrative) Sheet http://therapeuticsolutionsint.com/role/EquityDetailsNarrative Equity (Details Narrative) Details http://therapeuticsolutionsint.com/role/Equity 46 false false R47.htm 00000047 - Disclosure - Schedule of Future Minimum Lease Payments (Details) Sheet http://therapeuticsolutionsint.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails Schedule of Future Minimum Lease Payments (Details) Details 47 false false R48.htm 00000048 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://therapeuticsolutionsint.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://therapeuticsolutionsint.com/role/CommitmentsAndContingenciesTables 48 false false R49.htm 00000049 - Disclosure - Subsequent events (Details Narrative) Sheet http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative Subsequent events (Details Narrative) Details http://therapeuticsolutionsint.com/role/SubsequentEvents 49 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept NotesPayableRelatedPartiesClassifiedCurrent in us-gaap/2022 used in 16 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 132, 133, 7195, 7196, 9197, 9201, 9208, 9209, 9216, 9217, 9224, 9225, 9232, 9233, 9236, 9237 [dq-0542-Deprecated-Concept] Concept AccountsPayableRelatedPartiesCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 7175, 7176 [dq-0542-Deprecated-Concept] Concept NotesPayableRelatedPartiesCurrentAndNoncurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 9244, 9245 [dq-0542-Deprecated-Concept] Concept RelatedPartyTransactionDueFromToRelatedParty in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 9279 form10-k.htm ex31-1.htm ex31-2.htm ex32-1.htm tsoi-20221231.xsd tsoi-20221231_cal.xml tsoi-20221231_def.xml tsoi-20221231_lab.xml tsoi-20221231_pre.xml form10-k_004.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 67 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-k.htm": { "axisCustom": 0, "axisStandard": 19, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 650, "http://xbrl.sec.gov/dei/2022": 34 }, "contextCount": 196, "dts": { "calculationLink": { "local": [ "tsoi-20221231_cal.xml" ] }, "definitionLink": { "local": [ "tsoi-20221231_def.xml" ] }, "inline": { "local": [ "form10-k.htm" ] }, "labelLink": { "local": [ "tsoi-20221231_lab.xml" ] }, "presentationLink": { "local": [ "tsoi-20221231_pre.xml" ] }, "schema": { "local": [ "tsoi-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 442, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 70, "http://therapeuticsolutionsint.com/20221231": 40, "http://xbrl.sec.gov/dei/2022": 3, "total": 113 }, "keyCustom": 34, "keyStandard": 236, "memberCustom": 28, "memberStandard": 28, "nsprefix": "TSOI", "nsuri": "http://therapeuticsolutionsint.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://therapeuticsolutionsint.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "TSOI:DeferredCostsCapitalizedPrepaidAndOtherAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Prepaid expense and other current assets", "menuCat": "Notes", "order": "10", "role": "http://therapeuticsolutionsint.com/role/PrepaidExpenseAndOtherCurrentAssets", "shortName": "Prepaid expense and other current assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "TSOI:DeferredCostsCapitalizedPrepaidAndOtherAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Fixed assets", "menuCat": "Notes", "order": "11", "role": "http://therapeuticsolutionsint.com/role/FixedAssets", "shortName": "Fixed assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Other assets", "menuCat": "Notes", "order": "12", "role": "http://therapeuticsolutionsint.com/role/OtherAssets", "shortName": "Other assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Convertible notes payable", "menuCat": "Notes", "order": "13", "role": "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayable", "shortName": "Convertible notes payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Notes payable-related parties", "menuCat": "Notes", "order": "14", "role": "http://therapeuticsolutionsint.com/role/NotesPayable-relatedParties", "shortName": "Notes payable-related parties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Related party transactions", "menuCat": "Notes", "order": "15", "role": "http://therapeuticsolutionsint.com/role/RelatedPartyTransactions", "shortName": "Related party transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Income taxes", "menuCat": "Notes", "order": "16", "role": "http://therapeuticsolutionsint.com/role/IncomeTaxes", "shortName": "Income taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Equity", "menuCat": "Notes", "order": "17", "role": "http://therapeuticsolutionsint.com/role/Equity", "shortName": "Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Legal proceedings", "menuCat": "Notes", "order": "18", "role": "http://therapeuticsolutionsint.com/role/LegalProceedings", "shortName": "Legal proceedings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "19", "role": "http://therapeuticsolutionsint.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://therapeuticsolutionsint.com/role/BalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Subsequent events", "menuCat": "Notes", "order": "20", "role": "http://therapeuticsolutionsint.com/role/SubsequentEvents", "shortName": "Subsequent events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Basis of presentation and significant accounting policies (Policies)", "menuCat": "Policies", "order": "21", "role": "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies", "shortName": "Basis of presentation and significant accounting policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Basis of presentation and significant accounting policies (Tables)", "menuCat": "Tables", "order": "22", "role": "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables", "shortName": "Basis of presentation and significant accounting policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "TSOI:DeferredCostsCapitalizedPrepaidAndOtherAssetsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Prepaid expense and other current assets (Tables)", "menuCat": "Tables", "order": "23", "role": "http://therapeuticsolutionsint.com/role/PrepaidExpenseAndOtherCurrentAssetsTables", "shortName": "Prepaid expense and other current assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "TSOI:DeferredCostsCapitalizedPrepaidAndOtherAssetsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Fixed assets (Tables)", "menuCat": "Tables", "order": "24", "role": "http://therapeuticsolutionsint.com/role/FixedAssetsTables", "shortName": "Fixed assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Other assets (Tables)", "menuCat": "Tables", "order": "25", "role": "http://therapeuticsolutionsint.com/role/OtherAssetsTables", "shortName": "Other assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "TSOI:NotesPayableRelatedPartiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Notes payable-related parties (Tables)", "menuCat": "Tables", "order": "26", "role": "http://therapeuticsolutionsint.com/role/NotesPayable-relatedPartiesTables", "shortName": "Notes payable-related parties (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "TSOI:NotesPayableRelatedPartiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Income taxes (Tables)", "menuCat": "Tables", "order": "27", "role": "http://therapeuticsolutionsint.com/role/IncomeTaxesTables", "shortName": "Income taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Commitments and Contingencies (Tables)", "menuCat": "Tables", "order": "28", "role": "http://therapeuticsolutionsint.com/role/CommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:NatureOfOperations", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityIncorporationDateOfIncorporation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Organization and Business Description (Details Narrative)", "menuCat": "Details", "order": "29", "role": "http://therapeuticsolutionsint.com/role/OrganizationAndBusinessDescriptionDetailsNarrative", "shortName": "Organization and Business Description (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:NatureOfOperations", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityIncorporationDateOfIncorporation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscountCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://therapeuticsolutionsint.com/role/BalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscountCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Schedule of Change in Derivative Liability (Details)", "menuCat": "Details", "order": "30", "role": "http://therapeuticsolutionsint.com/role/ScheduleOfChangeInDerivativeLiabilityDetails", "shortName": "Schedule of Change in Derivative Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "lang": null, "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Basis of presentation and significant accounting policies (Details Narrative)", "menuCat": "Details", "order": "31", "role": "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "shortName": "Basis of presentation and significant accounting policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RestrictedCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Restricted cash (Details Narrative)", "menuCat": "Details", "order": "32", "role": "http://therapeuticsolutionsint.com/role/RestrictedCashDetailsNarrative", "shortName": "Restricted cash (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RestrictedCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "TSOI:DeferredCostsCapitalizedPrepaidAndOtherAssetsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "TSOI:PrepaidConsultingCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details)", "menuCat": "Details", "order": "33", "role": "http://therapeuticsolutionsint.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails", "shortName": "Schedule of Prepaid Expenses and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "TSOI:DeferredCostsCapitalizedPrepaidAndOtherAssetsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "TSOI:PrepaidConsultingCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Schedule of Fixed Assets (Details)", "menuCat": "Details", "order": "34", "role": "http://therapeuticsolutionsint.com/role/ScheduleOfFixedAssetsDetails", "shortName": "Schedule of Fixed Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - Fixed assets (Details Narrative)", "menuCat": "Details", "order": "35", "role": "http://therapeuticsolutionsint.com/role/FixedAssetsDetailsNarrative", "shortName": "Fixed assets (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "TSOI:PrepaidConsultingNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - Schedule of Other Assets (Details)", "menuCat": "Details", "order": "36", "role": "http://therapeuticsolutionsint.com/role/ScheduleOfOtherAssetsDetails", "shortName": "Schedule of Other Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "TSOI:PrepaidConsultingNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "TSOI:ScheduleOfNetLicensesTableTextBlock", "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - Schedule of Net Licenses (Details)", "menuCat": "Details", "order": "37", "role": "http://therapeuticsolutionsint.com/role/ScheduleOfNetLicensesDetails", "shortName": "Schedule of Net Licenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "TSOI:ScheduleOfNetLicensesTableTextBlock", "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - Other assets (Details Narrative)", "menuCat": "Details", "order": "38", "role": "http://therapeuticsolutionsint.com/role/OtherAssetsDetailsNarrative", "shortName": "Other assets (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromConvertibleDebt", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - Convertible notes payable (Details Narrative)", "menuCat": "Details", "order": "39", "role": "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative", "shortName": "Convertible notes payable (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31_us-gaap_ConvertibleNotesPayableMember", "decimals": "0", "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Statements of Operations", "menuCat": "Statements", "order": "4", "role": "http://therapeuticsolutionsint.com/role/StatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableRelatedPartiesClassifiedCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - Schedule of Notes Payable Related Parties (Details)", "menuCat": "Details", "order": "40", "role": "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetails", "shortName": "Schedule of Notes Payable Related Parties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "TSOI:NotesPayableRelatedPartiesTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "TSOI:NotesPayableRelatedPartiesTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31_custom_ScientificAdvisoryBoardMember_custom_NotesPayableOneMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - Schedule of Notes Payable Related Parties (Details) (Parenthetical)", "menuCat": "Details", "order": "41", "role": "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetailsParenthetical", "shortName": "Schedule of Notes Payable Related Parties (Details) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "TSOI:NotesPayableRelatedPartiesTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31_custom_ScientificAdvisoryBoardMember_custom_NotesPayableOneMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - Related party transactions (Details Narrative)", "menuCat": "Details", "order": "42", "role": "http://therapeuticsolutionsint.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related party transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - Schedule of Income tax Expense (Details)", "menuCat": "Details", "order": "43", "role": "http://therapeuticsolutionsint.com/role/ScheduleOfIncomeTaxExpenseDetails", "shortName": "Schedule of Income tax Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)", "menuCat": "Details", "order": "44", "role": "http://therapeuticsolutionsint.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails", "shortName": "Schedule of Deferred Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "TSOI:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxAndStateAndLocalIncomeTaxesRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - Income taxes (Details Narrative)", "menuCat": "Details", "order": "45", "role": "http://therapeuticsolutionsint.com/role/IncomeTaxesDetailsNarrative", "shortName": "Income taxes (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "TSOI:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxAndStateAndLocalIncomeTaxesRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CapitalUnitsAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - Equity (Details Narrative)", "menuCat": "Details", "order": "46", "role": "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative", "shortName": "Equity (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CapitalUnitsAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - Schedule of Future Minimum Lease Payments (Details)", "menuCat": "Details", "order": "47", "role": "http://therapeuticsolutionsint.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails", "shortName": "Schedule of Future Minimum Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AreaOfLand", "reportCount": 1, "unique": true, "unitRef": "Sqft", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - Commitments and Contingencies (Details Narrative)", "menuCat": "Details", "order": "48", "role": "http://therapeuticsolutionsint.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "Commitments and Contingencies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AreaOfLand", "reportCount": 1, "unique": true, "unitRef": "Sqft", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - Subsequent events (Details Narrative)", "menuCat": "Details", "order": "49", "role": "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative", "shortName": "Subsequent events (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2023-01-092023-01-09_us-gaap_SubsequentEventMember", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statements of Changes in Shareholders' Deficit", "menuCat": "Statements", "order": "5", "role": "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit", "shortName": "Consolidated Statements of Changes in Shareholders' Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "6", "role": "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - Organization and Business Description", "menuCat": "Notes", "order": "7", "role": "http://therapeuticsolutionsint.com/role/OrganizationAndBusinessDescription", "shortName": "Organization and Business Description", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Basis of presentation and significant accounting policies", "menuCat": "Notes", "order": "8", "role": "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPolicies", "shortName": "Basis of presentation and significant accounting policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Restricted cash", "menuCat": "Notes", "order": "9", "role": "http://therapeuticsolutionsint.com/role/RestrictedCash", "shortName": "Restricted cash", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 58, "tag": { "TSOI_AccruedInterestAddedToPrincipal": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accrued interest added to principal.", "label": "Accrued interest added to principal" } } }, "localname": "AccruedInterestAddedToPrincipal", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "TSOI_AccruedSalariesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued Salaries [Member]", "label": "Accrued Salaries [Member]" } } }, "localname": "AccruedSalariesMember", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/RelatedPartyTransactionsDetailsNarrative", "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "TSOI_AmortizationOfPrepaidStockBasedCompensation": { "auth_ref": [], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortization of prepaid stock based compensation.", "label": "Amortization of prepaid stock-based compensation" } } }, "localname": "AmortizationOfPrepaidStockBasedCompensation", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "TSOI_AmortizedLifeOfAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amortized life of agreement.", "label": "Amortized life of agreement" } } }, "localname": "AmortizedLifeOfAgreement", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/OtherAssetsDetailsNarrative" ], "xbrltype": "dateItemType" }, "TSOI_AnnualInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Annual interest rate.", "label": "Annual interest rate" } } }, "localname": "AnnualInterestRate", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/RestrictedCashDetailsNarrative" ], "xbrltype": "percentItemType" }, "TSOI_AssetsTransferAndLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets Transfer and License Agreement [Member]", "label": "Assets Transfer and License Agreement [Member]" } } }, "localname": "AssetsTransferAndLicenseAgreementMember", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/OtherAssetsDetailsNarrative" ], "xbrltype": "domainItemType" }, "TSOI_BusinessAdvisoryBoardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Advisory Board [Member]", "label": "Business Advisory Board [Member]" } } }, "localname": "BusinessAdvisoryBoardMember", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetailsParenthetical" ], "xbrltype": "domainItemType" }, "TSOI_CampbellNeurosciencesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Campbell Neurosciences Inc [Member]", "label": "Campbell Neurosciences Inc [Member]" } } }, "localname": "CampbellNeurosciencesIncMember", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "TSOI_CommonStockIssuedForAccruedSalariesValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Common stock issued for accrued salaries value.", "label": "Common stock issued for accrued salaries" } } }, "localname": "CommonStockIssuedForAccruedSalariesValue", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "TSOI_CommonStockIssuedForLicenseValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Common stock issued for license value.", "label": "CommonStockIssuedForLicenseValue", "verboseLabel": "Common stock issued for license" } } }, "localname": "CommonStockIssuedForLicenseValue", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "TSOI_CommonStockIssuedForPrepaidFeesValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Common stock issued for prepaid fees value.", "label": "CommonStockIssuedForPrepaidFeesValue", "verboseLabel": "Common stock issued for prepaid fees" } } }, "localname": "CommonStockIssuedForPrepaidFeesValue", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "TSOI_ConsultingServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consulting Services [Member]", "label": "Consulting Services [Member]" } } }, "localname": "ConsultingServicesMember", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "TSOI_ConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Notes [Member]", "label": "Convertible Notes [Member]" } } }, "localname": "ConvertibleNotesMember", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "TSOI_ConvertibleNotesPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable" } } }, "localname": "ConvertibleNotesPayableAbstract", "nsuri": "http://therapeuticsolutionsint.com/20221231", "xbrltype": "stringItemType" }, "TSOI_ConvertiblePromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Promissory Note [Member]", "label": "Convertible Promissory Note [Member]" } } }, "localname": "ConvertiblePromissoryNoteMember", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative", "http://therapeuticsolutionsint.com/role/OtherAssetsDetailsNarrative" ], "xbrltype": "domainItemType" }, "TSOI_DeferredCostsCapitalizedPrepaidAndOtherAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Costs Capitalized Prepaid And Other Assets [Text Block]", "label": "Prepaid expense and other current assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsTextBlock", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/PrepaidExpenseAndOtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "TSOI_DerivativeLiabilityMeasurementInputTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative liability, measurement input term.", "label": "Derivative liability, measurement input term" } } }, "localname": "DerivativeLiabilityMeasurementInputTerm", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "durationItemType" }, "TSOI_DisclosurePrepaidExpenseAndOtherCurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expense And Other Current Assets", "verboseLabel": "Schedule Of Prepaid Expenses And Other Current Assets" } } }, "localname": "DisclosurePrepaidExpenseAndOtherCurrentAssetsAbstract", "nsuri": "http://therapeuticsolutionsint.com/20221231", "xbrltype": "stringItemType" }, "TSOI_DividendConversionRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dividend conversion rate.", "label": "Dividend conversion rate" } } }, "localname": "DividendConversionRate", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "pureItemType" }, "TSOI_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxAndStateAndLocalIncomeTaxesRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective Income tax rate reconciliation at federal statutory income tax and state and local iincome taxes rate.", "label": "Federal and state income taxes rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxAndStateAndLocalIncomeTaxesRate", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "percentItemType" }, "TSOI_ExclusivePatentLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exclusive patent license agreement [Member]", "label": "Exclusive patent license agreement [Member]" } } }, "localname": "ExclusivePatentLicenseAgreementMember", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/OtherAssetsDetailsNarrative" ], "xbrltype": "domainItemType" }, "TSOI_FourOfficerAndOneDirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Four Officer and One Director [Member]", "label": "Four Officer and One Director [Member]" } } }, "localname": "FourOfficerAndOneDirectorMember", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "TSOI_FourOfficerOneDirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Four Officer One Director [Member]", "label": "Four Officer One Director [Member]" } } }, "localname": "FourOfficerOneDirectorMember", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "TSOI_IncreaseDecreaseInAccountPayableRelatedParties": { "auth_ref": [], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in Accounts payable - related parties.", "label": "Accounts payable - related parties" } } }, "localname": "IncreaseDecreaseInAccountPayableRelatedParties", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "TSOI_IncreaseDecreaseInRightOfUseAsset": { "auth_ref": [], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in right of use asset.", "label": "IncreaseDecreaseInRightOfUseAsset", "verboseLabel": "Right-of-use asset" } } }, "localname": "IncreaseDecreaseInRightOfUseAsset", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "TSOI_InitialPaymentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial Payment [Member]", "label": "Initial Payment [Member]" } } }, "localname": "InitialPaymentMember", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/OtherAssetsDetailsNarrative" ], "xbrltype": "domainItemType" }, "TSOI_LandDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Land Development [Member]", "label": "Land Development [Member]" } } }, "localname": "LandDevelopmentMember", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "TSOI_LicensesNoncurrent": { "auth_ref": [], "calculation": { "http://therapeuticsolutionsint.com/role/ScheduleOfOtherAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Licenses noncurrent.", "label": "Licenses, net" } } }, "localname": "LicensesNoncurrent", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "TSOI_NetOperatingLossCarryforwardsAreAvailableToOffsetTaxableIncome": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net operating loss carryforwards are available to offset taxable income.", "label": "Net operating loss carryforwards are available to offset taxable income" } } }, "localname": "NetOperatingLossCarryforwardsAreAvailableToOffsetTaxableIncome", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "TSOI_NetOperatingLossCarryforwardsExpirationDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net operating loss carryforwards, expiration, description.", "label": "Net operating loss carryforwards, expiration, description" } } }, "localname": "NetOperatingLossCarryforwardsExpirationDescription", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "TSOI_NotesPayableFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes Payable Five [Membe]", "label": "Notes Payable Five [Membe]" } } }, "localname": "NotesPayableFiveMember", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetails", "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetailsParenthetical" ], "xbrltype": "domainItemType" }, "TSOI_NotesPayableFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes Payable Four [Member]", "label": "Notes Payable Four [Member]" } } }, "localname": "NotesPayableFourMember", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetails", "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetailsParenthetical" ], "xbrltype": "domainItemType" }, "TSOI_NotesPayableOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes Payable One [Member]", "label": "Notes Payable One [Member]" } } }, "localname": "NotesPayableOneMember", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetails", "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetailsParenthetical" ], "xbrltype": "domainItemType" }, "TSOI_NotesPayableRelatedPartiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes Payable Related Parties [Table Text Block]", "label": "Schedule of Notes Payable Related Parties" } } }, "localname": "NotesPayableRelatedPartiesTableTextBlock", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/NotesPayable-relatedPartiesTables" ], "xbrltype": "textBlockItemType" }, "TSOI_NotesPayableThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes Payable Three [Member]", "label": "Notes Payable Three [Member]" } } }, "localname": "NotesPayableThreeMember", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "TSOI_NotesPayableTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes Payable Two [Member]", "label": "Notes Payable Two [Member]" } } }, "localname": "NotesPayableTwoMember", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetails", "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetailsParenthetical" ], "xbrltype": "domainItemType" }, "TSOI_OfficeFurnitureAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office Furniture and Equipment [Member]", "label": "Office Furniture and Equipment [Member]" } } }, "localname": "OfficeFurnitureAndEquipmentMember", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "TSOI_OneOfficerAndOneDirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Officer and One Director [Member]", "label": "One Officer and One Director [Member]" } } }, "localname": "OneOfficerAndOneDirectorMember", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "TSOI_OneOfficersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Officers [Member]", "label": "One Officers [Member]" } } }, "localname": "OneOfficersMember", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "TSOI_PatentExpiresAgreementDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Patent expires agreement date.", "label": "[custom:PatentExpiresAgreementDate]" } } }, "localname": "PatentExpiresAgreementDate", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/OtherAssetsDetailsNarrative" ], "xbrltype": "dateItemType" }, "TSOI_PrepaidConsultingCurrent": { "auth_ref": [], "calculation": { "http://therapeuticsolutionsint.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid consulting current.", "label": "Prepaid consulting" } } }, "localname": "PrepaidConsultingCurrent", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "TSOI_PrepaidConsultingNoncurrent": { "auth_ref": [], "calculation": { "http://therapeuticsolutionsint.com/role/ScheduleOfOtherAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid consulting, noncurrent.", "label": "Prepaid consulting, noncurrent", "verboseLabel": "Prepaid consulting" } } }, "localname": "PrepaidConsultingNoncurrent", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "TSOI_PrepaidFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepaid Fees [Member]", "label": "Prepaid Fees [Member]" } } }, "localname": "PrepaidFeesMember", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "TSOI_ReliefOfDerivativeLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Relief of derivative liabilities.", "label": "Relief of derivative liabilities" } } }, "localname": "ReliefOfDerivativeLiabilities", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "TSOI_RemainingConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Remaining Convertible Notes [Member]", "label": "Remaining Convertible Notes [Member]" } } }, "localname": "RemainingConvertibleNotesMember", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "TSOI_SalariesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Salaries [Member]", "label": "Salaries [Member]" } } }, "localname": "SalariesMember", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "TSOI_ScheduleOfNetLicensesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Net Licenses [Table Text Block]", "label": "Schedule of Net Licenses" } } }, "localname": "ScheduleOfNetLicensesTableTextBlock", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/OtherAssetsTables" ], "xbrltype": "textBlockItemType" }, "TSOI_ScientificAdvisoryBoardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Scientific Advisory Board [Member]", "label": "Scientific Advisory Board [Member]" } } }, "localname": "ScientificAdvisoryBoardMember", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetailsParenthetical" ], "xbrltype": "domainItemType" }, "TSOI_SecondPaymentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second Payment [Member]", "label": "Second Payment [Member]" } } }, "localname": "SecondPaymentMember", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/OtherAssetsDetailsNarrative" ], "xbrltype": "domainItemType" }, "TSOI_ShareBasedCompensationToRelatedParties": { "auth_ref": [], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share based compensation to related parties.", "label": "Stock-based compensation to related parties" } } }, "localname": "ShareBasedCompensationToRelatedParties", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "TSOI_SharesToBeIssued": { "auth_ref": [], "calculation": { "http://therapeuticsolutionsint.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Shares to be issued.", "label": "Shares to be issued" } } }, "localname": "SharesToBeIssued", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "TSOI_SharesToBeIssuedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares To Be Issued [Member]", "label": "Shares To Be Issued [Member]" } } }, "localname": "SharesToBeIssuedMember", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit" ], "xbrltype": "domainItemType" }, "TSOI_ShippingAndHandlingCostsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shipping and Handling Cost [Policy Text Block]", "label": "Shipping and Handling" } } }, "localname": "ShippingAndHandlingCostsPolicyTextBlock", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "TSOI_ShippingAndOtherEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shipping and Other Equipment [Member]", "label": "Shipping and Other Equipment [Member]" } } }, "localname": "ShippingAndOtherEquipmentMember", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "TSOI_StockIssuedDuringPeriodSharesForLicense": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares for license.", "label": "Common stock issued for license, shares" } } }, "localname": "StockIssuedDuringPeriodSharesForLicense", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "TSOI_StockIssuedDuringPeriodSharesForPrepaidFees": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock issued for prepaid fees, shares.", "label": "Common stock issued for prepaid fees, shares" } } }, "localname": "StockIssuedDuringPeriodSharesForPrepaidFees", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "TSOI_StockIssuedDuringPeriodSharesForSalaries": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares for salaries.", "label": "Common stock issued for salaries, shares" } } }, "localname": "StockIssuedDuringPeriodSharesForSalaries", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "TSOI_StockIssuedDuringPeriodSharesNewIssuesPreferredStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares new issues preferred stock.", "label": "Issuance of preferred stock, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssuesPreferredStock", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "TSOI_StockIssuedDuringPeriodValueForLicense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value for license.", "label": "Common stock issued for license" } } }, "localname": "StockIssuedDuringPeriodValueForLicense", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "TSOI_StockIssuedDuringPeriodValueForPrepaidFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock issued for prepaid fees.", "label": "Common stock issued for prepaid fees" } } }, "localname": "StockIssuedDuringPeriodValueForPrepaidFees", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "TSOI_StockIssuedDuringPeriodValueNewIssuesPreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value new issues preferred stock.", "label": "Issuance of preferred stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssuesPreferredStock", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "TSOI_StockIssuedDuringPeriodValuesForSalaries": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period values for salaries.", "label": "Common stock issued for salaries" } } }, "localname": "StockIssuedDuringPeriodValuesForSalaries", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "TSOI_SubscriptionReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subscription Receivable [Member]", "label": "Subscription Receivable [Member]" } } }, "localname": "SubscriptionReceivableMember", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit" ], "xbrltype": "domainItemType" }, "TSOI_WholesalePurchasePriceAndPaymentsDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Wholesale Purchase Price And Payments Description.", "label": "Payments description" } } }, "localname": "WholesalePurchasePriceAndPaymentsDescription", "nsuri": "http://therapeuticsolutionsint.com/20221231", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r534" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r534" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r531", "r533", "r534" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r531", "r533", "r534" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r531", "r533", "r534" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r531", "r533", "r534" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r520" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r523" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r526" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r522" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r522" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r522" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationDateOfIncorporation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date when an entity was incorporated", "label": "Entity incorporation date" } } }, "localname": "EntityIncorporationDateOfIncorporation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/OrganizationAndBusinessDescriptionDetailsNarrative" ], "xbrltype": "dateItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r536" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r534" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r522" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r522" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r522" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r522" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r527" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r528" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r521" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r529" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r530" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetailsParenthetical" ], "xbrltype": "domainItemType" }, "srt_ChiefFinancialOfficerMember": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "label": "Chief Financial Officer [Member]" } } }, "localname": "ChiefFinancialOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetailsParenthetical" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r265", "r266", "r267", "r268", "r336", "r465", "r478", "r488", "r489", "r511", "r513", "r519", "r574", "r595", "r596", "r597", "r598", "r599", "r600" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative", "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetailsParenthetical" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r265", "r266", "r267", "r268", "r336", "r465", "r478", "r488", "r489", "r511", "r513", "r519", "r574", "r595", "r596", "r597", "r598", "r599", "r600" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative", "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetailsParenthetical" ], "xbrltype": "domainItemType" }, "srt_OfficerMember": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "label": "Officer [Member]" } } }, "localname": "OfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r231", "r470", "r512", "r518", "r569", "r570", "r577", "r604" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r231", "r470", "r512", "r518", "r569", "r570", "r577", "r604" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r265", "r266", "r267", "r268", "r335", "r336", "r363", "r364", "r365", "r441", "r465", "r478", "r488", "r489", "r511", "r513", "r519", "r568", "r574", "r596", "r597", "r598", "r599", "r600" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative", "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetailsParenthetical" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r265", "r266", "r267", "r268", "r335", "r336", "r363", "r364", "r365", "r441", "r465", "r478", "r488", "r489", "r511", "r513", "r519", "r568", "r574", "r596", "r597", "r598", "r599", "r600" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative", "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetailsParenthetical" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r195", "r337", "r541", "r560" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/OtherAssetsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r195", "r337", "r541", "r542", "r560" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/OtherAssetsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r562", "r592" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/RelatedPartyTransactionsDetailsNarrative", "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetailsParenthetical", "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/RelatedPartyTransactionsDetailsNarrative", "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetailsParenthetical", "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r11", "r517" ], "calculation": { "http://therapeuticsolutionsint.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrent": { "auth_ref": [ "r11", "r109", "r110", "r556" ], "calculation": { "http://therapeuticsolutionsint.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable-related parties" } } }, "localname": "AccountsPayableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r235", "r236" ], "calculation": { "http://therapeuticsolutionsint.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://therapeuticsolutionsint.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses and other current liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalariesCurrent": { "auth_ref": [ "r15", "r495" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Salaries, Current" } } }, "localname": "AccruedSalariesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r66", "r147" ], "calculation": { "http://therapeuticsolutionsint.com/role/ScheduleOfFixedAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfFixedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r5", "r517" ], "calculation": { "http://therapeuticsolutionsint.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r367", "r368", "r369", "r557", "r558", "r559", "r583" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": { "auth_ref": [ "r74", "r79", "r386" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.", "label": "Additional paid in capital on convertible debt features" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r373" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising expense" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r154", "r239", "r246" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r31", "r43", "r104", "r302" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r43", "r60", "r63" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Patent amortization", "verboseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r203" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive securities excluded from computation of earnings per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land held.", "label": "Area of land" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/OtherAssetsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r113", "r123", "r150", "r177", "r222", "r225", "r229", "r244", "r269", "r270", "r272", "r273", "r274", "r275", "r276", "r278", "r279", "r397", "r401", "r411", "r517", "r572", "r573", "r593" ], "calculation": { "http://therapeuticsolutionsint.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r142", "r158", "r177", "r244", "r269", "r270", "r272", "r273", "r274", "r275", "r276", "r278", "r279", "r397", "r401", "r411", "r517", "r572", "r573", "r593" ], "calculation": { "http://therapeuticsolutionsint.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r338", "r339", "r340", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r362", "r363", "r364", "r365", "r366" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative", "http://therapeuticsolutionsint.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r93", "r95" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position)." } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalUnitsAuthorized": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.", "label": "Aggregate authorized capital" } } }, "localname": "CapitalUnitsAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r45", "r145", "r491" ], "calculation": { "http://therapeuticsolutionsint.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents", "periodEndLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets", "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.", "label": "Cash and Cash Equivalents Disclosure [Text Block]", "verboseLabel": "Restricted cash" } } }, "localname": "CashAndCashEquivalentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/RestrictedCash" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r39", "r45", "r52" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Total cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows:" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r39", "r45", "r52" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r39", "r103" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash, FDIC insured amount" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r151", "r152", "r153", "r177", "r197", "r198", "r200", "r202", "r210", "r211", "r244", "r269", "r272", "r273", "r274", "r278", "r279", "r308", "r309", "r311", "r315", "r322", "r411", "r490", "r540", "r553", "r561" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit", "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/OtherAssetsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r20", "r117", "r128" ], "calculation": { "http://therapeuticsolutionsint.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r69", "r263", "r264", "r484", "r571" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common shares reserve" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockDividendsShares": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits.", "label": "Common stock divident" } } }, "localname": "CommonStockDividendsShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r557", "r558", "r583" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheetsParenthetical", "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheetsParenthetical", "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares, issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r4", "r74" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares, outstanding", "verboseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheetsParenthetical", "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesSubscribedButUnissued": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.", "label": "Common stock, subscribed and issued" } } }, "localname": "CommonStockSharesSubscribedButUnissued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r4", "r517" ], "calculation": { "http://therapeuticsolutionsint.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.001 par value; 3,500,000,000 shares authorized; 2,617,390,830 and 2,311,123,860 shares issued and outstanding at December 31, 2022 and 2021, respectively." } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r87", "r496" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockAmountIssued1": { "auth_ref": [ "r48", "r49", "r50" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Common stock issued in conversion of convertible notes payable and interest" } } }, "localname": "ConversionOfStockAmountIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtCurrent": { "auth_ref": [ "r0" ], "calculation": { "http://therapeuticsolutionsint.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Convertible notes payable, net of discount of $175,063 and $225,800, at December 31, 2022 and 2021, respectively" } } }, "localname": "ConvertibleDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r0", "r114", "r122", "r132" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable [Member]" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative", "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative", "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r27", "r470" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of goods sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r48", "r50" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt conversion of convertible shares, value" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r48", "r50" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt conversion of convertible shares" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt conversion description" } } }, "localname": "DebtConversionDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r48", "r50" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt discount recorded in connection with derivative liability" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r72", "r175", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r296", "r303", "r304", "r306" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Notes payable-related parties" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/NotesPayable-relatedParties" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r0", "r1", "r2", "r114", "r115", "r122", "r181", "r280", "r281", "r282", "r283", "r284", "r286", "r292", "r293", "r294", "r295", "r297", "r298", "r299", "r300", "r301", "r302", "r420", "r506", "r507", "r508", "r509", "r510", "r554" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetails", "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r105", "r107", "r280", "r420", "r507", "r508" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r17", "r281" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Interest rate percentage", "verboseLabel": "Debt interest percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative", "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetailsParenthetical" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r159", "r506", "r585" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetailsParenthetical" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentMaturityDateDescription": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.", "label": "Debt maturity date description" } } }, "localname": "DebtInstrumentMaturityDateDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r19", "r181", "r280", "r281", "r282", "r283", "r284", "r286", "r292", "r293", "r294", "r295", "r297", "r298", "r299", "r300", "r301", "r302", "r420", "r506", "r507", "r508", "r509", "r510", "r554" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetails", "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetailsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r19", "r75", "r76", "r77", "r78", "r104", "r105", "r107", "r121", "r181", "r280", "r281", "r282", "r283", "r284", "r286", "r292", "r293", "r294", "r295", "r297", "r298", "r299", "r300", "r301", "r302", "r305", "r420", "r506", "r507", "r508", "r509", "r510", "r554" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r104", "r107", "r575" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": { "auth_ref": [ "r104", "r107" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.", "label": "Debt instrument, unamortized discount, current" } } }, "localname": "DebtInstrumentUnamortizedDiscountCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": { "auth_ref": [ "r48", "r49", "r50" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.", "label": "Original issuance discount on convertible notes payable" } } }, "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Schedule of Prepaid Expenses and Other Current Assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/PrepaidExpenseAndOtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r580" ], "calculation": { "http://therapeuticsolutionsint.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Net deferred tax asset" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r86", "r581" ], "calculation": { "http://therapeuticsolutionsint.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating loss carry-forward" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": { "auth_ref": [ "r86", "r581" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.", "label": "Federal net operating loss carryfowards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "auth_ref": [ "r86", "r581" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.", "label": "State net operating loss carryfowards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r381" ], "calculation": { "http://therapeuticsolutionsint.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsNoncurrent": { "auth_ref": [ "r544" ], "calculation": { "http://therapeuticsolutionsint.com/role/ScheduleOfOtherAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "Deposit" } } }, "localname": "DepositsAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r43", "r64" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "verboseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://therapeuticsolutionsint.com/role/FixedAssetsDetailsNarrative", "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r43", "r64" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Amortization expenses" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/OtherAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock": { "auth_ref": [ "r497" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for depreciation, depletion, and amortization of property and equipment costs, including methods used and estimated useful lives and how impairment of such assets is assessed and recognized.", "label": "Depreciation and Amortization" } } }, "localname": "DepreciationDepletionAndAmortizationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r160" ], "calculation": { "http://therapeuticsolutionsint.com/role/BalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative liabilities" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets", "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityMeasurementInput": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure derivative liability.", "label": "Derivative liability, measurement input" } } }, "localname": "DerivativeLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "decimalItemType" }, "us-gaap_DerivativeLossOnDerivative": { "auth_ref": [ "r403" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://therapeuticsolutionsint.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in the fair value of derivatives recognized in the income statement.", "label": "Loss on derivative liabilities", "negatedLabel": "Loss on derivative liabilities", "verboseLabel": "Loss on derivative liability" } } }, "localname": "DerivativeLossOnDerivative", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative", "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows", "http://therapeuticsolutionsint.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeMember": { "auth_ref": [ "r88" ], "lang": { "en-us": { "role": { "documentation": "This element represents types of derivative financial instruments which are financial instruments or other contractual arrangements with all three of the following characteristics: (a) it has (1) one or more underlyings and (2) one or more notional amounts or payment provisions or both. Those terms determine the amount of the settlement or settlements, and, in some cases, whether or not a settlement is required; (b) it requires no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; and (c) its terms require or permit net settlement, it can readily be settled net by a means outside the contract, or it provides for delivery of an asset that puts the recipient in a position not substantially different from net settlement. Notwithstanding the above characteristics, loan commitments that relate to the origination of mortgage loans that will be held for sale are accounted for as derivative instruments by the issuer of the loan commitment (that is, the potential lender).", "label": "Derivative [Member]" } } }, "localname": "DerivativeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r89", "r90", "r91", "r92", "r96", "r180" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivative Liabilities" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsPayableDateDeclaredDayMonthAndYear": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Date the dividend to be paid was declared, in YYYY-MM-DD format.", "label": "Dividend offer date" } } }, "localname": "DividendsPayableDateDeclaredDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DividendsPayableNature": { "auth_ref": [ "r48", "r49", "r50" ], "lang": { "en-us": { "role": { "documentation": "Describes the declaration as being a special dividend (over and above the normal dividend); as the annual, semi-annual, quarterly dividend, or other normal periodic dividend; or as some other type of dividend.", "label": "Dividend, description" } } }, "localname": "DividendsPayableNature", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r168", "r187", "r188", "r189", "r190", "r191", "r196", "r197", "r200", "r201", "r202", "r206", "r407", "r408", "r473", "r476", "r501" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net loss per share - basic and diluted" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r203", "r204", "r205", "r207" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Net Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r74", "r140", "r164", "r165", "r166", "r182", "r183", "r184", "r186", "r192", "r194", "r209", "r245", "r323", "r367", "r368", "r369", "r387", "r388", "r406", "r412", "r413", "r414", "r415", "r416", "r417", "r426", "r479", "r480", "r481" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Common stock shares percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues": { "auth_ref": [ "r99", "r100" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of issuances of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Issuance of new derivative liabilities" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfChangeInDerivativeLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease": { "auth_ref": [ "r98", "r100" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Change in fair market value of derivative liabilities" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfChangeInDerivativeLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet": { "auth_ref": [ "r586" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) into (out of) level 3 of the fair value hierarchy.", "label": "Conversions" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfChangeInDerivativeLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs": { "auth_ref": [ "r97", "r100" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfChangeInDerivativeLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueOfAssetsAcquired": { "auth_ref": [ "r48", "r49", "r50" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The fair value of assets acquired in noncash investing or financing activities.", "label": "Property and equipment purchased with note payable" } } }, "localname": "FairValueOfAssetsAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r101", "r102" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r241", "r242", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r305", "r320", "r404", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r504", "r563", "r564", "r565", "r605", "r606", "r607", "r608", "r609", "r610", "r611" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r148", "r260" ], "calculation": { "http://therapeuticsolutionsint.com/role/ScheduleOfNetLicensesDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfNetLicensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r62", "r472" ], "calculation": { "http://therapeuticsolutionsint.com/role/ScheduleOfNetLicensesDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Licenses" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfNetLicensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r62", "r471" ], "calculation": { "http://therapeuticsolutionsint.com/role/ScheduleOfNetLicensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Licenses, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfNetLicensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/OtherAssetsDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "auth_ref": [ "r94" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://therapeuticsolutionsint.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.", "label": "Change in fair value of derivative liabilities", "negatedLabel": "Change in fair value of derivative liabilities", "verboseLabel": "Gain loss on derivative liabilities" } } }, "localname": "GainLossOnDerivativeInstrumentsNetPretax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative", "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows", "http://therapeuticsolutionsint.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r29" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r26", "r177", "r222", "r224", "r228", "r230", "r244", "r269", "r270", "r272", "r273", "r274", "r275", "r276", "r278", "r279", "r411", "r503", "r572" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.", "label": "Long-lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r24", "r111", "r118", "r131", "r222", "r224", "r228", "r230", "r474", "r503" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "LOSS BEFORE PROVISION FOR INCOME TAXES" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r261", "r262" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative", "http://therapeuticsolutionsint.com/role/RelatedPartyTransactionsDetailsNarrative", "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative", "http://therapeuticsolutionsint.com/role/RelatedPartyTransactionsDetailsNarrative", "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r178", "r378", "r379", "r384", "r389", "r391", "r393", "r394", "r395" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r179", "r193", "r194", "r221", "r376", "r390", "r392", "r477" ], "calculation": { "http://therapeuticsolutionsint.com/role/ScheduleOfIncomeTaxExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://therapeuticsolutionsint.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provision for income taxes", "totalLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfIncomeTaxExpenseDetails", "http://therapeuticsolutionsint.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r163", "r374", "r375", "r379", "r380", "r383", "r385" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r579" ], "calculation": { "http://therapeuticsolutionsint.com/role/ScheduleOfIncomeTaxExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).", "label": "Permanent differences" } } }, "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r377" ], "calculation": { "http://therapeuticsolutionsint.com/role/ScheduleOfIncomeTaxExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Expected income tax at statutory rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": { "auth_ref": [ "r579" ], "calculation": { "http://therapeuticsolutionsint.com/role/ScheduleOfIncomeTaxExpenseDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.", "label": "Other" } } }, "localname": "IncomeTaxReconciliationOtherReconcilingItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r579" ], "calculation": { "http://therapeuticsolutionsint.com/role/ScheduleOfIncomeTaxExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "State tax" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r47" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r42" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r42" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r551" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "verboseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r42" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r551", "r589" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "verboseLabel": "Lease liability" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r42" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r61", "r467", "r468", "r469", "r471", "r498" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Intangible Assets" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r106", "r120", "r167", "r220", "r419" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r31", "r300", "r307", "r509", "r510" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest expenses" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r169", "r172", "r173" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r156", "r492", "r517" ], "calculation": { "http://therapeuticsolutionsint.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r144", "r155", "r208", "r255", "r256", "r257", "r466", "r499" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LaborAndRelatedExpense": { "auth_ref": [ "r549" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.", "label": "Salaries, wages, and related costs" } } }, "localname": "LaborAndRelatedExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.", "label": "Lease expiration date" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_LegalFees": { "auth_ref": [ "r28" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.", "label": "Legal and professional fees" } } }, "localname": "LegalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal proceedings" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/LegalProceedings" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r590" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Schedule of Future Minimum Lease Payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r425" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r588" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lease contract term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r14", "r177", "r244", "r269", "r270", "r272", "r273", "r274", "r275", "r276", "r278", "r279", "r398", "r401", "r402", "r411", "r502", "r572", "r593", "r594" ], "calculation": { "http://therapeuticsolutionsint.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r9", "r116", "r126", "r517", "r555", "r566", "r587" ], "calculation": { "http://therapeuticsolutionsint.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 equity (deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r16", "r143", "r177", "r244", "r269", "r270", "r272", "r273", "r274", "r275", "r276", "r278", "r279", "r398", "r401", "r402", "r411", "r517", "r572", "r593", "r594" ], "calculation": { "http://therapeuticsolutionsint.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LONG TERM LIABILITIES" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Convertible notes payable" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r19" ], "calculation": { "http://therapeuticsolutionsint.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Notes payable, net of current portion" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r19", "r71" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputConversionPriceMember": { "auth_ref": [ "r584" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using price per share at which convertible share can be converted into common stock.", "label": "Measurement Input, Conversion Price [Member]" } } }, "localname": "MeasurementInputConversionPriceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExercisePriceMember": { "auth_ref": [ "r584" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using agreed upon price for exchange of underlying asset.", "label": "Measurement Input, Exercise Price [Member]" } } }, "localname": "MeasurementInputExercisePriceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r584" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r584" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r584" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r584" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r584" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Measurement Input, Share Price [Member]" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r212", "r217" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Organization and Business Description" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/OrganizationAndBusinessDescription" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r171" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r171" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r39", "r41", "r44" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r25", "r44", "r119", "r130", "r141", "r161", "r162", "r166", "r177", "r185", "r187", "r188", "r189", "r190", "r193", "r194", "r199", "r222", "r224", "r228", "r230", "r244", "r269", "r270", "r272", "r273", "r274", "r275", "r276", "r278", "r279", "r408", "r411", "r503", "r572" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://therapeuticsolutionsint.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows", "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit", "http://therapeuticsolutionsint.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-cash investing and financing transactions:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r30" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://therapeuticsolutionsint.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes payable, current portion" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r10", "r109", "r556" ], "calculation": { "http://therapeuticsolutionsint.com/role/BalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Notes payable-related parties, net", "verboseLabel": "Notes payable related party, current" } } }, "localname": "NotesPayableRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets", "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r108", "r129", "r556" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties.", "label": "Notes payable related party, non-current" } } }, "localname": "NotesPayableRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r222", "r224", "r228", "r230", "r503" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r422" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "verboseLabel": "Lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r422" ], "calculation": { "http://therapeuticsolutionsint.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r422" ], "calculation": { "http://therapeuticsolutionsint.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Lease liability, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r421" ], "calculation": { "http://therapeuticsolutionsint.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets", "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r424", "r516" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating lease discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.", "label": "Other Assets Disclosure [Text Block]", "verboseLabel": "Other assets" } } }, "localname": "OtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/OtherAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r149" ], "calculation": { "http://therapeuticsolutionsint.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://therapeuticsolutionsint.com/role/ScheduleOfOtherAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets", "totalLabel": "Total" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets", "http://therapeuticsolutionsint.com/role/ScheduleOfOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r32" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other expense" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRent": { "auth_ref": [ "r40" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments to lessor's for use of assets under operating leases.", "label": "Payment for rent" } } }, "localname": "PaymentsForRent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDerivativeIssuanceCosts": { "auth_ref": [ "r38" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of a derivative security.", "label": "Derivative issuance liability" } } }, "localname": "PaymentsOfDerivativeIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r34" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/OtherAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r34" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable preferred class A stock or outstanding convertible preferred class A stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Preferred Class A [Member]" } } }, "localname": "PreferredClassAMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r3", "r308" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized", "verboseLabel": "Preferred Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheetsParenthetical", "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r3", "r308" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheetsParenthetical", "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheetsParenthetical", "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r3", "r517" ], "calculation": { "http://therapeuticsolutionsint.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.001 par value; 5,000,000 shares authorized, 2 shares and 0 shares issued and outstanding at December 31, 2022 and 2021, respectively" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockVotingRights": { "auth_ref": [ "r3", "r75" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Right of voting" } } }, "localname": "PreferredStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r547" ], "calculation": { "http://therapeuticsolutionsint.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://therapeuticsolutionsint.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets", "totalLabel": "Total" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets", "http://therapeuticsolutionsint.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r157", "r258", "r259", "r493" ], "calculation": { "http://therapeuticsolutionsint.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid costs" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r494", "r505", "r567" ], "calculation": { "http://therapeuticsolutionsint.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative", "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r36" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from convertible notes payable", "verboseLabel": "Debt original issuance discount" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative", "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r35" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from sale of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromOtherDeposits": { "auth_ref": [ "r550" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow for receipts of deposits classified as other.", "label": "Deposits" } } }, "localname": "ProceedsFromOtherDeposits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r134", "r135" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Consulting fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r141", "r161", "r162", "r170", "r177", "r185", "r193", "r194", "r222", "r224", "r228", "r230", "r244", "r269", "r270", "r272", "r273", "r274", "r275", "r276", "r278", "r279", "r396", "r399", "r400", "r408", "r411", "r474", "r503", "r514", "r515", "r548", "r572" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "verboseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/OrganizationAndBusinessDescriptionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfFixedAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r68", "r485", "r486", "r487" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Fixed assets" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/FixedAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r65", "r146" ], "calculation": { "http://therapeuticsolutionsint.com/role/ScheduleOfFixedAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Total" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfFixedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://therapeuticsolutionsint.com/role/ScheduleOfFixedAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r67", "r127", "r475", "r517" ], "calculation": { "http://therapeuticsolutionsint.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://therapeuticsolutionsint.com/role/ScheduleOfFixedAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets", "http://therapeuticsolutionsint.com/role/ScheduleOfFixedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule of Fixed Assets" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/FixedAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionDueFromToRelatedParty": { "auth_ref": [ "r271", "r272", "r273", "r277", "r278", "r279", "r556", "r591" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.", "label": "Payments" } } }, "localname": "RelatedPartyTransactionDueFromToRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.", "label": "Related Party Transaction, Rate" } } }, "localname": "RelatedPartyTransactionRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r427", "r428", "r429", "r430", "r431" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related party transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r37" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "negatedLabel": "Payments on notes payable" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r37" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Repayments of Related Party Debt", "negatedLabel": "Payments on notes payable to related party" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r83", "r136", "r601" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development", "verboseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://therapeuticsolutionsint.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r83" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r543", "r552", "r602", "r603" ], "calculation": { "http://therapeuticsolutionsint.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted cash", "periodEndLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets", "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r45", "r52", "r112", "r124", "r145" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted cash and non-cash equivalents" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/RestrictedCashDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashCurrentNatureOfRestrictionDescription": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Description of nature and provision of restriction as to withdrawal or usage on cash, classified as current.", "label": "Restricted cash description" } } }, "localname": "RestrictedCashCurrentNatureOfRestrictionDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/RestrictedCashDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r6", "r79", "r125", "r482", "r483", "r517" ], "calculation": { "http://therapeuticsolutionsint.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r140", "r182", "r183", "r184", "r186", "r192", "r194", "r245", "r367", "r368", "r369", "r387", "r388", "r406", "r479", "r481" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r218", "r219", "r223", "r226", "r227", "r231", "r232", "r233", "r332", "r333", "r470" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r334", "r500" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative", "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r582" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/OtherAssetsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "auth_ref": [ "r81", "r82" ], "lang": { "en-us": { "role": { "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative liabilities at fair value.", "label": "Schedule of Change in Derivative Liability" } } }, "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Income tax Expense" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.", "label": "Schedule of Other Assets" } } }, "localname": "ScheduleOfOtherAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/OtherAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://therapeuticsolutionsint.com/role/ScheduleOfFixedAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetails", "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r545", "r546", "r576" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r42" ], "calculation": { "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation to consultants" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r338", "r339", "r340", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r362", "r363", "r364", "r365", "r366" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative", "http://therapeuticsolutionsint.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r341", "r360", "r361", "r362", "r363", "r366", "r370", "r371" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "verboseLabel": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/OtherAssetsDetailsNarrative", "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetailsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares issued price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetails", "http://therapeuticsolutionsint.com/role/ScheduleOfNotesPayableRelatedPartiesDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative", "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative", "http://therapeuticsolutionsint.com/role/OtherAssetsDetailsNarrative", "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative", "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative", "http://therapeuticsolutionsint.com/role/OtherAssetsDetailsNarrative", "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r53", "r174" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Basis of presentation and significant accounting policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r151", "r152", "r153", "r177", "r197", "r198", "r200", "r202", "r210", "r211", "r244", "r269", "r272", "r273", "r274", "r278", "r279", "r308", "r309", "r311", "r315", "r322", "r411", "r490", "r540", "r553", "r561" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit", "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r23", "r74", "r140", "r164", "r165", "r166", "r182", "r183", "r184", "r186", "r192", "r194", "r209", "r245", "r323", "r367", "r368", "r369", "r387", "r388", "r406", "r412", "r413", "r414", "r415", "r416", "r417", "r426", "r479", "r480", "r481" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r182", "r183", "r184", "r209", "r470" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r48", "r49", "r50" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "verboseLabel": "Common stock issued for land development" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r22", "r74", "r75", "r79", "r297" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares", "terseLabel": "Conversion of common stock, shares", "verboseLabel": "Conversion of convertible notes" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative", "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit", "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Common stock issued for services, shares", "verboseLabel": "Shares issued for consulting services" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit", "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r3", "r4", "r74", "r79" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Common stock issued for cash, shares", "terseLabel": "Number of common stock issued", "verboseLabel": "Stock Issued During Period, Shares, New Issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative", "http://therapeuticsolutionsint.com/role/OtherAssetsDetailsNarrative", "http://therapeuticsolutionsint.com/role/RelatedPartyTransactionsDetailsNarrative", "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit", "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Common stock issued for land development, shares" } } }, "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r23", "r74", "r79" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities", "terseLabel": "Conversion of common stock", "verboseLabel": "Common stock issued for cash, shares" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative", "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit", "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Common stock issued for services", "verboseLabel": "Common stock issued for cash, shares" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative", "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r3", "r4", "r74", "r79" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Common stock issued for cash", "terseLabel": "Number of common stock issued, value", "verboseLabel": "Stock Issued During Period, Value, New Issues" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative", "http://therapeuticsolutionsint.com/role/OtherAssetsDetailsNarrative", "http://therapeuticsolutionsint.com/role/RelatedPartyTransactionsDetailsNarrative", "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit", "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Common stock issued for land development" } } }, "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r4", "r7", "r8", "r58", "r517", "r555", "r566", "r587" ], "calculation": { "http://therapeuticsolutionsint.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total shareholders\u2019 equity (deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets", "http://therapeuticsolutionsint.com/role/StatementsOfChangesInShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 Equity (Deficit):" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r80", "r176", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r321", "r323", "r405" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteSubscriptionsReceivable": { "auth_ref": [ "r3", "r4", "r7", "r73" ], "calculation": { "http://therapeuticsolutionsint.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital.", "label": "Stockholders' Equity Note, Subscriptions Receivable", "negatedLabel": "Subscription receivable" } } }, "localname": "StockholdersEquityNoteSubscriptionsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r418", "r433" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative", "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r418", "r433" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r418", "r433" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative", "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r418", "r433" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative", "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r432", "r434" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative", "http://therapeuticsolutionsint.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/EquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r137", "r138", "r139", "r237", "r238", "r240" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r241", "r242", "r305", "r320", "r404", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r563", "r564", "r565", "r605", "r606", "r607", "r608", "r609", "r610", "r611" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r582" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/OtherAssetsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UnusualOrInfrequentItemNatureOfEventOrTransaction": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Description of the nature of an event or transaction that is unusual in nature or infrequent in occurrence, or both.", "label": "Unusual or infrequent item, description" } } }, "localname": "UnusualOrInfrequentItemNatureOfEventOrTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/OrganizationAndBusinessDescriptionDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r55", "r56", "r57", "r213", "r214", "r215", "r216" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r382" ], "calculation": { "http://therapeuticsolutionsint.com/role/ScheduleOfIncomeTaxExpenseDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "negatedLabel": "Change in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VehiclesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment used primarily for road transportation.", "label": "Vehicles [Member]" } } }, "localname": "VehiclesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/ScheduleOfFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r196", "r202" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average shares outstanding - basic and diluted" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://therapeuticsolutionsint.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04.16(a))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "51", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e34017-109320", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516265-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r521": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r522": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r523": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r524": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r525": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r526": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r527": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r528": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r529": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r53": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r531": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r532": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r533": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r534": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r535": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r536": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r537": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r538": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r539": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r571": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r605": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r606": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r607": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r608": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r609": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r611": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "83", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126929950&loc=d3e34841-113949", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 68 0001493152-23-009468-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-009468-xbrl.zip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

1K@GX/86"R!;)+/Y \XJA%5:A^B0AH5]N--$T@?SXCEK7'F5D($ M.3X5TXSE"%.*)L=)@[K8&[RFGW\7A5[R8*(#DFAV8U"KHN63^+@Y'IW_M?Z2 MJ.0??G0ZJ>53GP"YV]3WCWADI^/9G_IO_X]MFHR=NCI?63 MF[Q5[U?73[_CRF5]^ZJ]%3.Y0_3YJPS. M;2M9V>A.51=3QZ/]=[._2O+@^_W@Y_)\( >_VS0 CGBT+YJ@GSB%JHE%A/^+P^/',[-T2:VY#_T]AY1"?R<5F 43R M^"\=4-P<9XS[7UES\%"14X<3"?# QH&^D@\XI^D6IAF(DF3@Q0IL(9S3%B=J M(*"S'_?'8&N9#M?6[4+O_^2(M]PYOK:X?$5EOUORN[*1L&CLO\KET^G#5S+6=AH>" M^MF< L!Z^M@,TWU@/)Z.HWPRF>%3B0.VK/:^ ;$4C"?3?"IYP((FZJ%^Q"D4 MQS-H/79JWX:U*/ I(<7G)$7&YNT 9KC.RG]^%7[W;F[>]YG M\ B!PW;OJ*KU71"93K=M7?E849M4(K?JX+[0!F_+2?RW+W2=T:HT3< MF^P1.X\SA^@\C@K[$2MHF4-4T*+"?L2I!9DCKDK)K.TA75Z7,#&GO#D>RD^_ M1E]:1N)EU_4'_W)S9L #A)P*P$VO_/A&QE]&6D)T((X/ Y%/U@42_H]#VHEL M(I/-@L/UA+1Y2%MPJI^0-@]I"]2)$]+F(6V!'O/'(6W)I)\)O6Q%5TM, X7M0QWR36)E=['R;K=4LE*DU_+BR>_EH_(WUWJ MY:K%;ZU.)4V6CI%=$8E;'"M[)$[M4,)<_S"-BZYG9N2MN;$1U8_< G?MAAB+ M+E0V1.)FDZ(3NY,7(9YZ1:]+M[5^/EWO;(/%=S=,.MX4K22?%; '28+/IY;G M#,TAU.T.C=HC[:XC$W8X,CFVE#&7"M86[B<*V \%Q)/"EN53J30O))X[.Y M))_(+,]S/A'#GH^'#?)/\VD^%Z$KZ+:.@'#_7FX]_U[^X:W^I=Y_SK5>/,M. M5LR^*H[^X6 UL!>'X^YS3-&#<_+EWX^3;WPO??^>Z6GVK7IR\IVU!ZQ.3NR)"[UWNBQK,O> X] M'NU_N9YH=!3MTM+[_W )[Z,+66(2!(E@GQX?B#Z\=(>OG7 >4&RUQ9ZBCOY9 M]C9ZK:F,"0,.Z>53@Y#S,U&2P"@6M1%L!^M)Q%DZT@9-% 7K6>;:B@96KR*J M\&+'G#8_PA9_\KP3QXN%EK>3K>GEP(+^S^4E5U&(*O_#U<4.\&*#O-I$D^#^ M=(*[O'0%A:P,HJ?>3JTQ2^&@! P+5%6'-2A[X6> 27(_3[Y#TE55[)L C/O7 MO]Q0D:TNKB[Q5]AR+6->=BKL0!BSS2G08SLQ\;J+3Y7+(,)<5/W+/8SZ $'1 M$%N*]"]W!X*)H?-.1Q2F@S?]Q[T+?_%9W&7P__X',!V&=(.(+Y$7PS0L2V]"@IV5W=.^!(]C#T X+D:29P>*:SKH\>RO=W1?Q0O.'A8^EC"#\?)S)* 4D,:_8$,'8$*(EF MEZNH^M!\-\N=*XTC2DC7>YQ*9)J"D&R.!\]BQW@9E8P^=A^U>["F$;T$))2+ M3.Z2"Z*9FX?EB]4Q&DU47WB1RH6U R&!PD6ZR?H%*0 D(O__721]C*8+V6:( MKWTLD4+C\V-2ETK*8G_XW/H3%^Z*;G!6EW"_B&AP94V&G5BY3R%6MUB>&: %RBF"&#&BCK6++M- J:2I7S?'H3OHE?:_V MA4$^GK*=2 8-%3!M%#!V(OQ&"(,5NS@L/S"7?:36 >:<")) MS.T0H0 !]<32N),GS7'[EVG9W=&WX6"=^JU5ND4X4C^+^OGL@N:UB'#N2OZU MV$WA'BFASY[Q/;A79_]:Q[UTZ/6 "W$QXR8Z2@0+7N&LL"7T)OE"5N#3ZNG<-I*?E=@.@^0<Y!-\/GFTS:BCXVP#L3Z%L4*.SV7B'Q$8NC24YRJ:TW71 MH#WY)WCL9]=^*_2&;YE&3)KWYNQF,/"Y/H-_/^3#FII&0G#L_":IK_>9(#E<_?3)9 *F=3*U!71^.&8/;._4*:3Z3$-;'WURW MGJM]%GLZL-*8GNBU-JRI+RJL>&6)F6>F'NSO7QKW62T^G]\\7@P"[?3V1K Y M3AHJF2:PI'XRN_!#[ MF<^_JKW[FIE*\=G\L9I^:^!N:XPE"'RR$,]Q M=C7A50$535)"U,@W.?/US;(+]\8Z7+36R84=/7UP]FWV^Y#$[B!)\(7TII;^ MP2)J:RR1C6W.6["#0U63# *ZZS5A_P9BLDY182 @F[QJCBN/]^4?>O=1_!F? MPW'N''#J^S"G0JM4/-&!NP''QRG,NB9Q9!<21U&BRI;I5Y@!6:0F'66OCQWM M:3!\^5U<9V;+]HP !U0,UCNP[MF7$P6=<0O?/)];2T'9MQ]L;=QM3T5)\\): M GFA"ZRRD-VJV@#T:]U@@=SB'*?(XPJ)E6HR/@G&3#, G:IMR]MDS#>W&-X8BG>8C\C,WQF8Z/UB%"WM9,R"7P5H0W3 M.GQU'"%[K/ZS M];"W-3XK"'PF$\_YE5UT?CF+=-8XDU(;X+G[08)T[>IWZVF=@H<-\QFF&(V[ MW'7Z[!Q;9HZ(7H35G6F;!9#< #OTTRJ2X/'LK*X%'\TMGSP8A+6&0N'DQ"[J8;$/NIFBWPZ?/)D?NW"'S M%%R/>4?3B'IW8TDC[]S.CO6(INQIM.R6]C"&*NAH-O56)LXF2FNUL< BYX=F MSV*"" 72KV^/S?%HD/J5_9:NYJNMO36TF"N:[J)4.;][8H^^Q[MS>_,)(<^G M$JNW[OV#A=:&^[A]J96#/2PDXQ5;&^LX!YS56'!<9HS04]C^Z+ M"I&-LE"]2>VSYU&Q\86KW-1^-+C*?>V6J]X]E1L/U;O/7+'T4'VJ/E3+C5,F MUA825^OBR&FO4I1>;<4@0"\@HJQ1714U"RP[; ?\056)A$BFP@Z]6)DZZ_Y:T[/'P M=W=W[8+F*$4NA,>O0T5FH6ST85=S]95PN(\0:8M9=QX]QUPW"#;"WBY&K/;OXX>?/YTH_FR>UYRV>9%LUAA5W,>_*&(XL HG ;"AY1G" M#;OREV6R?"9":YN=6IX+CN0#5N@/"YKE54!S:+'"1D;,-4*E;.E[5:X__'C< M9@;Z6MUVVRZHIVZ[&U-&,,'ZGO0=(Z/6#F0%C+#T>L+4U$4@B*N[COI=KN9* MOW:21CW7ZG1 QN94;!B*F] RU1!NWP4-B[ ;?SU#.G.,'7%6QMD6E>=<89T@ M]D(C-S7'R"WI&N48B22K(FZ+#>#RL74YG7>@W2'!^IG/4X=9]O$J9Z>> M^L:7=3I+Q7^8'9 <#B(R;OY*P[FU@10^#GQM,;LRD=UZ!=X\QRR.G\7)ZK5V M8$3UY,GU=OVE5GU-9Y-/9,^;4^VY#-\.H)&O$5WG M\EO,K)HGKD[I5?OU7Q8#AP12'OX7,R$&H-K1AC&F92B2163\H:C)DU\$KJP3 M0]'EV;QF2;610LIO$FU(=2]:I-QN$_2*LV.&'B^YY\)MO9,OF=]VF(LPBR\\ M2!1G"=S?LK.(#QBLQ/.%9Z<,\5=-TW,,#R?T]SW;3KO=Q9UE[.8R?%)8IY)W MW[;L >S']N.?0B;/)PKK>* B&\L;XPO5?GAJ17#1G=3DP]KVQ*9)H$D^E=ZI-Z"\-]%:;HZO[_.I M_/?![V1A)[WNHTK9Y#I2EF#=>%3YFER3T>A]G*S;+95$&KRZXE..@\LVGF3# M)]++P_:A>[:^;#UM^1&>IY'V_.2W.!R_13 5I&'W^RK!<*&H(DE65'U8U1@! MP>9/I.'=O=:+.35M" UUC[5@08C9P8+I>9SB WVJ!%N3,*XF>EQ8!$_PNJC( M=X3E!8V_]A6S_;EC](9Q#[Y?20'A:#-3V'^@ @;UNSYHIK8F]DFNO) [:0+; MWJ#M-3_F4Q$F!6U\:,_MBZSWR(/XAFDF 4'Q67RU]&&A/+36F=ZP"Z,E*#-P M#9R%BWCG9#F]6;%/ 5@CU^+/%AR1=FA[HD[A^.5C=1@*-KJ#+[Q5^: M[,7'JQ;I3=;=]/74DYZ]_763BJDO;R2%'V"^I'I^H.91DP,Y*@"P9C+J/F/2\M,GB7A\[&NQV[ 5)8*VGS3U8D MXMG3[=DL*3ZS"]4CO#L](H?5G)@X@M(1"?AML8>B0&#BRS9:U]]O?BM=LLH756ZQN((^"'AMD_YDUI]+_3'7N0E\-K=\,L06 M63[ESQ(*5/,Q$5?1#6<@8(40DZ*#,7_UZ;[;->V2+4N'K(=@:*?OS+ELDW<: MVJ%3=J)L7>Q=7M))/I4\.6GBW[0M*AGI'#;GV:G14UPL<9QI,@U1%7%L<$#J M_+[/M4O=D5Z]6Z@[;S;@%43;'I]:H%3_)H77V M;7NJ3ZH0J>G5%B51P9=$SGK=M)TB*,[R@UXW%$U2^J+*!%#M[2GU\^IK5FVL M$PR-1>UQY[*Y/A1.1,BQ^5S?A?W]$NZ23=O!".)"7/;Y:;NV+5YPLW::)%=8 MK.?<*!).4@SH-\_?$J\O/X5T:9]5W"OK-RI;Q_LEVV6;MX/DVT2.S^1.EM5Z M+J_4@FD;,<5R L3B1&Z&M=%H?)_7E9>#2829R]#H,Y7)@*CZQ-24]TXFF9-G M-(IG-$C;,0=D\WSA(+-33YWBXTI!S"ZI2RNS+R9S5,N57F(X^)WIO^QX5L?% MIWL"#" IJD*KSFBH.WHU-!AI5I>P%\-C:#4_[1?> JL;$Q/-+B'6*9]U&_FL M3O'M5,EMT2J)AC$"Z>&IX>7FN).K"W*^\_-9V&.YO5.B@G0S34QK[L#,Z;!Z M/#P*$N,H11?R?"*]\S[7^T38AD=G(UHMC7*REMUA'[&E*3]KMG%; MVJ8XWJ@1T'UXB[%Y&L2Q]W>9W)98&%+@$XG5*T+_\+X[$?9EXP8.?#(9T[XL M+RW:J/V%(SV>NF]?JV+'ZMHQ=@\NTX&^GYW[;;V7@ZWSOTH3Z1X>1>^:_UB8+ A_GY_]MQ\T M%9E.PCTH/6)R=V3(W>L]4>/9%SS7((;2_I?KB49'T2XMO0^BQ_OH@I*8!$,B M&"F9\F!1L[0M]A1U],^RM]%K365,&'#PI):WJM8GS]?5/]KE*)\:! QH49+T M'CP456HGOQQLZPF3VBD5!>GMB]R/0"OO 0L+-A46]'\N+[F*0E3Y'ZXN=H#5 M&W!H$4V"^],"=WGI"AU9&417?:;6F*5P4-: !:JJPV.42_$SP"2YGR?? >>V M*O9- ,;]ZU]NJ,A6%U>7^"MLN?,]=K #88P\Q^!A.S'QNHM/EMBN/=++LTH MN4*WXLG9AB=GCW!UUT0BO18QSL]2 L^A@AGO(IYMTU+:HYV=]4Q'NK-[<+,4 M.7Y-3$GLHQ0UT&LU-7I!M&R#U-J!!H6? $&NH9B?:)4_>W%S_.7V]FSH\?N*$(ICS;;U [ M)RFC@"$)F2B7EV7-4JP1]OHQ^CIC@6L0E[7VQ%=-";DO(22$9A/_$I(IH3E^ M[59_F\/1T'[M7G#P&$0'>Q[M8^7=S:%L]LRX57D]:(3A@WIP7U<61R,B&D1S MN1\6\T^TM5Q\*MH=V$HNB_(TD7/M- SU=$[;! R<"\+Y&240^"9 3MQ":F(N(M&I).(:?571 M+'B@I&"-H;+%GD"8YL$3$.T M]?O 6VU@2UDQ!EA/N[)[[@709A M\]#(!SP'9'VH35VBXK'N7:(1JB/D_C5=T,V1"<+TQ,HQ@TPG?8G8*>S\;.XN M('%I^A"D,E;ID#XZBGK$ZNHT@9Y2%)@7AB72 49@T>/) Y+;!ML>VZT D0&A M*.XY,5"0YH L6K#_ !?VF-+:K \+"!24_30O'X@3R%11510T'[FB+"OLE #B MASNZ2DNA+EMH&@H HL(! MU@&N@ 4RX$[D&+?&V:A5S\]@VYR\2MK!CC-0VT!YQ?;ITA%*.E"5V*%!(21# M )*$T*$I=96QWN^"U%1$^&@K$ECC0'(R<2C ,D0;J4'B6@;>JFC/MH'R5;7A M]7T1"%W5.PIQ0E=(2[((R^.ZH.)8W1-1Q*]NE(BJPI8;H&XH ZH%HJ[A&99( M-IS>PHT'T43>)!74DP%A$1I*'2+N(WI 0*\$XK$X*A_0Y\KVTT_C=;1C5U,U MW: DJ/,B#3YV#5U#@\@G&W1B]KLB/ !H9<3]77HH?Z"D$DY9W-\/5U5VP0U2 M6-VA,/CAIO[A1$[Q6[7G9_[V.W49,L@!8O2 /AR#]:LH*TAVKCD+0LG6E%>; M,(* (T^QN+YN@K8$_\^U"?754.,*7@\DT1WU:!C%>1% U-6'J'#QG&Y;?6*@ MZ6A2+=--'0#ZEZ7(?0 !2&?*&/"YH^@@/H$ZZ7&G$=MP/[/G MG$@Q;F7>E24/GJ HA\D2H#U)I+I]:P3:2)]8"FU2ATFUMHFB[C^FW;KT/W)= MQ?)4=3BF9-AVTQ&/J(ZA/*23A9#0T%7AJ#P*4A[(20#5IAVGX _=:H$FQ/55 M<00'ZD1FOC/MDQI&$[83@>X""4\', RZ;L?.%9M@11KW4T2R$3!R+E@&*PJ"FTID95(:3'CH6U/,S M2<A_@KO%M(S.[*29+$#')-.S^CCL/_@GS_9'$ //R;MKIL8_F) MG14U#=@;"5Y2@?4*_ E M\"&<+R)7QTY17+5:Y?K* !._7%I@1E?'O]OQ.P9JM>70@%^,W5)86$VJKBW04>'$]EQ?B(%_U]. M*.0R.2H]7/Z$I]NR@D&Y (*0@65TY5+0L4XH3 M.-S1R>(Q'/J=V>@JKJ6C\1E2?(? ^ZR$S1? 8EN.@DAEVV0 XZ^]6B*35PM*@JY3 F(#G&$U0@>D]E M9\#Y6;7TB&)?Y'!9"C5M&9&Z%](S>_+MC"2- >:*<4BE=+$%X:^/UUD4>9UA<-:G92&27DTND\SPV[BM2= M%D)@=$SX;YF38^JX;0"?/(F2Z?# ^1FH4&#QLGZCGD41%&(BE5:>@X5Z.Y!D MJFRKSWA!')Q)H.['C?'4-#@/=U1RU!D M1ZR@'&/&V$1D6>S3[$A4%='J<8_F":*BE@]*(*8K ?V:)E'1!T.H)FU3/9.KVRJ6 8YM;5<"CA\\CW*S/%3?OC[S@]W"G . M>2E'>%+=BAK(*!8HD'6"&3P6:+5],*O@'X5-!Z25M"+U>;E;Q;D[A7X^]A.+ M$3C?IQQ7FFFWVXJ$?@?\HHWAHC#GKNZEKI^?44O @K-"-.&F(5$'F"JF65W3 M=S_[T^:U.>X"%:&>C.4S2;X$+A[% !RS3U5:0=[UED"BR(+F:@T!_*-)97@]C(F 1TT0[RAMI2B'I$6(QE+=4QUYS6TGUP!<:BW>E2"#VA[&^,04R0%Q)ABQEBQ&C$/'F,@@(D*(E]A<7>G$&0$L/(/L_7J-2FGEGT,P[1]A6V_ ^>"K;-%PU M$@ORDC@0%95MG9LABI\ %LQEX5W 6\3E'9K@*1-5]&+O+)PAZ=0-S>/1 Y(. M]EW%9!ECFI6XB4KFI52-!R %E,7?T+\#:)3QT.UYZ8-=+U?5I5*:,*."D,?4 M:"^"ZT!SW'A47AIB M_H,;W16D'#3*-,D90*FDU MWTSOD1 33:'Z YRO5).BX>S'CXV/CK:(J7Q> 4I0QK#6^"HFW+B%J/2VS\5B MW:TX]1 MK^"Z3U)XMU)X-8O(DTF68TS93FN]R#7:;"(QYAQUP8H<7>I##1W8Z--09(4. M0_K(%4$B!O5".GU'L&2?P#YR=[KOM_'2 MF? $T493@!S5=NY+VCT88-X7-;F&65R.&FG>TR1PM$29()L2>Z6 V(MT/YH3 MCX"6G^F\)FU=_H6UNARR1KFQ"L82)LS>ZEJVT+VIB73:%%W]^9F__ET*Q)WB M89I@W\OZ_$TTO$VD+B\J1F6,9+C.']EV$NC9("-:=ZH1F@[B)-H-69(]K86W M6U;;5CVQRUS+0>^/K^UZ@1O'<8;:MHI5]/ SB%?J#V(7,T-[-!DSD EZX-"O M&0$.3,5"":O(A"FFG&;3> 06Q##'->]GL+/D)Y5H'=#1424%9*(4EP/GR13> M^ACV 53QH?JKEV.% 0>NJYA8W^NHX Y6O6LEU@1APAOM.GI]%[#KUG/>Y./9 MKUYR=&D7ASBE0.\QSY^BR?!:+#%&+.,I-^7['1J*1=/%V]Z*)TAEQGML:[AY MF-8(/SL)_N*(G<=X7+$T=S50>8,!#"S;\9_*G*X2V$J*Q=RH] 0/W5FF%-BL M@^/^.-(5#T 9B%8<65P(FC MWW'Y/1OS1Z'$"L8,@EUA,'U1W4$A M<'3Y$;\B?,]BP'A["0MY (T_%*M;U!P/;UY>QXU;K?]Y M^Z[9?:G&91!3];MVI6%5?E33.&+"";#C2*".INS:5[ 3/!RK$R%XP'6P,Y_I M)D2$>6:+C1*7361YQ\/J["Q3A%UZ=TN 7;W8K1ARW;3.,X).6J:VA+UHLN8 MD["=;)VVCJ(8E5;6EHAUTZ#9.LY"W'7\FIHFM!&[B8S*C8,WI5/OZ]1^TM=T3/LP9DQ@=MKA+%C$]!Y[) M$IRC_I]C0E'^9@PJ>B;:QXDELW$ )U)9NA')=TPJ3J<;EAL5R,_RA[U02CI1 MSEK[DCIXRKEVG5"KDTX@*H!!7HF1.G"25 M.7B2NG=U_]5HRC5XJ/OV;UH#\8$2#&&]PTT@([--TXCGD-@L16UG'-(I_!T" M\@)['LS&\S.P&S&W?*#(3@HN;* :M&M-WTB4V:8[W5O$["/%['TH'I/CDLAC$JF3A= MEFATE.;[MRDY*[1UGXTA19L%&EG=P5 W7N ')+KCVN-XIL7M-,7CMO3CGDUM=BGS!@YW(DB_C.5_&87 M,U!;R'JD1YOMT O=8^W*'H&TT3^A[5RH4DZ3 MK? UR)I]W\O*7GA^1M_HV'BTH4N#8',HUG^%O97*#\QCH#5 9A\/!W1BXN'E M/9662QT7ZX>*]Q7:0J1.;2&VTA8B]P>UA7"KVV/+JS@U<3@U<=CGD+]CF>>[ MIQ*]M4OPN+\Q*HN5I/*'8T3$\6YAW38D[))\?E:G'LK_%7MP4-:=Y#\J\<)& MX#'C^/+24[W=Y]"G%#79?4)@!E=XY-Z_:NSP.:'E*+7S#5$A4%2M*VQIQ=6*@B.#^SB3^ M^D#S+]E#L,C?1+46S%)141UO\-\F(5SYC4X+.C\K?OCH7,UT4L7=)@SP/P: _'@8E;;?2PHZ8;)9)&\WJOH<&P *=K.5DD\(O MFJA:(Z_BC0U28HL"I800V61U8;39?L=IM/(_F42"3R02'Q,)M,596J^(VA!M MNJ^C&FMRIT7@X?- .F?%EBH&TNG)05VB\ON#3: MG-&F;22\?-<)N',9%^YE*YY[(ULPK6+:Q8JY10L^/UNZ8H'W]XJ1H]-%@_DV M6<,/UJ)=#5Q-DWB\![F+"-"8KM*T]FSB+V0KS&9&1CHUE-[;P5'56!*FKE': M9"*1G1[WQ.F0RXX/1FZ@&$SZB>GM 7%*_;J^)*NV [^)M%F^W[^#=6ZEZ6"B MB;USZ#O.SZC$,\BS\^3>/$'ID"\55G]G/O@M5JA@\SH^N8V>)J#RG16L^@%? MYO3AI\">GSD"<]6GNXS)G"6TTFPH.F,N1FQ@%$L<F*[6X0ZONJSGUMTXJHPE)G- &\YMS%2]-I5 ML2;.,BUA]VK0<3R":;/Q(-A/RJ C$*A4<0G4$1P=#-VP5F$H#-@[_!9P0XW& MLC23'-6>'"<917;HW]/#W??F(Z&12TGO]5 9.?GV_\C &U>QU3:\D]H1/3"G MQ!=B.N%KIX=7#VO\6+":399P,VJ"X6(Z8=W (]0'4.=&NLU61'N8M8@?B6"S M@G!1IZ,F?C)K."$7A\[J+J% I0;/ BTEI;;!R/ MS0DH7*# Z7".=@A]!HZ(HO#0X1?X%IP1)P(,+ ]$'.B*S+KCT<$9[MR_() N MBIW.>VQ:(^?M(W)3L2>.';_@#U'MX8@96KSLH-BQ*]%9X?$[<[R:_APZ14.U M5D=5P"EUGMC P+/\O!=GH /K\D#3I$R/$ICJHL!6D!:B\#U$^PX;9&#VFFU1 MM;)!&9#JE>[!0EEZA T6/8(R<7XB*U@V_<:.'[E'',>E,E9G\IS>[.SVC$CX MR'UQAYTBB] &D-1&L>@"/#75?2\R!C7& D)#MZU+O7U)!8<[$(F"37D#21^=%;VPLA=&TXJTRG@UUI-3Y ,7EDSKS9.TB#[Z=\!,:QU^FRS2;= MX!!(RS_Z/G*_X'%X4-(9)&H ,I80YLQ!I_*+EJV[7+W7$LOC;UY2 OE9U&3\ MI_QJXTPT]#0O+M44@CV;HMS?'*=NE"_%WE7MWFB]FPK-3'/\M?!0'[Q MTA>?$ <@[X'>\2\N@(Y3G>8!KV6B@---+C6I1=]5.EW0,50%MA(;6^!@FIX_ M,*Z'JI8S"L[J&L3K3HS-@ DSZ8/^/:]%.TM,I3WDB4\E[T22><%[Z@;Q,$9/ MA[YNT3G$V*+%"\P$4FU9TUY4I_S)IZQG!V>@2\=)CG4;%]+GT'%^)H[\H_W[ M,%+D]I" -Q(1,V81$,6R6< 7.W533XPW1*M"9-K&Y)H]@JMZ[IN2;O1U=X:K M4WI;N:Z6W+I;QU4[TZFB,B4B\9XJ>VF1*H38!*+?3_03@;X43=.P+B_O434O MOBFF\_E6?%-Z=N^6IA(TQT^?*]E$,?E4)EY $E_ <_@*;V%,ZUS6B"$4LD7] M(!"BY@1 T5LP..WH9YHQ)%DP:5[W!=A.:U&_A(V%ZZJ69U5[J- /IRYFQ,,H9W^OY/6SOYINY+8!6;O Q#Z PNEK< MYH/5"! VT)Q-&PU@'OOJ6>_!^HI?M:RZ1O!B;3(98)1YMS3'W_(E)9_I]!]) MX=BZ?Q8 ^L=G^6?*?OR6)CCOEBWRW37W/FB0 U@')7VB&YT*%C?MUH:)U-S? MMND.$FDKAFE=*O!P]A<8MDX*-^\.Z*U4*S5/&0"]#Q;T0JR/7.!UGM:"7F?R(,M MB'5#RAV;D"DWQ\K79_WI6__1% D6C[O+/#^[\8=IG 3.SD NGI_)WB:@6XZF MRKD&$39&- D'IA^KI73$";V#R&ZW'YJ- ?>QZ"-M41QX!'K2X(=\'[W=LI3XG_W[K<]X+;Y[*@$YE0 =9!A1W_^!3NAAJ[;F' 98" M@Q8"C92CCC]'S\8N[@:.>E1'[BS%$;LA<)67^>T.N*13BJC.TNXM6&]D6>HD'-0:87DM^"!,B:3=4$2#)OG0 ASF4;GT'"I8TP.,_AX\ M'@<-,ALY-C-H4PRG*=;>!YU2-,?,":3A6%C=H,)6ICE:3AG$U&-9@QV36:1. MJB/FR Y8U1S-H421X3^-9>3S4ZSA]!AR'DXGA[H^^<"0:Z>$@/*:D_3ES"2= M@(IV8J!#>D$.,3<^A]4A- O'F]? LFQ$OTVG-W_5!^-$JK&[:@-":W+[ \0Z M.9@8MZ@'!$N#-+X'EUJ8EPV)EE9R/5TF:@@Q.P4AV+2,UOE,T\X'YJ.EI,Z: M1^&1@0/F//^--]I UQS9%Y@DYB[EX7S%KTZWC C/(L7TNEYH3RV73-H2ZZ%-B;XL5"3C6^_&O)M^N(3 MHN+\C"(#9:+O&PC@XY1G=\!K">;9A0Q?#=H1@8 I3>VB,^*GLN5X-OQ6P2), M9GS1\5!L1*XW)(J.?F)-N"31,&@$Q6TMN>CI$_?CR 1#?Z-U"6;PW&\1JG"Z MBJC9!7WB$DM)00S0LG+V USQ;J*ZQTE[3'AXRAK6F;PI%FMT@>>:XV)RM49& M(%&P)5S5P9FP"X1DT MFC?1@;E%K"%V2&#Y TZAL0+KIPF-)K7F^2F=4W2NOF1U)X[ZV_.L(:!'!_9@ M@;-3HP(ZDFG:O3YS@3AU:C/O=I:/1*ZP-M&L_LU?L+>ZCUS%ARX BZN=TSE\ MLI/[ZKE5P/P?<2J8<*K?R2,XER2PXJX"BK,A=4?QSR(Y"?<5UW*#.WA^)GC> MVZK6MRVO-0(=U8VM/EYMW:+-05@;8(U%?8E#>JS07J$3$] =1XG,#%(9-?98 MSG"0W*DWXGU@\AU217*:*OYFJ0<@=+09BJ"A1>HGI7=SP@=*1$2AM\@*UL:J M(R?WP?O4PB;'7GT1E>$S @I]/;#>3I>C);8J9J-J#$A:M&DT?:)/ ]O+0YYIJ;)DV8E!$@J2!VT0L$P]!96!>!/ MFL@*:;V-=RM8D3:&JQRKS!IH6I_F_G9T&F M45CL+U 56Z2.S6EGD^ ZFQ*3T4-L9\1TQ%10(005 7OQ, U6U^9X4#^>GZ'Y MQW*(6@1["$W,$V !"@H/.FYO%K_G7>N>VW> -:0ND6V5U-JA7L^BY7FX'G!_ MYB3P%H*>VW4?V1QG[59!_SZX^?E3/$XW&76A^+:18DZ%)$(88.3I+",B&MCE M#+6K^5[>WI8*1NX:8V26F>9)./ARF&/[#B;:E VTMS6G,!89/TF9L[-8+FLRW(+.1 M9=V%4:_1:?V=3*3Y9"K/)S.9#Q=N7J"?].B\.X_YC5>L,R<_0UN)Z4%'SEW) MOWR\P@7S'B[\%99Y^3_>0[WP3KX0YCB_(Y9/(474K3PJN77"A37MGDBV@5%I MFG.$HX8? ^<I6I(-(U4 >A6M0V\&5SZB)+3'J M+#GCZ#)-@INHLH:K(V8PE#O-N[*E?WW]?O_Z/% ]WHV&DXL%>Q\?$T=;\468 MZB8PU6V;X62!3^1R?"Z37)MW7"%79$N ].\,"$9R\BWY]2ZEM; MR/Y,U"2_6MQ?_B(:_7M_1!I<77RDBDG"_^_B%;@J.R..*I.,[RJ MFH1)C0145/KO(MX:9GNIGXG/Q>^ME,];ZZ!\NC I(N+VSZ?A.-L]QQ;2?"8A M+.784%(.(\9M,/))JY3G6WS"ML_=\DXLNYGA'[_37WH_%>'[55J(8-D=JC6W M,D=&S1G: ML;X/(VZ&NXS!8^:K*?S,79V,N*5&7+P\FRP(/&S*89MQ\X!(,HZ::_$DEZTB MN29+TOLX6;=A>Z/&P4HQ6TOE<%X;?[E)W$@9_:&6]GBMK,EAIM**2STD:VIE MQHA:N!:!?B+'R9R&,*%%3H&TBF*A.?[2N,Z6/M>?A]-4FN7G31OZI:_MGY]KZ0N/CV:+!'/6]V[ZBS* M_G/8@'N8/S\;LD%!,B8S8YXREC'J@51_$3-&Z=QLGE-Z?="4W684K,**9SUZ MG#I"G$!%-)/=ZLR?9$,N)J0 M,IWN.R!NAJ))18ZAH/ !Q8NH([>N;KI=@$;8L-R3#(DB0\JB@9%JLTZ,!LKW M*.W1Y][3'(M/YGWZ850J][K')B6*S?'SDZ@]#M/](4E>?+HC%I,-'*R3HPL] M5BEQA/V]T.* M2L%; +G;-!W;'. RIZ]U1K'2?@ML4KVF]\"PM+"@F=8_4P>]3&<<.M70W&2/ M.O0Y(3R@@$VN)M"O@C:=;&%#B< 2.:7M3^":NA<')]'K<4@95NK#M=ASXOQL M[NNHUBDC2NA@V(:"KJ AH8]R!35A@A^'J06%O]-O ]_#L(3JI1R.79&-3#\_ M,T&XL7K$ $CSU^,BP'$/T?9Q;(@J:>-<9[^S!Y9J>^LX*DXZ0N;';K$AI9\3 M;5>!>RS84;ALXKU+*NS\1F_7@0.M&-CJ_T"9%:10'!0IMC.N_U"7]9P&,K"]MR M(+!Z5PE$/.A[S(M/R6R.%U)9/A%:*>"TGH/=7S1$;[O;.)/M^]D4\K=YK?SZ MK?-^]G'=K-SP72QD^&0NQ6<+YF!AL%\KZ(QND? 1G-NWV^Z&SNMBNY M [-.@F?73(\OMST7.X=FI3P]/&E#YG<@Z/?L\;S&#ED2RRB OU6"?Q0UG. ' M6S)FF08+'1/7$[TW5WY:<_QTM2H,K/QDB.P-YE6]UIG?4HJ:#@=5&MHKI)9 M40#AY 8[38:V!TY,C$M=SHJ=]B3WT>^TY;1T=Y9\SZ 1&%^>P5X0L7V2A@A9&-)J-GD#BG$KPR% M6*(QXC0;IRP0F[5[1.'D]EG"":J!YSBO1%\0L))BP4+'Z"2C'22Q@3XM]Z"] M_(J-$O>@]X$]4YF$.U?1!]_TNKU]UG5YJ*@JE>PU;"_XT9V[Z%_NOID^NDWY MRSGAJ6^*'>L(B7M0@^7A"\& =N#<1+MI#10R)*R;8" ",:W7D: M.&9&,22[AT81ZY8HXX0"XKD3P<*:['),YU=@[RW6P!:!=!IP!162;>H-P2XL MP9?4VM/2:I$F4;__^NLEG?VNUQ7?'@\!>:EQO1""W>D6R118SOD%G?>7*1>1 M43FC;J1^MQX2WWX^"MGNKE$91\\)@4\6YN+QI(&LHX%X(JAF7"MF7S=%M=:^ MT;4.U238_E;=F:_3&Q\E*Z$8U%FV_[;F.'-WEDR(_A+I:,'06:77VVEC\3, M&E9ZIZ]73J3,:!)X&SO756^KW=_H("&F'8!&H='Q61T;XXET2)IW0),W5+R< M"MY[&!"&YW3=0+.AI@P9S61IRXF^TY'O"H MD*C;0L,.[JAAH!Y#ATZS&0IM51_2=8"F9;(.SQ.(<=22H'L$5#W_M2QH2,./ M !M/M2QWKA-JG@X8$C[=>OA'K^]WMT26A59KC MIV^)]G7C47A) B[<-3/GKKOL8Y7CQYN'%APY$Q1SIK,_5!9WG>WA6F +L@$5 MC'8QH41DPP![?5US,F8QL\% "\UVQ\Q0&:2S<37A3V:3+<[/.F#@&6C-RMBC M&1V^S$AD"O@IJRV2NEJ4:1S0C":))E(!%M_9'/?'/QI2ZUME])H^-A%4:HY? MU9*>Z7?3FM"]^!18ZTGN[#S'Q4<^QKQ-QW/E\#F-42L:%J 2^2,7N'AM1PQ& MP&?$>YWJ7UN6;>=V%/"[S *XU%3V)F?LG$:ZKCR 71/3()SJ$"CO<9A M 3HU )U]#(W9Y .4%N'NYOA[\O/CK[::3YJ'794=[L_(9+Y7OA9Z-U:M<_') M72_3A0-+/M9CZ0C=&G/W@%MV.+EW:>=0NU*K\:^C3P>*-L!BS4>!#?%EMEJ8DDAO!;X!P9/!4_M\32 ME\S1Y2Y4FF/0I!.)WN JUY#1L8R+/#^#9;ZS4NG#!GG" X2>?5MSITRRDB(+ M-X3E'%-/?\Y) 4AP_U4^>$Z1O9]:A0B"]USG6F(&'XMBJ%*]X]+YT$?013QJ$M@1HJ*QX;(^ MH($T!U&CJ11&WR!^FCK >'5^YO6QX.[TCP!SX6,0@$>*%-^5C@#Y8X7<_,0V M0ULZP8.0;A.#SG@5WX+1CHGAG0;Q/7$RPP.=^,IB"'@GYI4XG65PV*=E*"W; MA>.D/XV)$% M'QBQL9)Z6&9?-S"/)H@55YES'AW(_,"YOP8' ,.1#[K=HT_TL'ML^J!3&D6' MJ2U?)A:C!<9/^4NC<2QWD_&GR=4XY77TA8B6'ITWJ$N@=6*N;%CG GQDW] ' MBNPDSCB$'PJGTN84"^_HZ0:FZ[Q@23&-16$JC%=[Y\H%F@0$OV#R $TL"C[+ MG1GJ$"B& )T,I?C[OK@"-[[&,JLVTLJ>&FEMI9&6D'B_G;3V2,[;5.E.+:Y. M+:[VN8@CC7T Y$A.P:G?M,O-%O;G+')OAGF^.LX5"J?)P5^\,+SXUL+O$Y17KR!#$P,F&WVDW M(1?MYV?!$"GM_>%TK,#C"^PA51\19H"XL["]FN#@2&?:V2,X/)T:1L9 00L* M3!="L_)08^L8Z.VO $Y8ALVP ];"QF>PLZ29K!*Q%!Z7D<0EB+C&+;!!W[D*DX# M$98TB>(&C4^6<.F!>7Y&X4205H&F,)D**)3.C67*0KVR%.BHF@:#;8KKE\/B*GJU:"@4$'X4?<$%N$:CI M@,!<*T"0BD2U.D0S;*Q!VC:0%%I:[)$G3W:48_2&@/U/;K 9SY(4H^!TJ@5W M-WKC098NNUWN[_2Z:='\>(36^'I$-P9R#4X^BJD9=CH M[@/9DV7R#T^'J<,A>YE(\AS;(.YO=AKDT\D/3,C@."33.6- 6L QAD)&I61+ M34#/;P=GEVG!+_0Y3)(IF(=.6_F?GYE=0EV")KMDPB](\^8EW4 'JL[:=] > M_I=Z^](V)S+AX6BD[:_@+M>CATXX3->&+R_1 8L& O/]F:PR,+#0\[,6D8!O M ^>5ZU'VQ*GK(#9@.:^ /XNUT4+I3T' ,C97\-.<^Y[KRC>(9>B^#QB'WM"^ M4X%L?(8?/(E=M[+%H]Y +4+J^P23\]5)R/4<9!Z M;;+\12PY/-"%B>4+J/1P]S,X9]VS&'%PWE@$!&5A'5^-.3VU#KW1NZ^I5(/A M>Z=RKU3KC$;)\F/2[P%P,T$A'E^$=_J9?!E=0ZW]:+("H-!7IGZU;]2GXGTU MX\_IFUW[LA#VG$5N9PK$O)#U*B!-H2)>P/)\5@C+IPL/K7M)"]3,G\E4G-$X M%@RER,"&6BTQ\_E>OR?Y@SXG]]8;6#0QT0+_P?HCL$Q0#ER#WJOJ:%_,450F MZDDC/Z,Y?OA>+#VU'K^J/PZ^[R?S/*4\S].4&I,$VOHA].['R3+WR=FW<#H./2;RG\6;AV?S M5TM-!?.>@@3 .3;3)?U _ =&R']:"%"\PEI(\(G$_+PG5*RHE]5R)ISU==!C MF)8FHB-6PQ8+U")'1<1PK@LYI-VBKB*]I>K<<0\WT-9ZKN^USZ8PEX!E_R$7ZYX]BT@[$OB8 M=Z.8$W37HS=00^*KK1%.R%'5(,4S/P5<;3O)IS2L:]$Z*=HZUE/D)="G@6PE ML%QXKF\;../50I-%=+LSCGRG",>\+?1=R01UUP@?9\[F">V%"/D]; MN?+%S7K/:XX%(W/_6C:LQH-T')I+>I'F4JD\ZQW#_#*4Y8M/SM(GYG,XW6(F M#M-C56D6DF\<#2Y7H+"EFG8A/=$6;K-'(QD/&[W2[W19.&Q[R%F1%Z,QYU*E MVSO*=8*T=?.= X=\@I+0;3^ MOPO0+-U]3!>* >WNAVKW:K?/J<]9:?&@U(F\NA"PPM:T\L!:9^SNS.-WBIY, ML(V5E:I57M1NAG3C1X^P'?1$GDTY/_K5X1K.;^1GZEO^9\U A.W7YPGG&5(&>A]@X1A(+Z3R?":V: M"E]-Z-K#A<(Q8W7#BNM"*L'G"\O'G4?&:C@S!J,TSO*JL#H#8W0S7)BY*R<+ M;_GJS]^Y-;AP>E;Z)^]%BX5-R$F[B&8B;ZFKND\O.Q8>X86TL'0OERWQ@/&S M*;7GBO\TZ:V[=2YZ%3RBB%> Z:Z57,57/\,\=$G3J".K%8 M2"[7=:)2T&I/6H7&)O#>5 ,L>GD\M%P5K; M$RXARG,EQ*1CQ9,7#R PK(# 2"0R@O5(A.O!.A)C^E"B1-:L6GK$%JH7L0AUP &YI/9<(2%B+@>GW!\$=NU::Z0J; MIQ*K"XE(6^4)":=TSAGDO2#?I)AMCG\.$P^JU7Y3R<%G..QS"I3; )>VOP5Z M\9K?+D\]N9H0T]$?TQSK>36=^2Q]JSP??%M0%L/)S(WA *7UJMT?@W)/NTJ* M%Y\JRIO7^O=8XS3A+O =TMZ\$$PN"L4%Z.S+Z^]:5FVG\_G#;C9"B69Z!L<> MXRA^4*($UM?PI9=+FJ3^T(T4E& <,!EW.-;HS%:$R"GVLK/@0C(XN.Q;LC*H MEJU:,7.*O3#T",&NE[7>K?*2NDYV\J?8RSYC+^DHA]IG0S=I!F1W^;57(^Q3 M47Q3S&;3+V(2-?F6[@DJ+/:7?+5J9&Z3<4=N+C[ABP\WAK!4%:&(7V3=NBAN M^AA>V^!-9?AD&<>'P,3XWO+H#%G\B7452B>FR^==AZ\%^Z']-*NL$ M:&="0^[C]QWYV)A1)_&T+NED$GQ&2!]M_&ACYCL@+(8SW?5.F([-<2>&=Y7+ M?9^O;]Z(EJC?=6-*CYC%B0L+UQ4->2@:>P_B;LRJ<["[=J2)%U)A<^;^$);= M,C8S?&%C;(:S;B5.UG43G6KMMB*1BFW HFR#!"]W>?C^-E>ZL2K#1C*UQ3C2 M+$88*%S;A8554;O0'!W=N5S,,-U6;/3Z>6&9W/)C M[92-LF5Q=GR[&2[C$BO)N)Y8KQ?+=^-N^WMSG.S<=<8O%OG];1OV^D1>RM$< M# ML\CG(J*IW%6;LM+LF0&^&8^3/^OY+YGQ[\Z>#_3 ,K$DWUOG\8O_OY<,/]O2 M_L:21P;[FM]B?NF'TVYNLIL;2BPA%\F)L^INAHNP;)3#_(YX*:B!L]RH9DGB MQ_?'!HG1=3 KB))NICH#=M*3P..DVW>>_SA_DV*1+;D4G\B%3?PZY:AN;8\V M36#/I_E$5WU<:NT$N M'&<8O&W1],)**95]_'W[4[GRIQ<&[XTZ6B]XSPX'%";X0GJVX]'"Z83%Y5B: M&49(?MGMK]>9\MU3,EXLQ3!O,,OGS2EO+D=3!-VIF.>?9N3GG<(3\UC3KJW55?RKG+SZQCA_'G7.^X]Y ;L9R MK1WL,H4G^+S<\Z I$.'NYCC_X[JLO'YN#!+J01,<7<)!)I^GFV--U5+I._VE MG6I%2CYGK'!*/M]Q\OGR3/,"YH(>:59Y/J !OH*I_O#%(K]3+Z>L2D#U M:VGU[*_V4_MK2CUEE>\SJ[RTH*//G:Y)P58+M>+=^%$H-<<_;P?)'^W![^>' MV!/#WV=+'Q^S<3B;Y42>S^9B3P*_GK2DL5VSR125 MN?SX;-[HM]7$8^5A&_EGGYRW[C?&.6_I<3!,FA0S>*1+M4SB7W=,NZ^C9*- I?I3W'<5U0(P5,#C_I(A]?:D?*]U$K^$ M4T.?+43@0G$>$]\+:3Z;7)WO_^0 :?3MV;BU%Y@4N=538^*)C.::XTKU>^_Q MZNWM^7ORH'VF\8\==S'I>\#)&YVN\RDXS*(N=H# &N35)IH$T*5S;(P%)759 M&40_F9PF$.X56;K*E;R%RWV 0@+M_EEDSO>[6'H_C,P6N@8G7G?QJ7(Y,?W# M0=6_'!8._,,5#;&E2.X8$$3GG8XH%(3@7?]Q;\.??.IV*?N__P%4AV'=(.++ M98L <\+#^W2O'#S#PAPDNQL=>$3PS0@2>VN ! Y_U'WL_+&CR-.! _[PI7Q? MK)WB%V$;*DIY$=<[XCEVD4+X[6!EO81;FZ.!RVS M56G_UI3OK8-6/;R!+.%CPW%@.&:IZ!I!9K&&NI.L0J?$PH].[HW,]>#)777$ MZ3C6'F.]0!X]-^[K/=&=,&QQJH,X3NSA8'M.;.DXHMT)&)L'$3&^;HY_E*R; MSM?;X=55:EG$&$$&BN!*P<[&8!]^ ME'X_#^QN)J><8K#[C,$&2P%!:U$L(S'BY7,"KR07%X4?]2QUXU0 MO*D3.I/B,Q%Z?6\8@\U'X\A _5.PSLDO/@SP:964[WX6Y<25ND[.Q/J%/B$5 MAV( UN,/C"RI45M]^V*I_\GD>2&[>H_Z/[BX<$L;MZGK.\VGSXA80!^3*Z_OE0:%^5:X*\KZ!X>_!X\1OQYPM3*N\/+!Q)S" MN*G:^$75A,_E8N7QI3)(2%FO3BYXK^NK,U, @AVE30V:M%4U::_35 MU@A'A850X+DAX:A\!%&B:);.B:[#W/>E\_@ JO*FWB M>M+KH >[#GCV-Y*R C3 30>/4DEV61D#Q":0AWN#H[/14 #\_E64%:Y$X/6* M2:6@#;_! IVWR\0$9#);TB B]>F7'LKU11&^'VP9% M8XUM146X8 D# O35H<( 7HI$=&W8':[8[\,V,SGS=_7N^@/%:@O7?7ZFX,(! M<$"10H,SPZ[.=478G18A&GN/27F9DT2\$.]%+/2(U!4UU/#AIP'#HQ?O_N M.XS;3G?]YJ8$CQ$MJA1I!.56VT8R)6]$LI%( 0*5T4I?A,<2$)9#W7B!7RA# M ?O B:#C.R)(-ALU:+R$WENKBPK>K?]7:[?%#\ -R')>@ *S9(WV+:G)!A MB_\(^,!WJR,>UMP@%N@)]!G^TW!%$R(<'N3A,)EB6N%'KA;R+17_#D:G59S@ MF+2&I4LO57K=M6T U'786%UN=(']P609TI],1UL$-9%IB_#_J4#+<&-@=KWC*=+JC^XQI=.(4>B-&[)BUKMIUJ@#Q\ZD#B<-NI M9AY:7_)OMV])K;!,PXJV_'DJ:_(R*7A_I=R^D=&6ZUR\9#$1%;CJ726@N#'H M<>9Z@4^#$9\JS!KQ:,8%$L"D8*%DE_1>3\>W ?+AG 8931G?FM7& MA2"IXOUU,#GIS''I\.GP11_;DIQ_-"5E*1UZ:YOCRSDL"@/3H.Y26>)C(IF8 M[3>U!P+K@W2E1,9[]C2*8Z PJEV(3-9SE-PF%0SB2&RPMM I%$Z+Z>5B\PD? M[4O-?C_I6=I'(CM_#(6G5K_3NKM=3K-1<'#PHC,YW_8%Y3R!Z>AA+M =DS8H M"R%&US2%9@(EUO3*,KO00^ U?'M<])@8?OULCD?E&ZE[$:V[SZXI"[-!:>:: M+([0?4>TB3S!^1MQ,9-QF4K..%=W3FB35OOYV=;,=M!T.9$9IZC8W]@@;^'A M77A]9[3,%&?&_#9L<6Z9*4YMUW"'R/D9+FY1V[8%_O][T@,;'/N)!QN54I$I M-&7KUW'QI?4\N+HO?+]^O%(.DR\O32+](]L&LN1TKZ4U=PD+\Z<9= ]J#JXH MS"UW?E:DC'9+6229"1B"4WY VEF)LX"4S#9A#IY-78-^>BX[J7Q+&EC91G_1 M#-\4_-.JZ#[\!AX)5.[>W)0EARU2R;3#%JED)CI;.(VPG)46-7D.@8UE\:?Y MW-)?I-\O$>DY=9E,>W]E7!*-^,*5CI!YV+GX1+?Z_"R9IGN=.Y#3PW'HG)]U M0?+WF".50Y;#$HF^.*)D 70SHV$7@LV-V77F@UZ47FTX/*BAC=0[)5>14AV>8^YCM[@&#G[#59__5^SU_X4G#8BJ MTS[7QQ4665CF%7]#V!M=ZWB:\_]O[TM[$U>RO]]'RG?PTYJ6[I5(!AO,TCW_ ME@B$A&P0(.N;R-@&'(Q-O!#@TS^U> 7;&&.#26>D.TT27*XZ=>KL]3L^.+#. MN*7G]]\63.?Z[N7V=C8]2_?U+@O^M>@+_TJ_+:32R_W#T_/[_?L[;/MI)W D M=$L2<"?T^KXD%FR*9QY4,J#!P#O0"[I*:&A0#@7QK#(DORHDM])T>1:L8]\G M=N(.LP"*P4[ *UAA N05OK.G I<:@IO %Z]HV'-7*4Y/:T@J.(]07M49EJ^@ M :Q4 "J]>7,=.BVZ>_NHE=3"0[VSN!$<@.$];64!ZTMXO.<=IIU+ _B-*HBLSR/ >S^ H/0S^X4 V44#^LNKR V!4 MG4>A%WAITWK6RZ8BW=U-T!>AF'90 A(TH(0M-@ZXI%I:^?7J=J&)%@>84\(Q M)">W<^ E(;I,^"THJ"8N0;[P,]KI+!W$(49I#;.Z?[3OB7V0K "!$,WCZYC M(^/=/N6U6I&?A.'MD',?8,YX^V8'UV/Z.SW!OBF*L!0 E&38(N+VNRS67KIEI[L4VW."2]G8LUG,PX)6MGN M6 6E:0UF.:$K#=E8,>G&6,X>!NSB?@=[JR>]32[N'U MJ*B%VHYVK-%\DC_HJY?'>MZ]8ZPUEWUNER=%?OP!'H] 7P+1YB?B'I/^UQD+K$<9CGA, 5XMS E:Q\YSYC",)"!9HO,-D / M7KMK8F"UQT<CV@S. O8)<5^%1/X(PG96GYI>;(P D;\9K; M5!T:X\AH^R%M)Q#=9 Y_Z>8#4RL:9% +:V]Q.:A,155[[WSK&:/A>8[X8%6 M1J:UZ\P#7OX)OTGF:;2%MKO18T3(&( 11%VU]' &-O4$CAH<0)\8:^4,M6R_ M+IQ^ATA>A.D3FG$F6$,KP+UQ. $X#VI^0W#I3S .S/AB9"2*^DG8:L6J\95U M3=48R=Q?TZ&"-B7+*CIV)_&8QG!H3X$HI+,_3WV$'LX[6<%<9-V@R*05^U*F M/+1;/.[5$,@)]3)EG-VFJN@0H+*7*C,1P!.X!JJ-Q^;JLE+7H41O&*=4 MEQ8WK_.'44LI6Y*T:AQ0+'G,U<(=ZZ,I69)EG56S\2)W;-RL5#E2!=A_LY#) MTKZ-Q&SYABL.*BQY1)SL-YJE\KO5VF.TB=Y/M*E(9BDYEMBL7,MOE!3(0V][W7C3] MX_F6:XXH]][[IP[B3G2MP!8DS1*Y4J;HSQ+^Z:W\INFM!,[J??.ET:(?YO.1 M$-=^14MU[6:OM^9L,TX":[FS;68'>3&@+I?WOKZ 6T],W-NO3K\&'0? M+VX:6>$0M]ZYF)BVW@LN,5Q:-!LI+9J8-J\/J5=F^,KPPC#&M&AT!9U@6M2\ MX.+*BQK@"G[WZ%83H\M6MW]B-+$]J]Z52MWSNQG?Z\>5&(USPPXZ,>K(B[J8 MJ$"B--NVB=+CH\ UQ)HHG?JE2$T2""AIM_L4*7R_F2-U;?A.4J1H]>X<*;'; M%"F"-&:)>J7FSF=7'[7)"QN<(-U- M,C013\D[&5JF,U0QEREX(+Y\YT)3/N4:O*#.:.C6O2@P/4$4H/0[J#4<(-F[ MD-LW-&6,>]10$2!]"4XIE)9 /'J#'+G5 C92P,@0DD:4(52-C*T)>QS7TY\\ M,8;HP_ >ME-B(WRO4^*,43'(&%0ZK/(_,;##2!4E)"( X2 643!T/DG#40!DD3W%H$3+$G]'6%Q>@/6&'! M>(R))JBBZY431L&.B#68R?)SXP:YUY_@R\R(CSAWP?4(8+D0$7&,WMMG!,4 M^H%36)VCPMNH4SP#]L5A8?%3=-\./@B( &-A4 DC#(!3HCJ$SK5EUGC.TOEV M3$DP"(:1,Z+&"&L(@LNI^.W6>Y"_"5]T4&?H (\]4-VXC,VP[3!47J0[4 8G MN0\289PCE5@R.:U )68 M.>"?3_>(?D)_V01Y7'YN-FWS[AICU1E55/7U/5: MJ7';-Y_8=Q$AK\@8X[TM M3SEJ_+E0S&?*G@V)C8!"1S"!2!VGWG B'<(!&ML"1'YF(3RJ\7JN![PIQ&T>,DG@O5-0[HR&^=@-&*@IV3^' MNF\5A8WNZ?,LPW3(3]%./-[XKV(M%_DO86?LXW=3ARR2&2KO#T;NS%:$$$/' M1QC[LQM6#A&Z:@Z)RN)@#TI9A&R!_7@8"D NO\SQHNV'6LT3(6B,/D;?57^M M!F"6G/051JMY,YJYL;? ?]6QU=*0)KIFW@72;:1!STK:"$QG_VGYI;:GZ?L5 M.QB&P!HW2;B\3LQ;R M^W7Q1=6;U<,W\_S7&8FC<+&%?YE-QF:BJ2R""1J.:V %5NG0F0F=W$=SO?-- M=&3U;$'V'L\O'U3NX'G-FPSQ*$JCRB?OJR!_G@37]7QUMG(KQR>F-1CT*LWY M,_65V6IK#8G9BB)][YT"B:8(ZNBD#VM)W#4 ;M,_Z-;Q07)?&RR[#E;M+ C< M1+*-7^]N[IKJ;>[9,[Y\4"P80(LXQ5OV-$"^$1X%K+F_C\G<5UG!3CD*TB@9Z$]FNMZ?N"9W_*2N-TOCR\>2;X$U*KFQZ8#+>#(XI1;F#D28)49& M>72L9OM$9+&8AYU._!.1O%WL9%YU#38=UJP>!Y%PHR@2F1!);')C?BX(0Z8] M'10WV^2M=]>UOAWNL7<%:*&4('_ETXH._P$5J(8M\\3L[>@_> M"^CQW)FN/4BXDF9KZ"/7YE(CLM4>#5X[5Z65@EX\==6:A%'P!2>Q07EOP%(V M!#B*:R/SF2R-_O/O7ZY T:X9%6UF^U2TKRMB_I2HK!:ZP924NY1)X8'48'41 MHV? O_@5M-C5;HRJRK!)N7'OP/,:@%':@.H(B 'LP?P/K%;YUZ?\F&!1E1W\ M*ZRJ.3["%Q'P9$Z)AD1 G![X2,:G],:G#M,@DJ,21T&7)EB[Y?!$D4^ B\X0 MJ"(/2PWWVNWR7+AX^(()8U06H@'0<^9C*Y2P1:NKY /51>(*'@53R+>2YY0( MK]R7-A>_*VRF<;D,* FY?4^.[[NW]7?FU8Z77P0N/_$BH)@4\ I2;]&_DR#D MG76;[E,4"R/D2&>;):W'1PF5^A"A*GVB9G?6Y!4C<=>^:GWXN7[/M<3/JYO4 M15 #F3L5!3^YS?+8Y;^2W]R1++Y[_3IY+O$BF;I(5NS\%GO=CZ\KY"K[ 59S MW'4_/@(T:EPV=0P=K?"G]MQ=G+7(<>\S=:49T7AY1]4__AZ]E]3\ZYC,+3"' M-W?M:W%,YXI?F<=BKP$*$)7^)4#'1QX9@*A:.YGDDS?;.D(>[LUHX>L729<2 MT0NV,,\6A<55ZJS(M2F'8)*EN.!H'EQN%'M=R.XEYA8%1\-9M:9TLI7^](O( MS>2KC@J^5>6>2?FHUQ<.E;_<:KE=>NC5Z[6*>M7[\OP54T:>+/M>3O0O/UI3 M4^ES*_"0F'#; J0\7>0>'U\[]QSS-3AQ9U5(M#\_>@D\\F_D-;?4>^EF7UH] MJ5]DODCT9G?%2+[),:,8R56)I*ZINBQ'J$K27I+(BL1=F!1*Y$U?+CKDX\-M MLU#:8?%2- [S6&.P%#-KFF"V+%I!4_8TG_>#U?*0:_3?QDQNF=8H=SZJKX5' M_GV7E7#Q,I.OF(J#F6S\Z65F@J-^HVTE/>6F='SDDR_WP\\P 9;&#! SP'9> M+9QSY6$AM% @<,LJMX#75'5%X:/VM6Z;<_/+MI/-MEZ@K\A2_3WH6&Z695^9 M?!B38LU4HZ;9P8LR9-Z_9L8"W8$U($8IBA M8V8QE#"NW<#WYT]IP7#Y=D^,J5PB[.HV*YZ(;7O]RABI,IDA*=_@"C#Q(*[: MFOH8P ZHU,DLW7&7':VM?0I3EG%\9,F#6,LR^!FOL +":302DBL\7-S[>T1/""G5F.Q>/#TZ(R%,>?3=MUZN#LZP27A[GIM"-_:1TA_"V1E34F M7%+A"VV!LC:;Y+C=*6XO?DP(FF6//+F2=EL\WCPKRN?3I,,$*M@]^O)1>7-Y MK>?$_R8#K+M_,1Y,/AU8]K\L[A5%JOZM'.>.)GW>%63M0SZ_N$T=I%ER M'!=7@I *$H)^^ 2[@.W9(R\&9"@6I=9H6KDN,>T[^HLQF_^JM\O"!&6@/:^$ M!V:?J=U'SG=BSFV:CQE_EIKW]'BHU'8?0=_6B-MM7J:\05Z&_&NYRZU2J\]* M4\KE6RR]<2E7^M@KT4Q-.?>=J3E4I'YR[TC]I8V1^OT;S46!6"^?S=NE)_FU M?NM94KGX^IN>:-+:%&C6X?,:$LXU!>*1B_4X<5Y:J[X),%H<5]$R_D7&1\V M5O^^63G:E=U*[C*OEQ_R[^.-B_U2Q\6[N:T+6&\C21GUVMF!LI=;2+YR]>9S M-WNME5.3;XJ9O>*6CW3>-^:_:6(]N& Q1-1_WSP7>,.6'W$7@P_JK)^:6SZ1 M.2L%^?.U8/T'STQ;9,UO2[/^[+9_=W-V^%)L!V#]97^UP6.GEQKHB<28+"9AESVE M?.-Q&X#UER*#]<>:@(@[2[X0"J/"\&(^[SR)B67 PV MG$L/9J:4DYZL@5/["^>0"/*4!DM695'@S*59WRB@26@H3\GRHCB!\,K2 *7& MX,]@=JSYL_L=K"R*S$3E89H)?_I-? J<-H1+R_[T6JNFF&.@3"G+B"9E-7GB M)K7(]]$3G/F$\X\L#\6GZW4__M1/G 0S2?6;@#+B%U%1P#%@?Q-WX(Q@'$PP^07MET!DL MS""RR9R.(9QOAE/";W6PP';\BU^>7=GS):[&U$SQ.=S;.O[7^].]/&]76N /E9L,^+$*)&5OY30?Y)*KLH1D!4:"1\59 MT"ZU%#?1T<"?4"7(EUFSF;0_/C(OB'Z9I9F',<;E[$0Q]OY UCL^*A(H84?^ M)JJ^%3;_@#]I@J3SW+^'N- #W:*0O0C(%#8:\O=/HO4RN**DLT;N<5POY-+7 M:&C5%4FXT1!-E3/%G&^8(U2CH?+VC8;BWN0SY>E".BL/53Z_V2;OH-%0,GOL MW9\&G.A".9LI^-_^\<%*$7#1%+*YKCH^U[T1!K6M'$U#Y&"M\_1@2KQH^; M,X'RE!&X$[@@9B( Z6FVC%DJ4UR%P"'#MHRI.TYFA8-Z!=F"7;EB3:(%YM"0 MJG@&#@Z$C/X$J&LS>QW7/29R7N_*E]6;<;\C47:"I.(F%&$3"E8 .4G.P9-M M%HBO.\%QT6&W\MLMM?.E;]=_7JC&^D+G.8^B8U9&ZS=@L1H'B^ +\M97"8EU9V7IU/"U^?W^(O M>(U:[WI\E$B3FH1*M]/;/\0M.SM]_I:IO;!2+S4P/]OQ\H[*7JF-I&9"1=7I M93*WP,PU![?OZL4U7TE=Q5B:N]30OI5C>Z]]W1]^KV?UZWES7KUZ&C>OA*_! M7WLK@3T^"ML_9FL(J?VSU!8UL)7+475R,2W,NE]$;>Z@$);:4^!MW9'M$'G-+?6F5^?DK?Y2Z5U_D@IDO1O(>$N]>G1HJ9B3'GO! M*YOV9OI<:%8:Y,;NQ!;UM(?4/Z:T 4Y9\6]C)K=(:]T6N8'T>-4K;@S"F!IF MVD__F..C;UBR?360(3=K(-.'WXC212;XRMEJ%YG-Y$![71,2OOK 4GE:9":! MG<*2Z")#;@0D)3H/]I/T=;Y\N,L='@542$=K(1)7D:W?PHM]E:]/.W2#T;[0?)B4(\DN4F]5'7AD&VSQ)M:\3M M-/=(^S:Q\:XA^TO9RZU2;^^OM=HET[TI!>8Y#H.]DNV15/C.1NYUREW'31^" M&<,[Q M>Q9$GHS^-2LB C]"O3*BWY0O&$\"3@JK*RMQ(1=IY!E53&&$PU #7 M2SS@=VTH<\3G4&"'A* 2J@"FS2@H6 N_S??[\!KUU&$RX4=6+B*K/@D5"JG% MU1O)YMH\KB0[C2]3?\/3(*GHJJTCK^;?R:TS!,-W5\24]??EP]C"V"-6#4R] M-_FX+_29A9U7,Z>"%#R8R]HLFL?U#1^1\>7 (90I2A6=0% MPYV),CL"2YM8QZ*T=.G'\PD8M9[?7ROG5?&L]"/-I+8@N4H6))=;#)2H\MM" M%2;,N#?76YW\CS]W3IBN$[-08L(HL+3!VK0#P[WR9KGX6 R9X$ZAT<9T:V&R M=>&O?!BN[*A$#CO"VV+<9I[(^D>S<,.DF@'1BHZ/?-@)TEP5@&:3^[]VQD\6 MY<\JP&L4U/;@N?M:5BB+CD#K3$0&+!8P!__C3X<=\IP. 8F %L6GP]@BPM@C MHN4^'0FS[4;0K^&I%PXD]@="0@W A<5 B3],P%2-LU8!L5EM=%AC[A:P(H*\ M_>'\LC4"G DDP?_]H)8A;0-@^^4UXKP;(9\# V#]2QR4T;+RBU & MO7^H;#Y#Y4H9BJ;_=:S8"X/; .@.7(7O8_^QMLKR($O.Z\O^IDL58MX)?8'G ME@K=E[U(MQ?G#CD[AV]*EN=X7^U5KHOM,U*WS2#GW!48!5MB8QA"/1%F)T.! MXWCP'; 62ICU%)',YH']>V*QIYLU5TD2ABLVHF=Y.WHN!V BT'-2O"E?/=[7 M67$42,] ;WR#J8?)#GI.->IE 2J3\VPZOLE>XR.\5OY$/+&&K56 >/RK\X#$ ML#"439>NPPJ EH"N+%'AI@(*"9_)C,(1F%@90 3 ],"%Y3*$($&@>GP=PH@K M,=J:/DE./G(F6Q&L.-?B%:@OF %OILBYB2-+;AQSE+/IPN!.L]^04 6!QQ3S.Q<5$>-\[I*7?QN&C4SX;\4UWH73P,'L:/ MZLMS6WRMGMV_/%]EF2?P]^KP_/6Y/62>9HOK3D5^N*C/7Y_H+!@+_/UNV*N. M*LM^RC)^UU:;0:9B,RHWEUE6G^59MIC^S=@@\ABT'8$A2$/4!9,\!GF("AZ, M .4)M5+[D.A:R72ME?0JI?0.S5H%;8 K"48";\S@>SH,L)\U78&%EIQ/D5'% M]^S>&H_6P)/XH'+>^:X]'U9VVL^5'^[O7A[<9]6U]+V?TL [)V'(OI+(VC/9 MGY]['UJV>#Z%Q$TOW(/FZ.87Y2/WTB+>ZOD9Y&JI=O4]B[KWA=%')/4J%.,^\_EI=1 M6%K'AGXC'> W!E+*._*5TCV(P;^TX(O0=?W-<,S1^A U]>CN?3 M4(#"8K.(6,C(1T"@8/T78PBE)#J;K:@>*4 '^&ZI5Y+536DH\'WB? 9<>52N MU>P#W1/)O<_OU+U'?T.3M^9N3#VRH=3]E#>Z^'TEBA=G]8;P/MB[Q13:4DW" MN=__5I#U$?OMV(7KCVLYPTBN(?FL2FZU56M/?OY:5RXU\VA-3X_ MK(\,0HKYFN+375O?T"ZEZQMM4>GOW^$,; [S%<7GTLW!>C__.#6_]ZTX M#/$9]=KAP8O/^!>^9\-I^(K".#6?T M@C2>WE_+&;KH!0^VLZC?=ZSUX&*MD4*MDFS%6#.X-2W"?V"( MG]"05?@I+^GP4D"\(J2X)YTQ5'B[[')&%UNOXYZTX-*I-NS)1D<5SF?R>:]X MT7XTQ]F>-(=SVY\'BQ==SM7$\2"=NB.>;:?S^6_U\:T^0BS'LQH7JXZZ(#$2 M*S#B 6;IK+EOZY?79=U\>#%XD2\_2J-WM3WO S;.7TR M9%1A[W3>:8#8AYH>>L(FUR'&@_>WS@C9LP@5L_Y7#V*.^"9R_&:+D?H^?LV* MHT*:XX^!4(@)AGR342V-6;W3K-,W7"_---\FYKO]H=]CT'??DT]9U)?:CP?O M/#'RQ\M%3>]?UY_>4^G ;ZRY5M%VJ'RFE$U/Y#>W'__=N>G#;%%KEB:CQWY[#)M.EC+YK3?]VWO_&[SWWX0/V "*(OE4X)Y!C$5>56.[9TOOY9ZMN8QX M+BW5A>E&79@>WHOZ_>PQU[@;I?_V9VC0O"2OXNYWOPK32;%>?N[P0B[]^[7# MV[I!N^*EWFRR'W)9;UH7'U-IK_]]W:\DD-TUI?5J:UAXU(;O["#]!WROL=MT M[%=^,,RUIXN)V.ZG?[\.1R ?:*%P6A>_9;&P$^H<\+7L;M3GU6C964UG=W3+Z_OZ=;XB<53>.N%H2;B7X=X/=4"1MC?E#T:V/I-TN;PHO/!D+Y64 M#Y0H-NU3+"X]FR=NM:YT2$*_II!9KPYI@7+0&Y/_[)#%F]NC'#RV;Q;Y5JT_ M/ CQ5CED\>:F?.6:&]6NRHTZ2Z:2\ND1;[&VS4Z1>(N['7C6JU@N4+Q%NPCF M#X(7*Y!68L=S 6;'TZ/.EA<-I/+K:\D]^26\%AA^V:VTI[J&AS,=M.OZU.6?ZP^ ME-/,;$&5#ULS&U6BDN.V6 LB$N\%D027TW&(U$6MWLCU%+8WS-N)5%>[)<+9 M'P=8QJS)3NGE:JLM4C2^!0(D4RAZ];_[4E)RRXO>6$HN!IW&I/G$OX\;HR_# M/^26_%.@,X \*91[ 25)*:["2M=L=J)XJ$T4S^J7PPD.]!S!R3HX)F'A6D,J M'7RX*A)W)TNLI]XIR0\]CBZ*[RH73FZ DW022G;X+VM;X>&QJC3I'VH[_;-+ M-LINS4:&^I'OJ[S6XS_$%OWEV&A/:B@4&UE2\+^H\Y]WNU1'1\E*\6UQ+UQ) MD\7K_")?CM *, 6-.?D9+)_E__SO_YV<$'6!%[E?1(L9 /;H\!\Z+[%@"#I+ MG)R8)X<3IN'-'+Q ZQL%U*%LH[Z*X;HE>C5"\]=EFCSQX@4?=8E[M"TU9ZR? M. EFDNHW 9LR_R(J"M,3V-_$'3@^F)QW,B0AF7<^]5_S,?@GFP5-]OO??P&I MO:BN\,SHI,>#$P0&GZ"],N@,%F80V=QOQQ#.-\,IX;\1U_W\KQ=:9T_=!O5XZ-.\P9\:-YUB,9=][Q]5X$_5&XRX,?J:;(] M@!-97%66T/F'"N+X"*LN379>?']P MA^DP[RJ,I&(EKJ[O&>Z\/KO!*, R)X?Z1,NU\H]\JM6TU4>\[-M'O/2VZ%WF MV)'<*%]WR1]_VDY;D- 6*BKI6KUR 115&X$,I0VA#GJC*8_#& M.3%D.()A67 V.$+&=W55M-_%WX3*B(PRAYGYE@=^V#7##DR#+ M(>^*NR\*+[3N5+I]9,EW>K3.%_!^OY?-3Y8=]Y1=+XSJ!>1SY0SM$82'TLN5 M,(QM?ST+Q?*AMZ,4;3O.A]WZNW2I?;:H&+>C%/=V% JY#.EY&S29S<@<'SD+ M6TX)B"X'S@L\8>9I(E1> W3F<-$+_ MKG#VP1H)Q@]%I0T8C!-6^54@ ^M[) M4WR62XZCS,F\*ADG53L^PF?8GANN:R M5&:S>*"ESX_)QURJK&6/@!?]"*W3XRA6SYYZ56DFPR<_D4PV\0%/B>X0[#&8 M*?"?5'Z= (9?-S +P5- 88!=E75-U< >P\NF8&=7!3Y%&0*?(D^!VS=')N[Q M$60YR(*P7$(E>(D#;_5_DO@$8P?*?I_=K.D\W+ZN[/S[4HCRC%Y\THO1]=W" M[G9G3C0B$WF^-I$8HA?::$ A;VU+DAGAN,7+_>B*NJE_4.SN2;9EO Q(##^: MN:L#3P_*W#I "[$A'1_!_#UFP;Z7DU7@,1I@8%E#A>$ M@M>B/ZG1"P&!SC24O[I2_E?Y9!0.1K+P(XY#I&K "00,BV:W\EQ# DJ6MYS[ M&YEE(,>Y7[QDJ9BV3K%RJ^C3_M/K)V4'O74D(8&<==U)PM1;6^P;BH">VL^W MA&Z5:,;;WKQ)8SSFN>1(-<%F/7 1@F=F2IZXJ5@BJNB;*[2#JFA%4)+K^>Z1 M$77^"[(=/;^Z;)9';>4L'X[M,L04DB(B][G)F'KF6RU_ IZ7-]H/YCI ,].L M4HT7PLB?+%F6N6FHFZZP#JPA:)#;:R#0(HZ/$#M\ZZ6$I]P$>NE*!_M#(C\G M6$&5HBJH EG$D@)\*FTJ*2H2!WZH"0HP5N15)+O-Q,;B4DUXY8>.H*Z5$X>V/"51\OGRGX,]^W-MB!-K "7[GL>HU M1=0())G+&K8C^A3F2$+X[ M6G5H:@GZ)_@*.8VSID'ZZ3RJ?LIG:2PH\*>]&HI%MC2:36L7C/R>!D63/\G2 M]J<#\$V"XE5K?)/-SGZ\NBI-+ B4U!-U]4XY0?+VKG3VQXBK2?8BG2E^^RI[ M50H=?J(YRK6"%4,^JF* &9 W^],^X\AG%\/YQZ(VI)YS:= +Y9-LR?ZT]S1& M/J):6)O%B!*O"F&'>.J %'%;9?QPKA9D^OZ=3X\*V!O/K18D%WS:H7PK@)UG M+:CU\C]B&ILBR2QE1!#0IPVMLAC/8U>](*^HYL6T$#*+F*CT)\D3**7,3Q[& MV"YE?VY+V;^5K ]1PNOGL6:KW42/I]\==J5J+\;>CO6<[; M=?-9AZ"'?"EH\(2"0XSX,A#7=".A3QEI0^/37EWQV614&4P8\EP.:8>2]X48LL\U?^.(;(DC@@LI MNLQL/7"(LTPUZ+&WQ=/E5+IF6OE\?W 82"%DUA2_7,NT.P6Z;W .^4Z[UW8(Q".?< #$CD/C!0\/5Y8-8 MF0<]$!7^"O8XMC8.MF0#,V(F$T6> 1L4_%GQ:>5!OO&F.W#>[^.KOA;WP[O_ M;1Z<0U80!5R!I-7QF^$\=& ESZTO ^L930[\"^N51.L/O!H2K.#RIC#EF2>R MS-BWJ.O!"U6<'0^6G(9NI]GXE>RB=@N,D//U&'YB* +%M2S3&P5,,!54\ M\ M8V:94>!7O)E+-A8R@X?N+P<@U,!-4Q,,'/)KRD\A !0>$GL@('!^P, M?NP#^UO^5']YP S&+/H[[)#G=.C_AN&!+C2:?51#N>#TR;<8]FUQ\9REGIXN ME>?+7&*JPYKW&1#NGX6&\%!Z'G#OM/5"3E G(@/$$Z X8"MS19!?;/%/G.,] MC!URP]L*W\BKV]B$@Q[:+X(!S/R;6.\2EJ!':#R)0$_QHS_"X1][P!PC&GSR M>*B>+'+>5IW5SE>V(=AX'!( MY0Z2!GQ_V\>="[,V+EOP,N?=PMGZM2'JSGB)[PM:@#F #)DQT^B>GRT>]=S; MHBXW2T*E/ID#G1%,U0UQZ8$)XZBR@[="U2Z6W$OLX\Q)/4S M&/3:#%AYOO@_/H.2A:6O&Z#1_P3'=6/=H)B-,JAVP%* 1;8$N8VGH)X^<[N&0(=U]3+HOT@\KU M(\@0O]8*JXM!DX$B(NGV$M&XR8]6.SO.0,=GF^>#B:EO;! ,\Y9>@\+27!(&$8I&2"?:SPXGPK/P5BPJO):=0B;NC>DRAAPG_8F MW+UQPMM8M=GX4QL^5-K*Y=WG8#=ZQ3?*@:<*7$-47(-#PHRYKG1TY8LT4B@9 MO.E.[LS*S&<+F7QNO95YD%T64[Z?\8LDJE3.Y$L)[>9Z>>7C@;\)W;>Q9LND MF^O[TOWK[(//L@EZF*N"R&BMUC(34,1R_FG_O=FBC;*9&>C>G*1M9V_LS0-O MH9>2;8K-&D]LDS9N4%=Y6YQ+[.N"?,P57E-=SN+;GRZQQ/&RBE%A-$5@>L#R MA1T- W/&><^<\48COBWN2@)=/^]GAT^IWAE4M@(UI- '*D724*F #",=J(J> M,Q;MRE*@U:.R#M%>/TQ>!'0]8!0^J(8@L=(>.Z-> @;^K?*AS[+-SCP7)J-N M[C@!MIRHV*MV[/IWBGW[%/N>\^FDLXR)+ _Z3[>W@Q+YG47'Y"DZBEYH17@+\E#6YD5:TRBC('A@Z\!:3"UB=CIM:M MW"W*3^+;0J^\E[,OV5?Z/4K<;NL4^!VO$;(Y64($LR58.-T38[YI2*\&&Z ; MT#Z)ECE4)E< ],][8:!MD"KUEB9?C]K;IL[5:,J; M<-? H4S[9'_,1GHA1['RX_M.PP:&?GG\BE'+-5'W$#NU7QD0.I"U4M?RO5>[ MEB";[I6W(#D+$B1 ^[X)76 0:+;8&#T_%6:#VWOEA=I7!L0(2$';P'(^+:_S MT*-9(7..I:Q_SO$OB_^%I1@9,\4V#L;EWA:/@[E2..N^G'^0J8[Y'" VB.MV MU9!1"?-RD>3C0YB&($(!MB]3B?/@WIL;F)@U&IR$-T(4_+@TRG+-F^N%D%;*;V9$!%&^Z-]NUZ;\FDZV*^V6NZY.YJIQ=2^& M/CG3P<,\-^^01JP=O[3%#>90I(XBXM;D,$8T 7:")C'YC MY&D$B>CKFJX87:DS<"H8F<9U2(^/O.!,S5O%P ;W)W=%X2OF/+IR$\VBBR>! MT[* 2PKF.5V^K49=\S6%)R^>:X[^./$L/?!*\78KBCG]?U((8+"U[+6\;X60 M^W8^FP@*FJ@0G#<^& D/3F&.6C'J#;0_PF>E%CL"=M.1=\KT M-0A,FB5+B$7AEP2,]"1(P(45X 7M[Q;<03DHPN^ \D,%\HPU6$I&_.(],4\.G];9,]ZDSLA6WF6 M>S_^X*5_HQWM'*M75XZ/C-,/51I@=D%#N#,0&10<$E50<049!#,:#!1^X(-B MY+R 5,6C0'&K5JS!H'),(3'F MH#(%$O:GS&9*_N!OQF*0X^K"UHYRFI8(R\E.NKYT&P5Z)LEW@ATC;RWSI"=I M UI@>,T"0WRO3H#KT9.AVAGD._FU$P@';K^&!HGM[.:SPC1)CM4\V,N;WRRY M;1/>27&,BF^3\ MY=:F>N=&.FPSJ:K3B_(5K<+&,?V8W .CH/57@!$:9=QAX MOP4-NM0DH 74"; W6B+#HO"8V25 IM77%TVZJ9QY"FES#3 .QS+JT#S8";:K M6+G>9:'_>Z]AVX;7-%#\1?\H?4##:[BKTA2H7A1O-,)&RX"+2U%YG16 TX9KTP%EG>W:(&@][H(0ZW&GZTV[])4I)^H:?-L M%.Z0[$5\&CU6_%:QG<%"1G;'9V]5XT7F#V,: M1MK6QWIIJ%YT'P8TF3J;<)O=##(%<^5,L>QU)<>6A:KQSF\!F (!&**)]V8" M<*GMGGDV;AB)J_%37I0G3K=)?WD0AN_JDS3Q3A@L'Q'T8:(K[)!1458-8S+L M4R!ZKFR[=H]FAB=.N4@F(AOV3IG)K;9K?W(">WV>0 <1G"B)?(=G=5R69*6! L)20UG1NKPR MKO$]S:.AJ6->UKF%OZAU M[C+^U6&T"=U32]NOW;SVNTWM5T_[>Q4\XX)FXA^HV 4)6 7_'MRR#M?9H1)( M'2[?JHLGS_[^K';$]Z>!KK%I"953EMU)[: "(Q\Q.!1W"<;F24?;74F&-1KC MP>3NCAI=O(>+)2871DJ((P)#N*)+^" I'O*8>1H+28YNE6>?I%['JCW MK8].Q?L21"KD9Y(E&#DJDR>I#%WT:H 0.;I^%JD$(]ZMO>ZVGPN/YQ.I'2ZZ MGGP)1E([NR+^"F4R0U/?)1AIF[)++,+#)&@:;L:.>#&PTC^([?"OZ[)Y1/!Q MRH'CE$/'R?BTS7%RVR0H]J*=3\'_>011E[YA'LC)\Z>XD#2YQ@H[.Y KE/$\ MF#ET,'/VIW4'TS)@/)<:]=CFDJB&V[PV.(V\<]4N#:;-4N?I<9@289X2GB%+ M@0SC(^G-:V>?$)C"(!V@S14CZ<#7.#[*H1!0[ELAI,!.#E'!M5F\(5+Q5K/U MP=<*U>'E^4ZLJ:T,Y1AK\O(0I3=#T?XE7#NQCL/$"B)M:ZNG4=W+QX>'<&7* M>["-XR[)*\#+F-\5>:F8KM\.9//4O#.O/CO/3^%V9<">1>B'FHS<^\,:#.)Y3M#GOGI@V3?HG<20NAQ2*8?)&V]NXRSRSR:G\R M29\#7$GW^V_9+A2P,G2(*7U<5-X?K3R!NN*P%SPVJ2M.C'DFGSG^:G3#%(9\ MZNN*DV6AP+KB')G+%(M>,#??:?T#S5^%E=^>28F8CE\,^0F]^UH;]'*E$3E, ML?1?S5F$.KJQ9"[\XJM9&OVW2]60C4TUI)PK;Y6ZTKD=GK^4Q9UES0Z/,U<5 M36#QF'?N[/C(2)X17RAWECP$]@T_8,1;!J@11:U(7!55.P]XB06,$@;^.M3S M;XN2T'[X^.SJ[6[N0*"O*5_HZ]+;8J9=:-5"_ZYYQO[X@T@ ?%>9Y7EX(*'6\ /N?_X2!-L>-8,P8J,,,;-:L8,QQ/,@!$D52-TJT4 ZA !)08K MZPJ^T-W354'B52L_#_XB(O16743UR2*0H ,4YCDEJL8+) [> Y=9 5],L;^" MWNUH'2!(L ^%I-EM*U C #B +O69J:R@NV6RKL%$HFJ\7&:!X :*08<]@U0" MZ Y>@Y/FF#$S@$3IPQEGB DO,2(:4%:.CP3I';P%X\T"UAP*/0$5(.@&E*W* MBR+\&8P&O@]&!5.=X' ^'(#@I0$S,+H3R+!_!@&%\!0I$-RI ,T+X=T:Z.(> M:X#S0#T*8'LEH0]DU@0I*F-I"+.6(6 +) 5>X&$XJ+EX@N_W(W/45>"=YVZ&*'%!TX6Y9]:_O MH5%>@J8./]#;XJ/X>BNP^==N>W @UD3.UYJ@WQ:OS$VY_'#%#\32CS\.6N!. M-4YJ?%L686;NU1(;J'.-CW-)YTBX"%.PN[>, G0SOK69S;@:5:%+E@A0'NA_ M!LB@O@:T.-A=#HE#],L;'J+)5 8*CV4DSH1 8:3-45LA#2/2-UF>D50@'S-$ MM8)UL(@>-;M\X+9;KMZ?00&ABL(SS3Y$DH$@X7KGHZ\Y<<*G5Y/Z8G9;9CA' M>P_P")24$ 1FG8]J#Q\_WO8'O/%.9HI!.<(/'9I??9[7+*A^F_"":F3>P?:, MO5IZ%%P^CJKRO-WP#A(=1A60?ZW!%R.4=>W62;[>F&QT2FR)N[.1*F[,[4(/ MH7<'=N,+(!5LP?V+TQ5@#FK#5:=NW81__,D5?!KN$6A(+'S,GGT>;0Y)%X' M"QQM_P#OD6^<=[YG,:/(QCTU[UZ3S!)A[(:%R(Z(W*C0R5%P(+0@CIG#+G2\ MM$JLUN M[6S@?EW,W5"#=-;P!=R&AK/#_S=@"XH!0=8KS6V,1779-<=FTTG%I=Y9YRG$\IQH.!B YHP M_R3^,?>C)RN*_ F7K%@Q"$NN_WM*W#*:D?] 9C):FXIR"+^^!A=[G\@D,@:K MQN6-P/0$4=#F!I7G7=2[V]OU+Y-K;.LUH[TMVA_-45:F![49&;O_OY.]JJ-( MY?'16)"$L3XV3NG$T%<>'>L-FP5V,8:>BRC*GVKR?+O<=*IT5GE;#&:SBMRY M_GAJVL$7(%\F(@,( 7@-$*K##GE.%]$IQ$LE;HV58DO?U,SF"G83:-@(NFU3 M&IY &+9?L%>C_)M8C_M6@+!OQI.H@QQ^] ?".PM ?\-@=#],6#2-^U-W]-B& MUBX4@4[6P=ALX#^3,."C]32<&"32__T 4M?%9\)%(WF":K!&M^9UOWDQ2E_BSQWU,P/6=9CYJ9Y<]-: M7%^*;XLG8;0XYVOJZ[5];L-OD#+H_4-E\QDJ5\I0-/VOQUZMKA>[SD'LY_OH M?Y8)Z[$#P69,5/+%8,X$. >E3('TJI_S7VP ZQA8BY[A?H?"K>2!RJS-7QKY M1O\^RZ<]9'Z@.6A'0/A.GF+Q6\J@UNZ!,6%%GC.B-B<8*P#\*6A#G)C%1JS< M[PLLKX!WHVZ!,&H,TPI$^;#25/MN]NZN4 I5W>+[S-NB,#YG^N_".Y5ETWZ@ MC!Q4WC<'1;TMI-<^V1V]E(8!9]>9J)=N.;FBLJ:6, M6 ,96XF^>%FI*9-[K3SO^U;XKK8G_B[RC:/(=\(HFE$YX:#W2JPW+%S2P=?U MGG%M^KHR>*!*Q1"\^%W-&P(AQU4VCO)_''&E R.(*F;PI8?#LG:^ONH)W70D M)#K:]LRX^JK[0/'M)66B IQEIR\)XM)7*%V7>ASK+P% M+'28"T"_0\$'XZIG;/OZ2>5>;_OE:59R;ZNYJQ,X UCWB9>U=C?])N_I^B>W M74 ZMLPMRYYFLP7?W;*6EOF&CDR!<,RO%XZE^.WRO"4L\VFRA11RJM>N)[5J M\?T0[/*\_6GO=CD)9#1-9;*E33N..F[?C2Q0^937*Y\02%]> M$$;P,)>M8UV.]5B' D>LL*P"YKF,D5C5/O3K;+U0..NE!0L)']ZR_2GX@)JX M.IX+W#:T4R(SA9PO)D.0!HD5)2FMW--D'\YJ5TW^-;OOKM=[8)J@,L5@!Q%> M)< OWBD<9V+]UFRI["B-"M4_,/?=/S">_H'%OZA_X ':+=\=";\[$GYW)$S' M6??*VJ]DY;^;$Z;:"PL= O3/C\1K3R\N)Y>7=+D\XI_YE.9'0AO'VSI-"2/, MADV/Q+*M$RXW("N%DN)HM+7K_$@2V[64'\G[-PWXSH_L?_L(EZB1;L#^MB4_L +DVDRUD M,X6 S&@\A4MA6R,ZZQZ'!ADG5[28_LC04WC9 %I$M U],TX&O5&\IZC.G9KL'H7R*]J>]*Q^2S.1*A4R1 MW+3WV,;9>3IV]9-2;NP7];+$I5C_[84*O['P^%RD[_ZU^]JA^*'*] M_@G1&V$Y06]'#2B*-$\W12Z=78$3P!PZC,@W^VC@I?,)W/DI1&X0&1;%I>,K M QNP7+.0+RNWE6**DO34"47:GZSSZD.&Y").P(NAJ'RF1/E"640).54W#SFE MB67>[]]KN>&[K+;>?<*120>N]L,4RW6_%!FZ\A=N/Q#YJH91["3GQ5*4)RC^ M5H^/C)40UE*^-< .- #HWS(O%03IH=R*3-G2R#2SIE61454_J61,#WVG8HZ!VE)VH2AI]AL2)TP%3F=$_"SZ MFTE^4P8]2^.VON"J4Z5@R2"T3$BC*5IU&!Q"($MREJK).:5*L.'HO0PPTS?W M1)8\ MX3D"IP)*0]729\='568\Z?%@47>\KL@J*\!B$Q4?IPQX3XT7X8C0.5,FLH$[ M:1ZSZEW'.F:G1%<&I&-Y8!B>"T,R,F0,)NGK:S=*YFO%"VVN"^%X.LR'VPXX.HXD3U.R??^@0[XG7 MAC+7L!3O^S(UV[3/89:O%]LWG;?OQ\[7]F+>.N+E@)V6#L-$@ M97]Y4\G/]-Q('ABE?L%+B61L8 0U:&;DPES_A8S_1>K\XL,'!)L/Y!ON""%_ M2JNX?J'[;"T77,=]KA8W_69K1,\;O1R5(C=LD[.P71E">V=D\OYN,QN^HTR'T(PQ:V1\$.Y,SZ+@<;;*+1_.#XJ!C8_,#RE2VR M-"%93*\9]HS KFT)#^/S?0+.Q.%J YVZ] 7#BQTSL!79A)?@RH^/[@2)U^;$ M/^7LOV GYD9;,VWU<3C^WOHW'):C4X$PZ+"5(Z9Y#P8K!!&'7!RA!BR0H-A0 M>%96."!7-? ])$B&\B?J:L.R_$3SV@[4+H_HZZ(X)R8*?S)A!-AM 0@]R7B* M 8QN302>)[#QT$:"@TD\. 0J3+,)$CX T R X@Y:5_#)4Z(!!N)P@R\8Y^G8 M4S8CY 0.E3EZ[ICK!8<,QF6 K@ DY6<\JZ.K':P\F1M1*#Q5WHBOVC/^YB4W M+[6!8!,42#RX3[B=#">S.D:XMJ-8B+\0+>N-NW;%T-$]<\-Q.SAPT U[&Q7T M&4T3/;@+!@[%^7>Z(]$I!T"DPP;EX$P H0#/!-[72J=*E&C:#8**@KX2(\X7 MT"*!_??LUHZJ?=$%G+E5&'1M"%X]&-H-!\$'E7'O:[]'C O'MRY^BI3_M]_>S(W1Q^&VE@$'_X_4$L#!!0 ( M !>!?5:#?S+KA@X !(/ 0 9F]R;3$P+6M?,# T+FIP9YV59S3<:]?& M_V-&)\[H73 R6B1:E" 'B5&B!=%[CR#($#V(( G):$'4R!S=$$87O8[>(B/1 M>SMZ-_/(66_Y\GYXG^>ZU_ZTKW6O^[>NO>Y-G"3. G]HJFFH 2 0"+"Y.@!Q M"E %*,C(R,E(*'1\PU3,,*DY@=W?:/^0_?_ PO\CLO\!^U\N/$ #!EV%!X8"]X"M;\*P-*L$ M,K0MTL_-^YB#L^/9.BL3')7N6Z+-WZIOM5K%XN,FO_))L<'[V]0Q6#0[:\64 M"+ 2@45#+!' 7-60&69U6GKTIH)BW@-1]C@[; QKR2?4A^QG7MVY.2LA6W8. M>5B4WX.=RCHDH8!K?&MK*ZFU8Q';T299*N/!!H'V,'6Z^'K/!"'&*\TSM S< M.&RV&-T"^19081]\IAL9V@B\V%VNXN^/]?O*NH3>2I2.M .Z7'7S-=8T7S&= M[D&2@&8-FZ*_&4FQ[?DWRT]$0%*KG< Q5FDIX6[QN66 MRCAG'F)F,5 BT&HYAU%:OEU-T* MU1TB7-Q3>DUQK7/S$BIBBYUT>M>\Y8U+6DC,5=@E7KJ%STCSEG1I0$B!Y#S5I'=?FZV ^=%(PS3IS6-H,0\X$;+T(F/TJ> MUMM[V%N4DS9*7@I;Q/_$E\"%/[@B0U'E\SR,TZ'N'7--=##O]:\T.*D(H:>- MW@B?]VL;!@]F7>!_X@?R\M=],DUZGO5P!Z/4 6.16;>W[G=-Q[!:.'1=@IYM ME4OG;*V=^KV4BZ)QET>ZMBJ)?]6NEQQ9WMP;6EPZ069+9%6@?WTZBI]>&WL_ M]J9@SEW2>%C!,C1O>OV[S%&H@ZE[WPCS^N0B]P+$V%-[;[1O_\ZMU-CZ\@%% MR;6'F*(6#4WA"86L>96?KIF\(PFZ38U56C/)AG%+K0DU-&&9\D<8@\J*-YT_ ME8'@B//M =UY#>GE>TRABXX[*^=$X%S^>^'H[>R/505[%^_OGG01 3XTYC(8 M0P@?GSSQ(3R(A1,:$NC?$));*/,>BKFL_9VH,.7'E%BDBV^?FVKKQ)^$Z:R;"ZZ>QT1P/$_X$H\$"G;^;OU/]A_.V3/Z1 M8E$ 7*(USMX%1Y,84K3I-H#-@CRINQ>MUCA']L 7UN_4C]4)")LL.-C"OTP4 M4 L92:L+Q(RS$23Y=4^J3/ MMY>^?S=8',(W3%4UI([E_\HP5=&WVO0\KNB5$HR*NC -SK8N[8QW5+?8 9.= MZ@XG7F5RG)F$.ZEO8582B;1,F9I1$^=J?;>[VE9#,(K)&UR8H>7#6ZX-;R3' M['TIZX.\#-:U;@^11B=M^SSR:<,X"[PX<+,\DQQ:>VW(0.&'23$L>[@?]E)W M%&6!VGW]59ERMM&P*5<^['0LDS7"JF'"$UGB.RR*:R\SFQ)Y+9@J4!&W.!\1 M^O3+R)NFGG1,A_4I6Y <@0@0!K#KXTO32L-((@!U\_59P]_OY! X'Y$7VZ]7 MH#FG.G!7VC/O?MMOKYC[SO'&U. H9%0\)]3]T49@R/W10=I*JZ=[7UP_R,@U M]\B"=V&/<*+/[N_U7WT!-!6US>"?WWD7(.X>6\]A;Y;5KF MH3FM\J^;8KFI0R2]>1_H5!]&F8V*B744RPQIR,$@Q@/J&^\M'BN]+Q@,109^ MC4+#BU M"*5V'U1<9:D*4,J:R$08^!5,3C*9%^5_=CHO[-_GR=[0J6RJ;(K&N7HQKEZC MC UK.5!*ZG_!K?P"/[XT1%M !%PT&#N^[?'MO-VL63L9"VA0P\U?2[J3EN/A M49+'HI_=C&+R?C=]7@;*5BQ:,JB*)53):S7:ZY1_[*UM>"WGE1'YM3F87/I3 MX]LX7509?"F+;C\)76,DL2C+]DO96ZOX_80L:O2]F# M#IL+=>SKZ8&UN5B#@;6\YFAL1 8V*-XM!G-?3?@1[$-.@CQAI=0(^Q4_S5MZ=+^"RA.U'$VU;$K M];VNM>8B-I R2'$A4 ;[X?8Y+"[/0]VR[35W$CP:DV#A26=J.M7%]'V*0QSU MBLT@(4OG !.*W(;+=<@5F=Y%[ETM3_1.Y!X7]_K1_*'9#X>N5%BJ4?-*PFA^ M:3C.X.N80HNK#V>G@B>5O\5!=S%;PSTD$0%K?BMW MS=[I(PXA#WNMU*;Q^[I]1$#S*3LVLJ_B >V(!HSVJY%%?-30V6,=S/L3[0OI MK-,5/R*0C99I>T$$7KUM/^FZ"('KGBUB'0(1@[@5S]9E;%P261;2SX>C;]^R MS-7,^%<\&9DBP*1I3;6V9_G+XLM'O1X?X4%X@KC^LF"SS5W.D. -A]Z($,L0 M'?.L^L.#SW+TAG0<(CFKO=ZT_,8Z-TUS[]RC^W&]WI5FM-^/)T%TI%LKD;"J M& 5',^-)*UGN'--K(Y$"97QTE;@&!"H<\4VVIZ=$ ,59IO98^-FD7,N!U'SS M'Y1 9L3$RR.O34>+DX#>X/OKT-0M3U9W_Y(O@@[@;-OA)JC!Y-J="08->?+X M93U(0M_2HHT\36;$I(W1F7/*JUGY%=G.P#,]*FCCB(3 SK?,[R/34](=2>UY M$M@OG>*\A[9#64%&[EJMS!_QTOTQR7[Q?OOLKFC1SBI0U)S@FU=)/23?2.'1C)(\^LR6]GMB$W<6\> )-R MN0FPW4PM,ES$QN >EI1L4.:O'1E3/RMG)6W?BAZGTZ_^]H36N-G)9&NEJ@:U M??UN,VW%\J'9%LVP2'1?-$>V9=N])'4=$!RXMIPE<&QW[.Y0&1JSDGQ,_Z=2 M?V%I;H/.#19J?DK]EU,'_)QV=;$$T,D32\MUM?Q]\7,QJ-TAGTF''1$[ M.?L,<.<&'_>[/+Z,L-5[PE[:2(9WMY >%M<;. M!/)_0S Q54>5;&YCQ-RW/>FU:A5^E(LI>V1T<7J9C5T-E.STD7A_X]3EZ+#_WQUJ>,5VWLB&/L.%)8G$%7)X6%B/P2C68]B@.[;VQV &]Z7Y M8KT-FH<7-O41MC]TV'U1J#:*97:Z8=@B[+7,K08XDG."WT]4"Z*[(S+2S]<" M\I([Q)1].2A<35[6<"FVD*=5,,4N"CWMPB6;+(F=!CD+5:8OE/J7! @N*@_T M\6QFJ#[S>JYZ[:5ZLU.G3Z::LN MN2CRNW(]S[5.PY,SJ)\*FY0/7O?KPNIRQ?X MJ'_U^I0$U[-7(Y)J/1[%-53QZ8(MI,^ ]6<^^H-YUK!R!$/W;KV2CR1M4Z K M?-)]8>SQ):/W]14GDK6T7 V1_N=DYMX05-DUX^HA;L4-A*;6JXI?WGT.OC"R M]:)AQ'> 8?O)(>/8(X8$9^*/?P%02P,$% @ %X%]5I:FPX["#0 1I( M !$ !T!LP0N* N/!CM;VP,'0H_Y-+P_&OP^&8XF)^/QP/GYIW_\W<&_ MPW\.A\X9A< _<$Z9-QR'4_:C6#\D]CR MV+R=P(DD,A*9M.W'[>2O'?L%%5[&_&[_8B%^>+RA?]Y#^#8Z)>&#^$#HZ?[= M];LO;_[SEL*GV?+#\>/=[2?B/GVD7_Z[_\O^R6]O?[TYGW_\^.DB;O)0>#.8 M$P?!",710-F7F/>PM\7XO;N[O;WC_GEQ/M%T@YCPX#&@X:A]F3&8Q&_%"BZ'(EIHXL][*3F65I+F9"I6 M^;0 42U55^48?,D+##F_8;6KJA7/]G![9[B[DW+>3J[&&9.>(!'1*P1\XDO![D*J_B@7Q M8#WAZ1@@8%&P'L]*E4J6I"!UVDNX\9@$:B1.9@!2Q.[,%]G= MNHN^5 $1,K^&V [UL<1W$D%.+*GW=L';UX2CF3- :A)4N#Y?;\=AKST.SGAL=*HL.FSDIFCT0>B9,9">]!C,/) M#'OLC 4^KO]POJ(>E65LK-1VM-ZT1RMIQ:&A8[;S+R=IJ<>P@"$1L[. /50, MIE65'9W]-=!!D8Z6V>, [A6_)R']HM4R24(\]C M42AQ0WV-?=ZCD"W2UF>T@_BV"*)N0HTJT_\:3;%JQB%9.\XB::@'%MP;$))3 M#T.4BDDQ9H4R.QSOBG"LN!T/V7LG@XN]?T&H__YQ :$ [/]7BN4DXFI].Q(B MV]*T(;3"L;-=A",1Z4 L4X\+IJ0Z7BS6(5INCQ.X9_01?!,/L\#N]YVBWS5K M[]O5)*\H3-^:!7;?[I:F;=U_>]^N M#+6DR=S[=,M)*(AGI$EJ:^TPO"DO:*WP$MH'?U1JFS9Z?0VJ72=DN; MUHU3:[77K/1+<]N1W-TA:] M;:JO!Z\ZYV>"5"ZV@U':IIOYO][AU8E T^'E8KO#2QMR,RG8.[Q=#/PHP#28W!C MA(/3I7;0.25W-*#R*7%=DI-8A\,*Y5XY7Y'(7AV84^?E5O*=K($,SQ[%S;:W MU:/U)039,7_)%$<_I)M/$%7CW$!CA["4M2B<,.J!:8JU^8R#J$PYU 3==5CM M,);2%6;T35,7:3MZ0,8[NJ0I9Y3L[/I 7 6QD:^H0;*"P@Y8*:5A A:G-WI, MK FEZF!H([ C4LIYY)-,?1BTCQ$CQ50S1BHH[(B4DA[F&(GC5S]&;)A<@CRG MGH[Y-9A44-@Q*:5!3$Q0FI.*ZS&IR] : YL!PTTNFUX7YQH9K.!];\UNQ+GX1'IV=O$ZS<7W<7 C M""O>C-Z8VPYN*8VQ ;C]"]55R8OJT\!U:8R6U'8P*Q(:=6>)^SC;-$BSAV1) MZJ FNM:1V9&RYBQ63]?2M$4?2*LQ.H4I< X^NC]>/XY"/TVMUT^(+;GL"%J3 M&&D+#C:1[M-4XLEHI8>TYD%U=82T$=B!*N4V\@^O^S!8_RI -10U=7842OF, M6$KO_\;\:R3181?8_CR:GP,1@.LQ_:"_+AW;R&!'RIKEB(4[B71'BW=2^7U( M:WD4I&ZKW9[!#N&ZQT/Z,=CF589JU!JI[%"5,B.E5QW^O^%1_ZB;$V]@ZN@; M%P_4)7]' T'5G9>#I&S&87HTD(+187K-WE]HVM;C/$A)E&C+C8L:T:(WDH93 M$81[)2FE&R%1"%N W@&[J?*I $FE8C=/'3BJ'8S1[DN8')"[=4U&%@A>T=9S M)?]%C<3>MZZ1A0[[2J:>K%IY48-QZ*QK<'ZTO9*]IUDCIKG)19;NZB;+Y'OQ MMLM#-)QQZ82E6S1M]Z'&-[F>,T^+LK"H;\.4;ZB*ACN[P[V=K4?AKS1=1XF5 M&]93(N7;0(F:6UFKVA=UY.J#[DQM&\WN84VN?6W3:"6/"X$4:4&Z\M@LD-Q_KM:NZ M./DO?8NCN&7',!8B O\"YG?J8F&E)"YOZVII$*BG CB9\4C-'.K&ZP.<42CS M;_7$YT?QK9X#)YX(L_N=#WPV)S0<2Y@K2K01E[PXY^@E^"^<18NC02R.(HE5 M=61,#T;?@ =TJ50J&&"GZ8(95],I]> LXCC;XB8 -W\J.;)01'E;VA!VP:#) MC*K5P7UZJ*_&G&:R+ACS_M$+(H&[KFLBL2(YXS&ZYP!ED]H2=\$PXQG\-6=S M*@3C3^J17]ZD9K(N&).\X*>><$V!ZX2^#:?VY%TP;JR6X21(\FQY2VKJNJ#V M!#P6^I5:5U=U0>GB@9?:P9"O[8+J-Z $84"UV]!,U@5CS%,.5V$A)M55=DWQ MVP=6K[A9V3G%9Q@'+:KGJKNF_!F+>+WNN=K.J8Y+!XOJ9FT75)]X%+^K=YM& M_I*JA<$Q([RXA6@@ZH(AZ:N6%C/L)%TP B-AO$/@A8A?5=$%A4>>AXW[$Q(0 M3HO35%UE%Q1?.53M74(XI1P\R7B=VVNHNF"*"H.JW:KQ"SVZBZH(IQ9QH7:ZTC;KQ$RR95MW%OU1U M-/ X^.I'?F(CXLHY"T$2_O02)DCF?8JU/(VX>@M>ZZ1_E?&,<:,39<:MP[$& M2IVP.T9N+<-K6-;NGS&%T-)>&5BE;1J%V\!:H/]F06UIS1FJ&%_3E5UCHK$H696E,M9BZ:KAN SGZKSW*<3_C\,;>C^35]/?!>CG M::M'4LV$WXZ1R4U1E2]96%:$7[+9E:R#DV MFEM#WU63$W7'H00,_7+D^^#?LFN<:CRZ4"\:YS*O%K*N&EB%4;)*:L2R0-=5 M$UY7%@K+,VYGY&\DFF8E[AB$(RR13!;B3K'*S&@;!?2>@'^HP" M8J2O:'PJX=B>O"/ 5=X]I._F+=O6BK0C=M7?2%%MW!KT';'PPXP%($@ UQ'W M9NJ=2HZ8C+(C3/G?E(ZM7)/G:P^^41A&)$@G_1L$)5L/5-4\ QBDPOXL7^XI MR.IY6#*!%1Z&5-5OG)E_W>F]I/$E"[T&HW(D';4K#6%EX /^<3G%>R90K9"FJZK^NXA7W0M\OEK>M27?U*RD]"4.ET^GX"E5L_LM5'B]4:=C/=1<-S.29^ #)\%$ M$FR"84].B=6=UEBH)A7UBDA@W))A!O!7;Z43DP$NE*Y0&E$A\9P)7-ES_C1E M_(%P7XPXC):$:C5OV=5TBFM[M$!]CN:4+JD/^B(%W 8)9#>'1&WMAFHO,+RLI?2A&[_:A1__!U!+ P04 " 7 M@7U6@E6I43T2 H\P %0 '1S;VDM,C R,C$R,S%?8V%L+GAM;.U=;6_< M-A+^?L#]!YT/..0^;!S;2=NDS1W\$@<+N+9A.[W[5M 2UR:J)3>BY)?[]4=R MI5U)?%^O1!IH432UPQG-S$-RAN1P^,N_G^9Y\@ +B@C^O+/W]MU. G%*,H3O M/N]\NYX<7A]/ISL)+0'.0$XP_+R#R?DJ\0PP*4I/@Y^0WD%?\-.44Y+))C,E_DL(3L+Y8?_I1\>+OW M$T@F$P>^OT&+;U73%][XL%_33[N[CX^-;3![ (RG^H&]3,G=C>%V"LJ(K M;N^>WM7_+,E_R1'^XQ/_SRV@,&'VPO33$T6?=_AWZ\\^'KPEQ=WN_KMW>[O_ M_?7L.KV'>BHMO[^/'CKOC;IJG4\NFVR)MO'.PVXJPXL[]% MAO8M22CZ1(5X9R0%I8#=^IE$VX+_-&F:3?BO)GO[DX.]MT\TVVF,+RQ8D!Q> MP5G"_V3HK;Y:WK-NLH!5B5)*\HI+1!$N.7Z[O.WN,6']DPDNN-P7,(Y-R"U_<0EM0FCK+Q\&)=@@)B M1L):@]Q+1B7E( +SX0;G[&/T8G:QX%,$;V(3UDPUN*#']P#?03K%U_?,4/AE=(AI$S(OB#F#T/X'N(W7H0P9B%%@!E7YX6$%/(;'3!28ZK@D]MAY0Z MS-L>+ 91X10]PJXB:TE&#KL<1-/2S!V7.$FKC.#H=VVF[A:@K&= MDYNXS@P"K:)/8 E03L]!P7=2'JRA\^8^,&[Q$R-L+?AJYT8]<(?L.E>J]*[>/7,#I@.KV7+& MWMKH:8<.-'Q[E /IP'9N117>=M;3#BST.2S/4"JZJK?0>MJAPSQOGV@G'7/W MRU=\3S9#=YF6"%>=:-2_![FR"JV2UVG=2_F.NE7H[[G]^ R,W&JQ43M<[RYH M83"P^"=P!EE@D+'O+ZPF \J/W]#K1=^^Y4 ZX#:PK[1FJJ&#NJJL M"O@KPFA>S<\@H)!-,V(1ZQ_CN;(:>_WN[R:]68VR^>RKARN]27CF3M(J%\O& M,_9SAP(^E1!G,&OX<*$WS/$I4#4#]%9D7U5T M<@? 8I>#O OSDC:_$; +R.M?_+ZUZW5?PZ+-"%%!HO/.WO-=T"1=GJ- MG 97M]BEU7PNV$P0ZP\-_:P@(;J[+X7T82!49WS( M6/7;N8&R'Q044S9+'-:O=_#H%4PAZS1\=0=+^]@W4KDA]8\)IBKD; M)L4S$U./2[>5&P[O@^*@TBLFNZL//QU=I!.Q&TH?@J+D8868P.OFENE"F%C\ MNVZFBMW*EP59P*)\OLSYB1#.>/BQX,&M<:HR4\7AW+6CP:YP3 #5"?#X3BRL MK[@T%[-O;!QS)?4(6JO?.8;OMP_M#/76UX3P:H5CZE ]2;NG,+Y ::A#>\Q-83,: M(S(0BPIF/I.#@22T]_2!RZQV3!AUW?XJ'MN*D M;!QZ >T,CD'5F!!I97J0TB M*Q,W$'\,#^(&IHD)63F)V"7 ,%.Y8?=3>.QB>4) MOKN!Q5QU(5*8;P2YPR"U#3\'. M6.B4C F(PRQ#7&607P*43?$Q6*!RG<9UAL:B\173DS,B;ZXOI M[Z(>$[TA1W!*:;7.%FP9F[>3FX7>2;*;6"UW?-U>UH2'2SQOM;ECVDKN\7%Q M1C:A-YNG_* M&4IW0\0T/EOA,[\T[!%UVBE#QW*NNNG7V#$BYE H1QW<:8E"QWD;XN1<,Q<^_BP/W>1?*FP^^?X]T?L=0M[2CT MWJ30FE%"9DF+59"9Y6M!*+TLR,SDLSN-0H4<#Q!7\)2-*S[J"Y"6_T'E_7%% M2S*'Q9>G-*]XK3.>Q<3^Y5<<33'(!LQ">S8%4E(TLK&-XG)VM+R8?24D$U,E M+!Y0"NDUFP1-ODY/$]K5V8&S:QQ5^+_:7&W*F#AL)J^;AI%Y6<0^9^8]S.8( M(UHN;TO66X,CHM6\4R]$B::T,/& MBHD^U4VC?U1=[BM N"_H%+.@7M17H>>PO"Q@:=H%<><0>KKPA=+7-C'YJRDN M80&I/:"0&H:.JWU1TF@:U2@3-R,WF-UM=*$C<5^LW.P0USAJ(HMF/Q3AB@F^ MWG _@C-2P%95N2]/90&8Z1$&Q?.4F4_.;Z)7-2:9XW59A?6:A>[W2JDE7S8\\!$!V2^+>@0Q-)X@:@E" MCUAW<+7:6@*6H$?QWD]6=LZQ/[B?8]?,$X23-OM_@ 6A/R=29M>H>DL/7G:4 M_,%#2<8I6;(*-7]R$2X+\H"8:8Z>OU&83?'*31ZF;*5CN?SDP^-/+^$UD7AB MT_?DRIDHHDE?C.LCP-3B[WZSB5!810^0KGT$4_[+D#(;8J04=^G[-^1*^;2D M*O'=@3CX;L+&*/EH&=\H"[,-.^!.PTM'VT;[LG]NRXYP9OAB:+>P3[OQUJ!F M;CV<$S8U+-]'6SW7)+)P73P?9^'%(?1-AY?-LAL8*Z:QVA6?%Q@Y0524P&*J MS%$UUP]2!]+0]3E>/#J=S1,OIE-A [;B4?QRCL^:1\"4)>-](';CYXA]Q-L]+[/D M"&L664![)7%.Z$#GB%ZLVT#.EGD=+M9:5LN!U!'1B#>$G.TS_$ZL5A1EN4/G M86AFXHA@C/L^FZC[2@9HKQ1SXPS6A>O.T5$]@:[?F"@;[PE%[)(] -P/H5V!MRF'ZO4 &U;^_HM?3A M$>GYO@'5_G5";X-%M9YDTJ809B*_38 >*!I,\9 M1B**=*YQQ]#!)#'--NTNYU8-7$\1:1;29N//L6AX'&./EQ?EA;/?M:U%OI/V+5LM+6""2R:NQNI#4EZ=4I'U? M,;?R93:#J>DMFI'E".VYP]A=SBGV78A'>:\J9F.:U@Q1EJ*,V9BFR3C>@I<7 MQ1W =6X-,]Y1Q?X:4GH"5Q6=5TITKI[\F$P2GE.5$UH5D/W09I0 G"4-JZ3# M:ZQ;-$> (BH2^RC#OE'O&MUA-$,IW[58[MPSO"Y)CCI56#N*_M175'#F5VH6 M+=Y"8[KFGH 5^V2QXC^6\MTAH-;K8U^O-5&2"JJQI%6_ U^_%]0[D6ZKL/>N MKT+-*8%+5@(4PIDE]=,I">@=[0^MVREZ@IE)A[V^#H)B=#E5I_\=.?>E\2[L M.K:E*HSPL[2KSO*W'>%KQAP7[N M';$./\>L=V1N"H I2$4CM18?Y-EF+?=S4G88C*5"ZT:S6NH?^E(O*9)R23*6 MG+WJV1T1)3_$5YRE2T. MPL=H"M0/?E.XNJ7P>\6+V/&$/K7T^Y*77),EL*:+."HS1F?[DOO<.#I+WC1? M&K$R^P;VN.'3OL8:DI-^@366WQG1%@YAH$EWR=F[!H,!5&U%A2:5)-??C@T# MB-T*$DUB2[Z^'2H&$-L072P=J6K?A_HR%45 ML"UELSXR[T2\S7SW^H.\1%*5\X&B%Y&WUSH]QS" UWC/ABC-3Z1WS,MW9>K;6GT4=) MB\^VCUHN1&-Q0YIP7AZTZUAL<.5@>U\([R.].\2VS1MSY5-YBK8LG*0=M^Y& M81RKII:/-3H>:=^M[7B6ZZ X'$]+(5[^V!8+:9H/NL8QRJ5<%9A$&_WU().! MC6L;1?.(7$5SW\:][^@I0D_E3AA9M=@Z1IH!JAJ%7+<[#0:_E MJUBAL""@T<#H**2#C;:C8$R2ADMH1W&*, /VC#G>K%^\S+A&L=&%F;T,4EG6 M*7;*T!['#:G>M.9JD)AV>[X=<;6C20]WT4J1Y:=)%8UE2M77LUIXQ.<[WQK/6999#S725IGG99#F, M?]3JH2[[B04[]Y#Q KE:=^E\=0/=DS>=#XUZJJI.NG7JX.\5YZNZ)-Q8>GC_ M_1ICOS8>JZZS7IJ3U=!AX7 O$8TL_Q5,V4H#YOM?"9TB&E[D4GS?M,V;1Q3(*I14#Q>=(BS,_;17)&G[]Q-](Q" MAZ!;Z0@V.[T"J$])P23#G9YZ@F8SR%TL6OMQ9\CM#$/OY&P%>E>[O8(N(!80 MJU_A._&DH#?N&BZA:S=L!6RCA6)"^#>05TO;YCEYY&DL3:EAII-89389HFR= M7)GVO/TYA7Y4Q@_I32T5\U[".G#OZ\*S)%N5+HUQO#'UI&&<,,[-02#/D&PQ M#QW82[H;=WG5K4.=3/5D6=>N))0>LZ7@\XP4CZ#(#-.S%Y/0X;@)*^GXRMLX M,,!YI+GDG--!%JGE?X?VX9U.PW_P=02P,$% @ %X%]5MMQ M%,8B(0 )#$" !4 !T# M[_>'I_=G5U<'3IR@T$,!"?%O!R$Y^-O__/N_.?1_O_['X:%SZ>/ ^^*<$_?P M*IR17YP;M,!?G-]QB".4D.@7YP\4I.PWY-(/<.2CHQX\?/X?D&?T@T9_QSRY9J'5XGZ D MC5>]O7EY4_PO)_\U\,,_O[#_/*(8.U1?8?SE)?9_.V#?+3[[X^W/)'HZ.GGS MYOCH?[]=W[MSO$"'?LCTYN*#DHKUPJ,[_OSY\U'VU[)IH^7+8Q24WWA[5+*S MZIG^U4M6!-7&[X_R/U:;^H*N*TS'_I.:P_Z= K[Z:S.F(6N(T\=V8!"GC*/;#A$%] MQ-H>G1$ZE"GC62_S",]^.TABXM./G9P> <=SR9*M)JR) MC%DQ5>^,GLU1^(3CJ_!^3A4U)X%'%[ES//-=/]%A7:6?_H5!\?PR(#^TE-X@ MZH7-2?2$0O\?&;JGH?:] MVM/\7GWJ]2%"88Q<)1,MH^N%V2MZKEG@!_0BUR>G:2\L7?R5^LFKC)MZJUX8 MN<9/*+B-B(LQ._I)%02U[VD.+Q9^DFTNZ#)+IR:S7_24JC Q%$C[V4.ECS'^ M*Z7?O7AF'Y=NGX#VMFP\>MR #+(1:<'7 UM,^Q"XWK&I[8V:>-H=];W546,; M).A[VZ/&'D@P]+Y"C5WE#OHVVVKL@@1#&R9:5^V1V:+3GL6L&&-M:6#:OC<:NB-*@;1G/5=V%=IZ MAFE[9OH&)]>^FPU5;:9AVKZW>=HV44XZI/=+EWW-;OH>,A46[FJ[4?T1I-J5 M:9&T;NNV[7=05Z&^Y=;KIV?D5H>-PN!J#T%)!SVS?XYGF&X,//K]?'FB^X5R M)]MF0NGUU_=Y47=L*9#VZ ;6Y59,U?>F+DW2"'_S0W^1+JXQBC%=9K)#K/X> M3[6KH<_O^F92NZM!G,^ZW+]]A^UBGHG;(#$VSS3P,U&=ZJR^#\5.OOOP>321( M6)/GG4B>=4<.F3G5K@Q(HA0/6)/MO;IL1>>.'SK5[O\++4G\BU-^I1"Z%#L@ M;DW6@$4)DZBY(L7E4C)#\6.VGJ3QX1-"RR.V[SC"01*7O\EV(MD*5?QBNF*4 MZA9?T7^ND S0(PZRSTZ+QKRV1V:Y?JC�DX+MIM6J=1R7>Q""M:NGSE M_^+2[2@=C!=!]C5J/? 3^T?)V2PB"ZDJ"[41H015W5)&#AP2T:'TV\'QFS4O M 8FQ1[>>4

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